Ligand source activities (1 row/activity)





Ligands (move mouse cursor over ligand name to see structure) Receptor Activity Chemical information
Sel. page Common
name
GPCRdb
ID
Reference
ligand
Vendors

Species

Assay
Type

Activity
Type
Activity
Relation
Activity
Value
p-value
(-log)
Fold
selectivity
Tested
GPCRs
Assay
Description
Source

Mol
weight
Rot
Bonds
H don

H acc

LogP

Smiles

DOI

1222 1664 None 49 Human Functional pAC50 = 6 6.0 -23 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
3396 1664 None 49 Human Functional pAC50 = 6 6.0 -23 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
3396.0 1664 None 49 Human Functional pAC50 = 6 6.0 -23 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
85 1664 None 49 Human Functional pAC50 = 6 6.0 -23 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL46516 1664 None 49 Human Functional pAC50 = 6 6.0 -23 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
DB04842 1664 None 49 Human Functional pAC50 = 6 6.0 -23 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
2337 3256 None 77 Human Functional pAC50 = 6 6.0 -8 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
50 3256 None 77 Human Functional pAC50 = 6 6.0 -8 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
5002 3256 None 77 Human Functional pAC50 = 6 6.0 -8 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
5002.0 3256 None 77 Human Functional pAC50 = 6 6.0 -8 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL716 3256 None 77 Human Functional pAC50 = 6 6.0 -8 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
DB01224 3256 None 77 Human Functional pAC50 = 6 6.0 -8 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
5328940 100216 None 107 Human Functional pAC50 = 6 6.0 -1 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 529 9 1 8 5.2 COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl 10.1038/s41467-023-40064-9
CHEMBL288441 100216 None 107 Human Functional pAC50 = 6 6.0 -1 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 529 9 1 8 5.2 COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl 10.1038/s41467-023-40064-9
42890 9425 None 59 Human Functional pAC50 = 5 5.0 -1 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 497 3 5 10 1.0 CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O 10.1038/s41467-023-40064-9
CHEMBL1117 9425 None 59 Human Functional pAC50 = 5 5.0 -1 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 497 3 5 10 1.0 CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O 10.1038/s41467-023-40064-9
2162 41514 None 100 Human Functional pAC50 = 5 5.0 -3 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl 10.1038/s41467-023-40064-9
CHEMBL1491 41514 None 100 Human Functional pAC50 = 5 5.0 -3 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl 10.1038/s41467-023-40064-9
47979 78210 None 59 Human Functional pAC50 = 5 5.0 -3311 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 8 2 6 0.7 C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC 10.1038/s41467-023-40064-9
CHEMBL2105581 78210 None 59 Human Functional pAC50 = 5 5.0 -3311 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 8 2 6 0.7 C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC 10.1038/s41467-023-40064-9
2105 3054 None 37 Human Functional pAC50 = 6.0 6.0 -251 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
47811 3054 None 37 Human Functional pAC50 = 6.0 6.0 -251 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
48 3054 None 37 Human Functional pAC50 = 6.0 6.0 -251 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
CHEMBL531 3054 None 37 Human Functional pAC50 = 6.0 6.0 -251 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
DB01186 3054 None 37 Human Functional pAC50 = 6.0 6.0 -251 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
4209 3163 None 75 Human Functional pAC50 = 7.0 7.0 -891 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
4893 3163 None 75 Human Functional pAC50 = 7.0 7.0 -891 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
4893.0 3163 None 75 Human Functional pAC50 = 7.0 7.0 -891 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
503 3163 None 75 Human Functional pAC50 = 7.0 7.0 -891 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
5385 3163 None 75 Human Functional pAC50 = 7.0 7.0 -891 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
CHEMBL2 3163 None 75 Human Functional pAC50 = 7.0 7.0 -891 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
DB00457 3163 None 75 Human Functional pAC50 = 7.0 7.0 -891 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
5472 205818 None 75 Human Functional pAC50 = 6.0 6.0 -1 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
5472.0 205818 None 75 Human Functional pAC50 = 6.0 6.0 -1 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
CHEMBL1717 205818 None 75 Human Functional pAC50 = 6.0 6.0 -1 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
CHEMBL833 205818 None 75 Human Functional pAC50 = 6.0 6.0 -1 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
DB00208 205818 None 75 Human Functional pAC50 = 6.0 6.0 -1 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
1028 291 None 71 Human Functional pAC50 = 5.0 5.0 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
139148732 291 None 71 Human Functional pAC50 = 5.0 5.0 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
479 291 None 71 Human Functional pAC50 = 5.0 5.0 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5816 291 None 71 Human Functional pAC50 = 5.0 5.0 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5816.0 291 None 71 Human Functional pAC50 = 5.0 5.0 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
CHEMBL679 291 None 71 Human Functional pAC50 = 5.0 5.0 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
DB00668 291 None 71 Human Functional pAC50 = 5.0 5.0 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5360696 1406 None 30 Human Functional pAC50 = 5.0 5.0 -1737 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
6953 1406 None 30 Human Functional pAC50 = 5.0 5.0 -1737 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
842 1406 None 30 Human Functional pAC50 = 5.0 5.0 -1737 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
CHEMBL52440 1406 None 30 Human Functional pAC50 = 5.0 5.0 -1737 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
DB00514 1406 None 30 Human Functional pAC50 = 5.0 5.0 -1737 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
2200 20203 None 61 Human Functional pAC50 = 5.0 5.0 -6 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
2200.0 20203 None 61 Human Functional pAC50 = 5.0 5.0 -6 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
CHEMBL1256819 20203 None 61 Human Functional pAC50 = 5.0 5.0 -6 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
CHEMBL1305 20203 None 61 Human Functional pAC50 = 5.0 5.0 -6 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
DB08799 20203 None 61 Human Functional pAC50 = 5.0 5.0 -6 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
6436173 55116 None 45 Human Functional pAC50 = 5.0 5.0 -3 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 785 2 5 13 6.2 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
CHEMBL1617 55116 None 45 Human Functional pAC50 = 5.0 5.0 -3 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 785 2 5 13 6.2 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
108000 56853 None 39 Human Functional pAC50 = 5.0 5.0 -32 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 2 1 3 2.9 Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21 10.1038/s41467-023-40064-9
135418340 56853 None 39 Human Functional pAC50 = 5.0 5.0 -32 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 2 1 3 2.9 Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1643895 56853 None 39 Human Functional pAC50 = 5.0 5.0 -32 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 2 1 3 2.9 Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21 10.1038/s41467-023-40064-9
55645 84370 None 8 Human Functional pAC50 = 5.0 5.0 -3890 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 7 2 4 2.1 CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21 10.1038/s41467-023-40064-9
55645.0 84370 None 8 Human Functional pAC50 = 5.0 5.0 -3890 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 7 2 4 2.1 CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21 10.1038/s41467-023-40064-9
CHEMBL2218861 84370 None 8 Human Functional pAC50 = 5.0 5.0 -3890 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 7 2 4 2.1 CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21 10.1038/s41467-023-40064-9
135398735 136968 None 32 Human Functional pAC50 = 5.0 5.0 -4 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 822 4 6 15 4.3 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
136262914 136968 None 32 Human Functional pAC50 = 5.0 5.0 -4 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 822 4 6 15 4.3 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
CHEMBL374478 136968 None 32 Human Functional pAC50 = 5.0 5.0 -4 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 822 4 6 15 4.3 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
4976 203579 None 29 Human Functional pAC50 = 5.0 5.0 -1230 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 4 1 1 4.3 CNCCCC1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL668 203579 None 29 Human Functional pAC50 = 5.0 5.0 -1230 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 4 1 1 4.3 CNCCCC1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
242 470 None 124 Human Functional pAC50 = 7.0 7.0 -32 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
34 470 None 124 Human Functional pAC50 = 7.0 7.0 -32 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
60795 470 None 124 Human Functional pAC50 = 7.0 7.0 -32 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
60795.0 470 None 124 Human Functional pAC50 = 7.0 7.0 -32 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
CHEMBL1112 470 None 124 Human Functional pAC50 = 7.0 7.0 -32 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
DB01238 470 None 124 Human Functional pAC50 = 7.0 7.0 -32 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
213046 2385 None 59 Human Functional pAC50 = 6.0 6.0 -69 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
213046.0 2385 None 59 Human Functional pAC50 = 6.0 6.0 -69 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
4168 2385 None 59 Human Functional pAC50 = 6.0 6.0 -69 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
7461 2385 None 59 Human Functional pAC50 = 6.0 6.0 -69 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
CHEMBL1237021 2385 None 59 Human Functional pAC50 = 6.0 6.0 -69 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
DB08815 2385 None 59 Human Functional pAC50 = 6.0 6.0 -69 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
443955 204370 None 92 Human Functional pAC50 = 6.0 6.0 2 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 350 3 0 4 4.1 CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32 10.1038/s41467-023-40064-9
CHEMBL71752 204370 None 92 Human Functional pAC50 = 6.0 6.0 2 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 350 3 0 4 4.1 CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32 10.1038/s41467-023-40064-9
1613 2348 None 53 Human Functional pAC50 = 5.9 5.9 -144 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
205 2348 None 53 Human Functional pAC50 = 5.9 5.9 -144 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
3964 2348 None 53 Human Functional pAC50 = 5.9 5.9 -144 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
3964.0 2348 None 53 Human Functional pAC50 = 5.9 5.9 -144 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
CHEMBL831 2348 None 53 Human Functional pAC50 = 5.9 5.9 -144 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
DB00408 2348 None 53 Human Functional pAC50 = 5.9 5.9 -144 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
11626560 200937 None 94 Human Functional pAC50 = 5.9 5.9 -1 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 449 5 2 6 5.0 C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl 10.1038/s41467-023-40064-9
CHEMBL601719 200937 None 94 Human Functional pAC50 = 5.9 5.9 -1 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 449 5 2 6 5.0 C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl 10.1038/s41467-023-40064-9
55483 205097 None 40 Human Functional pAC50 = 5.9 5.9 -7 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 356 13 4 4 3.6 Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O 10.1038/s41467-023-40064-9
CHEMBL77622 205097 None 40 Human Functional pAC50 = 5.9 5.9 -7 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 356 13 4 4 3.6 Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O 10.1038/s41467-023-40064-9
2540 4401 None 111 Human Functional pAC50 = 4.9 4.9 -1737 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 610 10 1 11 6.3 CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 10.1038/s41467-023-40064-9
CHEMBL1014 4401 None 111 Human Functional pAC50 = 4.9 4.9 -1737 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 610 10 1 11 6.3 CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 10.1038/s41467-023-40064-9
8550 14424 None 57 Human Functional pAC50 = 4.9 4.9 -1 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 578 7 1 9 4.2 COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC 10.1038/s41467-023-40064-9
CHEMBL1200515 14424 None 57 Human Functional pAC50 = 4.9 4.9 -1 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 578 7 1 9 4.2 COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC 10.1038/s41467-023-40064-9
131411 15392 None 70 Human Functional pAC50 = 4.9 4.9 -4 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 476 7 1 6 5.2 CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12 10.1038/s41467-023-40064-9
28446253 15392 None 70 Human Functional pAC50 = 4.9 4.9 -4 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 476 7 1 6 5.2 CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12 10.1038/s41467-023-40064-9
CHEMBL1214598 15392 None 70 Human Functional pAC50 = 4.9 4.9 -4 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 476 7 1 6 5.2 CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12 10.1038/s41467-023-40064-9
11291 98796 None 25 Human Functional pAC50 = 4.9 4.9 -331 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 261 1 0 1 3.9 CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12 10.1038/s41467-023-40064-9
11291.0 98796 None 25 Human Functional pAC50 = 4.9 4.9 -331 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 261 1 0 1 3.9 CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12 10.1038/s41467-023-40064-9
CHEMBL278398 98796 None 25 Human Functional pAC50 = 4.9 4.9 -331 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 261 1 0 1 3.9 CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12 10.1038/s41467-023-40064-9
DB01619 98796 None 25 Human Functional pAC50 = 4.9 4.9 -331 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 261 1 0 1 3.9 CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12 10.1038/s41467-023-40064-9
2583 3776 None 118 Human Functional pAC50 = 4.9 4.9 -7079 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
592 3776 None 118 Human Functional pAC50 = 4.9 4.9 -7079 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
65999 3776 None 118 Human Functional pAC50 = 4.9 4.9 -7079 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
65999.0 3776 None 118 Human Functional pAC50 = 4.9 4.9 -7079 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
CHEMBL1017 3776 None 118 Human Functional pAC50 = 4.9 4.9 -7079 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
DB00966 3776 None 118 Human Functional pAC50 = 4.9 4.9 -7079 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
71496458 115564 None 87 Human Functional pAC50 = 4.9 4.9 -33 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 499 10 2 8 4.5 C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C 10.1038/s41467-023-40064-9
CHEMBL3353410 115564 None 87 Human Functional pAC50 = 4.9 4.9 -33 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 499 10 2 8 4.5 C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C 10.1038/s41467-023-40064-9
104850 3330 None 96 Human Functional pAC50 = 4.9 4.9 -1122 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
4150 3330 None 96 Human Functional pAC50 = 4.9 4.9 -1122 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
743 3330 None 96 Human Functional pAC50 = 4.9 4.9 -1122 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
CHEMBL111 3330 None 96 Human Functional pAC50 = 4.9 4.9 -1122 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
DB06155 3330 None 96 Human Functional pAC50 = 4.9 4.9 -1122 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
5282175 14432 None 36 Human Functional pAC50 = 4.9 4.9 -14 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 424 16 2 5 5.1 CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]1O 10.1038/s41467-023-40064-9
CHEMBL1200661 14432 None 36 Human Functional pAC50 = 4.9 4.9 -14 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 424 16 2 5 5.1 CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]1O 10.1038/s41467-023-40064-9
65948 18556 None 109 Human Functional pAC50 = 4.9 4.9 -5 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 582 9 2 9 4.7 CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1 10.1038/s41467-023-40064-9
CHEMBL1275868 18556 None 109 Human Functional pAC50 = 4.9 4.9 -5 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 582 9 2 9 4.7 CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1 10.1038/s41467-023-40064-9
2794 19380 None 85 Human Functional pAC50 = 4.9 4.9 -14 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 472 4 1 4 7.5 CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL1292 19380 None 85 Human Functional pAC50 = 4.9 4.9 -14 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 472 4 1 4 7.5 CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
7028 52380 None 22 Human Functional pAC50 = 4.9 4.9 -102 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 165 3 2 2 1.3 CN[C@@H](C)[C@@H](O)c1ccccc1 10.1038/s41467-023-40064-9
7028.0 52380 None 22 Human Functional pAC50 = 4.9 4.9 -102 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 165 3 2 2 1.3 CN[C@@H](C)[C@@H](O)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL1590 52380 None 22 Human Functional pAC50 = 4.9 4.9 -102 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 165 3 2 2 1.3 CN[C@@H](C)[C@@H](O)c1ccccc1 10.1038/s41467-023-40064-9
DB00852 52380 None 22 Human Functional pAC50 = 4.9 4.9 -102 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 165 3 2 2 1.3 CN[C@@H](C)[C@@H](O)c1ccccc1 10.1038/s41467-023-40064-9
2467 67425 None 51 Human Functional pAC50 = 4.9 4.9 -3 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 8 0 5 2.8 COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1 10.1038/s41467-023-40064-9
CHEMBL188921 67425 None 51 Human Functional pAC50 = 4.9 4.9 -3 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 8 0 5 2.8 COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1 10.1038/s41467-023-40064-9
2375 158394 None 106 Human Functional pAC50 = 4.9 4.9 -5 2
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 430 5 2 5 2.9 CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1 10.1038/s41467-023-40064-9
CHEMBL409 158394 None 106 Human Functional pAC50 = 4.9 4.9 -5 2
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 430 5 2 5 2.9 CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1 10.1038/s41467-023-40064-9
37264 189422 None 24 Human Functional pAC50 = 4.9 4.9 -8 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 435 6 2 10 1.3 COc1cc2c(N)nc(N3CCN(C(=O)OCC(C)(C)O)CC3)nc2c(OC)c1OC 10.1038/s41467-023-40064-9
CHEMBL513301 189422 None 24 Human Functional pAC50 = 4.9 4.9 -8 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 435 6 2 10 1.3 COc1cc2c(N)nc(N3CCN(C(=O)OCC(C)(C)O)CC3)nc2c(OC)c1OC 10.1038/s41467-023-40064-9
68867 78173 None 38 Human Functional pAC50 = 5.9 5.9 -61 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 402 7 2 6 3.1 CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1 10.1038/s41467-023-40064-9
68867.0 78173 None 38 Human Functional pAC50 = 5.9 5.9 -61 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 402 7 2 6 3.1 CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1 10.1038/s41467-023-40064-9
CHEMBL2104523 78173 None 38 Human Functional pAC50 = 5.9 5.9 -61 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 402 7 2 6 3.1 CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1 10.1038/s41467-023-40064-9
DB08810 78173 None 38 Human Functional pAC50 = 5.9 5.9 -61 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 402 7 2 6 3.1 CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1 10.1038/s41467-023-40064-9
68602 205126 None 80 Human Functional pAC50 = 5.9 5.9 -11 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C 10.1038/s41467-023-40064-9
CHEMBL77921 205126 None 80 Human Functional pAC50 = 5.9 5.9 -11 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C 10.1038/s41467-023-40064-9
2683 3834 None 60 Human Functional pAC50 = 5.9 5.9 -5 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
5487 3834 None 60 Human Functional pAC50 = 5.9 5.9 -5 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
5487.0 3834 None 60 Human Functional pAC50 = 5.9 5.9 -5 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
7308 3834 None 60 Human Functional pAC50 = 5.9 5.9 -5 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
CHEMBL1079 3834 None 60 Human Functional pAC50 = 5.9 5.9 -5 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
DB00697 3834 None 60 Human Functional pAC50 = 5.9 5.9 -5 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
4066 204626 None 78 Human Functional pAC50 = 4.9 4.9 -870 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 2 0 3 4.6 c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2 10.1038/s41467-023-40064-9
4066.0 204626 None 78 Human Functional pAC50 = 4.9 4.9 -870 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 2 0 3 4.6 c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2 10.1038/s41467-023-40064-9
CHEMBL73451 204626 None 78 Human Functional pAC50 = 4.9 4.9 -870 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 2 0 3 4.6 c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2 10.1038/s41467-023-40064-9
DB01071 204626 None 78 Human Functional pAC50 = 4.9 4.9 -870 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 2 0 3 4.6 c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2 10.1038/s41467-023-40064-9
1043 1582 None 14 Human Functional pAC50 = 6.9 6.9 -208 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
149 1582 None 14 Human Functional pAC50 = 6.9 6.9 -208 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
8223 1582 None 14 Human Functional pAC50 = 6.9 6.9 -208 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
8223.0 1582 None 14 Human Functional pAC50 = 6.9 6.9 -208 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
CHEMBL442 1582 None 14 Human Functional pAC50 = 6.9 6.9 -208 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
DB00696 1582 None 14 Human Functional pAC50 = 6.9 6.9 -208 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
202 1508 None 77 Human Functional pAC50 = 5.9 5.9 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
60835 1508 None 77 Human Functional pAC50 = 5.9 5.9 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
972 1508 None 77 Human Functional pAC50 = 5.9 5.9 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL1175 1508 None 77 Human Functional pAC50 = 5.9 5.9 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
DB00476 1508 None 77 Human Functional pAC50 = 5.9 5.9 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
124 2981 None 47 Human Functional pAC50 = 5.9 5.9 -144 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
2032 2981 None 47 Human Functional pAC50 = 5.9 5.9 -144 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
4636 2981 None 47 Human Functional pAC50 = 5.9 5.9 -144 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
4636.0 2981 None 47 Human Functional pAC50 = 5.9 5.9 -144 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
CHEMBL762 2981 None 47 Human Functional pAC50 = 5.9 5.9 -144 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
DB00935 2981 None 47 Human Functional pAC50 = 5.9 5.9 -144 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
2274 3173 None 58 Human Functional pAC50 = 5.9 5.9 -22 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
4917 3173 None 58 Human Functional pAC50 = 5.9 5.9 -22 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
4917.0 3173 None 58 Human Functional pAC50 = 5.9 5.9 -22 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
7279 3173 None 58 Human Functional pAC50 = 5.9 5.9 -22 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
CHEMBL728 3173 None 58 Human Functional pAC50 = 5.9 5.9 -22 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
DB00433 3173 None 58 Human Functional pAC50 = 5.9 5.9 -22 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
212 3806 None 47 Human Functional pAC50 = 5.9 5.9 -524 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
2639 3806 None 47 Human Functional pAC50 = 5.9 5.9 -524 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
941651 3806 None 47 Human Functional pAC50 = 5.9 5.9 -524 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
941651.0 3806 None 47 Human Functional pAC50 = 5.9 5.9 -524 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
CHEMBL1201 3806 None 47 Human Functional pAC50 = 5.9 5.9 -524 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
DB01623 3806 None 47 Human Functional pAC50 = 5.9 5.9 -524 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
56959 31556 None 103 Human Functional pAC50 = 5.9 5.9 3 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 427 9 2 6 2.3 COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 10.1038/s41467-023-40064-9
CHEMBL1404 31556 None 103 Human Functional pAC50 = 5.9 5.9 3 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 427 9 2 6 2.3 COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 10.1038/s41467-023-40064-9
CHEMBL1526084 31556 None 103 Human Functional pAC50 = 5.9 5.9 3 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 427 9 2 6 2.3 COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 10.1038/s41467-023-40064-9
70691408 78212 None 0 Human Functional pAC50 = 5.9 5.9 3 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 1 2 4 1.6 CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O 10.1038/s41467-023-40064-9
CHEMBL2105617 78212 None 0 Human Functional pAC50 = 5.9 5.9 3 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 1 2 4 1.6 CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O 10.1038/s41467-023-40064-9
4640 78266 None 30 Human Functional pAC50 = 5.9 5.9 -11 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 1 4 3.9 COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC 10.1038/s41467-023-40064-9
CHEMBL2107011 78266 None 30 Human Functional pAC50 = 5.9 5.9 -11 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 1 4 3.9 COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC 10.1038/s41467-023-40064-9
243 3202 None 91 Human Functional pAC50 = 4.9 4.9 -1202 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
3052762 3202 None 91 Human Functional pAC50 = 4.9 4.9 -1202 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
3052762.0 3202 None 91 Human Functional pAC50 = 4.9 4.9 -1202 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
3502 3202 None 91 Human Functional pAC50 = 4.9 4.9 -1202 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
CHEMBL117287 3202 None 91 Human Functional pAC50 = 4.9 4.9 -1202 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
DB06480 3202 None 91 Human Functional pAC50 = 4.9 4.9 -1202 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
67462786 120517 None 56 Human Functional pAC50 = 4.9 4.9 -3 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 9 1 8 4.2 COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1 10.1038/s41467-023-40064-9
CHEMBL3545376 120517 None 56 Human Functional pAC50 = 4.9 4.9 -3 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 9 1 8 4.2 COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1 10.1038/s41467-023-40064-9
122282 133509 None 57 Human Functional pAC50 = 4.9 4.9 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 198 0 0 2 -0.4 CN1C(=O)N(C)C2C1N(C)C(=O)N2C 10.1038/s41467-023-40064-9
CHEMBL3707390 133509 None 57 Human Functional pAC50 = 4.9 4.9 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 198 0 0 2 -0.4 CN1C(=O)N(C)C2C1N(C)C(=O)N2C 10.1038/s41467-023-40064-9
3198 205513 None 76 Human Functional pAC50 = 4.9 4.9 -50 37
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 6 0 3 5.8 Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL1201049 205513 None 76 Human Functional pAC50 = 4.9 4.9 -50 37
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 6 0 3 5.8 Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL808 205513 None 76 Human Functional pAC50 = 4.9 4.9 -50 37
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 6 0 3 5.8 Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
137 370 None 52 Human Functional pAC50 = 4.8 4.8 -6606 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
2119 370 None 52 Human Functional pAC50 = 4.8 4.8 -6606 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
563 370 None 52 Human Functional pAC50 = 4.8 4.8 -6606 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
66368 370 None 52 Human Functional pAC50 = 4.8 4.8 -6606 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
CHEMBL266195 370 None 52 Human Functional pAC50 = 4.8 4.8 -6606 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
DB00866 370 None 52 Human Functional pAC50 = 4.8 4.8 -6606 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
2343 14454 None 57 Human Functional pAC50 = 5.8 5.8 1 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 5 2 6 2.2 NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O 10.1038/s41467-023-40064-9
CHEMBL1201039 14454 None 57 Human Functional pAC50 = 5.8 5.8 1 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 5 2 6 2.2 NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O 10.1038/s41467-023-40064-9
2303 3187 None 68 Human Functional pAC50 = 4.8 4.8 -10000 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
4946 3187 None 68 Human Functional pAC50 = 4.8 4.8 -10000 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
564 3187 None 68 Human Functional pAC50 = 4.8 4.8 -10000 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
63 3187 None 68 Human Functional pAC50 = 4.8 4.8 -10000 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
91536 3187 None 68 Human Functional pAC50 = 4.8 4.8 -10000 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
CHEMBL27 3187 None 68 Human Functional pAC50 = 4.8 4.8 -10000 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
CHEMBL452861 3187 None 68 Human Functional pAC50 = 4.8 4.8 -10000 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
DB00571 3187 None 68 Human Functional pAC50 = 4.8 4.8 -10000 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
65859 19049 None 88 Human Functional pAC50 = 4.8 4.8 -1 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 236 4 2 4 0.2 OC[C@@H](O)CN1CCN(c2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL1288810 19049 None 88 Human Functional pAC50 = 4.8 4.8 -1 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 236 4 2 4 0.2 OC[C@@H](O)CN1CCN(c2ccccc2)CC1 10.1038/s41467-023-40064-9
5468 127228 None 85 Human Functional pAC50 = 4.8 4.8 -1 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 4 1 3 3.2 CC(C(=O)O)c1ccc(C(=O)c2ccccc2)s1 10.1038/s41467-023-40064-9
CHEMBL365795 127228 None 85 Human Functional pAC50 = 4.8 4.8 -1 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 4 1 3 3.2 CC(C(=O)O)c1ccc(C(=O)c2ccccc2)s1 10.1038/s41467-023-40064-9
31101 729 None 40 Human Functional pAC50 = 5.8 5.8 -323 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
31101.0 729 None 40 Human Functional pAC50 = 5.8 5.8 -323 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
35 729 None 40 Human Functional pAC50 = 5.8 5.8 -323 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
403 729 None 40 Human Functional pAC50 = 5.8 5.8 -323 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
CHEMBL493 729 None 40 Human Functional pAC50 = 5.8 5.8 -323 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
DB01200 729 None 40 Human Functional pAC50 = 5.8 5.8 -323 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
5311507 194815 None 41 Human Functional pAC50 = 6.8 6.8 -13 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
5311507.0 194815 None 41 Human Functional pAC50 = 6.8 6.8 -13 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
CHEMBL53904 194815 None 41 Human Functional pAC50 = 6.8 6.8 -13 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
DB01624 194815 None 41 Human Functional pAC50 = 6.8 6.8 -13 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
216416 111581 None 48 Human Functional pAC50 = 5.8 5.8 -18 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 413 6 1 3 5.7 Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1 10.1038/s41467-023-40064-9
CHEMBL328190 111581 None 48 Human Functional pAC50 = 5.8 5.8 -18 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 413 6 1 3 5.7 Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1 10.1038/s41467-023-40064-9
1547484 940 None 74 Human Functional pAC50 = 4.8 4.8 -38 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
1547484.0 940 None 74 Human Functional pAC50 = 4.8 4.8 -38 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
654 940 None 74 Human Functional pAC50 = 4.8 4.8 -38 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
9072 940 None 74 Human Functional pAC50 = 4.8 4.8 -38 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL43064 940 None 74 Human Functional pAC50 = 4.8 4.8 -38 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
DB00568 940 None 74 Human Functional pAC50 = 4.8 4.8 -38 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
2600 3779 None 74 Human Functional pAC50 = 4.8 4.8 -223 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
2608 3779 None 74 Human Functional pAC50 = 4.8 4.8 -223 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
5405 3779 None 74 Human Functional pAC50 = 4.8 4.8 -223 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
CHEMBL17157 3779 None 74 Human Functional pAC50 = 4.8 4.8 -223 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
DB00342 3779 None 74 Human Functional pAC50 = 4.8 4.8 -223 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
2812 4779 None 101 Human Functional pAC50 = 4.8 4.8 -165 44
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 344 4 0 2 5.4 Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1 10.1038/s41467-023-40064-9
CHEMBL104 4779 None 101 Human Functional pAC50 = 4.8 4.8 -165 44
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 344 4 0 2 5.4 Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1 10.1038/s41467-023-40064-9
54454 5258 None 88 Human Functional pAC50 = 4.8 4.8 -6 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 6 1 5 4.6 CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21 10.1038/s41467-023-40064-9
CHEMBL1064 5258 None 88 Human Functional pAC50 = 4.8 4.8 -6 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 6 1 5 4.6 CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21 10.1038/s41467-023-40064-9
4260 52558 None 31 Human Functional pAC50 = 4.8 4.8 -14 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 6 0 4 3.0 CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C 10.1038/s41467-023-40064-9
4260.0 52558 None 31 Human Functional pAC50 = 4.8 4.8 -14 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 6 0 4 3.0 CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C 10.1038/s41467-023-40064-9
CHEMBL159226 52558 None 31 Human Functional pAC50 = 4.8 4.8 -14 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 6 0 4 3.0 CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C 10.1038/s41467-023-40064-9
DB09205 52558 None 31 Human Functional pAC50 = 4.8 4.8 -14 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 6 0 4 3.0 CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C 10.1038/s41467-023-40064-9
4450 178228 None 69 Human Functional pAC50 = 4.8 4.8 -24 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 0 2 3.2 CN1CCOC(c2ccccc2)c2ccccc2C1 10.1038/s41467-023-40064-9
CHEMBL465026 178228 None 69 Human Functional pAC50 = 4.8 4.8 -24 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 0 2 3.2 CN1CCOC(c2ccccc2)c2ccccc2C1 10.1038/s41467-023-40064-9
4746 204891 None 31 Human Functional pAC50 = 4.8 4.8 -15 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 5.3 C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1 10.1038/s41467-023-40064-9
CHEMBL1334033 204891 None 31 Human Functional pAC50 = 4.8 4.8 -15 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 5.3 C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1 10.1038/s41467-023-40064-9
CHEMBL75880 204891 None 31 Human Functional pAC50 = 4.8 4.8 -15 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 5.3 C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1 10.1038/s41467-023-40064-9
168871 89130 None 14 Human Functional pAC50 = 7.8 7.8 -1 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 563 4 3 6 2.1 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 10.1038/s41467-023-40064-9
CHEMBL2365712 89130 None 14 Human Functional pAC50 = 7.8 7.8 -1 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 563 4 3 6 2.1 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 10.1038/s41467-023-40064-9
2342 599 None 39 Human Functional pAC50 = 5.8 5.8 -5 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
331 599 None 39 Human Functional pAC50 = 5.8 5.8 -5 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
7124 599 None 39 Human Functional pAC50 = 5.8 5.8 -5 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
CHEMBL1201250 599 None 39 Human Functional pAC50 = 5.8 5.8 -5 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
DB00767 599 None 39 Human Functional pAC50 = 5.8 5.8 -5 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
150 2509 None 21 Human Functional pAC50 = 5.8 5.8 -676 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
1764 2509 None 21 Human Functional pAC50 = 5.8 5.8 -676 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
8226 2509 None 21 Human Functional pAC50 = 5.8 5.8 -676 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
8226.0 2509 None 21 Human Functional pAC50 = 5.8 5.8 -676 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
CHEMBL1201356 2509 None 21 Human Functional pAC50 = 5.8 5.8 -676 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
DB00353 2509 None 21 Human Functional pAC50 = 5.8 5.8 -676 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
24826799 10798 None 104 Human Functional pAC50 = 4.8 4.8 -53 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 532 4 1 6 4.5 Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12 10.1038/s41467-023-40064-9
CHEMBL1171837 10798 None 104 Human Functional pAC50 = 4.8 4.8 -53 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 532 4 1 6 4.5 Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12 10.1038/s41467-023-40064-9
5039 63183 None 17 Human Functional pAC50 = 4.8 4.8 -74 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1 10.1038/s41467-023-40064-9
5039.0 63183 None 17 Human Functional pAC50 = 4.8 4.8 -74 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1 10.1038/s41467-023-40064-9
CHEMBL1790041 63183 None 17 Human Functional pAC50 = 4.8 4.8 -74 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1 10.1038/s41467-023-40064-9
DB00863 63183 None 17 Human Functional pAC50 = 4.8 4.8 -74 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1 10.1038/s41467-023-40064-9
49846579 106169 None 102 Human Functional pAC50 = 4.8 4.8 -7 2
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 867 13 3 11 8.7 CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1 10.1038/s41467-023-40064-9
CHEMBL3137309 106169 None 102 Human Functional pAC50 = 4.8 4.8 -7 2
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 867 13 3 11 8.7 CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1 10.1038/s41467-023-40064-9
3947 206395 None 53 Human Functional pAC50 = 4.8 4.8 -26 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 7 0 3 5.8 CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL87708 206395 None 53 Human Functional pAC50 = 4.8 4.8 -26 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 7 0 3 5.8 CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1 10.1038/s41467-023-40064-9
30323 62485 None 57 Human Functional pAC50 = 4.8 4.8 -8 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 527 4 5 11 1.0 COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 10.1038/s41467-023-40064-9
CHEMBL1563 62485 None 57 Human Functional pAC50 = 4.8 4.8 -8 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 527 4 5 11 1.0 COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 10.1038/s41467-023-40064-9
CHEMBL178 62485 None 57 Human Functional pAC50 = 4.8 4.8 -8 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 527 4 5 11 1.0 COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 10.1038/s41467-023-40064-9
5329102 194726 None 86 Human Functional pAC50 = 5.8 5.8 -16 37
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 398 7 3 3 3.3 CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C 10.1038/s41467-023-40064-9
CHEMBL535 194726 None 86 Human Functional pAC50 = 5.8 5.8 -16 37
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 398 7 3 3 3.3 CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C 10.1038/s41467-023-40064-9
124087 1389 None 114 Human Functional pAC50 = 4.8 4.8 -407 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
124087.0 1389 None 114 Human Functional pAC50 = 4.8 4.8 -407 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
7157 1389 None 114 Human Functional pAC50 = 4.8 4.8 -407 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
814 1389 None 114 Human Functional pAC50 = 4.8 4.8 -407 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
CHEMBL1172 1389 None 114 Human Functional pAC50 = 4.8 4.8 -407 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
DB00967 1389 None 114 Human Functional pAC50 = 4.8 4.8 -407 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
441074 19414 None 82 Human Functional pAC50 = 4.8 4.8 -13 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 4 1 4 3.2 C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12 10.1038/s41467-023-40064-9
CHEMBL1294 19414 None 82 Human Functional pAC50 = 4.8 4.8 -13 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 4 1 4 3.2 C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12 10.1038/s41467-023-40064-9
3294 2006 None 111 Human Functional pAC50 = 7.8 7.8 -18 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
71360 2006 None 111 Human Functional pAC50 = 7.8 7.8 -18 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
71360.0 2006 None 111 Human Functional pAC50 = 7.8 7.8 -18 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
87 2006 None 111 Human Functional pAC50 = 7.8 7.8 -18 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
CHEMBL14376 2006 None 111 Human Functional pAC50 = 7.8 7.8 -18 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
DB04946 2006 None 111 Human Functional pAC50 = 7.8 7.8 -18 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
2713 205271 None 82 Human Functional pAC50 = 5.8 5.8 -3 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
5353524 205271 None 82 Human Functional pAC50 = 5.8 5.8 -3 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
5360566 205271 None 82 Human Functional pAC50 = 5.8 5.8 -3 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
88536661 205271 None 82 Human Functional pAC50 = 5.8 5.8 -3 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
9552079 205271 None 82 Human Functional pAC50 = 5.8 5.8 -3 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL1330113 205271 None 82 Human Functional pAC50 = 5.8 5.8 -3 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL790 205271 None 82 Human Functional pAC50 = 5.8 5.8 -3 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
103 4153 None 61 Human Functional pAC50 = 5.7 5.7 -316 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
2875 4153 None 61 Human Functional pAC50 = 5.7 5.7 -316 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
5736 4153 None 61 Human Functional pAC50 = 5.7 5.7 -316 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
CHEMBL285802 4153 None 61 Human Functional pAC50 = 5.7 5.7 -316 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
DB09225 4153 None 61 Human Functional pAC50 = 5.7 5.7 -316 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
1201549 597 None 24 Human Functional pAC50 = 5.7 5.7 -426 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
1201549.0 597 None 24 Human Functional pAC50 = 5.7 5.7 -426 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
333 597 None 24 Human Functional pAC50 = 5.7 5.7 -426 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
7601 597 None 24 Human Functional pAC50 = 5.7 5.7 -426 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL1201203 597 None 24 Human Functional pAC50 = 5.7 5.7 -426 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL438151 597 None 24 Human Functional pAC50 = 5.7 5.7 -426 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
DB00245 597 None 24 Human Functional pAC50 = 5.7 5.7 -426 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
12574 2605 None 88 Human Functional pAC50 = 4.7 4.7 -26 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
4810 2605 None 88 Human Functional pAC50 = 4.7 4.7 -26 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
4810.0 2605 None 88 Human Functional pAC50 = 4.7 4.7 -26 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
CHEMBL19236 2605 None 88 Human Functional pAC50 = 4.7 4.7 -26 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
DB09242 2605 None 88 Human Functional pAC50 = 4.7 4.7 -26 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
5318 15576 None 49 Human Functional pAC50 = 4.7 4.7 -5 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL1200348 15576 None 49 Human Functional pAC50 = 4.7 4.7 -5 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL1221 15576 None 49 Human Functional pAC50 = 4.7 4.7 -5 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
3062316 33575 None 121 Human Functional pAC50 = 4.7 4.7 -3 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 487 7 3 9 3.3 Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1 10.1038/s41467-023-40064-9
CHEMBL1421 33575 None 121 Human Functional pAC50 = 4.7 4.7 -3 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 487 7 3 9 3.3 Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1 10.1038/s41467-023-40064-9
16363 596 None 53 Human Functional pAC50 = 5.7 5.7 -363 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
16363.0 596 None 53 Human Functional pAC50 = 5.7 5.7 -363 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
312 596 None 53 Human Functional pAC50 = 5.7 5.7 -363 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
9215 596 None 53 Human Functional pAC50 = 5.7 5.7 -363 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL297302 596 None 53 Human Functional pAC50 = 5.7 5.7 -363 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB12867 596 None 53 Human Functional pAC50 = 5.7 5.7 -363 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
135398737 958 None 93 Human Functional pAC50 = 7.7 7.7 -6 43
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
135398737.0 958 None 93 Human Functional pAC50 = 7.7 7.7 -6 43
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
38 958 None 93 Human Functional pAC50 = 7.7 7.7 -6 43
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
722 958 None 93 Human Functional pAC50 = 7.7 7.7 -6 43
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL42 958 None 93 Human Functional pAC50 = 7.7 7.7 -6 43
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
DB00363 958 None 93 Human Functional pAC50 = 7.7 7.7 -6 43
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
4418 34222 None 85 Human Functional pAC50 = 6.7 6.7 -3 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 392 7 1 5 3.4 COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1 10.1038/s41467-023-40064-9
4418.0 34222 None 85 Human Functional pAC50 = 6.7 6.7 -3 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 392 7 1 5 3.4 COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1 10.1038/s41467-023-40064-9
CHEMBL142635 34222 None 85 Human Functional pAC50 = 6.7 6.7 -3 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 392 7 1 5 3.4 COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1 10.1038/s41467-023-40064-9
DB12092 34222 None 85 Human Functional pAC50 = 6.7 6.7 -3 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 392 7 1 5 3.4 COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1 10.1038/s41467-023-40064-9
118422671 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
1887 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
189562.0 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
71301 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
71301.0 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
7246 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
9844194.0 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
CHEMBL2365658 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
CHEMBL3526436 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
CHEMBL434394 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
DB04861 2757 None 65 Human Functional pAC50 = 5.7 5.7 -660 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
214 3860 None 58 Human Functional pAC50 = 5.7 5.7 -134 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
2740 3860 None 58 Human Functional pAC50 = 5.7 5.7 -134 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
5566 3860 None 58 Human Functional pAC50 = 5.7 5.7 -134 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
5566.0 3860 None 58 Human Functional pAC50 = 5.7 5.7 -134 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
66064 3860 None 58 Human Functional pAC50 = 5.7 5.7 -134 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
CHEMBL422 3860 None 58 Human Functional pAC50 = 5.7 5.7 -134 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
DB00831 3860 None 58 Human Functional pAC50 = 5.7 5.7 -134 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
2335 11848 None 22 Human Functional pAC50 = 5.7 5.7 -14 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 10.1038/s41467-023-40064-9
8478 11848 None 22 Human Functional pAC50 = 5.7 5.7 -14 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 10.1038/s41467-023-40064-9
CHEMBL1182210 11848 None 22 Human Functional pAC50 = 5.7 5.7 -14 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 10.1038/s41467-023-40064-9
CHEMBL221753 11848 None 22 Human Functional pAC50 = 5.7 5.7 -14 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 10.1038/s41467-023-40064-9
CHEMBL2103737 78140 None 0 Human Functional pAC50 = 4.7 4.7 -3 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL None None None None 10.1038/s41467-023-40064-9
1830 2590 None 44 Human Functional pAC50 = 5.7 5.7 -58 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
207 2590 None 44 Human Functional pAC50 = 5.7 5.7 -58 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
23897 2590 None 44 Human Functional pAC50 = 5.7 5.7 -58 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
23897.0 2590 None 44 Human Functional pAC50 = 5.7 5.7 -58 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
CHEMBL460 2590 None 44 Human Functional pAC50 = 5.7 5.7 -58 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
DB01618 2590 None 44 Human Functional pAC50 = 5.7 5.7 -58 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
2393 3334 None 82 Human Functional pAC50 = 4.7 4.7 -3981 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
5078 3334 None 82 Human Functional pAC50 = 4.7 4.7 -3981 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
5078.0 3334 None 82 Human Functional pAC50 = 4.7 4.7 -3981 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
51 3334 None 82 Human Functional pAC50 = 4.7 4.7 -3981 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
CHEMBL905 3334 None 82 Human Functional pAC50 = 4.7 4.7 -3981 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
DB00953 3334 None 82 Human Functional pAC50 = 4.7 4.7 -3981 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
3236 67609 None 43 Human Functional pAC50 = 5.7 5.7 -1 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 5 0 2 3.6 CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1 10.1038/s41467-023-40064-9
CHEMBL1902981 67609 None 43 Human Functional pAC50 = 5.7 5.7 -1 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 5 0 2 3.6 CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1 10.1038/s41467-023-40064-9
1427 2013 None 54 Human Functional pAC50 = 5.7 5.7 -2691 30
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
357 2013 None 54 Human Functional pAC50 = 5.7 5.7 -2691 30
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
3696 2013 None 54 Human Functional pAC50 = 5.7 5.7 -2691 30
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
CHEMBL11 2013 None 54 Human Functional pAC50 = 5.7 5.7 -2691 30
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
DB00458 2013 None 54 Human Functional pAC50 = 5.7 5.7 -2691 30
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
2136 3095 None 30 Human Functional pAC50 = 5.7 5.7 -41 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
4768 3095 None 30 Human Functional pAC50 = 5.7 5.7 -41 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
4768.0 3095 None 30 Human Functional pAC50 = 5.7 5.7 -41 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
7268 3095 None 30 Human Functional pAC50 = 5.7 5.7 -41 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL753 3095 None 30 Human Functional pAC50 = 5.7 5.7 -41 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
DB00925 3095 None 30 Human Functional pAC50 = 5.7 5.7 -41 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
2220 3134 None 82 Human Functional pAC50 = 5.7 5.7 -758 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
27400 3134 None 82 Human Functional pAC50 = 5.7 5.7 -758 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
27400.0 3134 None 82 Human Functional pAC50 = 5.7 5.7 -758 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
93 3134 None 82 Human Functional pAC50 = 5.7 5.7 -758 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
CHEMBL294951 3134 None 82 Human Functional pAC50 = 5.7 5.7 -758 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
DB06153 3134 None 82 Human Functional pAC50 = 5.7 5.7 -758 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
4031 99313 None 28 Human Functional pAC50 = 5.7 5.7 -3 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 429 13 0 6 4.6 CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1 10.1038/s41467-023-40064-9
CHEMBL282121 99313 None 28 Human Functional pAC50 = 5.7 5.7 -3 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 429 13 0 6 4.6 CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1 10.1038/s41467-023-40064-9
16351 102730 None 47 Human Functional pAC50 = 5.7 5.7 -338 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 0 0 4 4.1 CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
16351.0 102730 None 47 Human Functional pAC50 = 5.7 5.7 -338 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 0 0 4 4.1 CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
CHEMBL304902 102730 None 47 Human Functional pAC50 = 5.7 5.7 -338 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 0 0 4 4.1 CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
DB13256 102730 None 47 Human Functional pAC50 = 5.7 5.7 -338 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 0 0 4 4.1 CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
2780 110529 None 36 Human Functional pAC50 = 5.7 5.7 -218 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 2 4 3.3 COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
2780.0 110529 None 36 Human Functional pAC50 = 5.7 5.7 -218 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 2 4 3.3 COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL325109 110529 None 36 Human Functional pAC50 = 5.7 5.7 -218 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 2 4 3.3 COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
DB13511 110529 None 36 Human Functional pAC50 = 5.7 5.7 -218 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 2 4 3.3 COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
11511120 78394 None 86 Human Functional pAC50 = 4.7 4.7 -2 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 7 2 6 5.2 COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1 10.1038/s41467-023-40064-9
CHEMBL2110732 78394 None 86 Human Functional pAC50 = 4.7 4.7 -2 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 7 2 6 5.2 COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1 10.1038/s41467-023-40064-9
107771 120248 None 49 Human Functional pAC50 = 4.7 4.7 -1 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 517 7 2 7 6.1 COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1 10.1038/s41467-023-40064-9
CHEMBL35228 120248 None 49 Human Functional pAC50 = 4.7 4.7 -1 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 517 7 2 7 6.1 COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1 10.1038/s41467-023-40064-9
3052776 206556 None 90 Human Functional pAC50 = 4.7 4.7 -2 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 171 2 1 1 1.9 C#CCN[C@@H]1CCc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL887 206556 None 90 Human Functional pAC50 = 4.7 4.7 -2 3
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 171 2 1 1 1.9 C#CCN[C@@H]1CCc2ccccc21 10.1038/s41467-023-40064-9
65709 59881 None 39 Human Functional pAC50 = 4.7 4.7 -8 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 365 8 0 5 3.3 CCN(CC)CCn1c(=O)c(Cc2ccc(OC)cc2)nc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1729803 59881 None 39 Human Functional pAC50 = 4.7 4.7 -8 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 365 8 0 5 3.3 CCN(CC)CCn1c(=O)c(Cc2ccc(OC)cc2)nc2ccccc21 10.1038/s41467-023-40064-9
25181577 78219 None 56 Human Functional pAC50 = 4.7 4.7 -7 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 574 9 2 9 5.0 CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1 10.1038/s41467-023-40064-9
CHEMBL2105695 78219 None 56 Human Functional pAC50 = 4.7 4.7 -7 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 574 9 2 9 5.0 CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1 10.1038/s41467-023-40064-9
2435 722 None 100 Human Functional pAC50 = 5.7 5.7 -7 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
2435.0 722 None 100 Human Functional pAC50 = 5.7 5.7 -7 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
395 722 None 100 Human Functional pAC50 = 5.7 5.7 -7 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
520 722 None 100 Human Functional pAC50 = 5.7 5.7 -7 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
5386 722 None 100 Human Functional pAC50 = 5.7 5.7 -7 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
CHEMBL844 722 None 100 Human Functional pAC50 = 5.7 5.7 -7 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
DB00484 722 None 100 Human Functional pAC50 = 5.7 5.7 -7 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
5440 28724 None 37 Human Functional pAC50 = 5.7 5.7 -707 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 399 6 0 5 5.0 CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
5440.0 28724 None 37 Human Functional pAC50 = 5.7 5.7 -707 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 399 6 0 5 5.0 CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
CHEMBL1378 28724 None 37 Human Functional pAC50 = 5.7 5.7 -707 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 399 6 0 5 5.0 CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
DB00372 28724 None 37 Human Functional pAC50 = 5.7 5.7 -707 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 399 6 0 5 5.0 CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
154257 178619 None 67 Human Functional pAC50 = 6.7 6.7 4 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 470 7 2 5 6.3 Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12 10.1038/s41467-023-40064-9
CHEMBL46740 178619 None 67 Human Functional pAC50 = 6.7 6.7 4 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 470 7 2 5 6.3 Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12 10.1038/s41467-023-40064-9
10219 188796 None 37 Human Functional pAC50 = 6.6 6.6 -1 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 10.1038/s41467-023-40064-9
CHEMBL493439 188796 None 37 Human Functional pAC50 = 6.6 6.6 -1 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 10.1038/s41467-023-40064-9
CHEMBL50588 188796 None 37 Human Functional pAC50 = 6.6 6.6 -1 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 10.1038/s41467-023-40064-9
1400 1957 None 70 Human Functional pAC50 = 5.6 5.6 -17 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
3658 1957 None 70 Human Functional pAC50 = 5.6 5.6 -17 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
3658.0 1957 None 70 Human Functional pAC50 = 5.6 5.6 -17 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
7199 1957 None 70 Human Functional pAC50 = 5.6 5.6 -17 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
91513 1957 None 70 Human Functional pAC50 = 5.6 5.6 -17 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL896 1957 None 70 Human Functional pAC50 = 5.6 5.6 -17 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
DB00557 1957 None 70 Human Functional pAC50 = 5.6 5.6 -17 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
2169 44847 None 35 Human Functional pAC50 = 5.6 5.6 -38 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 9 3 6 1.4 COc1ccccc1OCCNCC(O)c1ccc(C)c(S(N)(=O)=O)c1 10.1038/s41467-023-40064-9
CHEMBL152231 44847 None 35 Human Functional pAC50 = 5.6 5.6 -38 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 9 3 6 1.4 COc1ccccc1OCCNCC(O)c1ccc(C)c(S(N)(=O)=O)c1 10.1038/s41467-023-40064-9
9801 91585 None 35 Human Functional pAC50 = 5.6 5.6 -6 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 8 1 1 5.4 CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL24072 91585 None 35 Human Functional pAC50 = 5.6 5.6 -6 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 8 1 1 5.4 CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
1164 1630 None 26 Human Functional pAC50 = 4.6 4.6 -3235 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
1626 1630 None 26 Human Functional pAC50 = 4.6 4.6 -3235 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
3345 1630 None 26 Human Functional pAC50 = 4.6 4.6 -3235 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
3345.0 1630 None 26 Human Functional pAC50 = 4.6 4.6 -3235 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL596 1630 None 26 Human Functional pAC50 = 4.6 4.6 -3235 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
DB00813 1630 None 26 Human Functional pAC50 = 4.6 4.6 -3235 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
3658 4107 None 53 Human Functional pAC50 = 6.6 6.6 -12 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
517 4107 None 53 Human Functional pAC50 = 6.6 6.6 -12 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
5709 4107 None 53 Human Functional pAC50 = 6.6 6.6 -12 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
5709.0 4107 None 53 Human Functional pAC50 = 6.6 6.6 -12 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
CHEMBL312448 4107 None 53 Human Functional pAC50 = 6.6 6.6 -12 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
DB06694 4107 None 53 Human Functional pAC50 = 6.6 6.6 -12 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
5591 157531 None 90 Human Functional pAC50 = 4.6 4.6 -14 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 441 5 2 6 4.4 Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2 10.1038/s41467-023-40064-9
CHEMBL408 157531 None 90 Human Functional pAC50 = 4.6 4.6 -14 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 441 5 2 6 4.4 Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2 10.1038/s41467-023-40064-9
2267 559 None 71 Human Functional pAC50 = 5.6 5.6 -100 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
2267.0 559 None 71 Human Functional pAC50 = 5.6 5.6 -100 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
271 559 None 71 Human Functional pAC50 = 5.6 5.6 -100 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
7121 559 None 71 Human Functional pAC50 = 5.6 5.6 -100 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
CHEMBL639 559 None 71 Human Functional pAC50 = 5.6 5.6 -100 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
DB00972 559 None 71 Human Functional pAC50 = 5.6 5.6 -100 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
2318 154856 None 29 Human Functional pAC50 = 5.6 5.6 -3 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 351 7 1 3 4.1 CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL400599 154856 None 29 Human Functional pAC50 = 5.6 5.6 -3 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 351 7 1 3 4.1 CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1 10.1038/s41467-023-40064-9
2803 955 None 58 Human Functional pAC50 = 6.6 6.6 -15 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1038/s41467-023-40064-9
2803.0 955 None 58 Human Functional pAC50 = 6.6 6.6 -15 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1038/s41467-023-40064-9
516 955 None 58 Human Functional pAC50 = 6.6 6.6 -15 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1038/s41467-023-40064-9
704 955 None 58 Human Functional pAC50 = 6.6 6.6 -15 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1038/s41467-023-40064-9
CHEMBL134 955 None 58 Human Functional pAC50 = 6.6 6.6 -15 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1038/s41467-023-40064-9
DB00575 955 None 58 Human Functional pAC50 = 6.6 6.6 -15 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1038/s41467-023-40064-9
11434515 261 None 6 Human Functional pAC50 = 5.6 5.6 -13182 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
11434515.0 261 None 6 Human Functional pAC50 = 5.6 5.6 -13182 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
11519741 261 None 6 Human Functional pAC50 = 5.6 5.6 -13182 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
4484 261 None 6 Human Functional pAC50 = 5.6 5.6 -13182 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
7449 261 None 6 Human Functional pAC50 = 5.6 5.6 -13182 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
CHEMBL1194325 261 None 6 Human Functional pAC50 = 5.6 5.6 -13182 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
DB08897 261 None 6 Human Functional pAC50 = 5.6 5.6 -13182 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
2131 57407 None 25 Human Functional pAC50 = 5.6 5.6 -3 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 536 14 2 2 4.6 CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl 10.1038/s41467-023-40064-9
CHEMBL1652 57407 None 25 Human Functional pAC50 = 5.6 5.6 -3 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 536 14 2 2 4.6 CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl 10.1038/s41467-023-40064-9
54682461 84686 None 62 Human Functional pAC50 = 4.6 4.6 -5 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 602 11 2 6 7.3 CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1 10.1038/s41467-023-40064-9
CHEMBL222559 84686 None 62 Human Functional pAC50 = 4.6 4.6 -5 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 602 11 2 6 7.3 CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1 10.1038/s41467-023-40064-9
1343 1889 None 62 Human Functional pAC50 = 5.6 5.6 -11 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
3519 1889 None 62 Human Functional pAC50 = 5.6 5.6 -11 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
3519.0 1889 None 62 Human Functional pAC50 = 5.6 5.6 -11 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
522 1889 None 62 Human Functional pAC50 = 5.6 5.6 -11 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
CHEMBL862 1889 None 62 Human Functional pAC50 = 5.6 5.6 -11 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
DB01018 1889 None 62 Human Functional pAC50 = 5.6 5.6 -11 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
25102847 78221 None 93 Human Functional pAC50 = 4.6 4.6 -21 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 501 8 2 6 5.5 COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC 10.1038/s41467-023-40064-9
CHEMBL2105717 78221 None 93 Human Functional pAC50 = 4.6 4.6 -21 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 501 8 2 6 5.5 COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC 10.1038/s41467-023-40064-9
65700 78260 None 28 Human Functional pAC50 = 4.6 4.6 -77 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 238 1 1 2 3.3 CNC1Cc2ccccc2N(C)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL2106919 78260 None 28 Human Functional pAC50 = 4.6 4.6 -77 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 238 1 1 2 3.3 CNC1Cc2ccccc2N(C)c2ccccc21 10.1038/s41467-023-40064-9
2333 142335 None 97 Human Functional pAC50 = 4.6 4.6 -22 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 422 3 1 3 5.5 CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1 10.1038/s41467-023-40064-9
CHEMBL388590 142335 None 97 Human Functional pAC50 = 4.6 4.6 -22 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 422 3 1 3 5.5 CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1 10.1038/s41467-023-40064-9
10531 1420 None 21 Human Functional pAC50 = 7.6 7.6 -19 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
10531.0 1420 None 21 Human Functional pAC50 = 7.6 7.6 -19 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
121 1420 None 21 Human Functional pAC50 = 7.6 7.6 -19 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
888 1420 None 21 Human Functional pAC50 = 7.6 7.6 -19 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
CHEMBL1732 1420 None 21 Human Functional pAC50 = 7.6 7.6 -19 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
DB00320 1420 None 21 Human Functional pAC50 = 7.6 7.6 -19 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
1960 2857 None 67 Human Functional pAC50 = 6.6 6.6 -11 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
439260 2857 None 67 Human Functional pAC50 = 6.6 6.6 -11 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
439260.0 2857 None 67 Human Functional pAC50 = 6.6 6.6 -11 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
505 2857 None 67 Human Functional pAC50 = 6.6 6.6 -11 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
CHEMBL1437 2857 None 67 Human Functional pAC50 = 6.6 6.6 -11 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
DB00368 2857 None 67 Human Functional pAC50 = 6.6 6.6 -11 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5282136 60284 None 73 Human Functional pAC50 = 5.6 5.6 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 11 1 6 2.7 O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1 10.1038/s41467-023-40064-9
5282136.0 60284 None 73 Human Functional pAC50 = 5.6 5.6 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 11 1 6 2.7 O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1 10.1038/s41467-023-40064-9
CHEMBL1742461 60284 None 73 Human Functional pAC50 = 5.6 5.6 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 11 1 6 2.7 O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1 10.1038/s41467-023-40064-9
DB12770 60284 None 73 Human Functional pAC50 = 5.6 5.6 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 11 1 6 2.7 O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1 10.1038/s41467-023-40064-9
9429 202133 None 58 Human Functional pAC50 = 5.6 5.6 -275 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 6 0 6 3.2 CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1 10.1038/s41467-023-40064-9
9429.0 202133 None 58 Human Functional pAC50 = 5.6 5.6 -275 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 6 0 6 3.2 CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1 10.1038/s41467-023-40064-9
CHEMBL609109 202133 None 58 Human Functional pAC50 = 5.6 5.6 -275 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 6 0 6 3.2 CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1 10.1038/s41467-023-40064-9
DB01622 202133 None 58 Human Functional pAC50 = 5.6 5.6 -275 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 6 0 6 3.2 CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1 10.1038/s41467-023-40064-9
260 3869 None 54 Human Functional pAC50 = 4.6 4.6 -7 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
2775 3869 None 54 Human Functional pAC50 = 4.6 4.6 -7 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
656665 3869 None 54 Human Functional pAC50 = 4.6 4.6 -7 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL56564 3869 None 54 Human Functional pAC50 = 4.6 4.6 -7 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB11699 3869 None 54 Human Functional pAC50 = 4.6 4.6 -7 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
60065 84369 None 6 Human Functional pAC50 = 4.6 4.6 -17 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 505 7 1 8 4.2 COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1 10.1038/s41467-023-40064-9
CHEMBL2218858 84369 None 6 Human Functional pAC50 = 4.6 4.6 -17 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 505 7 1 8 4.2 COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1 10.1038/s41467-023-40064-9
CHEMBL4743867 214033 None 14 Human Functional pAC50 = 6.6 6.6 -89 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL None None None OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1 10.1038/s41467-023-40064-9
1028 291 None 71 Human Functional pAC50 = 5.6 5.6 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
139148732 291 None 71 Human Functional pAC50 = 5.6 5.6 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
479 291 None 71 Human Functional pAC50 = 5.6 5.6 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5816 291 None 71 Human Functional pAC50 = 5.6 5.6 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5816.0 291 None 71 Human Functional pAC50 = 5.6 5.6 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
CHEMBL679 291 None 71 Human Functional pAC50 = 5.6 5.6 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
DB00668 291 None 71 Human Functional pAC50 = 5.6 5.6 -44 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
3151 1462 None 97 Human Functional pAC50 = 5.6 5.6 -602 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
3151.0 1462 None 97 Human Functional pAC50 = 5.6 5.6 -602 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
945 1462 None 97 Human Functional pAC50 = 5.6 5.6 -602 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
965 1462 None 97 Human Functional pAC50 = 5.6 5.6 -602 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL219916 1462 None 97 Human Functional pAC50 = 5.6 5.6 -602 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB01184 1462 None 97 Human Functional pAC50 = 5.6 5.6 -602 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
47319 26464 None 35 Human Functional pAC50 = 5.6 5.6 1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 929 24 0 12 8.1 COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC 10.1038/s41467-023-40064-9
CHEMBL1360 26464 None 35 Human Functional pAC50 = 5.6 5.6 1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 929 24 0 12 8.1 COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC 10.1038/s41467-023-40064-9
4846 27987 None 53 Human Functional pAC50 = 5.6 5.6 -1 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 308 1 2 6 2.2 O=C(O)c1cc(O)c2c3nc4ccccc4oc-3cc(=O)c2n1 10.1038/s41467-023-40064-9
CHEMBL1372341 27987 None 53 Human Functional pAC50 = 5.6 5.6 -1 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 308 1 2 6 2.2 O=C(O)c1cc(O)c2c3nc4ccccc4oc-3cc(=O)c2n1 10.1038/s41467-023-40064-9
5639 98895 None 75 Human Functional pAC50 = 5.6 5.6 -53 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 7 1 8 0.7 COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1 10.1038/s41467-023-40064-9
CHEMBL279229 98895 None 75 Human Functional pAC50 = 5.6 5.6 -53 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 7 1 8 0.7 COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1 10.1038/s41467-023-40064-9
2179 167518 None 76 Human Functional pAC50 = 5.6 5.6 -2 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 393 5 2 5 4.5 COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12 10.1038/s41467-023-40064-9
CHEMBL1256655 167518 None 76 Human Functional pAC50 = 5.6 5.6 -2 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 393 5 2 5 4.5 COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12 10.1038/s41467-023-40064-9
CHEMBL43 167518 None 76 Human Functional pAC50 = 5.6 5.6 -2 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 393 5 2 5 4.5 COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12 10.1038/s41467-023-40064-9
180 401 None 56 Human Functional pAC50 = 6.5 6.5 -281 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
200 401 None 56 Human Functional pAC50 = 6.5 6.5 -281 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
2160 401 None 56 Human Functional pAC50 = 6.5 6.5 -281 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
2160.0 401 None 56 Human Functional pAC50 = 6.5 6.5 -281 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
CHEMBL629 401 None 56 Human Functional pAC50 = 6.5 6.5 -281 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
DB00321 401 None 56 Human Functional pAC50 = 6.5 6.5 -281 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
26757 207978 None 31 Human Functional pAC50 = 5.5 5.5 -7 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 187 4 0 1 2.2 C#CCN(C)[C@H](C)Cc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL972 207978 None 31 Human Functional pAC50 = 5.5 5.5 -7 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 187 4 0 1 2.2 C#CCN(C)[C@H](C)Cc1ccccc1 10.1038/s41467-023-40064-9
154417 23181 None 60 Human Functional pAC50 = 4.5 4.5 -7079 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@H](CO)c1ccccc1)C2 10.1038/s41467-023-40064-9
CHEMBL1331216 23181 None 60 Human Functional pAC50 = 4.5 4.5 -7079 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@H](CO)c1ccccc1)C2 10.1038/s41467-023-40064-9
2601 3780 None 33 Human Functional pAC50 = 8.5 8.5 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
443951 3780 None 33 Human Functional pAC50 = 8.5 8.5 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
56 3780 None 33 Human Functional pAC50 = 8.5 8.5 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
CHEMBL73151 3780 None 33 Human Functional pAC50 = 8.5 8.5 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
DB13399 3780 None 33 Human Functional pAC50 = 8.5 8.5 1 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
102 4127 None 48 Human Functional pAC50 = 8.5 8.5 -2 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
3659 4127 None 48 Human Functional pAC50 = 8.5 8.5 -2 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
8969 4127 None 48 Human Functional pAC50 = 8.5 8.5 -2 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
8969.0 4127 None 48 Human Functional pAC50 = 8.5 8.5 -2 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
CHEMBL15245 4127 None 48 Human Functional pAC50 = 8.5 8.5 -2 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
DB01392 4127 None 48 Human Functional pAC50 = 8.5 8.5 -2 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
37 778 None 60 Human Functional pAC50 = 6.5 6.5 -63 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
460 778 None 60 Human Functional pAC50 = 6.5 6.5 -63 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
54746 778 None 60 Human Functional pAC50 = 6.5 6.5 -63 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
54746.0 778 None 60 Human Functional pAC50 = 6.5 6.5 -63 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
CHEMBL1201087 778 None 60 Human Functional pAC50 = 6.5 6.5 -63 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
DB00248 778 None 60 Human Functional pAC50 = 6.5 6.5 -63 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
129211 3749 None 78 Human Functional pAC50 = 6.5 6.5 -660 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
129211.0 3749 None 78 Human Functional pAC50 = 6.5 6.5 -660 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
2562 3749 None 78 Human Functional pAC50 = 6.5 6.5 -660 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
488 3749 None 78 Human Functional pAC50 = 6.5 6.5 -660 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
CHEMBL836 3749 None 78 Human Functional pAC50 = 6.5 6.5 -660 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
DB00706 3749 None 78 Human Functional pAC50 = 6.5 6.5 -660 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
3036780.0 107531 None 20 Human Functional pAC50 = 6.5 6.5 -1513 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
46780481 107531 None 20 Human Functional pAC50 = 6.5 6.5 -1513 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
9903970 107531 None 20 Human Functional pAC50 = 6.5 6.5 -1513 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
9903970.0 107531 None 20 Human Functional pAC50 = 6.5 6.5 -1513 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
CHEMBL3187365 107531 None 20 Human Functional pAC50 = 6.5 6.5 -1513 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
CHEMBL3544974 107531 None 20 Human Functional pAC50 = 6.5 6.5 -1513 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
CHEMBL504548 107531 None 20 Human Functional pAC50 = 6.5 6.5 -1513 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
DB06216 107531 None 20 Human Functional pAC50 = 6.5 6.5 -1513 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
1782 2518 None 84 Human Functional pAC50 = 5.5 5.5 -144 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
241 2518 None 84 Human Functional pAC50 = 5.5 5.5 -144 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
4168 2518 None 84 Human Functional pAC50 = 5.5 5.5 -144 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
4168.0 2518 None 84 Human Functional pAC50 = 5.5 5.5 -144 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
CHEMBL86 2518 None 84 Human Functional pAC50 = 5.5 5.5 -144 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
DB01233 2518 None 84 Human Functional pAC50 = 5.5 5.5 -144 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
2286 3183 None 51 Human Functional pAC50 = 5.5 5.5 -602 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
4927 3183 None 51 Human Functional pAC50 = 5.5 5.5 -602 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
4927.0 3183 None 51 Human Functional pAC50 = 5.5 5.5 -602 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
7282 3183 None 51 Human Functional pAC50 = 5.5 5.5 -602 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
CHEMBL643 3183 None 51 Human Functional pAC50 = 5.5 5.5 -602 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
DB01069 3183 None 51 Human Functional pAC50 = 5.5 5.5 -602 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
44112 121290 None 48 Human Functional pAC50 = 5.5 5.5 -269 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 7 2 4 4.5 Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 10.1038/s41467-023-40064-9
CHEMBL357995 121290 None 48 Human Functional pAC50 = 5.5 5.5 -269 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 7 2 4 4.5 Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 10.1038/s41467-023-40064-9
2726 919 None 68 Human Functional pAC50 = 5.5 5.5 -501 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
2726.0 919 None 68 Human Functional pAC50 = 5.5 5.5 -501 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
621 919 None 68 Human Functional pAC50 = 5.5 5.5 -501 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
83 919 None 68 Human Functional pAC50 = 5.5 5.5 -501 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
CHEMBL71 919 None 68 Human Functional pAC50 = 5.5 5.5 -501 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
DB00477 919 None 68 Human Functional pAC50 = 5.5 5.5 -501 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
191 403 None 98 Human Functional pAC50 = 5.5 5.5 -524 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
201 403 None 98 Human Functional pAC50 = 5.5 5.5 -524 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
2170 403 None 98 Human Functional pAC50 = 5.5 5.5 -524 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
2170.0 403 None 98 Human Functional pAC50 = 5.5 5.5 -524 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
CHEMBL1113 403 None 98 Human Functional pAC50 = 5.5 5.5 -524 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
DB00543 403 None 98 Human Functional pAC50 = 5.5 5.5 -524 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
228 445 None 28 Human Functional pAC50 = 5.5 5.5 -758 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
33 445 None 28 Human Functional pAC50 = 5.5 5.5 -758 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
6005 445 None 28 Human Functional pAC50 = 5.5 5.5 -758 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
6005.0 445 None 28 Human Functional pAC50 = 5.5 5.5 -758 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
CHEMBL53 445 None 28 Human Functional pAC50 = 5.5 5.5 -758 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
DB00714 445 None 28 Human Functional pAC50 = 5.5 5.5 -758 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
4413 98073 None 57 Human Functional pAC50 = 5.5 5.5 1 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 347 4 5 4 2.6 N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1 10.1038/s41467-023-40064-9
CHEMBL273264 98073 None 57 Human Functional pAC50 = 5.5 5.5 1 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 347 4 5 4 2.6 N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1 10.1038/s41467-023-40064-9
60753 194684 None 40 Human Functional pAC50 = 5.5 5.5 1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 384 14 2 4 4.2 CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1 10.1038/s41467-023-40064-9
CHEMBL533 194684 None 40 Human Functional pAC50 = 5.5 5.5 1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 384 14 2 4 4.2 CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1 10.1038/s41467-023-40064-9
11079 2733 None 63 Human Functional pAC50 = 6.5 6.5 -13 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
3369 2733 None 63 Human Functional pAC50 = 6.5 6.5 -13 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
4436 2733 None 63 Human Functional pAC50 = 6.5 6.5 -13 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
4436.0 2733 None 63 Human Functional pAC50 = 6.5 6.5 -13 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
5509 2733 None 63 Human Functional pAC50 = 6.5 6.5 -13 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL761 2733 None 63 Human Functional pAC50 = 6.5 6.5 -13 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
DB06711 2733 None 63 Human Functional pAC50 = 6.5 6.5 -13 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
2865 4143 None 73 Human Functional pAC50 = 6.5 6.5 -138 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
59 4143 None 73 Human Functional pAC50 = 6.5 6.5 -138 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
60854 4143 None 73 Human Functional pAC50 = 6.5 6.5 -138 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
60854.0 4143 None 73 Human Functional pAC50 = 6.5 6.5 -138 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL708 4143 None 73 Human Functional pAC50 = 6.5 6.5 -138 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
DB00246 4143 None 73 Human Functional pAC50 = 6.5 6.5 -138 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
2351 4300 None 49 Human Functional pAC50 = 5.5 5.5 -1 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 366 10 0 3 4.8 CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1 10.1038/s41467-023-40064-9
CHEMBL1008 4300 None 49 Human Functional pAC50 = 5.5 5.5 -1 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 366 10 0 3 4.8 CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1 10.1038/s41467-023-40064-9
CHEMBL1257078 4300 None 49 Human Functional pAC50 = 5.5 5.5 -1 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 366 10 0 3 4.8 CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1 10.1038/s41467-023-40064-9
3157 1470 None 71 Human Functional pAC50 = 6.5 6.5 -446 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
3157.0 1470 None 71 Human Functional pAC50 = 6.5 6.5 -446 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
7170 1470 None 71 Human Functional pAC50 = 6.5 6.5 -446 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
954 1470 None 71 Human Functional pAC50 = 6.5 6.5 -446 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
CHEMBL707 1470 None 71 Human Functional pAC50 = 6.5 6.5 -446 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
DB00590 1470 None 71 Human Functional pAC50 = 6.5 6.5 -446 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
100 3805 None 58 Human Functional pAC50 = 5.5 5.5 -162 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
2637 3805 None 58 Human Functional pAC50 = 5.5 5.5 -162 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
5452 3805 None 58 Human Functional pAC50 = 5.5 5.5 -162 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
CHEMBL479 3805 None 58 Human Functional pAC50 = 5.5 5.5 -162 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
DB00679 3805 None 58 Human Functional pAC50 = 5.5 5.5 -162 38
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
3584 3777 None 64 Human Functional pAC50 = 6.5 6.5 -1548 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
5401 3777 None 64 Human Functional pAC50 = 6.5 6.5 -1548 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
5401.0 3777 None 64 Human Functional pAC50 = 6.5 6.5 -1548 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
7302 3777 None 64 Human Functional pAC50 = 6.5 6.5 -1548 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
CHEMBL611 3777 None 64 Human Functional pAC50 = 6.5 6.5 -1548 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
DB01162 3777 None 64 Human Functional pAC50 = 6.5 6.5 -1548 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
213 3853 None 55 Human Functional pAC50 = 6.5 6.5 -107 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
2717 3853 None 55 Human Functional pAC50 = 6.5 6.5 -107 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
5533 3853 None 55 Human Functional pAC50 = 6.5 6.5 -107 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
5533.0 3853 None 55 Human Functional pAC50 = 6.5 6.5 -107 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
CHEMBL621 3853 None 55 Human Functional pAC50 = 6.5 6.5 -107 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
DB00656 3853 None 55 Human Functional pAC50 = 6.5 6.5 -107 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
134 2514 None 24 Human Functional pAC50 = 5.5 5.5 -1819 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
1775 2514 None 24 Human Functional pAC50 = 5.5 5.5 -1819 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
9681 2514 None 24 Human Functional pAC50 = 5.5 5.5 -1819 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
9681.0 2514 None 24 Human Functional pAC50 = 5.5 5.5 -1819 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
CHEMBL1065 2514 None 24 Human Functional pAC50 = 5.5 5.5 -1819 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
DB00247 2514 None 24 Human Functional pAC50 = 5.5 5.5 -1819 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
11658860 2344 None 51 Human Functional pAC50 = 5.4 5.4 -316 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
2941 2344 None 51 Human Functional pAC50 = 5.4 5.4 -316 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
4374 2344 None 51 Human Functional pAC50 = 5.4 5.4 -316 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
CHEMBL360328 2344 None 51 Human Functional pAC50 = 5.4 5.4 -316 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
DB04871 2344 None 51 Human Functional pAC50 = 5.4 5.4 -316 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
2470 3653 None 50 Human Functional pAC50 = 6.4 6.4 -6165 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
3300 3653 None 50 Human Functional pAC50 = 6.4 6.4 -6165 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
5265 3653 None 50 Human Functional pAC50 = 6.4 6.4 -6165 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
99 3653 None 50 Human Functional pAC50 = 6.4 6.4 -6165 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL267930 3653 None 50 Human Functional pAC50 = 6.4 6.4 -6165 23
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
19675 51670 None 43 Human Functional pAC50 = 6.4 6.4 -28 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 7 1 5 5.0 CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
CHEMBL1584 51670 None 43 Human Functional pAC50 = 6.4 6.4 -28 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 7 1 5 5.0 CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
4756 16649 None 50 Human Functional pAC50 = 5.4 5.4 -1 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 213 2 2 5 2.7 Nc1ccc(/N=N/c2ccccc2)c(N)n1 10.1038/s41467-023-40064-9
CHEMBL1201022 16649 None 50 Human Functional pAC50 = 5.4 5.4 -1 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 213 2 2 5 2.7 Nc1ccc(/N=N/c2ccccc2)c(N)n1 10.1038/s41467-023-40064-9
CHEMBL1242 16649 None 50 Human Functional pAC50 = 5.4 5.4 -1 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 213 2 2 5 2.7 Nc1ccc(/N=N/c2ccccc2)c(N)n1 10.1038/s41467-023-40064-9
5210 33338 None 48 Human Functional pAC50 = 5.4 5.4 -1 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
CHEMBL1200765 33338 None 48 Human Functional pAC50 = 5.4 5.4 -1 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
CHEMBL1419 33338 None 48 Human Functional pAC50 = 5.4 5.4 -1 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
2895 203592 None 41 Human Functional pAC50 = 5.4 5.4 -186 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 275 3 0 1 4.6 CN(C)CCC=C1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
2895.0 203592 None 41 Human Functional pAC50 = 5.4 5.4 -186 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 275 3 0 1 4.6 CN(C)CCC=C1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL669 203592 None 41 Human Functional pAC50 = 5.4 5.4 -186 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 275 3 0 1 4.6 CN(C)CCC=C1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
DB00924 203592 None 41 Human Functional pAC50 = 5.4 5.4 -186 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 275 3 0 1 4.6 CN(C)CCC=C1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
68617 205527 None 62 Human Functional pAC50 = 5.4 5.4 -12 30
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1709 205527 None 62 Human Functional pAC50 = 5.4 5.4 -12 30
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL809 205527 None 62 Human Functional pAC50 = 5.4 5.4 -12 30
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 10.1038/s41467-023-40064-9
2407 3372 None 76 Human Functional pAC50 = 6.4 6.4 -120 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
59227 3372 None 76 Human Functional pAC50 = 6.4 6.4 -120 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
59227.0 3372 None 76 Human Functional pAC50 = 6.4 6.4 -120 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
941 3372 None 76 Human Functional pAC50 = 6.4 6.4 -120 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
CHEMBL1303 3372 None 76 Human Functional pAC50 = 6.4 6.4 -120 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
DB05271 3372 None 76 Human Functional pAC50 = 6.4 6.4 -120 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
6337614 12996 None 54 Human Functional pAC50 = 5.4 5.4 -3 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 296 1 0 2 2.7 O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2 10.1038/s41467-023-40064-9
CHEMBL1189679 12996 None 54 Human Functional pAC50 = 5.4 5.4 -3 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 296 1 0 2 2.7 O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2 10.1038/s41467-023-40064-9
319 1324 None 44 Human Functional pAC50 = 6.4 6.4 -407 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
321 1324 None 44 Human Functional pAC50 = 6.4 6.4 -407 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
444031 1324 None 44 Human Functional pAC50 = 6.4 6.4 -407 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
444031.0 1324 None 44 Human Functional pAC50 = 6.4 6.4 -407 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
784 1324 None 44 Human Functional pAC50 = 6.4 6.4 -407 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
CHEMBL1346 1324 None 44 Human Functional pAC50 = 6.4 6.4 -407 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
DB00496 1324 None 44 Human Functional pAC50 = 6.4 6.4 -407 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
1593 2340 None 66 Human Functional pAC50 = 6.4 6.4 -1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
30668 2340 None 66 Human Functional pAC50 = 6.4 6.4 -1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
30668.0 2340 None 66 Human Functional pAC50 = 6.4 6.4 -1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
9868 2340 None 66 Human Functional pAC50 = 6.4 6.4 -1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
CHEMBL17860 2340 None 66 Human Functional pAC50 = 6.4 6.4 -1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
DB04948 2340 None 66 Human Functional pAC50 = 6.4 6.4 -1 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
3149 12614 None 15 Human Functional pAC50 = 5.4 5.4 -11 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 334 15 0 1 6.1 CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL1187011 12614 None 15 Human Functional pAC50 = 5.4 5.4 -11 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 334 15 0 1 6.1 CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1 10.1038/s41467-023-40064-9
3949 100614 None 50 Human Functional pAC50 = 5.4 5.4 -4 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 468 8 0 5 4.9 COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC 10.1038/s41467-023-40064-9
CHEMBL29188 100614 None 50 Human Functional pAC50 = 5.4 5.4 -4 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 468 8 0 5 4.9 COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC 10.1038/s41467-023-40064-9
2520 204008 None 70 Human Functional pAC50 = 5.4 5.4 -38 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 454 13 0 6 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
CHEMBL1280 204008 None 70 Human Functional pAC50 = 5.4 5.4 -38 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 454 13 0 6 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
CHEMBL6966 204008 None 70 Human Functional pAC50 = 5.4 5.4 -38 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 454 13 0 6 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
5453 203619 None 102 Human Functional pAC50 = 5.4 5.4 -100 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 189 3 0 1 0.2 S=P(N1CC1)(N1CC1)N1CC1 10.1038/s41467-023-40064-9
CHEMBL671 203619 None 102 Human Functional pAC50 = 5.4 5.4 -100 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 189 3 0 1 0.2 S=P(N1CC1)(N1CC1)N1CC1 10.1038/s41467-023-40064-9
2398 954 None 62 Human Functional pAC50 = 5.4 5.4 -1819 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
2801 954 None 62 Human Functional pAC50 = 5.4 5.4 -1819 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
2801.0 954 None 62 Human Functional pAC50 = 5.4 5.4 -1819 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
701 954 None 62 Human Functional pAC50 = 5.4 5.4 -1819 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
CHEMBL415 954 None 62 Human Functional pAC50 = 5.4 5.4 -1819 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
DB01242 954 None 62 Human Functional pAC50 = 5.4 5.4 -1819 36
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
4940 14470 None 35 Human Functional pAC50 = 5.4 5.4 -151 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 5 0 4 4.8 CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2 10.1038/s41467-023-40064-9
CHEMBL1201210 14470 None 35 Human Functional pAC50 = 5.4 5.4 -151 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 5 0 4 4.8 CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2 10.1038/s41467-023-40064-9
5357 98736 None 41 Human Functional pAC50 = 5.4 5.4 -407 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 7 1 5 1.7 CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC 10.1038/s41467-023-40064-9
CHEMBL277945 98736 None 41 Human Functional pAC50 = 5.4 5.4 -407 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 7 1 5 1.7 CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC 10.1038/s41467-023-40064-9
4452 2762 None 19 Human Functional pAC50 = 6.3 6.3 -1513 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 6 2 4 3.8 COc1cc(NC)c(cc1C(=O)NC1CCN(C1C)Cc1ccccc1)Cl 10.1038/s41467-023-40064-9
983 2762 None 19 Human Functional pAC50 = 6.3 6.3 -1513 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 6 2 4 3.8 COc1cc(NC)c(cc1C(=O)NC1CCN(C1C)Cc1ccccc1)Cl 10.1038/s41467-023-40064-9
CHEMBL20734 2762 None 19 Human Functional pAC50 = 6.3 6.3 -1513 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 6 2 4 3.8 COc1cc(NC)c(cc1C(=O)NC1CCN(C1C)Cc1ccccc1)Cl 10.1038/s41467-023-40064-9
209 3057 None 97 Human Functional pAC50 = 6.3 6.3 -199 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
2113 3057 None 97 Human Functional pAC50 = 6.3 6.3 -199 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
4748 3057 None 97 Human Functional pAC50 = 6.3 6.3 -199 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
4748.0 3057 None 97 Human Functional pAC50 = 6.3 6.3 -199 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
CHEMBL567 3057 None 97 Human Functional pAC50 = 6.3 6.3 -199 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
DB00850 3057 None 97 Human Functional pAC50 = 6.3 6.3 -199 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
2351 3286 None 64 Human Functional pAC50 = 6.3 6.3 -93 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
2820 3286 None 64 Human Functional pAC50 = 6.3 6.3 -93 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
5035 3286 None 64 Human Functional pAC50 = 6.3 6.3 -93 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
CHEMBL81 3286 None 64 Human Functional pAC50 = 6.3 6.3 -93 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
DB00481 3286 None 64 Human Functional pAC50 = 6.3 6.3 -93 27
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
16362 3125 None 71 Human Functional pAC50 = 6.3 6.3 -52 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
16362.0 3125 None 71 Human Functional pAC50 = 6.3 6.3 -52 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
2172 3125 None 71 Human Functional pAC50 = 6.3 6.3 -52 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
90 3125 None 71 Human Functional pAC50 = 6.3 6.3 -52 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL1423 3125 None 71 Human Functional pAC50 = 6.3 6.3 -52 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB01100 3125 None 71 Human Functional pAC50 = 6.3 6.3 -52 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
47641 202871 None 32 Human Functional pAC50 = 5.3 5.3 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 5 0 1 5.0 CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12 10.1038/s41467-023-40064-9
CHEMBL626 202871 None 32 Human Functional pAC50 = 5.3 5.3 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 5 0 1 5.0 CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12 10.1038/s41467-023-40064-9
2165 203783 None 71 Human Functional pAC50 = 5.3 5.3 -3 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 355 6 2 4 5.2 CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O 10.1038/s41467-023-40064-9
3647519 203783 None 71 Human Functional pAC50 = 5.3 5.3 -3 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 355 6 2 4 5.2 CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O 10.1038/s41467-023-40064-9
CHEMBL682 203783 None 71 Human Functional pAC50 = 5.3 5.3 -3 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 355 6 2 4 5.2 CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O 10.1038/s41467-023-40064-9
1353 1911 None 93 Human Functional pAC50 = 5.3 5.3 -1023 39
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
3559 1911 None 93 Human Functional pAC50 = 5.3 5.3 -1023 39
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
3559.0 1911 None 93 Human Functional pAC50 = 5.3 5.3 -1023 39
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
86 1911 None 93 Human Functional pAC50 = 5.3 5.3 -1023 39
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
CHEMBL54 1911 None 93 Human Functional pAC50 = 5.3 5.3 -1023 39
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
DB00502 1911 None 93 Human Functional pAC50 = 5.3 5.3 -1023 39
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
1212 1662 None 50 Human Functional pAC50 = 6.3 6.3 -138 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
204 1662 None 50 Human Functional pAC50 = 6.3 6.3 -138 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
3372 1662 None 50 Human Functional pAC50 = 6.3 6.3 -138 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
3372.0 1662 None 50 Human Functional pAC50 = 6.3 6.3 -138 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
CHEMBL726 1662 None 50 Human Functional pAC50 = 6.3 6.3 -138 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
DB00623 1662 None 50 Human Functional pAC50 = 6.3 6.3 -138 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
135 2532 None 43 Human Functional pAC50 = 7.3 7.3 -34 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
1796 2532 None 43 Human Functional pAC50 = 7.3 7.3 -34 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
4184 2532 None 43 Human Functional pAC50 = 7.3 7.3 -34 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
4184.0 2532 None 43 Human Functional pAC50 = 7.3 7.3 -34 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
CHEMBL6437 2532 None 43 Human Functional pAC50 = 7.3 7.3 -34 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
DB06148 2532 None 43 Human Functional pAC50 = 7.3 7.3 -34 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
2695 3841 None 81 Human Functional pAC50 = 5.3 5.3 -6 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
5504 3841 None 81 Human Functional pAC50 = 5.3 5.3 -6 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
7310 3841 None 81 Human Functional pAC50 = 5.3 5.3 -6 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
CHEMBL770 3841 None 81 Human Functional pAC50 = 5.3 5.3 -6 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
DB00797 3841 None 81 Human Functional pAC50 = 5.3 5.3 -6 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
240 944 None 43 Human Functional pAC50 = 5.3 5.3 -371 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
2769 944 None 43 Human Functional pAC50 = 5.3 5.3 -371 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
44279790 944 None 43 Human Functional pAC50 = 5.3 5.3 -371 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
660 944 None 43 Human Functional pAC50 = 5.3 5.3 -371 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
CHEMBL1729 944 None 43 Human Functional pAC50 = 5.3 5.3 -371 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
CHEMBL560739 944 None 43 Human Functional pAC50 = 5.3 5.3 -371 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
DB00604 944 None 43 Human Functional pAC50 = 5.3 5.3 -371 22
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
2995 204405 None 53 Human Functional pAC50 = 5.3 5.3 -1905 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
2995.0 204405 None 53 Human Functional pAC50 = 5.3 5.3 -1905 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1696 204405 None 53 Human Functional pAC50 = 5.3 5.3 -1905 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL72 204405 None 53 Human Functional pAC50 = 5.3 5.3 -1905 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
DB01151 204405 None 53 Human Functional pAC50 = 5.3 5.3 -1905 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
26987 949 None 33 Human Functional pAC50 = 6.3 6.3 -190 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
26987.0 949 None 33 Human Functional pAC50 = 6.3 6.3 -190 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
6063 949 None 33 Human Functional pAC50 = 6.3 6.3 -190 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
671 949 None 33 Human Functional pAC50 = 6.3 6.3 -190 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
CHEMBL1626 949 None 33 Human Functional pAC50 = 6.3 6.3 -190 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
DB00283 949 None 33 Human Functional pAC50 = 6.3 6.3 -190 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
20628 96548 None 28 Human Functional pAC50 = 5.3 5.3 -13 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 6 1 5 3.7 CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12 10.1038/s41467-023-40064-9
CHEMBL26291 96548 None 28 Human Functional pAC50 = 5.3 5.3 -13 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 6 1 5 3.7 CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12 10.1038/s41467-023-40064-9
2389 3331 None 118 Human Functional pAC50 = 7.3 7.3 -23 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
5073 3331 None 118 Human Functional pAC50 = 7.3 7.3 -23 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
5073.0 3331 None 118 Human Functional pAC50 = 7.3 7.3 -23 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
96 3331 None 118 Human Functional pAC50 = 7.3 7.3 -23 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
CHEMBL85 3331 None 118 Human Functional pAC50 = 7.3 7.3 -23 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
DB00734 3331 None 118 Human Functional pAC50 = 7.3 7.3 -23 29
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
2472 67284 None 48 Human Functional pAC50 = 6.3 6.3 3 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 1 7 2.1 CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1 10.1038/s41467-023-40064-9
CHEMBL188185 67284 None 48 Human Functional pAC50 = 6.3 6.3 3 4
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 1 7 2.1 CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1 10.1038/s41467-023-40064-9
4034 55822 None 55 Human Functional pAC50 = 5.3 5.3 -13 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 390 5 0 2 5.6 Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1 10.1038/s41467-023-40064-9
4034.0 55822 None 55 Human Functional pAC50 = 5.3 5.3 -13 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 390 5 0 2 5.6 Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1 10.1038/s41467-023-40064-9
CHEMBL1623 55822 None 55 Human Functional pAC50 = 5.3 5.3 -13 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 390 5 0 2 5.6 Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1 10.1038/s41467-023-40064-9
DB00737 55822 None 55 Human Functional pAC50 = 5.3 5.3 -13 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 390 5 0 2 5.6 Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1 10.1038/s41467-023-40064-9
54477 84653 None 36 Human Functional pAC50 = 5.3 5.3 -104 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 6 1 4 2.7 CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC 10.1038/s41467-023-40064-9
CHEMBL22242 84653 None 36 Human Functional pAC50 = 5.3 5.3 -104 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 6 1 4 2.7 CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC 10.1038/s41467-023-40064-9
1971 2866 None 38 Human Functional pAC50 = 6.3 6.3 -467 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
2404 2866 None 38 Human Functional pAC50 = 6.3 6.3 -467 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
4543 2866 None 38 Human Functional pAC50 = 6.3 6.3 -467 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
4543.0 2866 None 38 Human Functional pAC50 = 6.3 6.3 -467 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL445 2866 None 38 Human Functional pAC50 = 6.3 6.3 -467 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
DB00540 2866 None 38 Human Functional pAC50 = 6.3 6.3 -467 32
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
1816 2540 None 102 Human Functional pAC50 = 6.3 6.3 -43 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
4205 2540 None 102 Human Functional pAC50 = 6.3 6.3 -43 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
4205.0 2540 None 102 Human Functional pAC50 = 6.3 6.3 -43 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
7241 2540 None 102 Human Functional pAC50 = 6.3 6.3 -43 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
CHEMBL654 2540 None 102 Human Functional pAC50 = 6.3 6.3 -43 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
DB00370 2540 None 102 Human Functional pAC50 = 6.3 6.3 -43 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
135398745 2914 None 112 Human Functional pAC50 = 6.3 6.3 -52 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
135398745.0 2914 None 112 Human Functional pAC50 = 6.3 6.3 -52 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
47 2914 None 112 Human Functional pAC50 = 6.3 6.3 -52 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
CHEMBL715 2914 None 112 Human Functional pAC50 = 6.3 6.3 -52 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
DB00334 2914 None 112 Human Functional pAC50 = 6.3 6.3 -52 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
5048 3133 None 64 Human Functional pAC50 = 5.2 5.2 -3981 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
8924 3133 None 64 Human Functional pAC50 = 5.2 5.2 -3981 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
9948102 3133 None 64 Human Functional pAC50 = 5.2 5.2 -3981 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
9948102.0 3133 None 64 Human Functional pAC50 = 5.2 5.2 -3981 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
CHEMBL462605 3133 None 64 Human Functional pAC50 = 5.2 5.2 -3981 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
DB11642 3133 None 64 Human Functional pAC50 = 5.2 5.2 -3981 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
2585 803 None 103 Human Functional pAC50 = 7.2 7.2 -95 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
2585.0 803 None 103 Human Functional pAC50 = 7.2 7.2 -95 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
522 803 None 103 Human Functional pAC50 = 7.2 7.2 -95 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
551 803 None 103 Human Functional pAC50 = 7.2 7.2 -95 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
CHEMBL723 803 None 103 Human Functional pAC50 = 7.2 7.2 -95 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
DB01136 803 None 103 Human Functional pAC50 = 7.2 7.2 -95 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
3152 188411 None 103 Human Functional pAC50 = 5.2 5.2 -14 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 0 4 4.4 COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 10.1038/s41467-023-40064-9
CHEMBL502 188411 None 103 Human Functional pAC50 = 5.2 5.2 -14 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 0 4 4.4 COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 10.1038/s41467-023-40064-9
5365247 138429 None 33 Human Functional pAC50 = 6.2 6.2 -4 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 316 4 0 2 3.8 CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1 10.1038/s41467-023-40064-9
CHEMBL37744 138429 None 33 Human Functional pAC50 = 6.2 6.2 -4 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 316 4 0 2 3.8 CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1 10.1038/s41467-023-40064-9
1890 2759 None 49 Human Functional pAC50 = 6.2 6.2 -4 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
4449 2759 None 49 Human Functional pAC50 = 6.2 6.2 -4 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
7247 2759 None 49 Human Functional pAC50 = 6.2 6.2 -4 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
CHEMBL623 2759 None 49 Human Functional pAC50 = 6.2 6.2 -4 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
DB01149 2759 None 49 Human Functional pAC50 = 6.2 6.2 -4 24
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
2435 3590 None 83 Human Functional pAC50 = 5.2 5.2 -1548 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
60149 3590 None 83 Human Functional pAC50 = 5.2 5.2 -1548 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
98 3590 None 83 Human Functional pAC50 = 5.2 5.2 -1548 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
CHEMBL12713 3590 None 83 Human Functional pAC50 = 5.2 5.2 -1548 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
DB06144 3590 None 83 Human Functional pAC50 = 5.2 5.2 -1548 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
4567 9948 None 34 Human Functional pAC50 = 6.2 6.2 -11 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 3 3 3.4 CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1 10.1038/s41467-023-40064-9
CHEMBL114655 9948 None 34 Human Functional pAC50 = 6.2 6.2 -11 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 3 3 3.4 CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1 10.1038/s41467-023-40064-9
1530 2182 None 50 Human Functional pAC50 = 5.2 5.2 -467 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
3827 2182 None 50 Human Functional pAC50 = 5.2 5.2 -467 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
3827.0 2182 None 50 Human Functional pAC50 = 5.2 5.2 -467 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
7206 2182 None 50 Human Functional pAC50 = 5.2 5.2 -467 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
CHEMBL534 2182 None 50 Human Functional pAC50 = 5.2 5.2 -467 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
DB00920 2182 None 50 Human Functional pAC50 = 5.2 5.2 -467 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
5482 14420 None 80 Human Functional pAC50 = 5.2 5.2 -3 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 386 6 0 4 5.9 Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1 10.1038/s41467-023-40064-9
CHEMBL1200438 14420 None 80 Human Functional pAC50 = 5.2 5.2 -3 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 386 6 0 4 5.9 Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1 10.1038/s41467-023-40064-9
1524 2181 None 96 Human Functional pAC50 = 5.2 5.2 -1548 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
197 2181 None 96 Human Functional pAC50 = 5.2 5.2 -1548 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
3822 2181 None 96 Human Functional pAC50 = 5.2 5.2 -1548 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
3822.0 2181 None 96 Human Functional pAC50 = 5.2 5.2 -1548 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
88 2181 None 96 Human Functional pAC50 = 5.2 5.2 -1548 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
CHEMBL51 2181 None 96 Human Functional pAC50 = 5.2 5.2 -1548 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
DB12465 2181 None 96 Human Functional pAC50 = 5.2 5.2 -1548 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
4011 82408 None 49 Human Functional pAC50 = 5.2 5.2 -549 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 10.1038/s41467-023-40064-9
CHEMBL21731 82408 None 49 Human Functional pAC50 = 5.2 5.2 -549 26
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 10.1038/s41467-023-40064-9
9417 133512 None 54 Human Functional pAC50 = 5.2 5.2 -83 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 363 6 1 4 3.3 OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1 10.1038/s41467-023-40064-9
CHEMBL1524185 133512 None 54 Human Functional pAC50 = 5.2 5.2 -83 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 363 6 1 4 3.3 OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1 10.1038/s41467-023-40064-9
CHEMBL370753 133512 None 54 Human Functional pAC50 = 5.2 5.2 -83 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 363 6 1 4 3.3 OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1 10.1038/s41467-023-40064-9
5311017 120604 None 11 Human Functional pAC50 = 6.2 6.2 2 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 239 5 0 1 3.8 C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1 10.1038/s41467-023-40064-9
5311017.0 120604 None 11 Human Functional pAC50 = 6.2 6.2 2 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 239 5 0 1 3.8 C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL3545985 120604 None 11 Human Functional pAC50 = 6.2 6.2 2 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 239 5 0 1 3.8 C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1 10.1038/s41467-023-40064-9
DB00865 120604 None 11 Human Functional pAC50 = 6.2 6.2 2 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 239 5 0 1 3.8 C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1 10.1038/s41467-023-40064-9
68712 100338 None 60 Human Functional pAC50 = 5.2 5.2 -1 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1038/s41467-023-40064-9
CHEMBL289480 100338 None 60 Human Functional pAC50 = 5.2 5.2 -1 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1038/s41467-023-40064-9
3926 207241 None 40 Human Functional pAC50 = 6.2 6.2 -1 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 491 9 1 3 5.8 Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1038/s41467-023-40064-9
CHEMBL92870 207241 None 40 Human Functional pAC50 = 6.2 6.2 -1 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 491 9 1 3 5.8 Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1038/s41467-023-40064-9
21772 78399 None 31 Human Functional pAC50 = 5.2 5.2 -457 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 293 4 0 1 4.5 CC(CC1c2ccccc2CCc2ccccc21)CN(C)C 10.1038/s41467-023-40064-9
CHEMBL2110816 78399 None 31 Human Functional pAC50 = 5.2 5.2 -457 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 293 4 0 1 4.5 CC(CC1c2ccccc2CCc2ccccc21)CN(C)C 10.1038/s41467-023-40064-9
179 400 None 115 Human Functional pAC50 = 6.2 6.2 -104 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
2159 400 None 115 Human Functional pAC50 = 6.2 6.2 -104 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
2159.0 400 None 115 Human Functional pAC50 = 6.2 6.2 -104 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
963 400 None 115 Human Functional pAC50 = 6.2 6.2 -104 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
CHEMBL243712 400 None 115 Human Functional pAC50 = 6.2 6.2 -104 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
DB06288 400 None 115 Human Functional pAC50 = 6.2 6.2 -104 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
104870 98880 None 47 Human Functional pAC50 = 6.2 6.2 -2 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 10.1038/s41467-023-40064-9
5374 98880 None 47 Human Functional pAC50 = 6.2 6.2 -2 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 10.1038/s41467-023-40064-9
CHEMBL279085 98880 None 47 Human Functional pAC50 = 6.2 6.2 -2 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 10.1038/s41467-023-40064-9
2291 3184 None 58 Human Functional pAC50 = 5.2 5.2 -134 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
2561 3184 None 58 Human Functional pAC50 = 5.2 5.2 -134 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
4932 3184 None 58 Human Functional pAC50 = 5.2 5.2 -134 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
4932.0 3184 None 58 Human Functional pAC50 = 5.2 5.2 -134 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
CHEMBL631 3184 None 58 Human Functional pAC50 = 5.2 5.2 -134 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
DB01182 3184 None 58 Human Functional pAC50 = 5.2 5.2 -134 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
19910 37408 None 106 Human Functional pAC50 = 5.2 5.2 -1 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 190 1 1 4 1.8 O=[N+]([O-])c1ccc(O)c2ncccc12 10.1038/s41467-023-40064-9
CHEMBL1454910 37408 None 106 Human Functional pAC50 = 5.2 5.2 -1 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 190 1 1 4 1.8 O=[N+]([O-])c1ccc(O)c2ncccc12 10.1038/s41467-023-40064-9
17676 7072 None 29 Human Functional pAC50 = 6.1 6.1 -165 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
17676.0 7072 None 29 Human Functional pAC50 = 6.1 6.1 -165 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
5281082 7072 None 29 Human Functional pAC50 = 6.1 6.1 -165 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
CHEMBL1085 7072 None 29 Human Functional pAC50 = 6.1 6.1 -165 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
DB01063 7072 None 29 Human Functional pAC50 = 6.1 6.1 -165 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
2477 745 None 59 Human Functional pAC50 = 5.1 5.1 -316 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
2477.0 745 None 59 Human Functional pAC50 = 5.1 5.1 -316 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
36 745 None 59 Human Functional pAC50 = 5.1 5.1 -316 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
437 745 None 59 Human Functional pAC50 = 5.1 5.1 -316 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
CHEMBL49 745 None 59 Human Functional pAC50 = 5.1 5.1 -316 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
DB00490 745 None 59 Human Functional pAC50 = 5.1 5.1 -316 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
162265 202274 None 22 Human Functional pAC50 = 5.1 5.1 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 10.1038/s41467-023-40064-9
4786 202274 None 22 Human Functional pAC50 = 5.1 5.1 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL61006 202274 None 22 Human Functional pAC50 = 5.1 5.1 - 1
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 10.1038/s41467-023-40064-9
16722836 18985 None 99 Human Functional pAC50 = 5.1 5.1 -6 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 524 10 3 8 4.8 Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1 10.1038/s41467-023-40064-9
CHEMBL1287853 18985 None 99 Human Functional pAC50 = 5.1 5.1 -6 13
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 524 10 3 8 4.8 Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1 10.1038/s41467-023-40064-9
5210 33338 None 48 Human Functional pAC50 = 6.1 6.1 -1 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
CHEMBL1200765 33338 None 48 Human Functional pAC50 = 6.1 6.1 -1 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
CHEMBL1419 33338 None 48 Human Functional pAC50 = 6.1 6.1 -1 8
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
1234 189221 None 56 Human Functional pAC50 = 5.1 5.1 -28 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 14 0 7 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
CHEMBL1256940 189221 None 56 Human Functional pAC50 = 5.1 5.1 -28 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 14 0 7 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
CHEMBL51149 189221 None 56 Human Functional pAC50 = 5.1 5.1 -28 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 14 0 7 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
135409453 3773 None 41 Human Functional pAC50 = 6.1 6.1 -263 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
226 3773 None 41 Human Functional pAC50 = 6.1 6.1 -263 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
CHEMBL76370 3773 None 41 Human Functional pAC50 = 6.1 6.1 -263 35
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
43815 186920 None 64 Human Functional pAC50 = 5.1 5.1 -77 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 4 1 4 3.3 Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1 10.1038/s41467-023-40064-9
CHEMBL1708 186920 None 64 Human Functional pAC50 = 5.1 5.1 -77 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 4 1 4 3.3 Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1 10.1038/s41467-023-40064-9
CHEMBL490 186920 None 64 Human Functional pAC50 = 5.1 5.1 -77 20
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 4 1 4 3.3 Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1 10.1038/s41467-023-40064-9
2218 15283 None 23 Human Functional pAC50 = 5.1 5.1 -10 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 8 0 2 4.4 CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1 10.1038/s41467-023-40064-9
CHEMBL1213033 15283 None 23 Human Functional pAC50 = 5.1 5.1 -10 12
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 8 0 2 4.4 CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1 10.1038/s41467-023-40064-9
36811 1454 None 37 Human Functional pAC50 = 6.1 6.1 -28 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
36811.0 1454 None 37 Human Functional pAC50 = 6.1 6.1 -28 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
535 1454 None 37 Human Functional pAC50 = 6.1 6.1 -28 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
937 1454 None 37 Human Functional pAC50 = 6.1 6.1 -28 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
CHEMBL926 1454 None 37 Human Functional pAC50 = 6.1 6.1 -28 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
DB00841 1454 None 37 Human Functional pAC50 = 6.1 6.1 -28 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
2146 3100 None 67 Human Functional pAC50 = 5.1 5.1 -181 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
485 3100 None 67 Human Functional pAC50 = 5.1 5.1 -181 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
6041 3100 None 67 Human Functional pAC50 = 5.1 5.1 -181 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
6041.0 3100 None 67 Human Functional pAC50 = 5.1 5.1 -181 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
CHEMBL1215 3100 None 67 Human Functional pAC50 = 5.1 5.1 -181 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
DB00388 3100 None 67 Human Functional pAC50 = 5.1 5.1 -181 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
2448 99323 None 70 Human Functional pAC50 = 5.1 5.1 -363 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 419 6 1 3 4.5 O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1 10.1038/s41467-023-40064-9
2448.0 99323 None 70 Human Functional pAC50 = 5.1 5.1 -363 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 419 6 1 3 4.5 O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1 10.1038/s41467-023-40064-9
CHEMBL28218 99323 None 70 Human Functional pAC50 = 5.1 5.1 -363 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 419 6 1 3 4.5 O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1 10.1038/s41467-023-40064-9
DB12401 99323 None 70 Human Functional pAC50 = 5.1 5.1 -363 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 419 6 1 3 4.5 O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1 10.1038/s41467-023-40064-9
115 343 None 71 Human Functional pAC50 = 6.1 6.1 -14 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
2092 343 None 71 Human Functional pAC50 = 6.1 6.1 -14 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
2092.0 343 None 71 Human Functional pAC50 = 6.1 6.1 -14 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
7109 343 None 71 Human Functional pAC50 = 6.1 6.1 -14 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
CHEMBL709 343 None 71 Human Functional pAC50 = 6.1 6.1 -14 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
DB00346 343 None 71 Human Functional pAC50 = 6.1 6.1 -14 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
3158 56267 None 27 Human Functional pAC50 = 6.1 6.1 -1202 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
3158.0 56267 None 27 Human Functional pAC50 = 6.1 6.1 -1202 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1628227 56267 None 27 Human Functional pAC50 = 6.1 6.1 -1202 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
DB01142 56267 None 27 Human Functional pAC50 = 6.1 6.1 -1202 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
2142 3096 None 58 Human Functional pAC50 = 6.1 6.1 -31 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
4920903 3096 None 58 Human Functional pAC50 = 6.1 6.1 -31 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
502 3096 None 58 Human Functional pAC50 = 6.1 6.1 -31 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
5775 3096 None 58 Human Functional pAC50 = 6.1 6.1 -31 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
5775.0 3096 None 58 Human Functional pAC50 = 6.1 6.1 -31 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
CHEMBL597 3096 None 58 Human Functional pAC50 = 6.1 6.1 -31 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
DB00692 3096 None 58 Human Functional pAC50 = 6.1 6.1 -31 18
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
72093 35061 None 9 Human Functional pAC50 = 5.1 5.1 -7 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 483 16 1 4 6.3 CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1 10.1038/s41467-023-40064-9
CHEMBL1433361 35061 None 9 Human Functional pAC50 = 5.1 5.1 -7 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 483 16 1 4 6.3 CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1 10.1038/s41467-023-40064-9
CHEMBL2103773 35061 None 9 Human Functional pAC50 = 5.1 5.1 -7 28
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 483 16 1 4 6.3 CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1 10.1038/s41467-023-40064-9
1549120 196486 None 85 Human Functional pAC50 = 5.1 5.1 -5 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 319 4 1 4 2.9 CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL56337 196486 None 85 Human Functional pAC50 = 5.1 5.1 -5 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 319 4 1 4 2.9 CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1 10.1038/s41467-023-40064-9
2284 3182 None 33 Human Functional pAC50 = 6.1 6.1 -56 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
4926 3182 None 33 Human Functional pAC50 = 6.1 6.1 -56 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
7281 3182 None 33 Human Functional pAC50 = 6.1 6.1 -56 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
CHEMBL564 3182 None 33 Human Functional pAC50 = 6.1 6.1 -56 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
DB00420 3182 None 33 Human Functional pAC50 = 6.1 6.1 -56 34
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
156419 938 None 74 Human Functional pAC50 = 6.1 6.1 -13 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
156419.0 938 None 74 Human Functional pAC50 = 6.1 6.1 -13 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
3308 938 None 74 Human Functional pAC50 = 6.1 6.1 -13 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
647 938 None 74 Human Functional pAC50 = 6.1 6.1 -13 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
CHEMBL1201284 938 None 74 Human Functional pAC50 = 6.1 6.1 -13 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
DB01012 938 None 74 Human Functional pAC50 = 6.1 6.1 -13 15
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
3180 14473 None 41 Human Functional pAC50 = 5.1 5.1 -2 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 8 0 3 3.9 CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1 10.1038/s41467-023-40064-9
CHEMBL1201217 14473 None 41 Human Functional pAC50 = 5.1 5.1 -2 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 8 0 3 3.9 CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1 10.1038/s41467-023-40064-9
68555 103112 None 21 Human Functional pAC50 = 5.1 5.1 -190 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 7 1 5 2.6 CNCCc1ccc(OC(=O)C(C)C)c(OC(=O)C(C)C)c1 10.1038/s41467-023-40064-9
CHEMBL307739 103112 None 21 Human Functional pAC50 = 5.1 5.1 -190 7
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 7 1 5 2.6 CNCCc1ccc(OC(=O)C(C)C)c(OC(=O)C(C)C)c1 10.1038/s41467-023-40064-9
3081361 93934 None 123 Human Functional pAC50 = 6.1 6.1 -1 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 474 5 1 5 4.4 COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1 10.1038/s41467-023-40064-9
CHEMBL24828 93934 None 123 Human Functional pAC50 = 6.1 6.1 -1 14
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 474 5 1 5 4.4 COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1 10.1038/s41467-023-40064-9
1385580 29276 None 76 Human Functional pAC50 = 6.1 6.1 -104 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
4615 29276 None 76 Human Functional pAC50 = 6.1 6.1 -104 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
4615.0 29276 None 76 Human Functional pAC50 = 6.1 6.1 -104 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL13828 29276 None 76 Human Functional pAC50 = 6.1 6.1 -104 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
DB12877 29276 None 76 Human Functional pAC50 = 6.1 6.1 -104 19
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
3689 102771 None 55 Human Functional pAC50 = 6.1 6.1 -128 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 325 5 2 3 3.8 CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL1372983 102771 None 55 Human Functional pAC50 = 6.1 6.1 -128 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 325 5 2 3 3.8 CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL305187 102771 None 55 Human Functional pAC50 = 6.1 6.1 -128 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 325 5 2 3 3.8 CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
22323 15299 None 32 Human Functional pAC50 = 5.1 5.1 -5 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 2 5 2 2.9 CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1 10.1038/s41467-023-40064-9
9571037 15299 None 32 Human Functional pAC50 = 5.1 5.1 -5 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 2 5 2 2.9 CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1 10.1038/s41467-023-40064-9
CHEMBL1213553 15299 None 32 Human Functional pAC50 = 5.1 5.1 -5 11
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 2 5 2 2.9 CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1 10.1038/s41467-023-40064-9
73348210.0 210949 None 0 Human Functional pAC50 = 5.1 5.1 -169 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL None None None NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O 10.1038/s41467-023-40064-9
CHEMBL3039583 210949 None 0 Human Functional pAC50 = 5.1 5.1 -169 17
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL None None None NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O 10.1038/s41467-023-40064-9
21722 17992 None 31 Human Functional pAC50 = 5.1 5.1 -22 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 2 4.3 CN(C)CCCn1c2c(c3ccccc31)CCCCCC2 10.1038/s41467-023-40064-9
CHEMBL126224 17992 None 31 Human Functional pAC50 = 5.1 5.1 -22 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 2 4.3 CN(C)CCCn1c2c(c3ccccc31)CCCCCC2 10.1038/s41467-023-40064-9
2099 9307 None 55 Human Functional pAC50 = 5.0 5.0 -109 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 294 2 1 3 2.4 Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O 10.1038/s41467-023-40064-9
CHEMBL1110 9307 None 55 Human Functional pAC50 = 5.0 5.0 -109 5
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 294 2 1 3 2.4 Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O 10.1038/s41467-023-40064-9
2762 3863 None 31 Human Functional pAC50 = 5.0 5.0 -301 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
5587 3863 None 31 Human Functional pAC50 = 5.0 5.0 -301 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
5587.0 3863 None 31 Human Functional pAC50 = 5.0 5.0 -301 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
7318 3863 None 31 Human Functional pAC50 = 5.0 5.0 -301 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
CHEMBL1241 3863 None 31 Human Functional pAC50 = 5.0 5.0 -301 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
DB00792 3863 None 31 Human Functional pAC50 = 5.0 5.0 -301 9
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
2372 106468 None 40 Human Functional pAC50 = 5.0 5.0 -354 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 345 10 2 5 2.6 COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC 10.1038/s41467-023-40064-9
CHEMBL314010 106468 None 40 Human Functional pAC50 = 5.0 5.0 -354 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 345 10 2 5 2.6 COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC 10.1038/s41467-023-40064-9
3337 206367 None 27 Human Functional pAC50 = 5.0 5.0 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
3337.0 206367 None 27 Human Functional pAC50 = 5.0 5.0 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
65801 206367 None 27 Human Functional pAC50 = 5.0 5.0 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
66264 206367 None 27 Human Functional pAC50 = 5.0 5.0 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
91452 206367 None 27 Human Functional pAC50 = 5.0 5.0 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
CHEMBL87493 206367 None 27 Human Functional pAC50 = 5.0 5.0 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
DB00574 206367 None 27 Human Functional pAC50 = 5.0 5.0 -2 6
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
2202 3132 None 96 Human Functional pAC50 = 6.0 6.0 -16 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
4850 3132 None 96 Human Functional pAC50 = 6.0 6.0 -16 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
4850.0 3132 None 96 Human Functional pAC50 = 6.0 6.0 -16 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
49 3132 None 96 Human Functional pAC50 = 6.0 6.0 -16 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
CHEMBL1371770 3132 None 96 Human Functional pAC50 = 6.0 6.0 -16 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
DB12478 3132 None 96 Human Functional pAC50 = 6.0 6.0 -16 10
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
25382 9157 None 37 Human Functional pAC50 = 5.0 5.0 -263 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 3 0 1 4.7 CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL110094 9157 None 37 Human Functional pAC50 = 5.0 5.0 -263 21
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 3 0 1 4.7 CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21 10.1038/s41467-023-40064-9
135564886 14493 None 5 Human Functional pAC50 = 5.0 5.0 -3 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
135673376 14493 None 5 Human Functional pAC50 = 5.0 5.0 -3 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
137157436 14493 None 5 Human Functional pAC50 = 5.0 5.0 -3 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
145948239 14493 None 5 Human Functional pAC50 = 5.0 5.0 -3 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
71587099 14493 None 5 Human Functional pAC50 = 5.0 5.0 -3 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
CHEMBL1201304 14493 None 5 Human Functional pAC50 = 5.0 5.0 -3 25
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
3191 102858 None 97 Human Functional pAC50 = 5.0 5.0 -89 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 10.1038/s41467-023-40064-9
3191.0 102858 None 97 Human Functional pAC50 = 5.0 5.0 -89 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 10.1038/s41467-023-40064-9
CHEMBL305660 102858 None 97 Human Functional pAC50 = 5.0 5.0 -89 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 10.1038/s41467-023-40064-9
DB11742 102858 None 97 Human Functional pAC50 = 5.0 5.0 -89 33
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 10.1038/s41467-023-40064-9
2247 505 None 81 Human Functional pAC50 = 5.0 5.0 -323 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
249 505 None 81 Human Functional pAC50 = 5.0 5.0 -323 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
2603 505 None 81 Human Functional pAC50 = 5.0 5.0 -323 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
CHEMBL296419 505 None 81 Human Functional pAC50 = 5.0 5.0 -323 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
DB00637 505 None 81 Human Functional pAC50 = 5.0 5.0 -323 42
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
5284550 41721 None 15 Human Functional pAC50 = 5.0 5.0 -512 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
5284550.0 41721 None 15 Human Functional pAC50 = 5.0 5.0 -512 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL108947 41721 None 15 Human Functional pAC50 = 5.0 5.0 -512 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1492500 41721 None 15 Human Functional pAC50 = 5.0 5.0 -512 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
DB09167 41721 None 15 Human Functional pAC50 = 5.0 5.0 -512 16
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
521 1404 None 69 Human Functional pEC50 = 9.3 9.3 -4 5
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
5311068 1404 None 69 Human Functional pEC50 = 9.3 9.3 -4 5
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
5311068.0 1404 None 69 Human Functional pEC50 = 9.3 9.3 -4 5
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
835 1404 None 69 Human Functional pEC50 = 9.3 9.3 -4 5
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
CHEMBL778 1404 None 69 Human Functional pEC50 = 9.3 9.3 -4 5
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
DB00633 1404 None 69 Human Functional pEC50 = 9.3 9.3 -4 5
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
1593 2340 None 66 Human Functional pEC50 = 8.9 8.9 -1 6
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
30668 2340 None 66 Human Functional pEC50 = 8.9 8.9 -1 6
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
30668.0 2340 None 66 Human Functional pEC50 = 8.9 8.9 -1 6
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
9868 2340 None 66 Human Functional pEC50 = 8.9 8.9 -1 6
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
CHEMBL17860 2340 None 66 Human Functional pEC50 = 8.9 8.9 -1 6
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
DB04948 2340 None 66 Human Functional pEC50 = 8.9 8.9 -1 6
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
57345628 71183 None 0 Human Functional pEC50 = 8.7 8.7 1659 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956195 71183 None 0 Human Functional pEC50 = 8.7 8.7 1659 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
57345628 71183 None 0 Human Functional pEC50 = 8.7 8.7 1659 2
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL1956195 71183 None 0 Human Functional pEC50 = 8.7 8.7 1659 2
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
70695474 77672 None 0 Human Functional pEC50 = 8.7 8.7 794 2
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL2089156 77672 None 0 Human Functional pEC50 = 8.7 8.7 794 2
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
44292386 101482 None 0 Human Functional pEC50 = 8.7 8.7 35 2
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 296 4 1 3 3.5 C(=C/c1ccccc1)\C[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL297827 101482 None 0 Human Functional pEC50 = 8.7 8.7 35 2
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 296 4 1 3 3.5 C(=C/c1ccccc1)\C[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
16757089 92291 None 1 Human Functional pEC50 = 8 8.0 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL242693 92291 None 1 Human Functional pEC50 = 8 8.0 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
57345626 71180 None 2 Human Functional pEC50 = 8 8.0 31 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956192 71180 None 2 Human Functional pEC50 = 8 8.0 31 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1016/j.bmc.2012.01.035
24906199 187665 None 15 Human Functional pEC50 = 8 8.0 6 3
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 258 4 1 3 3.1 CC(Oc1ccccc1C1CCCC1)C1=NCCN1 10.1021/jm800250z
CHEMBL495096 187665 None 15 Human Functional pEC50 = 8 8.0 6 3
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 258 4 1 3 3.1 CC(Oc1ccccc1C1CCCC1)C1=NCCN1 10.1021/jm800250z
16757089 92291 None 1 Human Functional pEC50 = 8 8.0 - 1
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL242693 92291 None 1 Human Functional pEC50 = 8 8.0 - 1
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
49836306 18575 None 0 Human Functional pEC50 = 7 7.0 31 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 C[C@@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276247 18575 None 0 Human Functional pEC50 = 7 7.0 31 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 C[C@@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
11361608 84745 None 1 Human Functional pEC50 = 7 7.0 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL222928 84745 None 1 Human Functional pEC50 = 7 7.0 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
11361608 84745 None 1 Human Functional pEC50 = 7 7.0 - 1
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222928 84745 None 1 Human Functional pEC50 = 7 7.0 - 1
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
44269140 33553 None 0 Human Functional pEC50 = 7 7.0 17 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 248 5 1 4 2.2 CC(C)Oc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL14208 33553 None 0 Human Functional pEC50 = 7 7.0 17 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 248 5 1 4 2.2 CC(C)Oc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
44371745 49289 None 0 Human Functional pEC50 = 7 7.0 100 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 4 1 3 2.0 CCc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL156336 49289 None 0 Human Functional pEC50 = 7 7.0 100 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 4 1 3 2.0 CCc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
57402718 71189 None 2 Human Functional pEC50 = 7 7.0 -3 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 4 1 4 1.3 CC(Oc1ccccc1C=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956201 71189 None 2 Human Functional pEC50 = 7 7.0 -3 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 4 1 4 1.3 CC(Oc1ccccc1C=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
11097789 102998 None 1 Human Functional pEC50 = 7 7.0 -16 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 239 4 2 4 2.0 CSc1cc(F)ccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL306792 102998 None 1 Human Functional pEC50 = 7 7.0 -16 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 239 4 2 4 2.0 CSc1cc(F)ccc1NCC1=NCCN1 10.1021/jm000542r
11361608 84745 None 1 Human Functional pEC50 = 7 7.0 - 1
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL222928 84745 None 1 Human Functional pEC50 = 7 7.0 - 1
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
24906196 187246 None 0 Human Functional pEC50 = 6 6.0 - 1
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 261 6 1 5 1.8 CCO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL492639 187246 None 0 Human Functional pEC50 = 6 6.0 - 1
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 261 6 1 5 1.8 CCO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
135453290 133606 None 33 Human Functional pEC50 = 5 5.0 -5011 7
Activity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assayActivity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assay
ChEMBL 191 2 2 4 1.1 C[C@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
CHEMBL371300 133606 None 33 Human Functional pEC50 = 5 5.0 -5011 7
Activity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assayActivity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assay
ChEMBL 191 2 2 4 1.1 C[C@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
57399145 71184 None 0 Human Functional pEC50 = 5 5.0 -3 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 234 5 1 4 1.9 CCOc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956196 71184 None 0 Human Functional pEC50 = 5 5.0 -3 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 234 5 1 4 1.9 CCOc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
131829 204727 None 15 Human Functional pEC50 = 7.0 7.0 -37 3
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 295 1 4 5 1.7 Brc1c(NC2=NCCN2)ccc2c1NCCN2 10.1016/0960-894X(95)00391-6
CHEMBL74283 204727 None 15 Human Functional pEC50 = 7.0 7.0 -37 3
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 295 1 4 5 1.7 Brc1c(NC2=NCCN2)ccc2c1NCCN2 10.1016/0960-894X(95)00391-6
9859437 168022 None 0 Human Functional pEC50 = 7.0 7.0 1 3
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 230 2 3 4 2.3 Cc1c(Nc2ncc[nH]2)ccc2c1NCCO2 10.1021/jm9605142
CHEMBL432155 168022 None 0 Human Functional pEC50 = 7.0 7.0 1 3
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 230 2 3 4 2.3 Cc1c(Nc2ncc[nH]2)ccc2c1NCCO2 10.1021/jm9605142
11043720 92172 None 0 Human Functional pEC50 = 7.0 7.0 257 3
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL242265 92172 None 0 Human Functional pEC50 = 7.0 7.0 257 3
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
11043720 92172 None 0 Human Functional pEC50 = 7.0 7.0 257 3
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL242265 92172 None 0 Human Functional pEC50 = 7.0 7.0 257 3
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
10221005 204322 None 0 Human Functional pEC50 = 6.0 6.0 -575 3
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 267 4 2 5 0.8 Cc1ccc(S(C)(=O)=O)c(NCC2=NCCN2)c1 10.1021/jm000542r
CHEMBL71479 204322 None 0 Human Functional pEC50 = 6.0 6.0 -575 3
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 267 4 2 5 0.8 Cc1ccc(S(C)(=O)=O)c(NCC2=NCCN2)c1 10.1021/jm000542r
57345627 71182 None 0 Human Functional pEC50 = 6.9 6.9 13 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 230 4 1 3 2.5 C=C(C)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956194 71182 None 0 Human Functional pEC50 = 6.9 6.9 13 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 230 4 1 3 2.5 C=C(C)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
2683 3834 None 60 Human Functional pEC50 = 5.9 5.9 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
5487 3834 None 60 Human Functional pEC50 = 5.9 5.9 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
5487.0 3834 None 60 Human Functional pEC50 = 5.9 5.9 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
7308 3834 None 60 Human Functional pEC50 = 5.9 5.9 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
CHEMBL1079 3834 None 60 Human Functional pEC50 = 5.9 5.9 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
DB00697 3834 None 60 Human Functional pEC50 = 5.9 5.9 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
49836304 18571 None 1 Human Functional pEC50 = 6.9 6.9 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276219 18571 None 1 Human Functional pEC50 = 6.9 6.9 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
24906159 187405 None 12 Human Functional pEC50 = 6.9 6.9 3 3
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 233 4 2 5 1.3 CC(Oc1ccccc1/C=N/O)C1=NCCN1 10.1021/jm800250z
CHEMBL493675 187405 None 12 Human Functional pEC50 = 6.9 6.9 3 3
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 233 4 2 5 1.3 CC(Oc1ccccc1/C=N/O)C1=NCCN1 10.1021/jm800250z
44292385 101121 None 0 Human Functional pEC50 = 7.9 7.9 - 1
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 270 3 1 3 2.6 c1ccc(C[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL295186 101121 None 0 Human Functional pEC50 = 7.9 7.9 - 1
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 270 3 1 3 2.6 c1ccc(C[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
1242 3613 None 27 Human Functional pEC50 = 5.9 5.9 -10 3
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
935 3613 None 27 Human Functional pEC50 = 5.9 5.9 -10 3
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL286080 3613 None 27 Human Functional pEC50 = 5.9 5.9 -10 3
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
185076 187090 None 5 Human Functional pEC50 = 7.9 7.9 -11 3
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL49137 187090 None 5 Human Functional pEC50 = 7.9 7.9 -11 3
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
42669828 121718 None 2 Human Functional pEC50 = 3.8 3.8 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 243 5 1 3 2.7 Cc1ccccc1Cn1ccnc1CNC(C)C 10.1016/j.bmc.2015.01.013
CHEMBL3588911 121718 None 2 Human Functional pEC50 = 3.8 3.8 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 243 5 1 3 2.7 Cc1ccccc1Cn1ccnc1CNC(C)C 10.1016/j.bmc.2015.01.013
11140345 204171 None 0 Human Functional pEC50 = 7.8 7.8 -2 5
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 239 4 2 4 2.0 CSc1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70692 204171 None 0 Human Functional pEC50 = 7.8 7.8 -2 5
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 239 4 2 4 2.0 CSc1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
45487962 197485 None 0 Human Functional pEC50 = 6.8 6.8 -2 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 218 4 1 3 2.1 CCCc1ccccc1COC1=NCCN1 10.1021/jm901262f
CHEMBL569933 197485 None 0 Human Functional pEC50 = 6.8 6.8 -2 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 218 4 1 3 2.1 CCCc1ccccc1COC1=NCCN1 10.1021/jm901262f
11361608 84745 None 1 Human Functional pEC50 = 6.8 6.8 - 1
Agonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulationAgonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222928 84745 None 1 Human Functional pEC50 = 6.8 6.8 - 1
Agonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulationAgonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
11277479 84750 None 0 Human Functional pEC50 = 5.8 5.8 - 1
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1cccc(-c2ccccc2OC(C)C2=NCCN2)c1 10.1021/jm0408215
CHEMBL222973 84750 None 0 Human Functional pEC50 = 5.8 5.8 - 1
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1cccc(-c2ccccc2OC(C)C2=NCCN2)c1 10.1021/jm0408215
57345625 71179 None 0 Human Functional pEC50 = 6.8 6.8 -1 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 224 3 1 3 2.1 CC(Oc1ccccc1Cl)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956191 71179 None 0 Human Functional pEC50 = 6.8 6.8 -1 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 224 3 1 3 2.1 CC(Oc1ccccc1Cl)C1=NCCN1 10.1016/j.bmc.2012.01.035
13178306 121709 None 2 Human Functional pEC50 = 6.8 6.8 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 187 3 2 2 2.3 Cc1ccccc1NCc1cnc[nH]1 10.1016/j.bmc.2015.01.013
CHEMBL3588902 121709 None 2 Human Functional pEC50 = 6.8 6.8 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 187 3 2 2 2.3 Cc1ccccc1NCc1cnc[nH]1 10.1016/j.bmc.2015.01.013
10333157 151238 None 0 Human Functional pEC50 = 7.7 7.7 3 3
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL396013 151238 None 0 Human Functional pEC50 = 7.7 7.7 3 3
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
10333157 151238 None 0 Human Functional pEC50 = 7.7 7.7 3 3
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL396013 151238 None 0 Human Functional pEC50 = 7.7 7.7 3 3
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
49836302 18566 None 1 Human Functional pEC50 = 6.7 6.7 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/jm100977d
CHEMBL1276139 18566 None 1 Human Functional pEC50 = 6.7 6.7 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/jm100977d
49836302 18566 None 1 Human Functional pEC50 = 6.7 6.7 - 1
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml300064v
CHEMBL1276139 18566 None 1 Human Functional pEC50 = 6.7 6.7 - 1
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml300064v
68712 100338 None 60 Human Functional pEC50 = 6.7 6.7 -1 7
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
CHEMBL289480 100338 None 60 Human Functional pEC50 = 6.7 6.7 -1 7
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
57395731 71190 None 0 Human Functional pEC50 = 6.7 6.7 -3 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 4 1 4 1.7 CC(=O)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956202 71190 None 0 Human Functional pEC50 = 6.7 6.7 -3 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 4 1 4 1.7 CC(=O)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
481 2892 None 7 Human Functional pEC50 = 5.7 5.7 -8 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 248 4 3 4 0.2 NC[C@@H](c1cc(ccc1F)NS(=O)(=O)C)O 10.1021/jm000542r
9838763 2892 None 7 Human Functional pEC50 = 5.7 5.7 -8 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 248 4 3 4 0.2 NC[C@@H](c1cc(ccc1F)NS(=O)(=O)C)O 10.1021/jm000542r
CHEMBL72958 2892 None 7 Human Functional pEC50 = 5.7 5.7 -8 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 248 4 3 4 0.2 NC[C@@H](c1cc(ccc1F)NS(=O)(=O)C)O 10.1021/jm000542r
10199335 204747 None 0 Human Functional pEC50 = 5.7 5.7 -120 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL74467 204747 None 0 Human Functional pEC50 = 5.7 5.7 -120 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
218362 204800 None 5 Human Functional pEC50 = 8.7 8.7 -1 3
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 216 1 1 3 2.0 c1ccc2c(c1)CCCC2NC1=NCCO1 10.1016/0960-894X(94)85032-1
CHEMBL75030 204800 None 5 Human Functional pEC50 = 8.7 8.7 -1 3
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 216 1 1 3 2.0 c1ccc2c(c1)CCCC2NC1=NCCO1 10.1016/0960-894X(94)85032-1
11109088 204180 None 0 Human Functional pEC50 = 8.6 8.6 -6 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 255 4 2 4 2.5 CSc1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70751 204180 None 0 Human Functional pEC50 = 8.6 8.6 -6 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 255 4 2 4 2.5 CSc1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
23622576 172772 None 0 Human Functional pEC50 = 7.7 7.7 3 3
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 272 4 1 3 3.5 CC(Oc1ccccc1C1CCCCC1)C1=NCCN1 10.1021/jm800250z
CHEMBL451229 172772 None 0 Human Functional pEC50 = 7.7 7.7 3 3
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 272 4 1 3 3.5 CC(Oc1ccccc1C1CCCCC1)C1=NCCN1 10.1021/jm800250z
44292232 101321 None 0 Human Functional pEC50 = 7.7 7.7 -1 3
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 222 3 1 3 2.2 CCC[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL296660 101321 None 0 Human Functional pEC50 = 7.7 7.7 -1 3
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 222 3 1 3 2.2 CCC[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
44314200 102952 None 0 Human Functional pEC50 = 7.6 7.6 1 3
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 230 1 1 3 2.4 c1ccc2c(c1)CCCC2NC1=NCCCO1 10.1016/0960-894X(94)85032-1
CHEMBL306377 102952 None 0 Human Functional pEC50 = 7.6 7.6 1 3
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 230 1 1 3 2.4 c1ccc2c(c1)CCCC2NC1=NCCCO1 10.1016/0960-894X(94)85032-1
45487955 198310 None 0 Human Functional pEC50 = 7.6 7.6 125 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 232 4 1 3 2.7 CCCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL576078 198310 None 0 Human Functional pEC50 = 7.6 7.6 125 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 232 4 1 3 2.7 CCCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
49836301 18567 None 1 Human Functional pEC50 = 7.6 7.6 39 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/jm100977d
CHEMBL1276140 18567 None 1 Human Functional pEC50 = 7.6 7.6 39 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/jm100977d
49836308 18784 None 0 Human Functional pEC50 = 7.6 7.6 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 C[C@@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL1278084 18784 None 0 Human Functional pEC50 = 7.6 7.6 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 C[C@@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
49836301 18567 None 1 Human Functional pEC50 = 7.6 7.6 39 2
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml300064v
CHEMBL1276140 18567 None 1 Human Functional pEC50 = 7.6 7.6 39 2
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml300064v
49836307 18785 None 0 Human Functional pEC50 = 5.6 5.6 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 C[C@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL1278085 18785 None 0 Human Functional pEC50 = 5.6 5.6 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 C[C@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
10266032 188881 None 0 Human Functional pEC50 = 7.6 7.6 - 1
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 286 5 1 3 3.5 c1ccc(CCC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL50720 188881 None 0 Human Functional pEC50 = 7.6 7.6 - 1
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 286 5 1 3 3.5 c1ccc(CCC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
44421258 84746 None 0 Human Functional pEC50 = 5.6 5.6 1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL1204386 84746 None 0 Human Functional pEC50 = 5.6 5.6 1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL222933 84746 None 0 Human Functional pEC50 = 5.6 5.6 1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
44371755 48777 None 0 Human Functional pEC50 = 7.6 7.6 -1 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 3 1 3 2.1 Cc1cccc(C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL155866 48777 None 0 Human Functional pEC50 = 7.6 7.6 -1 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 3 1 3 2.1 Cc1cccc(C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
44371864 51141 None 0 Human Functional pEC50 = 7.6 7.6 -2 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 246 5 1 3 2.6 CCc1cccc(CC)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL157955 51141 None 0 Human Functional pEC50 = 7.6 7.6 -2 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 246 5 1 3 2.6 CCc1cccc(CC)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
11000184 13052 None 0 Human Functional pEC50 = 7.6 7.6 -8 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1190038 13052 None 0 Human Functional pEC50 = 7.6 7.6 -8 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL540035 13052 None 0 Human Functional pEC50 = 7.6 7.6 -8 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
10859076 13682 None 0 Human Functional pEC50 = 7.6 7.6 -5 4
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1194763 13682 None 0 Human Functional pEC50 = 7.6 7.6 -5 4
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL553276 13682 None 0 Human Functional pEC50 = 7.6 7.6 -5 4
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
45487958 198391 None 0 Human Functional pEC50 = 5.5 5.5 -1 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 190 2 1 3 1.5 Cc1ccccc1COC1=NCCN1 10.1021/jm901262f
CHEMBL576819 198391 None 0 Human Functional pEC50 = 5.5 5.5 -1 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 190 2 1 3 1.5 Cc1ccccc1COC1=NCCN1 10.1021/jm901262f
2435 722 None 100 Human Functional pEC50 = 8.5 8.5 -7 10
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
2435.0 722 None 100 Human Functional pEC50 = 8.5 8.5 -7 10
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
395 722 None 100 Human Functional pEC50 = 8.5 8.5 -7 10
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
520 722 None 100 Human Functional pEC50 = 8.5 8.5 -7 10
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
5386 722 None 100 Human Functional pEC50 = 8.5 8.5 -7 10
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
CHEMBL844 722 None 100 Human Functional pEC50 = 8.5 8.5 -7 10
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
DB00484 722 None 100 Human Functional pEC50 = 8.5 8.5 -7 10
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
3086326 204531 None 22 Human Functional pEC50 = 7.5 7.5 -13 3
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 247 1 2 5 1.7 Clc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL72753 204531 None 22 Human Functional pEC50 = 7.5 7.5 -13 3
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 247 1 2 5 1.7 Clc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
57400959 71188 None 0 Human Functional pEC50 = 6.5 6.5 1 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 268 4 1 5 0.9 CC(Oc1ccccc1S(C)(=O)=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956200 71188 None 0 Human Functional pEC50 = 6.5 6.5 1 3
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 268 4 1 5 0.9 CC(Oc1ccccc1S(C)(=O)=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
70693375 77671 None 0 Human Functional pEC50 = 6.5 6.5 12 2
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL2089155 77671 None 0 Human Functional pEC50 = 6.5 6.5 12 2
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
24906241 192817 None 0 Human Functional pEC50 = 5.5 5.5 7 2
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
CHEMBL522151 192817 None 0 Human Functional pEC50 = 5.5 5.5 7 2
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
434526 77568 None 28 Human Functional pEC50 = 5.5 5.5 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 194 3 1 4 1.9 NCCSc1nc2ccccc2o1 10.1016/j.bmc.2015.01.013
CHEMBL2087646 77568 None 28 Human Functional pEC50 = 5.5 5.5 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 194 3 1 4 1.9 NCCSc1nc2ccccc2o1 10.1016/j.bmc.2015.01.013
9816461 10719 None 7 Human Functional pEC50 = 5.5 5.5 -60 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 253 4 2 5 0.5 CS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL117094 10719 None 7 Human Functional pEC50 = 5.5 5.5 -60 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 253 4 2 5 0.5 CS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL544290 10719 None 7 Human Functional pEC50 = 5.5 5.5 -60 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 253 4 2 5 0.5 CS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
32238 22655 None 114 Human Functional pEC50 = 3.5 3.5 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 256 3 1 3 2.9 OC(Cn1ccnc1)c1ccc(Cl)cc1Cl 10.1016/j.bmc.2015.01.013
CHEMBL1327 22655 None 114 Human Functional pEC50 = 3.5 3.5 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 256 3 1 3 2.9 OC(Cn1ccnc1)c1ccc(Cl)cc1Cl 10.1016/j.bmc.2015.01.013
2146 3100 None 67 Human Functional pEC50 = 6.5 6.5 -181 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
485 3100 None 67 Human Functional pEC50 = 6.5 6.5 -181 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
6041 3100 None 67 Human Functional pEC50 = 6.5 6.5 -181 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
6041.0 3100 None 67 Human Functional pEC50 = 6.5 6.5 -181 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
CHEMBL1215 3100 None 67 Human Functional pEC50 = 6.5 6.5 -181 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
DB00388 3100 None 67 Human Functional pEC50 = 6.5 6.5 -181 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
122180567 121711 None 0 Human Functional pEC50 = 5.5 5.5 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 261 4 1 3 3.8 c1cncc(-c2ccccc2NCc2ccncc2)c1 10.1016/j.bmc.2015.01.013
CHEMBL3588904 121711 None 0 Human Functional pEC50 = 5.5 5.5 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 261 4 1 3 3.8 c1cncc(-c2ccccc2NCc2ccncc2)c1 10.1016/j.bmc.2015.01.013
49836303 18572 None 1 Human Functional pEC50 = 7.5 7.5 89 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276220 18572 None 1 Human Functional pEC50 = 7.5 7.5 89 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
24906197 187666 None 0 Human Functional pEC50 = 5.5 5.5 8 2
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 323 7 1 5 3.0 CC(Oc1ccccc1/C=N/OCc1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL495097 187666 None 0 Human Functional pEC50 = 5.5 5.5 8 2
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 323 7 1 5 3.0 CC(Oc1ccccc1/C=N/OCc1ccccc1)C1=NCCN1 10.1021/jm800250z
11300487 85002 None 0 Human Functional pEC50 = 6.4 6.4 - 1
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1ccccc1-c1ccccc1OC(C)C1=NCCN1 10.1021/jm0408215
CHEMBL223830 85002 None 0 Human Functional pEC50 = 6.4 6.4 - 1
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1ccccc1-c1ccccc1OC(C)C1=NCCN1 10.1021/jm0408215
16757089 92291 None 1 Human Functional pEC50 = 7.4 7.4 - 1
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL242693 92291 None 1 Human Functional pEC50 = 7.4 7.4 - 1
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
45487956 198367 None 0 Human Functional pEC50 = 7.4 7.4 25 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 230 3 1 3 2.6 CC(OC1=NCCN1)c1ccccc1C1CC1 10.1021/jm901262f
CHEMBL576623 198367 None 0 Human Functional pEC50 = 7.4 7.4 25 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 230 3 1 3 2.6 CC(OC1=NCCN1)c1ccccc1C1CC1 10.1021/jm901262f
44549156 18570 None 0 Human Functional pEC50 = 7.4 7.4 79 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276218 18570 None 0 Human Functional pEC50 = 7.4 7.4 79 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
11265631 136409 None 0 Human Functional pEC50 = 7.4 7.4 9 3
Agonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulationAgonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
CHEMBL373535 136409 None 0 Human Functional pEC50 = 7.4 7.4 9 3
Agonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulationAgonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
2765 943 None 19 Human Functional pEC50 = 6.4 6.4 -38 7
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
515 943 None 19 Human Functional pEC50 = 6.4 6.4 -38 7
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
CHEMBL13852 943 None 19 Human Functional pEC50 = 6.4 6.4 -38 7
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
DB09202 943 None 19 Human Functional pEC50 = 6.4 6.4 -38 7
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
44269089 97005 None 0 Human Functional pEC50 = 6.4 6.4 -1 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 4 1 3 2.6 CC(Oc1ccccc1C(C)C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL266613 97005 None 0 Human Functional pEC50 = 6.4 6.4 -1 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 4 1 3 2.6 CC(Oc1ccccc1C(C)C)C1=NCCN1 10.1016/j.bmc.2012.01.035
44314198 104412 None 0 Human Functional pEC50 = 8.4 8.4 -2 3
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCCC1NC1=NCCO1 10.1016/0960-894X(94)85032-1
CHEMBL310335 104412 None 0 Human Functional pEC50 = 8.4 8.4 -2 3
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCCC1NC1=NCCO1 10.1016/0960-894X(94)85032-1
9815707 101469 None 0 Human Functional pEC50 = 8.4 8.4 -2 3
Alpha-2C adrenergic receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha-2C adrenergic receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCC[C@@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL297752 101469 None 0 Human Functional pEC50 = 8.4 8.4 -2 3
Alpha-2C adrenergic receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha-2C adrenergic receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCC[C@@H]1NC1=NCCO1 10.1021/jm9905256
11058166 204705 None 0 Human Functional pEC50 = 6.4 6.4 -10 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1cccc(F)c1NCC1=NCCN1 10.1021/jm000542r
CHEMBL74114 204705 None 0 Human Functional pEC50 = 6.4 6.4 -10 2
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1cccc(F)c1NCC1=NCCN1 10.1021/jm000542r
11346584 136984 None 0 Human Functional pEC50 = 7.3 7.3 112 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL374584 136984 None 0 Human Functional pEC50 = 7.3 7.3 112 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
11346584 136984 None 0 Human Functional pEC50 = 7.3 7.3 112 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL374584 136984 None 0 Human Functional pEC50 = 7.3 7.3 112 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm0408215
11346584 136984 None 0 Human Functional pEC50 = 7.3 7.3 112 2
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm061487a
CHEMBL374584 136984 None 0 Human Functional pEC50 = 7.3 7.3 112 2
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm061487a
57345629 71185 None 0 Human Functional pEC50 = 7.3 7.3 269 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956197 71185 None 0 Human Functional pEC50 = 7.3 7.3 269 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
46743607 121712 None 0 Human Functional pEC50 = 3.3 3.3 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 264 5 2 3 2.8 c1ccc(-c2nc(CNCc3cccnc3)c[nH]2)cc1 10.1016/j.bmc.2015.01.013
CHEMBL3588905 121712 None 0 Human Functional pEC50 = 3.3 3.3 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 264 5 2 3 2.8 c1ccc(-c2nc(CNCc3cccnc3)c[nH]2)cc1 10.1016/j.bmc.2015.01.013
11140347 204533 None 1 Human Functional pEC50 = 8.3 8.3 -3 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 239 4 2 4 2.0 CSc1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72768 204533 None 1 Human Functional pEC50 = 8.3 8.3 -3 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 239 4 2 4 2.0 CSc1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
11108001 10872 None 2 Human Functional pEC50 = 8.3 8.3 1 5
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL117248 10872 None 2 Human Functional pEC50 = 8.3 8.3 1 5
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL540542 10872 None 2 Human Functional pEC50 = 8.3 8.3 1 5
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
45487145 197659 None 0 Human Functional pEC50 = 7.3 7.3 19 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 230 4 1 3 2.5 C=CCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL570973 197659 None 0 Human Functional pEC50 = 7.3 7.3 19 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 230 4 1 3 2.5 C=CCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
24906198 187664 None 3 Human Functional pEC50 = 7.3 7.3 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm100977d
CHEMBL495095 187664 None 3 Human Functional pEC50 = 7.3 7.3 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm100977d
11265631 136409 None 0 Human Functional pEC50 = 7.3 7.3 9 3
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
CHEMBL373535 136409 None 0 Human Functional pEC50 = 7.3 7.3 9 3
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
24906198 187664 None 3 Human Functional pEC50 = 7.3 7.3 - 1
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml300064v
CHEMBL495095 187664 None 3 Human Functional pEC50 = 7.3 7.3 - 1
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml300064v
24906198 187664 None 3 Human Functional pEC50 = 7.3 7.3 - 1
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL495095 187664 None 3 Human Functional pEC50 = 7.3 7.3 - 1
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
11265631 136409 None 0 Human Functional pEC50 = 7.3 7.3 9 3
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm061487a
CHEMBL373535 136409 None 0 Human Functional pEC50 = 7.3 7.3 9 3
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm061487a
11173568 84641 None 0 Human Functional pEC50 = 6.3 6.3 -1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 281 4 2 4 2.7 CC(Oc1ccccc1-c1cccc(N)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222371 84641 None 0 Human Functional pEC50 = 6.3 6.3 -1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 281 4 2 4 2.7 CC(Oc1ccccc1-c1cccc(N)c1)C1=NCCN1 10.1021/jm0408215
24906160 169456 None 0 Human Functional pEC50 = 6.3 6.3 - 1
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 247 5 1 5 1.4 CO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL442815 169456 None 0 Human Functional pEC50 = 6.3 6.3 - 1
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 247 5 1 5 1.4 CO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
11090351 163391 None 0 Human Functional pEC50 = 6.3 6.3 -20 2
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL419448 163391 None 0 Human Functional pEC50 = 6.3 6.3 -20 2
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
10221004 204231 None 0 Human Functional pEC50 = 5.3 5.3 -20 2
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 267 5 2 5 0.9 CCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70973 204231 None 0 Human Functional pEC50 = 5.3 5.3 -20 2
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 267 5 2 5 0.9 CCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
11079 2733 None 63 Human Functional pEC50 = 7.3 7.3 -13 7
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
3369 2733 None 63 Human Functional pEC50 = 7.3 7.3 -13 7
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
4436 2733 None 63 Human Functional pEC50 = 7.3 7.3 -13 7
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
4436.0 2733 None 63 Human Functional pEC50 = 7.3 7.3 -13 7
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
5509 2733 None 63 Human Functional pEC50 = 7.3 7.3 -13 7
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
CHEMBL761 2733 None 63 Human Functional pEC50 = 7.3 7.3 -13 7
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
DB06711 2733 None 63 Human Functional pEC50 = 7.3 7.3 -13 7
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
2803 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
2803.0 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
516 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
704 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
CHEMBL134 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
DB00575 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
10382537 204166 None 12 Human Functional pEC50 = 7.3 7.3 -4 2
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 339 1 2 5 1.6 Ic1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL70676 204166 None 12 Human Functional pEC50 = 7.3 7.3 -4 2
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 339 1 2 5 1.6 Ic1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
2803 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl nan
2803.0 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl nan
516 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl nan
704 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl nan
CHEMBL134 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl nan
DB00575 955 None 58 Human Functional pEC50 = 7.3 7.3 -15 14
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl nan
44371744 50321 None 0 Human Functional pEC50 = 7.3 7.3 8 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 270 7 1 3 2.9 C=CCc1cccc(CC=C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL157206 50321 None 0 Human Functional pEC50 = 7.3 7.3 8 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 270 7 1 3 2.9 C=CCc1cccc(CC=C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
135399666 168763 None 7 Human Functional pEC50 = 5.3 5.3 -66 6
Activity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assayActivity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assay
ChEMBL 191 2 2 4 1.1 C[C@@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
CHEMBL437314 168763 None 7 Human Functional pEC50 = 5.3 5.3 -66 6
Activity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assayActivity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assay
ChEMBL 191 2 2 4 1.1 C[C@@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
2803 955 None 58 Human Functional pEC50 = 7.2 7.2 -15 14
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm100977d
2803.0 955 None 58 Human Functional pEC50 = 7.2 7.2 -15 14
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm100977d
516 955 None 58 Human Functional pEC50 = 7.2 7.2 -15 14
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm100977d
704 955 None 58 Human Functional pEC50 = 7.2 7.2 -15 14
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm100977d
CHEMBL134 955 None 58 Human Functional pEC50 = 7.2 7.2 -15 14
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm100977d
DB00575 955 None 58 Human Functional pEC50 = 7.2 7.2 -15 14
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm100977d
44352207 18856 None 1 Human Functional pEC50 = 7.2 7.2 1 3
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL128168 18856 None 1 Human Functional pEC50 = 7.2 7.2 1 3
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
44352207 18856 None 1 Human Functional pEC50 = 7.2 7.2 1 3
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL128168 18856 None 1 Human Functional pEC50 = 7.2 7.2 1 3
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
44352207 18856 None 1 Human Functional pEC50 = 7.2 7.2 1 3
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL128168 18856 None 1 Human Functional pEC50 = 7.2 7.2 1 3
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm800250z
44352207 18856 None 1 Human Functional pEC50 = 7.2 7.2 1 3
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL128168 18856 None 1 Human Functional pEC50 = 7.2 7.2 1 3
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
11360447 85001 None 0 Human Functional pEC50 = 7.2 7.2 -1 3
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1cccs1)C1=NCCN1 10.1021/jm0408215
CHEMBL223829 85001 None 0 Human Functional pEC50 = 7.2 7.2 -1 3
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1cccs1)C1=NCCN1 10.1021/jm0408215
49836305 18576 None 0 Human Functional pEC50 = 8.2 8.2 9 3
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 C[C@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276248 18576 None 0 Human Functional pEC50 = 8.2 8.2 9 3
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 C[C@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
10176999 103554 None 21 Human Functional pEC50 = 8.2 8.2 1 3
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 231 2 2 4 2.2 Cc1c(Nc2ncc[nH]2)ccc2c1OCCO2 10.1021/jm9605142
CHEMBL308570 103554 None 21 Human Functional pEC50 = 8.2 8.2 1 3
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 231 2 2 4 2.2 Cc1c(Nc2ncc[nH]2)ccc2c1OCCO2 10.1021/jm9605142
11211035 85003 None 0 Human Functional pEC50 = 7.2 7.2 1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL223836 85003 None 0 Human Functional pEC50 = 7.2 7.2 1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm0408215
11211035 85003 None 0 Human Functional pEC50 = 7.2 7.2 1 2
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm061487a
CHEMBL223836 85003 None 0 Human Functional pEC50 = 7.2 7.2 1 2
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm061487a
9971924 184226 None 0 Human Functional pEC50 = 7.2 7.2 -1 2
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 298 5 1 3 3.4 c1ccc(CCC[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL48341 184226 None 0 Human Functional pEC50 = 7.2 7.2 -1 2
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 298 5 1 3 3.4 c1ccc(CCC[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
45487089 197640 None 0 Human Functional pEC50 = 7.2 7.2 79 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 204 2 1 3 2.0 Cc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL570863 197640 None 0 Human Functional pEC50 = 7.2 7.2 79 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 204 2 1 3 2.0 Cc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
57393922 71186 None 0 Human Functional pEC50 = 6.2 6.2 5 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 5 1 4 2.0 C=COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956198 71186 None 0 Human Functional pEC50 = 6.2 6.2 5 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 5 1 4 2.0 C=COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
10923927 204178 None 0 Human Functional pEC50 = 5.2 5.2 - 1
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 279 3 2 5 0.8 O=S1(=O)CCCc2cccc(NCC3=NCCN3)c21 10.1021/jm000542r
CHEMBL70740 204178 None 0 Human Functional pEC50 = 5.2 5.2 - 1
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 279 3 2 5 0.8 O=S1(=O)CCCc2cccc(NCC3=NCCN3)c21 10.1021/jm000542r
770500 121716 None 3 Human Functional pEC50 = 3.2 3.2 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 242 4 2 3 2.4 NCC(=O)Nc1ccccc1Oc1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL3588909 121716 None 3 Human Functional pEC50 = 3.2 3.2 - 1
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 242 4 2 3 2.4 NCC(=O)Nc1ccccc1Oc1ccccc1 10.1016/j.bmc.2015.01.013
11034737 204528 None 0 Human Functional pEC50 = 8.1 8.1 -1 4
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 289 4 2 4 2.8 CSc1ccc(C(F)(F)F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72724 204528 None 0 Human Functional pEC50 = 8.1 8.1 -1 4
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 289 4 2 4 2.8 CSc1ccc(C(F)(F)F)cc1NCC1=NCCN1 10.1021/jm000542r
16757182 153251 None 0 Human Functional pEC50 = 6.1 6.1 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL397753 153251 None 0 Human Functional pEC50 = 6.1 6.1 - 1
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
16757182 153251 None 0 Human Functional pEC50 = 6.1 6.1 - 1
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL397753 153251 None 0 Human Functional pEC50 = 6.1 6.1 - 1
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
294234 102893 None 3 Human Functional pEC50 = 7.1 7.1 -2 3
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 182 1 1 3 1.7 C1CCCC(NC2=NCCO2)CC1 10.1016/0960-894X(94)85032-1
CHEMBL305928 102893 None 3 Human Functional pEC50 = 7.1 7.1 -2 3
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 182 1 1 3 1.7 C1CCCC(NC2=NCCO2)CC1 10.1016/0960-894X(94)85032-1
24906200 193156 None 0 Human Functional pEC50 = 6.1 6.1 1 2
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 328 5 1 3 4.5 c1ccc(-c2ccccc2OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
CHEMBL523048 193156 None 0 Human Functional pEC50 = 6.1 6.1 1 2
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 328 5 1 3 4.5 c1ccc(-c2ccccc2OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
57395732 71191 None 0 Human Functional pEC50 = 7.1 7.1 2 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 342 5 1 3 4.8 CC(Oc1c(-c2ccccc2)cccc1-c1ccccc1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956203 71191 None 0 Human Functional pEC50 = 7.1 7.1 2 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 342 5 1 3 4.8 CC(Oc1c(-c2ccccc2)cccc1-c1ccccc1)C1=NCCN1 10.1016/j.bmc.2012.01.035
1960 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
439260 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
439260.0 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
505 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
CHEMBL1437 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
DB00368 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
1960 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
439260 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
439260.0 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
505 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
CHEMBL1437 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
DB00368 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
57395663 71181 None 0 Human Functional pEC50 = 6.1 6.1 -3 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.5 CC(Oc1ccccc1C(F)(F)F)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956193 71181 None 0 Human Functional pEC50 = 6.1 6.1 -3 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.5 CC(Oc1ccccc1C(F)(F)F)C1=NCCN1 10.1016/j.bmc.2012.01.035
1960 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
439260 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
439260.0 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
505 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
CHEMBL1437 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
DB00368 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
24906201 187353 None 0 Human Functional pEC50 = 6.1 6.1 15 2
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
CHEMBL493272 187353 None 0 Human Functional pEC50 = 6.1 6.1 15 2
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
9947861 204162 None 0 Human Functional pEC50 = 6.1 6.1 -281 3
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70634 204162 None 0 Human Functional pEC50 = 6.1 6.1 -281 3
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
1960 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
439260 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
439260.0 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
505 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
CHEMBL1437 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
DB00368 2857 None 67 Human Functional pEC50 = 6.1 6.1 -11 18
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
2435 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
2435.0 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
395 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
520 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
5386 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
CHEMBL844 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
DB00484 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
10934575 204486 None 0 Human Functional pEC50 = 8.1 8.1 -81 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 4 2 4 2.1 CSc1ccc(C)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72441 204486 None 0 Human Functional pEC50 = 8.1 8.1 -81 5
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 4 2 4 2.1 CSc1ccc(C)cc1NCC1=NCCN1 10.1021/jm000542r
11173544 166261 None 0 Human Functional pEC50 = 6.1 6.1 - 1
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1ccc(-c2ccccc2OC(C)C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL426900 166261 None 0 Human Functional pEC50 = 6.1 6.1 - 1
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1ccc(-c2ccccc2OC(C)C2=NCCN2)cc1 10.1021/jm0408215
15675860 204429 None 0 Human Functional pEC50 = 6.1 6.1 1 2
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 305 1 2 5 2.1 Cc1cnc2c(Br)c(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
CHEMBL72147 204429 None 0 Human Functional pEC50 = 6.1 6.1 1 2
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 305 1 2 5 2.1 Cc1cnc2c(Br)c(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
44312036 204565 None 1 Human Functional pEC50 = 6.1 6.1 19 2
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 305 1 2 5 2.2 CC1CN=C(Nc2ccc3nccnc3c2Br)N1 10.1016/0960-894X(95)00391-6
CHEMBL72995 204565 None 1 Human Functional pEC50 = 6.1 6.1 19 2
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 305 1 2 5 2.2 CC1CN=C(Nc2ccc3nccnc3c2Br)N1 10.1016/0960-894X(95)00391-6
2435 722 None 100 Human Functional pEC50 = 8.0 8.0 -7 10
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
2435.0 722 None 100 Human Functional pEC50 = 8.0 8.0 -7 10
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
395 722 None 100 Human Functional pEC50 = 8.0 8.0 -7 10
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
520 722 None 100 Human Functional pEC50 = 8.0 8.0 -7 10
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
5386 722 None 100 Human Functional pEC50 = 8.0 8.0 -7 10
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
CHEMBL844 722 None 100 Human Functional pEC50 = 8.0 8.0 -7 10
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
DB00484 722 None 100 Human Functional pEC50 = 8.0 8.0 -7 10
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
11371902 141638 None 0 Human Functional pEC50 = 7.0 7.0 -1 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL385310 141638 None 0 Human Functional pEC50 = 7.0 7.0 -1 2
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
11140033 20683 None 0 Human Functional pEC50 = 7.0 7.0 4 3
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 265 4 2 3 3.2 CC(Nc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL130884 20683 None 0 Human Functional pEC50 = 7.0 7.0 4 3
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 265 4 2 3 3.2 CC(Nc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
11371902 141638 None 0 Human Functional pEC50 = 7.0 7.0 -1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm0408215
CHEMBL385310 141638 None 0 Human Functional pEC50 = 7.0 7.0 -1 2
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm0408215
57402717 71187 None 2 Human Functional pEC50 = 5.0 5.0 10 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 220 4 1 4 1.5 COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956199 71187 None 2 Human Functional pEC50 = 5.0 5.0 10 2
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 220 4 1 4 1.5 COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
156735109 186605 None 0 Human Functional pIC50 = 10.1 10.1 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 505 8 1 7 4.0 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(COC4CCC4)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
CHEMBL4878875 186605 None 0 Human Functional pIC50 = 10.1 10.1 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 505 8 1 7 4.0 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(COC4CCC4)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
156735161 186368 None 0 Human Functional pIC50 = 9.6 9.6 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 465 5 1 6 3.5 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC4(CC4)C3)C(F)C2)s1 10.1021/acsmedchemlett.1c00423
CHEMBL4875484 186368 None 0 Human Functional pIC50 = 9.6 9.6 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 465 5 1 6 3.5 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC4(CC4)C3)C(F)C2)s1 10.1021/acsmedchemlett.1c00423
164617361 184835 None 0 Human Functional pIC50 = 9.5 9.5 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 499 6 1 7 3.8 COc1cccc2c1CN(C1CCN(c3ncc(C(=O)NCc4ncc(F)cc4F)s3)CC1)CC2 10.1021/acsmedchemlett.1c00423
CHEMBL4852159 184835 None 0 Human Functional pIC50 = 9.5 9.5 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 499 6 1 7 3.8 COc1cccc2c1CN(C1CCN(c3ncc(C(=O)NCc4ncc(F)cc4F)s3)CC1)CC2 10.1021/acsmedchemlett.1c00423
156735115 186425 None 0 Human Functional pIC50 = 9.4 9.4 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 527 8 1 7 3.9 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(OCC4CC4(F)F)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
CHEMBL4876214 186425 None 0 Human Functional pIC50 = 9.4 9.4 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 527 8 1 7 3.9 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(OCC4CC4(F)F)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
156735204 185910 None 0 Human Functional pIC50 = 9.4 9.4 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 483 5 1 6 4.1 Cc1ccc2c(c1)CN(C1CCN(c3ncc(C(=O)NCc4ncc(F)cc4F)s3)CC1)CC2 10.1021/acsmedchemlett.1c00423
CHEMBL4868807 185910 None 0 Human Functional pIC50 = 9.4 9.4 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 483 5 1 6 4.1 Cc1ccc2c(c1)CN(C1CCN(c3ncc(C(=O)NCc4ncc(F)cc4F)s3)CC1)CC2 10.1021/acsmedchemlett.1c00423
156735188 185758 None 0 Human Functional pIC50 = 9.3 9.3 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 505 8 1 7 4.0 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(OCC4CCC4)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
CHEMBL4866383 185758 None 0 Human Functional pIC50 = 9.3 9.3 - 1
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 505 8 1 7 4.0 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(OCC4CCC4)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
136 3292 None 32 Human Functional pIC50 = 7.8 7.8 - 1
Antagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulationAntagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulation
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
223 3292 None 32 Human Functional pIC50 = 7.8 7.8 - 1
Antagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulationAntagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulation
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
643606 3292 None 32 Human Functional pIC50 = 7.8 7.8 - 1
Antagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulationAntagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulation
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
CHEMBL10347 3292 None 32 Human Functional pIC50 = 7.8 7.8 - 1
Antagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulationAntagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulation
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
11306100 168507 None 0 Human Functional pKi = 10.5 10.5 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 477 9 0 7 3.5 COCCOc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL435352 168507 None 0 Human Functional pKi = 10.5 10.5 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 477 9 0 7 3.5 COCCOc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11271808 60994 None 0 Human Functional pKi = 10 10.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 490 9 0 7 3.5 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OCCN(C)C)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL176261 60994 None 0 Human Functional pKi = 10 10.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 490 9 0 7 3.5 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OCCN(C)C)cc4OC[C@H]32)CC1 10.1021/jm049619s
135519400 63894 None 0 Human Functional pKi = 10 10.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 419 5 1 6 3.2 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(O)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL180470 63894 None 0 Human Functional pKi = 10 10.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 419 5 1 6 3.2 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(O)cc4OC[C@H]32)CC1 10.1021/jm049619s
135440165 78945 None 0 Human Functional pKi = 10 10.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112985 78945 None 0 Human Functional pKi = 10 10.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
11214030 60544 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 491 8 0 8 3.1 COCC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL175853 60544 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 491 8 0 8 3.1 COCC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
44387789 60575 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 433 6 0 6 3.5 COc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL176002 60575 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 433 6 0 6 3.5 COc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11259744 60796 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 461 6 0 7 3.4 CC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL176116 60796 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 461 6 0 7 3.4 CC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11785961 63280 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 535 13 0 8 4.0 CCOCCOCCOc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL179237 63280 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 535 13 0 8 4.0 CCOCCOCCOc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
44324800 206948 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL91157 206948 None 0 Human Functional pKi = 9.7 9.7 - 0
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
11785068 60556 None 0 Human Functional pKi = 9.5 9.5 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 487 7 0 7 3.8 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)C5CC5)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL175911 60556 None 0 Human Functional pKi = 9.5 9.5 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 487 7 0 7 3.8 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)C5CC5)cc4OC[C@H]32)CC1 10.1021/jm049619s
11260018 63859 None 0 Human Functional pKi = 9.3 9.3 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 473 7 0 7 3.6 C=CC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL180322 63859 None 0 Human Functional pKi = 9.3 9.3 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 473 7 0 7 3.6 C=CC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11190988 131803 None 0 Human Functional pKi = 9.3 9.3 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 487 7 0 6 4.8 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC5CCCC5)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL369378 131803 None 0 Human Functional pKi = 9.3 9.3 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 487 7 0 6 4.8 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC5CCCC5)cc4OC[C@H]32)CC1 10.1021/jm049619s
11318438 165984 None 0 Human Functional pKi = 9.3 9.3 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 524 7 0 8 4.1 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)c5ccncc5)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL425324 165984 None 0 Human Functional pKi = 9.3 9.3 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 524 7 0 8 4.1 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)c5ccncc5)cc4OC[C@H]32)CC1 10.1021/jm049619s
44324972 163372 None 0 Human Functional pKi = 9.2 9.2 - 0
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL419316 163372 None 0 Human Functional pKi = 9.2 9.2 - 0
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
11191321 62985 None 0 Human Functional pKi = 8.8 8.8 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 503 6 0 7 4.5 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)C(C)(C)C)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL178588 62985 None 0 Human Functional pKi = 8.8 8.8 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 503 6 0 7 4.5 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)C(C)(C)C)cc4OC[C@H]32)CC1 10.1021/jm049619s
135405894 78930 None 0 Human Functional pKi = 8.8 8.8 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 470 8 1 8 2.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(CCOc4ccc(F)cc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112969 78930 None 0 Human Functional pKi = 8.8 8.8 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 470 8 1 8 2.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(CCOc4ccc(F)cc4)CC3)[C@@H]1CN2 10.1021/jm049619s
44579272 187095 None 0 Human Functional pKi = 8.8 8.8 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 499 7 0 9 4.3 c1ccc(Oc2ncccc2-c2noc(CN3CCCN(CC4COc5ccccc5O4)CC3)n2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL491420 187095 None 0 Human Functional pKi = 8.8 8.8 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 499 7 0 9 4.3 c1ccc(Oc2ncccc2-c2noc(CN3CCCN(CC4COc5ccccc5O4)CC3)n2)cc1 10.1016/j.bmcl.2008.08.055
71450907 78939 None 0 Human Functional pKi = 8.8 8.8 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 389 5 0 5 3.1 C(=C/c1ccccc1)\CN1CCN(C[C@@H]2ON=C3c4ccccc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL2112978 78939 None 0 Human Functional pKi = 8.8 8.8 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 389 5 0 5 3.1 C(=C/c1ccccc1)\CN1CCN(C[C@@H]2ON=C3c4ccccc4OC[C@H]32)CC1 10.1021/jm049619s
44579187 189679 None 0 Human Functional pKi = 8.7 8.7 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 513 8 1 8 3.3 N#Cc1cccc(Oc2ncccc2C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)c1 10.1016/j.bmcl.2008.08.055
CHEMBL515331 189679 None 0 Human Functional pKi = 8.7 8.7 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 513 8 1 8 3.3 N#Cc1cccc(Oc2ncccc2C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)c1 10.1016/j.bmcl.2008.08.055
25110718 193309 None 0 Human Functional pKi = 8.7 8.7 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL524153 193309 None 0 Human Functional pKi = 8.7 8.7 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
44387798 166273 None 0 Human Functional pKi = 8.0 8.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 458 7 0 5 3.9 CC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(CCC/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL426959 166273 None 0 Human Functional pKi = 8.0 8.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 458 7 0 5 3.9 CC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(CCC/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
71456239 78940 None 0 Human Functional pKi = 7.0 7.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 385 5 0 4 3.8 C1=C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL2112979 78940 None 0 Human Functional pKi = 7.0 7.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 385 5 0 4 3.8 C1=C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
136044137 78937 None 0 Human Functional pKi = 7.9 7.9 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 472 6 1 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112976 78937 None 0 Human Functional pKi = 7.9 7.9 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 472 6 1 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CN2 10.1021/jm049619s
135499867 78941 None 0 Human Functional pKi = 7.8 7.8 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 388 5 1 5 3.2 C(=C/c1ccccc1)\CN1CCN(C[C@@H]2ON=C3c4ccccc4NC[C@H]32)CC1 10.1021/jm049619s
CHEMBL2112981 78941 None 0 Human Functional pKi = 7.8 7.8 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 388 5 1 5 3.2 C(=C/c1ccccc1)\CN1CCN(C[C@@H]2ON=C3c4ccccc4NC[C@H]32)CC1 10.1021/jm049619s
11224953 78934 None 0 Human Functional pKi = 8.6 8.6 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 459 6 1 5 3.3 CCNC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL2112973 78934 None 0 Human Functional pKi = 8.6 8.6 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 459 6 1 5 3.3 CCNC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
10758200 63417 None 0 Human Functional pKi = 7.7 7.7 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 322 4 0 3 3.2 c1ccc(CN2CCN(CC3CCc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL179648 63417 None 0 Human Functional pKi = 7.7 7.7 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 322 4 0 3 3.2 c1ccc(CN2CCN(CC3CCc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
44579184 190953 None 4 Human Functional pKi = 7.6 7.6 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 340 4 0 5 2.7 COc1ccccc1N1CCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL518592 190953 None 4 Human Functional pKi = 7.6 7.6 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 340 4 0 5 2.7 COc1ccccc1N1CCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
135519421 78935 None 0 Human Functional pKi = 7.6 7.6 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 456 6 1 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc(Cl)cc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112974 78935 None 0 Human Functional pKi = 7.6 7.6 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 456 6 1 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc(Cl)cc4)CC3)[C@@H]1CN2 10.1021/jm049619s
44579185 181814 None 1 Human Functional pKi = 7.6 7.6 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL477816 181814 None 1 Human Functional pKi = 7.6 7.6 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
44324737 207238 None 0 Human Functional pKi = 8.5 8.5 - 0
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL92860 207238 None 0 Human Functional pKi = 8.5 8.5 - 0
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1021/jm049619s
135477797 78932 None 0 Human Functional pKi = 8.4 8.4 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112971 78932 None 0 Human Functional pKi = 8.4 8.4 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
44579230 181544 None 0 Human Functional pKi = 8.4 8.4 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 468 10 1 7 2.8 CCCCOc1cccc(C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)n1 10.1016/j.bmcl.2008.08.055
CHEMBL476569 181544 None 0 Human Functional pKi = 8.4 8.4 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 468 10 1 7 2.8 CCCCOc1cccc(C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)n1 10.1016/j.bmcl.2008.08.055
71456240 78942 None 0 Human Functional pKi = 8.4 8.4 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 415 6 0 5 3.8 COc1ccc2c(c1)C=C[C@@H]1C2=NO[C@H]1CN1CCN(C/C=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL2112982 78942 None 0 Human Functional pKi = 8.4 8.4 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 415 6 0 5 3.8 COc1ccc2c(c1)C=C[C@@H]1C2=NO[C@H]1CN1CCN(C/C=C/c2ccccc2)CC1 10.1021/jm049619s
44579228 181654 None 0 Human Functional pKi = 7.5 7.5 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 467 7 2 7 2.9 CC(C)(C)Nc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL477608 181654 None 0 Human Functional pKi = 7.5 7.5 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 467 7 2 7 2.9 CC(C)(C)Nc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
71456238 78938 None 0 Human Functional pKi = 8.4 8.4 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 504 9 0 7 4.4 COc1cc2c(cc1OC)N(C)C[C@@H]1C2=NO[C@H]1CN1CCN(CCC/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL2112977 78938 None 0 Human Functional pKi = 8.4 8.4 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 504 9 0 7 4.4 COc1cc2c(cc1OC)N(C)C[C@@H]1C2=NO[C@H]1CN1CCN(CCC/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11200476 78931 None 0 Human Functional pKi = 8.4 8.4 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 402 5 0 5 3.2 CN1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL2112970 78931 None 0 Human Functional pKi = 8.4 8.4 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 402 5 0 5 3.2 CN1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
44579229 189616 None 0 Human Functional pKi = 8.3 8.3 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 468 10 1 7 2.8 CCCCOc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL514837 189616 None 0 Human Functional pKi = 8.3 8.3 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 468 10 1 7 2.8 CCCCOc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
135545454 78943 None 0 Human Functional pKi = 8.3 8.3 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 448 7 1 7 3.2 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112983 78943 None 0 Human Functional pKi = 8.3 8.3 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 448 7 1 7 3.2 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
44324765 111568 None 0 Human Functional pKi = 8.2 8.2 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL328114 111568 None 0 Human Functional pKi = 8.2 8.2 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
71461647 78933 None 0 Human Functional pKi = 8.2 8.2 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 439 5 0 5 4.4 COc1ccc2c(c1)C=C[C@@H]1C2=NO[C@H]1CN1CCN(Cc2ccc3ccccc3c2)CC1 10.1021/jm049619s
CHEMBL2112972 78933 None 0 Human Functional pKi = 8.2 8.2 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 439 5 0 5 4.4 COc1ccc2c(c1)C=C[C@@H]1C2=NO[C@H]1CN1CCN(Cc2ccc3ccccc3c2)CC1 10.1021/jm049619s
44579271 187094 None 0 Human Functional pKi = 8.2 8.2 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 475 9 0 7 4.2 c1ccc(Oc2ncccc2COCCN2CCCN(CC3COc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL491419 187094 None 0 Human Functional pKi = 8.2 8.2 - 0
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 475 9 0 7 4.2 c1ccc(Oc2ncccc2COCCN2CCCN(CC3COc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
10073773 161123 None 16 Human Functional pKi = 6.2 6.2 - 0
Inhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assayInhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assay
ChEMBL 477 5 0 6 3.4 COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br 10.1021/acs.jmedchem.6b01662
10073773.0 161123 None 16 Human Functional pKi = 6.2 6.2 - 0
Inhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assayInhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assay
ChEMBL 477 5 0 6 3.4 COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br 10.1021/acs.jmedchem.6b01662
CHEMBL4082473 161123 None 16 Human Functional pKi = 6.2 6.2 - 0
Inhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assayInhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assay
ChEMBL 477 5 0 6 3.4 COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br 10.1021/acs.jmedchem.6b01662
CHEMBL4117187 161123 None 16 Human Functional pKi = 6.2 6.2 - 0
Inhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assayInhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assay
ChEMBL 477 5 0 6 3.4 COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br 10.1021/acs.jmedchem.6b01662
DB06140 161123 None 16 Human Functional pKi = 6.2 6.2 - 0
Inhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assayInhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assay
ChEMBL 477 5 0 6 3.4 COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br 10.1021/acs.jmedchem.6b01662
44324765 111568 None 0 Human Functional pKi = 8.1 8.1 - 0
Binding affinity for Alpha-2C adrenergic receptorBinding affinity for Alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL328114 111568 None 0 Human Functional pKi = 8.1 8.1 - 0
Binding affinity for Alpha-2C adrenergic receptorBinding affinity for Alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
136274357 78944 None 0 Human Functional pKi = 8.0 8.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 412 4 1 5 3.8 c1ccc2c(c1)NC[C@@H]1C2=NO[C@H]1CN1CCN(Cc2ccc3ccccc3c2)CC1 10.1021/jm049619s
CHEMBL2112984 78944 None 0 Human Functional pKi = 8.0 8.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 412 4 1 5 3.8 c1ccc2c(c1)NC[C@@H]1C2=NO[C@H]1CN1CCN(Cc2ccc3ccccc3c2)CC1 10.1021/jm049619s
11385652 78936 None 0 Human Functional pKi = 8.0 8.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 460 6 0 6 3.7 CCOC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL2112975 78936 None 0 Human Functional pKi = 8.0 8.0 - 0
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 460 6 0 6 3.7 CCOC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
1343 1889 None 62 Human Functional pEC50 = 8.3 8.3 -11 12
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
3519 1889 None 62 Human Functional pEC50 = 8.3 8.3 -11 12
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
3519.0 1889 None 62 Human Functional pEC50 = 8.3 8.3 -11 12
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
522 1889 None 62 Human Functional pEC50 = 8.3 8.3 -11 12
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
CHEMBL862 1889 None 62 Human Functional pEC50 = 8.3 8.3 -11 12
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
DB01018 1889 None 62 Human Functional pEC50 = 8.3 8.3 -11 12
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
2683 3834 None 60 Human Functional pEC50 = 8.2 8.2 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
5487 3834 None 60 Human Functional pEC50 = 8.2 8.2 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
5487.0 3834 None 60 Human Functional pEC50 = 8.2 8.2 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
7308 3834 None 60 Human Functional pEC50 = 8.2 8.2 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
CHEMBL1079 3834 None 60 Human Functional pEC50 = 8.2 8.2 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
DB00697 3834 None 60 Human Functional pEC50 = 8.2 8.2 -5 6
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
2803 955 None 58 Human Functional pEC50 = 8.2 8.2 -15 14
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
2803.0 955 None 58 Human Functional pEC50 = 8.2 8.2 -15 14
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
516 955 None 58 Human Functional pEC50 = 8.2 8.2 -15 14
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
704 955 None 58 Human Functional pEC50 = 8.2 8.2 -15 14
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
CHEMBL134 955 None 58 Human Functional pEC50 = 8.2 8.2 -15 14
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
DB00575 955 None 58 Human Functional pEC50 = 8.2 8.2 -15 14
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
2435 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
2435.0 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
395 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
520 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
5386 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
CHEMBL844 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
DB00484 722 None 100 Human Functional pEC50 = 8.1 8.1 -7 10
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
124 2981 None 47 Human Functional pEC50 = 6.9 6.9 -144 24
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
2032 2981 None 47 Human Functional pEC50 = 6.9 6.9 -144 24
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636 2981 None 47 Human Functional pEC50 = 6.9 6.9 -144 24
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636.0 2981 None 47 Human Functional pEC50 = 6.9 6.9 -144 24
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
CHEMBL762 2981 None 47 Human Functional pEC50 = 6.9 6.9 -144 24
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
DB00935 2981 None 47 Human Functional pEC50 = 6.9 6.9 -144 24
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
2803 955 None 58 Human Functional pEC50 = 5.7 5.7 -15 14
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
2803.0 955 None 58 Human Functional pEC50 = 5.7 5.7 -15 14
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
516 955 None 58 Human Functional pEC50 = 5.7 5.7 -15 14
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
704 955 None 58 Human Functional pEC50 = 5.7 5.7 -15 14
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
CHEMBL134 955 None 58 Human Functional pEC50 = 5.7 5.7 -15 14
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
DB00575 955 None 58 Human Functional pEC50 = 5.7 5.7 -15 14
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
12574 2605 None 88 Human Functional pEC50 = 5.0 5.0 -26 8
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
4810 2605 None 88 Human Functional pEC50 = 5.0 5.0 -26 8
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
4810.0 2605 None 88 Human Functional pEC50 = 5.0 5.0 -26 8
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
CHEMBL19236 2605 None 88 Human Functional pEC50 = 5.0 5.0 -26 8
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
DB09242 2605 None 88 Human Functional pEC50 = 5.0 5.0 -26 8
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
3952 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5353646 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5353646.0 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5443 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5702063 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5702063.0 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
CHEMBL1331786 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
CHEMBL420 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
DB00629 1888 None 38 Human Functional pEC50 = 5.9 5.9 -18 21
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
2435 722 None 100 Human Functional pEC50 = 6.4 6.4 -7 10
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
2435.0 722 None 100 Human Functional pEC50 = 6.4 6.4 -7 10
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
395 722 None 100 Human Functional pEC50 = 6.4 6.4 -7 10
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
520 722 None 100 Human Functional pEC50 = 6.4 6.4 -7 10
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
5386 722 None 100 Human Functional pEC50 = 6.4 6.4 -7 10
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
CHEMBL844 722 None 100 Human Functional pEC50 = 6.4 6.4 -7 10
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
DB00484 722 None 100 Human Functional pEC50 = 6.4 6.4 -7 10
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
1960 2857 None 67 Human Functional pEC50 = 6.3 6.3 -11 18
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260 2857 None 67 Human Functional pEC50 = 6.3 6.3 -11 18
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260.0 2857 None 67 Human Functional pEC50 = 6.3 6.3 -11 18
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
505 2857 None 67 Human Functional pEC50 = 6.3 6.3 -11 18
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
CHEMBL1437 2857 None 67 Human Functional pEC50 = 6.3 6.3 -11 18
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
DB00368 2857 None 67 Human Functional pEC50 = 6.3 6.3 -11 18
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
12574 2605 None 88 Human Functional pEC50 = 6.9 6.9 -26 8
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810 2605 None 88 Human Functional pEC50 = 6.9 6.9 -26 8
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810.0 2605 None 88 Human Functional pEC50 = 6.9 6.9 -26 8
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
CHEMBL19236 2605 None 88 Human Functional pEC50 = 6.9 6.9 -26 8
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
DB09242 2605 None 88 Human Functional pEC50 = 6.9 6.9 -26 8
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
523 4106 None 93 Human Functional pEC50 = 7.1 7.1 -1 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
5707 4106 None 93 Human Functional pEC50 = 7.1 7.1 -1 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
CHEMBL297362 4106 None 93 Human Functional pEC50 = 7.1 7.1 -1 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
DB11477 4106 None 93 Human Functional pEC50 = 7.1 7.1 -1 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
1028 291 None 71 Human Functional pEC50 = 7.6 7.6 -44 19
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
139148732 291 None 71 Human Functional pEC50 = 7.6 7.6 -44 19
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
479 291 None 71 Human Functional pEC50 = 7.6 7.6 -44 19
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816 291 None 71 Human Functional pEC50 = 7.6 7.6 -44 19
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816.0 291 None 71 Human Functional pEC50 = 7.6 7.6 -44 19
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL679 291 None 71 Human Functional pEC50 = 7.6 7.6 -44 19
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00668 291 None 71 Human Functional pEC50 = 7.6 7.6 -44 19
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
11079 2733 None 63 Human Functional pEC50 = 7.7 7.7 -13 7
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
3369 2733 None 63 Human Functional pEC50 = 7.7 7.7 -13 7
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436 2733 None 63 Human Functional pEC50 = 7.7 7.7 -13 7
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436.0 2733 None 63 Human Functional pEC50 = 7.7 7.7 -13 7
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
5509 2733 None 63 Human Functional pEC50 = 7.7 7.7 -13 7
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
CHEMBL761 2733 None 63 Human Functional pEC50 = 7.7 7.7 -13 7
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
DB06711 2733 None 63 Human Functional pEC50 = 7.7 7.7 -13 7
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
1960 2857 None 67 Human Functional pEC50 = 7.7 7.7 -11 18
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260 2857 None 67 Human Functional pEC50 = 7.7 7.7 -11 18
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260.0 2857 None 67 Human Functional pEC50 = 7.7 7.7 -11 18
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
505 2857 None 67 Human Functional pEC50 = 7.7 7.7 -11 18
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL1437 2857 None 67 Human Functional pEC50 = 7.7 7.7 -11 18
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00368 2857 None 67 Human Functional pEC50 = 7.7 7.7 -11 18
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
2803 955 None 58 Human Functional pEC50 = 7.8 7.8 -15 14
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
2803.0 955 None 58 Human Functional pEC50 = 7.8 7.8 -15 14
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
516 955 None 58 Human Functional pEC50 = 7.8 7.8 -15 14
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
704 955 None 58 Human Functional pEC50 = 7.8 7.8 -15 14
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
CHEMBL134 955 None 58 Human Functional pEC50 = 7.8 7.8 -15 14
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
DB00575 955 None 58 Human Functional pEC50 = 7.8 7.8 -15 14
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
1343 1889 None 62 Human Functional pEC50 = 8 8.0 -11 12
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519 1889 None 62 Human Functional pEC50 = 8 8.0 -11 12
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519.0 1889 None 62 Human Functional pEC50 = 8 8.0 -11 12
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
522 1889 None 62 Human Functional pEC50 = 8 8.0 -11 12
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
CHEMBL862 1889 None 62 Human Functional pEC50 = 8 8.0 -11 12
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
DB01018 1889 None 62 Human Functional pEC50 = 8 8.0 -11 12
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
2435 722 None 100 Human Functional pEC50 = 8.2 8.2 -7 10
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
2435.0 722 None 100 Human Functional pEC50 = 8.2 8.2 -7 10
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
395 722 None 100 Human Functional pEC50 = 8.2 8.2 -7 10
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
520 722 None 100 Human Functional pEC50 = 8.2 8.2 -7 10
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
5386 722 None 100 Human Functional pEC50 = 8.2 8.2 -7 10
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
CHEMBL844 722 None 100 Human Functional pEC50 = 8.2 8.2 -7 10
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
DB00484 722 None 100 Human Functional pEC50 = 8.2 8.2 -7 10
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
3952 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646.0 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5443 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5702063 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5702063.0 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL1331786 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL420 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
DB00629 1888 None 38 Human Functional pEC50 = 8.4 8.4 -18 21
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
521 1404 None 69 Human Functional pEC50 = 9.6 9.6 -4 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068 1404 None 69 Human Functional pEC50 = 9.6 9.6 -4 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068.0 1404 None 69 Human Functional pEC50 = 9.6 9.6 -4 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
835 1404 None 69 Human Functional pEC50 = 9.6 9.6 -4 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
CHEMBL778 1404 None 69 Human Functional pEC50 = 9.6 9.6 -4 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
DB00633 1404 None 69 Human Functional pEC50 = 9.6 9.6 -4 5
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
30699 217704 None 0 Human Functional pIC50 = 8.3 8.3 -1 14
NoneNone
Drug Central 423 7 2 8 0.5 CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1=CC=NC=C1)C2=O)C(O)=O None
2337 3256 None 77 Human Functional pIC50 = 8.2 8.2 -8 29
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
50 3256 None 77 Human Functional pIC50 = 8.2 8.2 -8 29
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002 3256 None 77 Human Functional pIC50 = 8.2 8.2 -8 29
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002.0 3256 None 77 Human Functional pIC50 = 8.2 8.2 -8 29
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
CHEMBL716 3256 None 77 Human Functional pIC50 = 8.2 8.2 -8 29
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
DB01224 3256 None 77 Human Functional pIC50 = 8.2 8.2 -8 29
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
1225 1471 None 26 Human Functional pIC50 = 8.2 8.2 -3 11
NoneNone
Drug Central 279 3 0 2 4.0 CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C None
3958 1471 None 26 Human Functional pIC50 = 8.2 8.2 -3 11
NoneNone
Drug Central 279 3 0 2 4.0 CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C None
667468.0 1471 None 26 Human Functional pIC50 = 8.2 8.2 -3 11
NoneNone
Drug Central 279 3 0 2 4.0 CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C None
667477 1471 None 26 Human Functional pIC50 = 8.2 8.2 -3 11
NoneNone
Drug Central 279 3 0 2 4.0 CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C None
667477.0 1471 None 26 Human Functional pIC50 = 8.2 8.2 -3 11
NoneNone
Drug Central 279 3 0 2 4.0 CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C None
CHEMBL101740 1471 None 26 Human Functional pIC50 = 8.2 8.2 -3 11
NoneNone
Drug Central 279 3 0 2 4.0 CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C None
CHEMBL860 1471 None 26 Human Functional pIC50 = 8.2 8.2 -3 11
NoneNone
Drug Central 279 3 0 2 4.0 CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C None
DB01142 1471 None 26 Human Functional pIC50 = 8.2 8.2 -3 11
NoneNone
Drug Central 279 3 0 2 4.0 CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C None
1816 2540 None 102 Human Functional pIC50 = 6.7 6.7 -43 12
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
4205 2540 None 102 Human Functional pIC50 = 6.7 6.7 -43 12
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
4205.0 2540 None 102 Human Functional pIC50 = 6.7 6.7 -43 12
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
7241 2540 None 102 Human Functional pIC50 = 6.7 6.7 -43 12
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
CHEMBL654 2540 None 102 Human Functional pIC50 = 6.7 6.7 -43 12
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
DB00370 2540 None 102 Human Functional pIC50 = 6.7 6.7 -43 12
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
102 4127 None 48 Human Functional pIC50 = 7.4 7.4 -2 20
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
3659 4127 None 48 Human Functional pIC50 = 7.4 7.4 -2 20
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
8969 4127 None 48 Human Functional pIC50 = 7.4 7.4 -2 20
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
8969.0 4127 None 48 Human Functional pIC50 = 7.4 7.4 -2 20
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
CHEMBL15245 4127 None 48 Human Functional pIC50 = 7.4 7.4 -2 20
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
DB01392 4127 None 48 Human Functional pIC50 = 7.4 7.4 -2 20
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
12577 2563 None 0 Human Functional pIC50 = 8.9 8.9 - 1
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 25080296
189711 2563 None 0 Human Functional pIC50 = 8.9 8.9 - 1
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 25080296
CHEMBL1257057 2563 None 0 Human Functional pIC50 = 8.9 8.9 - 1
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 25080296
12574 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
12574 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
4810 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810.0 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
4810.0 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
CHEMBL19236 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
CHEMBL19236 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
DB09242 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
DB09242 2605 None 88 Human Functional pIC50 = 6.5 6.5 -26 8
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
1028 291 None 71 Human Functional pIC50 = 6.7 6.7 -44 19
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
139148732 291 None 71 Human Functional pIC50 = 6.7 6.7 -44 19
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
479 291 None 71 Human Functional pIC50 = 6.7 6.7 -44 19
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816 291 None 71 Human Functional pIC50 = 6.7 6.7 -44 19
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816.0 291 None 71 Human Functional pIC50 = 6.7 6.7 -44 19
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL679 291 None 71 Human Functional pIC50 = 6.7 6.7 -44 19
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00668 291 None 71 Human Functional pIC50 = 6.7 6.7 -44 19
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
523 4106 None 93 Human Functional pIC50 = 6.8 6.8 -1 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
5707 4106 None 93 Human Functional pIC50 = 6.8 6.8 -1 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
CHEMBL297362 4106 None 93 Human Functional pIC50 = 6.8 6.8 -1 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
DB11477 4106 None 93 Human Functional pIC50 = 6.8 6.8 -1 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
3952 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
3952 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5353646 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646.0 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5353646.0 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5443 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5443 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5702063 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5702063 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5702063.0 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5702063.0 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL1331786 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
CHEMBL1331786 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL420 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
CHEMBL420 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
DB00629 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
DB00629 1888 None 38 Human Functional pIC50 = 7.0 7.0 -18 21
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
11079 2733 None 63 Human Functional pIC50 = 7.1 7.1 -13 7
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
3369 2733 None 63 Human Functional pIC50 = 7.1 7.1 -13 7
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436 2733 None 63 Human Functional pIC50 = 7.1 7.1 -13 7
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436.0 2733 None 63 Human Functional pIC50 = 7.1 7.1 -13 7
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
5509 2733 None 63 Human Functional pIC50 = 7.1 7.1 -13 7
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
CHEMBL761 2733 None 63 Human Functional pIC50 = 7.1 7.1 -13 7
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
DB06711 2733 None 63 Human Functional pIC50 = 7.1 7.1 -13 7
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
1343 1889 None 62 Human Functional pIC50 = 7.2 7.2 -11 12
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519 1889 None 62 Human Functional pIC50 = 7.2 7.2 -11 12
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519.0 1889 None 62 Human Functional pIC50 = 7.2 7.2 -11 12
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
522 1889 None 62 Human Functional pIC50 = 7.2 7.2 -11 12
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
CHEMBL862 1889 None 62 Human Functional pIC50 = 7.2 7.2 -11 12
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
DB01018 1889 None 62 Human Functional pIC50 = 7.2 7.2 -11 12
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3658 4107 None 53 Human Functional pIC50 = 7.2 7.2 -12 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
517 4107 None 53 Human Functional pIC50 = 7.2 7.2 -12 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
5709 4107 None 53 Human Functional pIC50 = 7.2 7.2 -12 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
5709.0 4107 None 53 Human Functional pIC50 = 7.2 7.2 -12 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
CHEMBL312448 4107 None 53 Human Functional pIC50 = 7.2 7.2 -12 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
DB06694 4107 None 53 Human Functional pIC50 = 7.2 7.2 -12 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
1960 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
1960 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260.0 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260.0 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
505 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
505 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL1437 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
CHEMBL1437 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00368 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
DB00368 2857 None 67 Human Functional pIC50 = 7.6 7.6 -11 18
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
2803 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
2803 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
2803.0 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
2803.0 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
516 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
516 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
704 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
704 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
CHEMBL134 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
CHEMBL134 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
DB00575 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
DB00575 955 None 58 Human Functional pIC50 = 7.6 7.6 -15 14
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
124 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
124 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
2032 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
2032 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
4636 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
4636.0 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636.0 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
CHEMBL762 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
CHEMBL762 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
DB00935 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
DB00935 2981 None 47 Human Functional pIC50 = 7.8 7.8 -144 24
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
2435 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
2435 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
2435.0 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
2435.0 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
395 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
395 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
520 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
520 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
5386 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
5386 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
CHEMBL844 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
CHEMBL844 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
DB00484 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
DB00484 722 None 100 Human Functional pIC50 = 8.3 8.3 -7 10
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
521 1404 None 69 Human Functional pIC50 = 9.2 9.2 -4 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068 1404 None 69 Human Functional pIC50 = 9.2 9.2 -4 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068.0 1404 None 69 Human Functional pIC50 = 9.2 9.2 -4 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
835 1404 None 69 Human Functional pIC50 = 9.2 9.2 -4 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
CHEMBL778 1404 None 69 Human Functional pIC50 = 9.2 9.2 -4 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
DB00633 1404 None 69 Human Functional pIC50 = 9.2 9.2 -4 5
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
3930 2151 None 43 Human Functional pKB = 7.4 7.4 - 1
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 17220913
3930 2151 None 43 Human Functional pKB = 7.4 7.4 - 1
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 35224877
540335 2151 None 43 Human Functional pKB = 7.4 7.4 - 1
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 17220913
540335 2151 None 43 Human Functional pKB = 7.4 7.4 - 1
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 35224877
CHEMBL106525 2151 None 43 Human Functional pKB = 7.4 7.4 - 1
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 17220913
CHEMBL106525 2151 None 43 Human Functional pKB = 7.4 7.4 - 1
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 35224877
13130 2965 None 0 Human Functional pKB = 9.8 9.8 - 1
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.9 [H][C@@]12N(CCC[C@@]1(C)OCC)CCC3=C2OC4=C3C=CC=C4 23718812
171037438 2965 None 0 Human Functional pKB = 9.8 9.8 - 1
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.9 [H][C@@]12N(CCC[C@@]1(C)OCC)CCC3=C2OC4=C3C=CC=C4 23718812




Ligands (move mouse cursor over ligand name to see structure) Receptor Activity Chemical information
Sel. page Common
name
GPCRdb
ID
Reference
ligand
Vendors

Species

Assay
Type
Activity
Type
Activity
Relation
Activity
Value
p-value
(-log)
Fold
selectivity
Tested
GPCRs
Assay
Description
Source

Mol
weight
Rot
Bonds
H don

H acc

LogP

Smiles

DOI

57345628 71183 None 0 Human Binding pEC50 = 8.7 8.7 -26 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1956195 71183 None 0 Human Binding pEC50 = 8.7 8.7 -26 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
70695474 77672 None 0 Human Binding pEC50 = 8.7 8.7 -47 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL2089156 77672 None 0 Human Binding pEC50 = 8.7 8.7 -47 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
57345626 71180 None 2 Human Binding pEC50 = 8 8.0 -12 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1021/ml400232p
CHEMBL1956192 71180 None 2 Human Binding pEC50 = 8 8.0 -12 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1021/ml400232p
72947315 92489 None 0 Human Binding pEC50 = 6 6.0 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 232 5 1 4 1.6 c1ccc(OC2CC2)c(OCC2=NCCN2)c1 10.1021/ml400232p
CHEMBL2431280 92489 None 0 Human Binding pEC50 = 6 6.0 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 232 5 1 4 1.6 c1ccc(OC2CC2)c(OCC2=NCCN2)c1 10.1021/ml400232p
134137108 142727 None 0 Human Binding pEC50 = 6.9 6.9 - 0
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 217 5 2 3 2.1 CCCc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
CHEMBL3892351 142727 None 0 Human Binding pEC50 = 6.9 6.9 - 0
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 217 5 2 3 2.1 CCCc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
49836304 18571 None 1 Human Binding pEC50 = 6.9 6.9 -2 3
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276219 18571 None 1 Human Binding pEC50 = 6.9 6.9 -2 3
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
44352155 116808 None 0 Human Binding pEC50 = 6.8 6.8 - 0
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 251 4 2 3 2.8 c1ccc(-c2ccccc2NCC2=NCCN2)cc1 10.1021/acsmedchemlett.6b00290
CHEMBL337862 116808 None 0 Human Binding pEC50 = 6.8 6.8 - 0
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 251 4 2 3 2.8 c1ccc(-c2ccccc2NCC2=NCCN2)cc1 10.1021/acsmedchemlett.6b00290
44269013 30342 None 1 Human Binding pEC50 = 6.8 6.8 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 218 5 1 3 2.0 CCCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL13917 30342 None 1 Human Binding pEC50 = 6.8 6.8 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 218 5 1 3 2.0 CCCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
134156190 151365 None 0 Human Binding pEC50 = 6.8 6.8 - 0
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 215 5 2 3 1.8 C=CCc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
CHEMBL3961335 151365 None 0 Human Binding pEC50 = 6.8 6.8 - 0
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 215 5 2 3 1.8 C=CCc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
49836302 18566 None 1 Human Binding pEC50 = 6.7 6.7 -1 3
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml400232p
CHEMBL1276139 18566 None 1 Human Binding pEC50 = 6.7 6.7 -1 3
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml400232p
129928082 144194 None 1 Human Binding pEC50 = 7.7 7.7 - 0
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 189 3 2 3 1.4 Cc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
CHEMBL3904276 144194 None 1 Human Binding pEC50 = 7.7 7.7 - 0
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 189 3 2 3 1.4 Cc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
13123534 189453 None 1 Human Binding pEC50 = 6.7 6.7 - 1
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 209 3 2 3 1.8 Clc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
CHEMBL51358 189453 None 1 Human Binding pEC50 = 6.7 6.7 - 1
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 209 3 2 3 1.8 Clc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
72947314 92490 None 0 Human Binding pEC50 = 6.6 6.6 -8 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.0 c1ccc(OCC2=NCCN2)c(CC2CC2)c1 10.1021/ml400232p
CHEMBL2431281 92490 None 0 Human Binding pEC50 = 6.6 6.6 -8 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.0 c1ccc(OCC2=NCCN2)c(CC2CC2)c1 10.1021/ml400232p
49836301 18567 None 1 Human Binding pEC50 = 7.6 7.6 -1 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml400232p
CHEMBL1276140 18567 None 1 Human Binding pEC50 = 7.6 7.6 -1 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml400232p
73291731 92491 None 0 Human Binding pEC50 = 7.6 7.6 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 232 5 1 3 2.4 CCCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
CHEMBL2431282 92491 None 0 Human Binding pEC50 = 7.6 7.6 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 232 5 1 3 2.4 CCCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
70693375 77671 None 0 Human Binding pEC50 = 6.5 6.5 -5 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL2089155 77671 None 0 Human Binding pEC50 = 6.5 6.5 -5 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
49836303 18572 None 1 Human Binding pEC50 = 7.5 7.5 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276220 18572 None 1 Human Binding pEC50 = 7.5 7.5 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
44549156 18570 None 0 Human Binding pEC50 = 7.4 7.4 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276218 18570 None 0 Human Binding pEC50 = 7.4 7.4 -10 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
2765 943 None 19 Human Binding pEC50 = 6.4 6.4 -15 9
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
515 943 None 19 Human Binding pEC50 = 6.4 6.4 -15 9
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
CHEMBL13852 943 None 19 Human Binding pEC50 = 6.4 6.4 -15 9
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
DB09202 943 None 19 Human Binding pEC50 = 6.4 6.4 -15 9
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
57345629 71185 None 0 Human Binding pEC50 = 7.3 7.3 -45 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1956197 71185 None 0 Human Binding pEC50 = 7.3 7.3 -45 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1021/ml400232p
24906198 187664 None 3 Human Binding pEC50 = 7.3 7.3 -3 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
CHEMBL495095 187664 None 3 Human Binding pEC50 = 7.3 7.3 -3 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
44269006 32353 None 1 Human Binding pEC50 = 7.2 7.2 -1 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 5 1 3 1.8 C=CCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL14107 32353 None 1 Human Binding pEC50 = 7.2 7.2 -1 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 5 1 3 1.8 C=CCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
28918670 92487 None 2 Human Binding pEC50 = 7.0 7.0 -4 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 254 3 1 3 1.8 Brc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL2431279 92487 None 2 Human Binding pEC50 = 7.0 7.0 -4 4
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 254 3 1 3 1.8 Brc1ccccc1OCC1=NCCN1 10.1021/ml400232p
44376984 56223 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 485 3 0 5 4.0 Cc1nc2ccc(I)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL162682 56223 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 485 3 0 5 4.0 Cc1nc2ccc(I)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44377200 57420 None 1 Human Binding pIC50 = 9.2 9.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 437 3 0 5 4.1 Cc1nc2ccc(Br)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL165350 57420 None 1 Human Binding pIC50 = 9.2 9.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 437 3 0 5 4.1 Cc1nc2ccc(Br)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
22120332 56045 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 389 4 0 6 3.4 COc1cccn2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc12 10.1016/s0960-894x(99)00591-0
CHEMBL162490 56045 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 389 4 0 6 3.4 COc1cccn2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc12 10.1016/s0960-894x(99)00591-0
44377036 120156 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccc(Cl)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL351483 120156 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccc(Cl)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44376954 55740 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 387 3 0 5 4.0 Cc1cc(C)n2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc2c1 10.1016/s0960-894x(99)00591-0
CHEMBL162232 55740 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 387 3 0 5 4.0 Cc1cc(C)n2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc2c1 10.1016/s0960-894x(99)00591-0
44376923 56427 None 0 Human Binding pIC50 = 9.0 9.0 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1nc2cccc(C)n2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL163190 56427 None 0 Human Binding pIC50 = 9.0 9.0 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1nc2cccc(C)n2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44376958 57479 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1ccn2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc2c1 10.1016/s0960-894x(99)00591-0
CHEMBL165796 57479 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1ccn2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc2c1 10.1016/s0960-894x(99)00591-0
22120322 55921 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1ccc2nc(C)c(CCN3CCc4oc5ccccc5c4C3)c(=O)n2c1 10.1016/s0960-894x(99)00591-0
CHEMBL162370 55921 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1ccc2nc(C)c(CCN3CCc4oc5ccccc5c4C3)c(=O)n2c1 10.1016/s0960-894x(99)00591-0
44377035 120130 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1nc2c(C)cccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL351200 120130 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1nc2c(C)cccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44376993 56484 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 427 3 0 5 4.7 Cc1nc2c(Cl)cc(Cl)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL163247 56484 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 427 3 0 5 4.7 Cc1nc2c(Cl)cc(Cl)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44376900 56268 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 375 3 1 6 3.1 Cc1nc2c(O)cccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL162826 56268 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 375 3 1 6 3.1 Cc1nc2c(O)cccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
3045401 56059 None 32 Human Binding pIC50 = 8.8 8.8 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 359 3 0 5 3.4 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL162501 56059 None 32 Human Binding pIC50 = 8.8 8.8 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 359 3 0 5 3.4 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
10531 1420 None 21 Human Binding pIC50 = 8 8.0 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
10531.0 1420 None 21 Human Binding pIC50 = 8 8.0 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
121 1420 None 21 Human Binding pIC50 = 8 8.0 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
888 1420 None 21 Human Binding pIC50 = 8 8.0 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
CHEMBL1732 1420 None 21 Human Binding pIC50 = 8 8.0 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
DB00320 1420 None 21 Human Binding pIC50 = 8 8.0 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
3151 1462 None 97 Human Binding pIC50 = 6 6.0 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
3151.0 1462 None 97 Human Binding pIC50 = 6 6.0 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
945 1462 None 97 Human Binding pIC50 = 6 6.0 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
965 1462 None 97 Human Binding pIC50 = 6 6.0 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
CHEMBL219916 1462 None 97 Human Binding pIC50 = 6 6.0 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
DB01184 1462 None 97 Human Binding pIC50 = 6 6.0 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
3158 56267 None 27 Human Binding pIC50 = 6.0 6.0 -1047 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 nan
3158.0 56267 None 27 Human Binding pIC50 = 6.0 6.0 -1047 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 nan
CHEMBL1628227 56267 None 27 Human Binding pIC50 = 6.0 6.0 -1047 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 nan
DB01142 56267 None 27 Human Binding pIC50 = 6.0 6.0 -1047 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 nan
16220269 189660 None 0 Human Binding pIC50 = 5.0 5.0 - 0
Inhibition of adrenergic Alpha-2C receptorInhibition of adrenergic Alpha-2C receptor
ChEMBL 361 3 1 2 4.4 CC[C@@H]1O[C@](/C=C/C2CC2)(C(F)(F)F)c2c(ccc(F)c2F)NC1=O 10.1073/pnas.0605125104
CHEMBL515170 189660 None 0 Human Binding pIC50 = 5.0 5.0 - 0
Inhibition of adrenergic Alpha-2C receptorInhibition of adrenergic Alpha-2C receptor
ChEMBL 361 3 1 2 4.4 CC[C@@H]1O[C@](/C=C/C2CC2)(C(F)(F)F)c2c(ccc(F)c2F)NC1=O 10.1073/pnas.0605125104
2142 3096 None 58 Human Binding pIC50 = 7.0 7.0 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
4920903 3096 None 58 Human Binding pIC50 = 7.0 7.0 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
502 3096 None 58 Human Binding pIC50 = 7.0 7.0 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
5775 3096 None 58 Human Binding pIC50 = 7.0 7.0 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
5775.0 3096 None 58 Human Binding pIC50 = 7.0 7.0 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
CHEMBL597 3096 None 58 Human Binding pIC50 = 7.0 7.0 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
DB00692 3096 None 58 Human Binding pIC50 = 7.0 7.0 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
25014630 83539 None 1 Human Binding pIC50 = 5.0 5.0 - 0
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 326 3 3 4 3.3 N=C(Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1 10.1016/j.ejmech.2012.07.006
CHEMBL2203713 83539 None 1 Human Binding pIC50 = 5.0 5.0 - 0
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 326 3 3 4 3.3 N=C(Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1 10.1016/j.ejmech.2012.07.006
3952 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5353646 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5353646.0 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5443 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5702063 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5702063.0 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
CHEMBL1331786 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
CHEMBL420 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
DB00629 1888 None 38 Human Binding pIC50 = 6.0 6.0 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
44318454 206009 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 312 2 0 3 3.5 CN(C)CC1CC2c3ccccc3Cc3ccc(F)cc3N2O1 10.1016/s0960-894x(01)00721-1
CHEMBL84931 206009 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 312 2 0 3 3.5 CN(C)CC1CC2c3ccccc3Cc3ccc(F)cc3N2O1 10.1016/s0960-894x(01)00721-1
5472 205818 None 75 Human Binding pIC50 = 5.9 5.9 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
5472.0 205818 None 75 Human Binding pIC50 = 5.9 5.9 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
CHEMBL1717 205818 None 75 Human Binding pIC50 = 5.9 5.9 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
CHEMBL833 205818 None 75 Human Binding pIC50 = 5.9 5.9 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
DB00208 205818 None 75 Human Binding pIC50 = 5.9 5.9 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
1043 1582 None 14 Human Binding pIC50 = 7.9 7.9 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
149 1582 None 14 Human Binding pIC50 = 7.9 7.9 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
8223 1582 None 14 Human Binding pIC50 = 7.9 7.9 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
8223.0 1582 None 14 Human Binding pIC50 = 7.9 7.9 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
CHEMBL442 1582 None 14 Human Binding pIC50 = 7.9 7.9 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
DB00696 1582 None 14 Human Binding pIC50 = 7.9 7.9 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
277 1301 None 62 Human Binding pIC50 = 5.9 5.9 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
2913 1301 None 62 Human Binding pIC50 = 5.9 5.9 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
2913.0 1301 None 62 Human Binding pIC50 = 5.9 5.9 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
765 1301 None 62 Human Binding pIC50 = 5.9 5.9 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
CHEMBL516 1301 None 62 Human Binding pIC50 = 5.9 5.9 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
DB00434 1301 None 62 Human Binding pIC50 = 5.9 5.9 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
CHEMBL5070958 214249 None 3 Human Binding pIC50 = 4.9 4.9 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL None None None NCCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21 10.1021/acs.jmedchem.1c01564
9951544 57376 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 375 3 0 5 3.8 Cc1nc2ccccn2c(=O)c1CCN1CCc2sc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL165181 57376 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 375 3 0 5 3.8 Cc1nc2ccccn2c(=O)c1CCN1CCc2sc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
123132228 156306 None 53 Human Binding pIC50 = 4.9 4.9 - 0
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 369 5 1 8 2.4 CS(=O)(=O)c1ccc(-c2cnc(NCc3ccco3)n3cnnc23)cc1 10.1021/acs.jmedchem.1c02148
CHEMBL4065484 156306 None 53 Human Binding pIC50 = 4.9 4.9 - 0
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 369 5 1 8 2.4 CS(=O)(=O)c1ccc(-c2cnc(NCc3ccco3)n3cnnc23)cc1 10.1021/acs.jmedchem.1c02148
10331436 324 None 10 Human Binding pIC50 = 4.9 4.9 - 6
Inhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligandInhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligand
ChEMBL 230 2 2 2 2.4 C[C@@H](Cc1c[nH]c2c1c1CCCOc1cc2)N 10.1021/jm030205t
160 324 None 10 Human Binding pIC50 = 4.9 4.9 - 6
Inhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligandInhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligand
ChEMBL 230 2 2 2 2.4 C[C@@H](Cc1c[nH]c2c1c1CCCOc1cc2)N 10.1021/jm030205t
CHEMBL133455 324 None 10 Human Binding pIC50 = 4.9 4.9 - 6
Inhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligandInhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligand
ChEMBL 230 2 2 2 2.4 C[C@@H](Cc1c[nH]c2c1c1CCCOc1cc2)N 10.1021/jm030205t
2105 3054 None 37 Human Binding pIC50 = 5.9 5.9 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
47811 3054 None 37 Human Binding pIC50 = 5.9 5.9 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
48 3054 None 37 Human Binding pIC50 = 5.9 5.9 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
CHEMBL531 3054 None 37 Human Binding pIC50 = 5.9 5.9 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
DB01186 3054 None 37 Human Binding pIC50 = 5.9 5.9 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
2398 954 None 62 Human Binding pIC50 = 5.9 5.9 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
2801 954 None 62 Human Binding pIC50 = 5.9 5.9 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
2801.0 954 None 62 Human Binding pIC50 = 5.9 5.9 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
701 954 None 62 Human Binding pIC50 = 5.9 5.9 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
CHEMBL415 954 None 62 Human Binding pIC50 = 5.9 5.9 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
DB01242 954 None 62 Human Binding pIC50 = 5.9 5.9 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
15730 71118 None 80 Human Binding pIC50 = 4.9 4.9 1 10
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 206 7 1 1 4.3 CCCCCCCCc1ccc(O)cc1 nan
CHEMBL195437 71118 None 80 Human Binding pIC50 = 4.9 4.9 1 10
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 206 7 1 1 4.3 CCCCCCCCc1ccc(O)cc1 nan
1548953 207679 None 27 Human Binding pIC50 = 5.8 5.8 1 17
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
CHEMBL954 207679 None 27 Human Binding pIC50 = 5.8 5.8 1 17
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
2683 102888 None 25 Human Binding pIC50 = 5.8 5.8 -30 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
CHEMBL305906 102888 None 25 Human Binding pIC50 = 5.8 5.8 -30 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
CHEMBL334255 102888 None 25 Human Binding pIC50 = 5.8 5.8 -30 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
448537 160250 None 89 Human Binding pIC50 = 4.8 4.8 -21 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
CHEMBL411 160250 None 89 Human Binding pIC50 = 4.8 4.8 -21 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
1212 1662 None 50 Human Binding pIC50 = 6.8 6.8 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
204 1662 None 50 Human Binding pIC50 = 6.8 6.8 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
3372 1662 None 50 Human Binding pIC50 = 6.8 6.8 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
3372.0 1662 None 50 Human Binding pIC50 = 6.8 6.8 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
CHEMBL726 1662 None 50 Human Binding pIC50 = 6.8 6.8 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
DB00623 1662 None 50 Human Binding pIC50 = 6.8 6.8 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
138753276 177177 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Inhibition of adrenergic receptor alpha2c (unknown origin)Inhibition of adrenergic receptor alpha2c (unknown origin)
ChEMBL 302 4 2 3 2.8 CO[C@H]1CCN(Cc2c(C)cc(C)c3[nH]ccc23)[C@H](CO)C1 10.1021/acs.jmedchem.9b01870
CHEMBL4634827 177177 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Inhibition of adrenergic receptor alpha2c (unknown origin)Inhibition of adrenergic receptor alpha2c (unknown origin)
ChEMBL 302 4 2 3 2.8 CO[C@H]1CCN(Cc2c(C)cc(C)c3[nH]ccc23)[C@H](CO)C1 10.1021/acs.jmedchem.9b01870
196129 67798 None 17 Human Binding pIC50 = 5.8 5.8 -295 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
CHEMBL1909065 67798 None 17 Human Binding pIC50 = 5.8 5.8 -295 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
8447 188949 None 84 Human Binding pIC50 = 5.8 5.8 -3 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
CHEMBL508112 188949 None 84 Human Binding pIC50 = 5.8 5.8 -3 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
73453 29616 None 24 Human Binding pIC50 = 7.8 7.8 -3 17
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 561 4 3 6 2.0 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 nan
CHEMBL1385840 29616 None 24 Human Binding pIC50 = 7.8 7.8 -3 17
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 561 4 3 6 2.0 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 nan
100 3805 None 58 Human Binding pIC50 = 6.8 6.8 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
2637 3805 None 58 Human Binding pIC50 = 6.8 6.8 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
5452 3805 None 58 Human Binding pIC50 = 6.8 6.8 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
CHEMBL479 3805 None 58 Human Binding pIC50 = 6.8 6.8 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
DB00679 3805 None 58 Human Binding pIC50 = 6.8 6.8 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
3168 9262 None 92 Human Binding pIC50 = 5.8 5.8 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
3168.0 9262 None 92 Human Binding pIC50 = 5.8 5.8 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
CHEMBL1108 9262 None 92 Human Binding pIC50 = 5.8 5.8 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
DB00450 9262 None 92 Human Binding pIC50 = 5.8 5.8 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
135 2532 None 43 Human Binding pIC50 = 6.8 6.8 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
1796 2532 None 43 Human Binding pIC50 = 6.8 6.8 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
4184 2532 None 43 Human Binding pIC50 = 6.8 6.8 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
4184.0 2532 None 43 Human Binding pIC50 = 6.8 6.8 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
CHEMBL6437 2532 None 43 Human Binding pIC50 = 6.8 6.8 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
DB06148 2532 None 43 Human Binding pIC50 = 6.8 6.8 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
138753277 177295 None 1 Human Binding pIC50 = 6.8 6.8 - 0
Inhibition of adrenergic receptor alpha2c (unknown origin)Inhibition of adrenergic receptor alpha2c (unknown origin)
ChEMBL 303 1 2 3 3.3 Cc1cc(Br)c(NC2=NCCN2)c2ccccc12 10.1021/acs.jmedchem.9b01870
CHEMBL4636550 177295 None 1 Human Binding pIC50 = 6.8 6.8 - 0
Inhibition of adrenergic receptor alpha2c (unknown origin)Inhibition of adrenergic receptor alpha2c (unknown origin)
ChEMBL 303 1 2 3 3.3 Cc1cc(Br)c(NC2=NCCN2)c2ccccc12 10.1021/acs.jmedchem.9b01870
2162 41514 None 100 Human Binding pIC50 = 5.8 5.8 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
CHEMBL1491 41514 None 100 Human Binding pIC50 = 5.8 5.8 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
10219 188796 None 37 Human Binding pIC50 = 6.7 6.7 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
CHEMBL493439 188796 None 37 Human Binding pIC50 = 6.7 6.7 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
CHEMBL50588 188796 None 37 Human Binding pIC50 = 6.7 6.7 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
1353 1911 None 93 Human Binding pIC50 = 5.7 5.7 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
3559 1911 None 93 Human Binding pIC50 = 5.7 5.7 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
3559.0 1911 None 93 Human Binding pIC50 = 5.7 5.7 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
86 1911 None 93 Human Binding pIC50 = 5.7 5.7 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
CHEMBL54 1911 None 93 Human Binding pIC50 = 5.7 5.7 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
DB00502 1911 None 93 Human Binding pIC50 = 5.7 5.7 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
9904205 205850 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 294 2 0 3 3.4 CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1 10.1016/s0960-894x(01)00721-1
CHEMBL83658 205850 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 294 2 0 3 3.4 CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1 10.1016/s0960-894x(01)00721-1
11057 176149 None 23 Human Binding pIC50 = 5.7 5.7 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
3468 176149 None 23 Human Binding pIC50 = 5.7 5.7 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
CHEMBL459265 176149 None 23 Human Binding pIC50 = 5.7 5.7 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
CHEMBL64894 176149 None 23 Human Binding pIC50 = 5.7 5.7 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
133 2496 None 52 Human Binding pIC50 = 6.7 6.7 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
1723 2496 None 52 Human Binding pIC50 = 6.7 6.7 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
28693 2496 None 52 Human Binding pIC50 = 6.7 6.7 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
CHEMBL19215 2496 None 52 Human Binding pIC50 = 6.7 6.7 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
DB13520 2496 None 52 Human Binding pIC50 = 6.7 6.7 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
213 3853 None 55 Human Binding pIC50 = 5.7 5.7 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
2717 3853 None 55 Human Binding pIC50 = 5.7 5.7 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
5533 3853 None 55 Human Binding pIC50 = 5.7 5.7 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
5533.0 3853 None 55 Human Binding pIC50 = 5.7 5.7 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
CHEMBL621 3853 None 55 Human Binding pIC50 = 5.7 5.7 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
DB00656 3853 None 55 Human Binding pIC50 = 5.7 5.7 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
2247 505 None 81 Human Binding pIC50 = 5.7 5.7 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
249 505 None 81 Human Binding pIC50 = 5.7 5.7 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
2603 505 None 81 Human Binding pIC50 = 5.7 5.7 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
CHEMBL296419 505 None 81 Human Binding pIC50 = 5.7 5.7 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
DB00637 505 None 81 Human Binding pIC50 = 5.7 5.7 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
2335 11848 None 22 Human Binding pIC50 = 5.7 5.7 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
8478 11848 None 22 Human Binding pIC50 = 5.7 5.7 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
CHEMBL1182210 11848 None 22 Human Binding pIC50 = 5.7 5.7 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
CHEMBL221753 11848 None 22 Human Binding pIC50 = 5.7 5.7 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
1816 2540 None 102 Human Binding pIC50 = 6.7 6.7 -38 18
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
4205 2540 None 102 Human Binding pIC50 = 6.7 6.7 -38 18
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
4205.0 2540 None 102 Human Binding pIC50 = 6.7 6.7 -38 18
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
7241 2540 None 102 Human Binding pIC50 = 6.7 6.7 -38 18
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
CHEMBL654 2540 None 102 Human Binding pIC50 = 6.7 6.7 -38 18
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
DB00370 2540 None 102 Human Binding pIC50 = 6.7 6.7 -38 18
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
44377007 57148 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3c(Cl)cccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL164612 57148 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3c(Cl)cccc3c2C1 10.1016/s0960-894x(99)00591-0
44376975 55986 None 0 Human Binding pIC50 = 8.6 8.6 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 435 5 0 5 4.6 O=c1c(CCN2CCc3oc4ccccc4c3C2)c(Cc2ccccc2)nc2ccccn12 10.1016/s0960-894x(99)00591-0
CHEMBL162436 55986 None 0 Human Binding pIC50 = 8.6 8.6 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 435 5 0 5 4.6 O=c1c(CCN2CCc3oc4ccccc4c3C2)c(Cc2ccccc2)nc2ccccn12 10.1016/s0960-894x(99)00591-0
CHEMBL5082142 214787 None 0 Human Binding pIC50 = 4.7 4.7 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL None None None c1cnc2c(c1)CN[C@@H](CN(CCCCN1CCOCC1)[C@H]1CCCc3cccnc31)C2 10.1021/acs.jmedchem.1c01564
1971 2866 None 38 Human Binding pIC50 = 6.7 6.7 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
2404 2866 None 38 Human Binding pIC50 = 6.7 6.7 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
4543 2866 None 38 Human Binding pIC50 = 6.7 6.7 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
4543.0 2866 None 38 Human Binding pIC50 = 6.7 6.7 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
CHEMBL445 2866 None 38 Human Binding pIC50 = 6.7 6.7 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
DB00540 2866 None 38 Human Binding pIC50 = 6.7 6.7 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
45482789 198925 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Inhibition of adrenergic Alpha-2C receptorInhibition of adrenergic Alpha-2C receptor
ChEMBL 428 4 2 2 4.5 CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1 10.1016/j.bmcl.2009.09.002
CHEMBL584554 198925 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Inhibition of adrenergic Alpha-2C receptorInhibition of adrenergic Alpha-2C receptor
ChEMBL 428 4 2 2 4.5 CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1 10.1016/j.bmcl.2009.09.002
CHEMBL5081505 214749 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL None None None c1cnc2c(c1)CN[C@@H](CN(CCCC1CCNCC1)[C@H]1CCCc3cccnc31)C2 10.1021/acs.jmedchem.1c01564
12488 1657 None 56 Human Binding pIC50 = 6.7 6.7 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
941361 1657 None 56 Human Binding pIC50 = 6.7 6.7 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
CHEMBL30008 1657 None 56 Human Binding pIC50 = 6.7 6.7 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
DB04841 1657 None 56 Human Binding pIC50 = 6.7 6.7 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
57345320 3832 None 9 Human Binding pIC50 = 4.6 4.6 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 364 7 2 4 3.2 NCCCCN([C@H]1CCCc2c1nccc2)C[C@@H]1NCc2c(C1)cccc2 10.1021/acs.jmedchem.1c01564
9882 3832 None 9 Human Binding pIC50 = 4.6 4.6 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 364 7 2 4 3.2 NCCCCN([C@H]1CCCc2c1nccc2)C[C@@H]1NCc2c(C1)cccc2 10.1021/acs.jmedchem.1c01564
CHEMBL3091687 3832 None 9 Human Binding pIC50 = 4.6 4.6 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 364 7 2 4 3.2 NCCCCN([C@H]1CCCc2c1nccc2)C[C@@H]1NCc2c(C1)cccc2 10.1021/acs.jmedchem.1c01564
28417 40039 None 49 Human Binding pIC50 = 4.6 4.6 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
28417.0 40039 None 49 Human Binding pIC50 = 4.6 4.6 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
CHEMBL1479 40039 None 49 Human Binding pIC50 = 4.6 4.6 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
DB01406 40039 None 49 Human Binding pIC50 = 4.6 4.6 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
2286 3183 None 51 Human Binding pIC50 = 5.6 5.6 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
4927 3183 None 51 Human Binding pIC50 = 5.6 5.6 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
4927.0 3183 None 51 Human Binding pIC50 = 5.6 5.6 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
7282 3183 None 51 Human Binding pIC50 = 5.6 5.6 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
CHEMBL643 3183 None 51 Human Binding pIC50 = 5.6 5.6 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
DB01069 3183 None 51 Human Binding pIC50 = 5.6 5.6 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
1028 291 None 71 Human Binding pIC50 = 5.6 5.6 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
139148732 291 None 71 Human Binding pIC50 = 5.6 5.6 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
479 291 None 71 Human Binding pIC50 = 5.6 5.6 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
5816 291 None 71 Human Binding pIC50 = 5.6 5.6 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
5816.0 291 None 71 Human Binding pIC50 = 5.6 5.6 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
CHEMBL679 291 None 71 Human Binding pIC50 = 5.6 5.6 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
DB00668 291 None 71 Human Binding pIC50 = 5.6 5.6 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
222757 99376 None 73 Human Binding pIC50 = 4.6 4.6 1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
CHEMBL282575 99376 None 73 Human Binding pIC50 = 4.6 4.6 1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
2284 3182 None 33 Human Binding pIC50 = 6.6 6.6 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
4926 3182 None 33 Human Binding pIC50 = 6.6 6.6 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
7281 3182 None 33 Human Binding pIC50 = 6.6 6.6 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
CHEMBL564 3182 None 33 Human Binding pIC50 = 6.6 6.6 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
DB00420 3182 None 33 Human Binding pIC50 = 6.6 6.6 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
124 2981 None 47 Human Binding pIC50 = 5.6 5.6 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
2032 2981 None 47 Human Binding pIC50 = 5.6 5.6 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
4636 2981 None 47 Human Binding pIC50 = 5.6 5.6 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
4636.0 2981 None 47 Human Binding pIC50 = 5.6 5.6 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
CHEMBL762 2981 None 47 Human Binding pIC50 = 5.6 5.6 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
DB00935 2981 None 47 Human Binding pIC50 = 5.6 5.6 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
102 4127 None 48 Human Binding pIC50 = 7.6 7.6 -2 49
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
3659 4127 None 48 Human Binding pIC50 = 7.6 7.6 -2 49
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
8969 4127 None 48 Human Binding pIC50 = 7.6 7.6 -2 49
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
8969.0 4127 None 48 Human Binding pIC50 = 7.6 7.6 -2 49
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
CHEMBL15245 4127 None 48 Human Binding pIC50 = 7.6 7.6 -2 49
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
DB01392 4127 None 48 Human Binding pIC50 = 7.6 7.6 -2 49
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
44377006 57463 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccc(Cl)cc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL165677 57463 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccc(Cl)cc3c2C1 10.1016/s0960-894x(99)00591-0
3191 102858 None 97 Human Binding pIC50 = 6.6 6.6 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
3191.0 102858 None 97 Human Binding pIC50 = 6.6 6.6 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
CHEMBL305660 102858 None 97 Human Binding pIC50 = 6.6 6.6 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
DB11742 102858 None 97 Human Binding pIC50 = 6.6 6.6 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
2353 101112 None 82 Human Binding pIC50 = 5.6 5.6 -1 4
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
CHEMBL12089 101112 None 82 Human Binding pIC50 = 5.6 5.6 -1 4
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
CHEMBL295124 101112 None 82 Human Binding pIC50 = 5.6 5.6 -1 4
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
44376927 55637 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 461 3 0 5 5.0 Cc1nc2c(Cl)cc(C(F)(F)F)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL162147 55637 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 461 3 0 5 5.0 Cc1nc2c(Cl)cc(C(F)(F)F)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL5076569 214449 None 0 Human Binding pIC50 = 4.5 4.5 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL None None None NCCCCN(C[C@H]1Cc2cccnc2CN1)[C@H]1CCCc2cccnc21 10.1021/acs.jmedchem.1c01564
4011 82408 None 49 Human Binding pIC50 = 5.5 5.5 -28 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
CHEMBL21731 82408 None 49 Human Binding pIC50 = 5.5 5.5 -28 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
6918276 15611 None 7 Human Binding pIC50 = 5.5 5.5 -47 8
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 559 18 4 9 1.7 CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS nan
CHEMBL1221512 15611 None 7 Human Binding pIC50 = 5.5 5.5 -47 8
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 559 18 4 9 1.7 CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS nan
60838 183874 None 99 Human Binding pIC50 = 5.5 5.5 -1 2
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
CHEMBL481 183874 None 99 Human Binding pIC50 = 5.5 5.5 -1 2
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
191 403 None 98 Human Binding pIC50 = 5.5 5.5 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
201 403 None 98 Human Binding pIC50 = 5.5 5.5 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
2170 403 None 98 Human Binding pIC50 = 5.5 5.5 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
2170.0 403 None 98 Human Binding pIC50 = 5.5 5.5 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
CHEMBL1113 403 None 98 Human Binding pIC50 = 5.5 5.5 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
DB00543 403 None 98 Human Binding pIC50 = 5.5 5.5 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
657255 199084 None 34 Human Binding pIC50 = 5.5 5.5 -8 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 nan
CHEMBL588119 199084 None 34 Human Binding pIC50 = 5.5 5.5 -8 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 nan
102 4127 None 48 Human Binding pIC50 = 7.4 7.4 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
3659 4127 None 48 Human Binding pIC50 = 7.4 7.4 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
8969 4127 None 48 Human Binding pIC50 = 7.4 7.4 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
8969.0 4127 None 48 Human Binding pIC50 = 7.4 7.4 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
CHEMBL15245 4127 None 48 Human Binding pIC50 = 7.4 7.4 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
DB01392 4127 None 48 Human Binding pIC50 = 7.4 7.4 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
2726 919 None 68 Human Binding pIC50 = 6.4 6.4 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
2726.0 919 None 68 Human Binding pIC50 = 6.4 6.4 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
621 919 None 68 Human Binding pIC50 = 6.4 6.4 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
83 919 None 68 Human Binding pIC50 = 6.4 6.4 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
CHEMBL71 919 None 68 Human Binding pIC50 = 6.4 6.4 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
DB00477 919 None 68 Human Binding pIC50 = 6.4 6.4 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
2600 3779 None 74 Human Binding pIC50 = 5.4 5.4 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
2608 3779 None 74 Human Binding pIC50 = 5.4 5.4 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
5405 3779 None 74 Human Binding pIC50 = 5.4 5.4 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
CHEMBL17157 3779 None 74 Human Binding pIC50 = 5.4 5.4 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
DB00342 3779 None 74 Human Binding pIC50 = 5.4 5.4 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
134551 358 None 27 Human Binding pIC50 = 7.4 7.4 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
271 358 None 27 Human Binding pIC50 = 7.4 7.4 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
885 358 None 27 Human Binding pIC50 = 7.4 7.4 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
CHEMBL1403281 358 None 27 Human Binding pIC50 = 7.4 7.4 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
237 204865 None 48 Human Binding pIC50 = 5.4 5.4 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
CHEMBL546257 204865 None 48 Human Binding pIC50 = 5.4 5.4 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
CHEMBL554190 204865 None 48 Human Binding pIC50 = 5.4 5.4 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
CHEMBL7568 204865 None 48 Human Binding pIC50 = 5.4 5.4 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
121432827 192246 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 344 4 1 7 2.7 c1cncc(-c2cnc(NCc3cccc4c3CCO4)n3cnnc23)c1 10.1021/acs.jmedchem.1c02148
CHEMBL5205327 192246 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 344 4 1 7 2.7 c1cncc(-c2cnc(NCc3cccc4c3CCO4)n3cnnc23)c1 10.1021/acs.jmedchem.1c02148
CHEMBL1200633 208600 None 3 Human Binding pIC50 = 5.4 5.4 -1 8
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL None None None CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O nan
1201549 597 None 24 Human Binding pIC50 = 6.4 6.4 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
1201549.0 597 None 24 Human Binding pIC50 = 6.4 6.4 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
333 597 None 24 Human Binding pIC50 = 6.4 6.4 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
7601 597 None 24 Human Binding pIC50 = 6.4 6.4 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
CHEMBL1201203 597 None 24 Human Binding pIC50 = 6.4 6.4 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
CHEMBL438151 597 None 24 Human Binding pIC50 = 6.4 6.4 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
DB00245 597 None 24 Human Binding pIC50 = 6.4 6.4 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
1588 2325 None 27 Human Binding pIC50 = 8.4 8.4 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
28864 2325 None 27 Human Binding pIC50 = 8.4 8.4 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
28864.0 2325 None 27 Human Binding pIC50 = 8.4 8.4 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
43 2325 None 27 Human Binding pIC50 = 8.4 8.4 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
CHEMBL157138 2325 None 27 Human Binding pIC50 = 8.4 8.4 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
DB00589 2325 None 27 Human Binding pIC50 = 8.4 8.4 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
3561 19077 None 39 Human Binding pIC50 = 5.4 5.4 -2 11
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
CHEMBL1289 19077 None 39 Human Binding pIC50 = 5.4 5.4 -2 11
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
5353853 17986 None 47 Human Binding pIC50 = 5.4 5.4 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
9556529 17986 None 47 Human Binding pIC50 = 5.4 5.4 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
CHEMBL1262 17986 None 47 Human Binding pIC50 = 5.4 5.4 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
441383 20333 None 57 Human Binding pIC50 = 6.4 6.4 2 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
CHEMBL1306 20333 None 57 Human Binding pIC50 = 6.4 6.4 2 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
135 2532 None 43 Human Binding pIC50 = 7.4 7.4 -6 58
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
1796 2532 None 43 Human Binding pIC50 = 7.4 7.4 -6 58
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
4184 2532 None 43 Human Binding pIC50 = 7.4 7.4 -6 58
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
4184.0 2532 None 43 Human Binding pIC50 = 7.4 7.4 -6 58
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
CHEMBL6437 2532 None 43 Human Binding pIC50 = 7.4 7.4 -6 58
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
DB06148 2532 None 43 Human Binding pIC50 = 7.4 7.4 -6 58
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
2337 3256 None 77 Human Binding pIC50 = 6.4 6.4 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
50 3256 None 77 Human Binding pIC50 = 6.4 6.4 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
5002 3256 None 77 Human Binding pIC50 = 6.4 6.4 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
5002.0 3256 None 77 Human Binding pIC50 = 6.4 6.4 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
CHEMBL716 3256 None 77 Human Binding pIC50 = 6.4 6.4 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
DB01224 3256 None 77 Human Binding pIC50 = 6.4 6.4 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
2406 100404 None 89 Human Binding pIC50 = 5.4 5.4 -11 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
CHEMBL290106 100404 None 89 Human Binding pIC50 = 5.4 5.4 -11 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
68617 205527 None 62 Human Binding pIC50 = 5.4 5.4 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
CHEMBL1709 205527 None 62 Human Binding pIC50 = 5.4 5.4 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
CHEMBL809 205527 None 62 Human Binding pIC50 = 5.4 5.4 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
6761 67799 None 19 Human Binding pIC50 = 7.4 7.4 -3 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
CHEMBL1909072 67799 None 19 Human Binding pIC50 = 7.4 7.4 -3 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
5318 15576 None 49 Human Binding pIC50 = 5.3 5.3 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
CHEMBL1200348 15576 None 49 Human Binding pIC50 = 5.3 5.3 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
CHEMBL1221 15576 None 49 Human Binding pIC50 = 5.3 5.3 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
CHEMBL508338 188966 None 0 Human Binding pIC50 = 5.3 5.3 -25 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL None None None None nan
31101 729 None 40 Human Binding pIC50 = 6.3 6.3 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
31101.0 729 None 40 Human Binding pIC50 = 6.3 6.3 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
35 729 None 40 Human Binding pIC50 = 6.3 6.3 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
403 729 None 40 Human Binding pIC50 = 6.3 6.3 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
CHEMBL493 729 None 40 Human Binding pIC50 = 6.3 6.3 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
DB01200 729 None 40 Human Binding pIC50 = 6.3 6.3 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
1836 2592 None 59 Human Binding pIC50 = 5.3 5.3 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
3340 2592 None 59 Human Binding pIC50 = 5.3 5.3 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
5281040 2592 None 59 Human Binding pIC50 = 5.3 5.3 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
5281040.0 2592 None 59 Human Binding pIC50 = 5.3 5.3 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
CHEMBL787 2592 None 59 Human Binding pIC50 = 5.3 5.3 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
DB00471 2592 None 59 Human Binding pIC50 = 5.3 5.3 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
12575 1988 None 30 Human Binding pIC50 = 7.3 7.3 -8 17
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
54459 1988 None 30 Human Binding pIC50 = 7.3 7.3 -8 17
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
54459.0 1988 None 30 Human Binding pIC50 = 7.3 7.3 -8 17
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
CHEMBL10316 1988 None 30 Human Binding pIC50 = 7.3 7.3 -8 17
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
DB12551 1988 None 30 Human Binding pIC50 = 7.3 7.3 -8 17
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
135398745 2914 None 112 Human Binding pIC50 = 6.3 6.3 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
135398745.0 2914 None 112 Human Binding pIC50 = 6.3 6.3 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
47 2914 None 112 Human Binding pIC50 = 6.3 6.3 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
CHEMBL715 2914 None 112 Human Binding pIC50 = 6.3 6.3 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
DB00334 2914 None 112 Human Binding pIC50 = 6.3 6.3 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
11080 29085 None 79 Human Binding pIC50 = 4.3 4.3 -3 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 185 1 0 2 3.6 S=C=Nc1cccc2ccccc12 nan
CHEMBL1381098 29085 None 79 Human Binding pIC50 = 4.3 4.3 -3 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 185 1 0 2 3.6 S=C=Nc1cccc2ccccc12 nan
44376845 55545 None 1 Human Binding pIC50 = 7.2 7.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 419 5 0 7 3.4 COc1cc2nc(C)c(CCN3CCc4oc5ccccc5c4C3)c(=O)n2cc1OC 10.1016/s0960-894x(99)00591-0
CHEMBL162058 55545 None 1 Human Binding pIC50 = 7.2 7.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 419 5 0 7 3.4 COc1cc2nc(C)c(CCN3CCc4oc5ccccc5c4C3)c(=O)n2cc1OC 10.1016/s0960-894x(99)00591-0
180 401 None 56 Human Binding pIC50 = 7.2 7.2 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
200 401 None 56 Human Binding pIC50 = 7.2 7.2 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
2160 401 None 56 Human Binding pIC50 = 7.2 7.2 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
2160.0 401 None 56 Human Binding pIC50 = 7.2 7.2 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
CHEMBL629 401 None 56 Human Binding pIC50 = 7.2 7.2 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
DB00321 401 None 56 Human Binding pIC50 = 7.2 7.2 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
44376936 57474 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 4 0 5 3.7 Cc1nc2ccccn2c(=O)c1CCCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL165776 57474 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 4 0 5 3.7 Cc1nc2ccccn2c(=O)c1CCCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
3584 3777 None 64 Human Binding pIC50 = 5.2 5.2 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
5401 3777 None 64 Human Binding pIC50 = 5.2 5.2 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
5401.0 3777 None 64 Human Binding pIC50 = 5.2 5.2 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
7302 3777 None 64 Human Binding pIC50 = 5.2 5.2 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
CHEMBL611 3777 None 64 Human Binding pIC50 = 5.2 5.2 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
DB01162 3777 None 64 Human Binding pIC50 = 5.2 5.2 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
1343 1889 None 62 Human Binding pIC50 = 5.2 5.2 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
3519 1889 None 62 Human Binding pIC50 = 5.2 5.2 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
3519.0 1889 None 62 Human Binding pIC50 = 5.2 5.2 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
522 1889 None 62 Human Binding pIC50 = 5.2 5.2 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
CHEMBL862 1889 None 62 Human Binding pIC50 = 5.2 5.2 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
DB01018 1889 None 62 Human Binding pIC50 = 5.2 5.2 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
4209 3163 None 75 Human Binding pIC50 = 6.2 6.2 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
4893 3163 None 75 Human Binding pIC50 = 6.2 6.2 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
4893.0 3163 None 75 Human Binding pIC50 = 6.2 6.2 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
503 3163 None 75 Human Binding pIC50 = 6.2 6.2 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
5385 3163 None 75 Human Binding pIC50 = 6.2 6.2 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
CHEMBL2 3163 None 75 Human Binding pIC50 = 6.2 6.2 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
DB00457 3163 None 75 Human Binding pIC50 = 6.2 6.2 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
1547484 940 None 74 Human Binding pIC50 = 6.2 6.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
1547484.0 940 None 74 Human Binding pIC50 = 6.2 6.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
654 940 None 74 Human Binding pIC50 = 6.2 6.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
9072 940 None 74 Human Binding pIC50 = 6.2 6.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
CHEMBL43064 940 None 74 Human Binding pIC50 = 6.2 6.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
DB00568 940 None 74 Human Binding pIC50 = 6.2 6.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
3598 187821 None 76 Human Binding pIC50 = 5.2 5.2 -1 7
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
CHEMBL496 187821 None 76 Human Binding pIC50 = 5.2 5.2 -1 7
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
135398737 958 None 93 Human Binding pIC50 = 8.1 8.1 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
135398737.0 958 None 93 Human Binding pIC50 = 8.1 8.1 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
38 958 None 93 Human Binding pIC50 = 8.1 8.1 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
722 958 None 93 Human Binding pIC50 = 8.1 8.1 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
CHEMBL42 958 None 93 Human Binding pIC50 = 8.1 8.1 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
DB00363 958 None 93 Human Binding pIC50 = 8.1 8.1 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
42574 15287 None 90 Human Binding pIC50 = 5.2 5.2 -18 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 662 4 2 3 7.1 Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O nan
CHEMBL12131 15287 None 90 Human Binding pIC50 = 5.2 5.2 -18 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 662 4 2 3 7.1 Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O nan
2351 3286 None 64 Human Binding pIC50 = 6.1 6.1 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
2820 3286 None 64 Human Binding pIC50 = 6.1 6.1 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
5035 3286 None 64 Human Binding pIC50 = 6.1 6.1 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
CHEMBL81 3286 None 64 Human Binding pIC50 = 6.1 6.1 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
DB00481 3286 None 64 Human Binding pIC50 = 6.1 6.1 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
42636941 178949 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of [3H]RX821002 form human recombinant Alpha-2C adrenergic receptorDisplacement of [3H]RX821002 form human recombinant Alpha-2C adrenergic receptor
ChEMBL 343 5 0 5 4.4 CCCN1CCC(COc2nc3scc(C)c3n3cccc23)CC1 10.1016/j.bmc.2008.11.045
CHEMBL470432 178949 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of [3H]RX821002 form human recombinant Alpha-2C adrenergic receptorDisplacement of [3H]RX821002 form human recombinant Alpha-2C adrenergic receptor
ChEMBL 343 5 0 5 4.4 CCCN1CCC(COc2nc3scc(C)c3n3cccc23)CC1 10.1016/j.bmc.2008.11.045
240 944 None 43 Human Binding pIC50 = 6.1 6.1 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
2769 944 None 43 Human Binding pIC50 = 6.1 6.1 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
44279790 944 None 43 Human Binding pIC50 = 6.1 6.1 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
660 944 None 43 Human Binding pIC50 = 6.1 6.1 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
CHEMBL1729 944 None 43 Human Binding pIC50 = 6.1 6.1 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
CHEMBL560739 944 None 43 Human Binding pIC50 = 6.1 6.1 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
DB00604 944 None 43 Human Binding pIC50 = 6.1 6.1 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
104903 56344 None 17 Human Binding pIC50 = 5.1 5.1 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
CHEMBL1630578 56344 None 17 Human Binding pIC50 = 5.1 5.1 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
107715 200945 None 22 Human Binding pIC50 = 8.1 8.1 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
CHEMBL1255837 200945 None 22 Human Binding pIC50 = 8.1 8.1 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
CHEMBL601773 200945 None 22 Human Binding pIC50 = 8.1 8.1 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
2274 3173 None 58 Human Binding pIC50 = 7.1 7.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
4917 3173 None 58 Human Binding pIC50 = 7.1 7.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
4917.0 3173 None 58 Human Binding pIC50 = 7.1 7.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
7279 3173 None 58 Human Binding pIC50 = 7.1 7.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
CHEMBL728 3173 None 58 Human Binding pIC50 = 7.1 7.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
DB00433 3173 None 58 Human Binding pIC50 = 7.1 7.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
CHEMBL5077132 214484 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL None None None CN(CCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21)C1CCOCC1 10.1021/acs.jmedchem.1c01564
10381889 107069 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 328 2 0 3 4.1 CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1 10.1016/s0960-894x(01)00721-1
CHEMBL315772 107069 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 328 2 0 3 4.1 CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1 10.1016/s0960-894x(01)00721-1
132256889 190447 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 378 5 1 7 3.6 COc1cccc(F)c1CNc1ccc(-c2cnc(C)nc2C)c2nncn12 10.1021/acs.jmedchem.1c02148
CHEMBL5178464 190447 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 378 5 1 7 3.6 COc1cccc(F)c1CNc1ccc(-c2cnc(C)nc2C)c2nncn12 10.1021/acs.jmedchem.1c02148
CHEMBL5083458 214863 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL None None None c1cnc2c(c1)CN[C@@H](CN(CCCCNC1COC1)[C@H]1CCCc3cccnc31)C2 10.1021/acs.jmedchem.1c01564
2389 3331 None 118 Human Binding pIC50 = 8.0 8.0 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
5073 3331 None 118 Human Binding pIC50 = 8.0 8.0 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
5073.0 3331 None 118 Human Binding pIC50 = 8.0 8.0 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
96 3331 None 118 Human Binding pIC50 = 8.0 8.0 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
CHEMBL85 3331 None 118 Human Binding pIC50 = 8.0 8.0 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
DB00734 3331 None 118 Human Binding pIC50 = 8.0 8.0 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
2585 803 None 103 Human Binding pIC50 = 7.1 7.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
2585.0 803 None 103 Human Binding pIC50 = 7.1 7.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
522 803 None 103 Human Binding pIC50 = 7.1 7.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
551 803 None 103 Human Binding pIC50 = 7.1 7.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
CHEMBL723 803 None 103 Human Binding pIC50 = 7.1 7.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
DB01136 803 None 103 Human Binding pIC50 = 7.1 7.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
26987 949 None 33 Human Binding pIC50 = 7.0 7.0 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
26987.0 949 None 33 Human Binding pIC50 = 7.0 7.0 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
6063 949 None 33 Human Binding pIC50 = 7.0 7.0 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
671 949 None 33 Human Binding pIC50 = 7.0 7.0 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
CHEMBL1626 949 None 33 Human Binding pIC50 = 7.0 7.0 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
DB00283 949 None 33 Human Binding pIC50 = 7.0 7.0 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
136019934 144530 None 0 Human Binding pKi = 10 10.0 7 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
CHEMBL390718 144530 None 0 Human Binding pKi = 10 10.0 7 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
44324800 206948 None 0 Human Binding pKi = 10 10.0 5 7
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL91157 206948 None 0 Human Binding pKi = 10 10.0 5 7
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44324800 206948 None 0 Human Binding pKi = 10 10.0 5 7
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL91157 206948 None 0 Human Binding pKi = 10 10.0 5 7
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
49781228 17205 None 1 Human Binding pKi = 9.9 9.9 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
CHEMBL1256414 17205 None 1 Human Binding pKi = 9.9 9.9 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
52944548 17152 None 0 Human Binding pKi = 9.8 9.8 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 2 1 1 3.0 CC[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1255723 17152 None 0 Human Binding pKi = 9.8 9.8 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 2 1 1 3.0 CC[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
49781228 17205 None 1 Human Binding pKi = 9.8 9.8 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
CHEMBL1256414 17205 None 1 Human Binding pKi = 9.8 9.8 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
44330168 4319 None 0 Human Binding pKi = 9.7 9.7 1 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4cccs4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL100879 4319 None 0 Human Binding pKi = 9.7 9.7 1 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4cccs4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330668 4436 None 0 Human Binding pKi = 9.7 9.7 5 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccsc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL101596 4436 None 0 Human Binding pKi = 9.7 9.7 5 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccsc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330617 96620 None 0 Human Binding pKi = 9.7 9.7 5 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccc(F)c4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL263424 96620 None 0 Human Binding pKi = 9.7 9.7 5 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccc(F)c4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
11225779 107732 None 0 Human Binding pKi = 9.7 9.7 1 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cc(F)ccc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL319119 107732 None 0 Human Binding pKi = 9.7 9.7 1 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cc(F)ccc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324972 163372 None 0 Human Binding pKi = 9.7 9.7 2 4
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL419316 163372 None 0 Human Binding pKi = 9.7 9.7 2 4
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324800 206948 None 0 Human Binding pKi = 9.7 9.7 5 7
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL91157 206948 None 0 Human Binding pKi = 9.7 9.7 5 7
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330653 208232 None 0 Human Binding pKi = 9.7 9.7 8 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccs4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL98646 208232 None 0 Human Binding pKi = 9.7 9.7 8 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccs4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324972 163372 None 0 Human Binding pKi = 9.7 9.7 2 4
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL419316 163372 None 0 Human Binding pKi = 9.7 9.7 2 4
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44325050 207281 None 0 Human Binding pKi = 9.7 9.7 3 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL93171 207281 None 0 Human Binding pKi = 9.7 9.7 3 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44324972 163372 None 0 Human Binding pKi = 9.7 9.7 2 4
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL419316 163372 None 0 Human Binding pKi = 9.7 9.7 2 4
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
49781228 17205 None 1 Human Binding pKi = 9.6 9.6 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
CHEMBL1256414 17205 None 1 Human Binding pKi = 9.6 9.6 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
16655023 107441 None 2 Human Binding pKi = 9.6 9.6 5 7
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
CHEMBL318235 107441 None 2 Human Binding pKi = 9.6 9.6 5 7
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
52941512 17198 None 0 Human Binding pKi = 9.5 9.5 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 2.6 C[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256378 17198 None 0 Human Binding pKi = 9.5 9.5 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 2.6 C[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
44330369 111582 None 0 Human Binding pKi = 9.5 9.5 4 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccsc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL328195 111582 None 0 Human Binding pKi = 9.5 9.5 4 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccsc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
10480357 208218 None 0 Human Binding pKi = 9.5 9.5 9 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL98541 208218 None 0 Human Binding pKi = 9.5 9.5 9 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330114 108082 None 0 Human Binding pKi = 9.4 9.4 1 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 453 7 0 8 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccco4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL319530 108082 None 0 Human Binding pKi = 9.4 9.4 1 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 453 7 0 8 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccco4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330635 208426 None 0 Human Binding pKi = 9.4 9.4 2 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 493 8 0 8 3.5 COc1ccccc1/C=C(\C)CN1CCN(C[C@@H]2ON=C3c4cc(OC)c(OC)cc4OC[C@H]32)CC1 10.1016/j.bmcl.2004.03.031
CHEMBL99868 208426 None 0 Human Binding pKi = 9.4 9.4 2 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 493 8 0 8 3.5 COc1ccccc1/C=C(\C)CN1CCN(C[C@@H]2ON=C3c4cc(OC)c(OC)cc4OC[C@H]32)CC1 10.1016/j.bmcl.2004.03.031
52948958 17153 None 0 Human Binding pKi = 9.4 9.4 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 238 3 1 1 3.4 CCC[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1255724 17153 None 0 Human Binding pKi = 9.4 9.4 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 238 3 1 1 3.4 CCC[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
44579228 181654 None 0 Human Binding pKi = 9.3 9.3 13 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 467 7 2 7 2.9 CC(C)(C)Nc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL477608 181654 None 0 Human Binding pKi = 9.3 9.3 13 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 467 7 2 7 2.9 CC(C)(C)Nc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
102 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
3659 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
8969 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
8969.0 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
CHEMBL15245 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
DB01392 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
102 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
3659 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
8969 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
8969.0 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
CHEMBL15245 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
DB01392 4127 None 48 Human Binding pKi = 9.3 9.3 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
44330645 208434 None 0 Human Binding pKi = 9.3 9.3 3 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 453 7 0 8 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccco4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL99916 208434 None 0 Human Binding pKi = 9.3 9.3 3 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 453 7 0 8 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccco4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324765 111568 None 0 Human Binding pKi = 9.3 9.3 2 5
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL328114 111568 None 0 Human Binding pKi = 9.3 9.3 2 5
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44324765 111568 None 0 Human Binding pKi = 9.3 9.3 2 5
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL328114 111568 None 0 Human Binding pKi = 9.3 9.3 2 5
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
49781222 17251 None 0 Human Binding pKi = 9.3 9.3 -2 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 3.0 C[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256609 17251 None 0 Human Binding pKi = 9.3 9.3 -2 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 3.0 C[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
44579230 181544 None 0 Human Binding pKi = 9.2 9.2 8 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 468 10 1 7 2.8 CCCCOc1cccc(C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)n1 10.1016/j.bmcl.2008.08.055
CHEMBL476569 181544 None 0 Human Binding pKi = 9.2 9.2 8 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 468 10 1 7 2.8 CCCCOc1cccc(C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)n1 10.1016/j.bmcl.2008.08.055
44330368 112192 None 0 Human Binding pKi = 9.2 9.2 3 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 479 7 1 8 3.2 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(O)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL329065 112192 None 0 Human Binding pKi = 9.2 9.2 3 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 479 7 1 8 3.2 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(O)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44325049 111523 None 0 Human Binding pKi = 9.2 9.2 2 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C(\C)c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL327875 111523 None 0 Human Binding pKi = 9.2 9.2 2 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C(\C)c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
1588 2325 None 27 Human Binding pKi = 9.2 9.2 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
28864 2325 None 27 Human Binding pKi = 9.2 9.2 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
28864.0 2325 None 27 Human Binding pKi = 9.2 9.2 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
43 2325 None 27 Human Binding pKi = 9.2 9.2 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
CHEMBL157138 2325 None 27 Human Binding pKi = 9.2 9.2 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
DB00589 2325 None 27 Human Binding pKi = 9.2 9.2 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
11203101 71683 None 0 Human Binding pKi = 9.2 9.2 44 3
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 515 7 3 5 4.1 O=C(CCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)OCc1ccccc1 10.1016/j.bmcl.2005.03.116
CHEMBL196451 71683 None 0 Human Binding pKi = 9.2 9.2 44 3
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 515 7 3 5 4.1 O=C(CCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)OCc1ccccc1 10.1016/j.bmcl.2005.03.116
16655023 107441 None 2 Human Binding pKi = 9.2 9.2 5 7
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
CHEMBL318235 107441 None 2 Human Binding pKi = 9.2 9.2 5 7
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
16655023 107441 None 2 Human Binding pKi = 9.2 9.2 5 7
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL318235 107441 None 2 Human Binding pKi = 9.2 9.2 5 7
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330427 163375 None 0 Human Binding pKi = 9.2 9.2 4 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccc(F)c4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL419336 163375 None 0 Human Binding pKi = 9.2 9.2 4 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccc(F)c4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330598 207638 None 0 Human Binding pKi = 9.2 9.2 8 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4cccc(F)c4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL95218 207638 None 0 Human Binding pKi = 9.2 9.2 8 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4cccc(F)c4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
108094 3423 None 27 Human Binding pKi = 9.1 9.1 -2 4
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 10.1021/jm800250z
526 3423 None 27 Human Binding pKi = 9.1 9.1 -2 4
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 10.1021/jm800250z
528 3423 None 27 Human Binding pKi = 9.1 9.1 -2 4
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 10.1021/jm800250z
CHEMBL10332 3423 None 27 Human Binding pKi = 9.1 9.1 -2 4
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 10.1021/jm800250z
499 4077 None 18 Human Binding pKi = 9.1 9.1 -3 14
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 10.1021/jm00018a001
5685 4077 None 18 Human Binding pKi = 9.1 9.1 -3 14
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 10.1021/jm00018a001
CHEMBL25554 4077 None 18 Human Binding pKi = 9.1 9.1 -3 14
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 10.1021/jm00018a001
44579229 189616 None 0 Human Binding pKi = 9.1 9.1 6 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 468 10 1 7 2.8 CCCCOc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL514837 189616 None 0 Human Binding pKi = 9.1 9.1 6 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 468 10 1 7 2.8 CCCCOc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
44579187 189679 None 0 Human Binding pKi = 9.1 9.1 25 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 513 8 1 8 3.3 N#Cc1cccc(Oc2ncccc2C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)c1 10.1016/j.bmcl.2008.08.055
CHEMBL515331 189679 None 0 Human Binding pKi = 9.1 9.1 25 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 513 8 1 8 3.3 N#Cc1cccc(Oc2ncccc2C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)c1 10.1016/j.bmcl.2008.08.055
44438167 148970 None 0 Human Binding pKi = 9.1 9.1 52 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 505 7 1 7 3.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NC4CN5CCC4CC5)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL394218 148970 None 0 Human Binding pKi = 9.1 9.1 52 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 505 7 1 7 3.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NC4CN5CCC4CC5)cc13)CC2 10.1016/j.bmcl.2006.12.094
102 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
3659 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
8969 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
8969.0 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
CHEMBL15245 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
DB01392 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
10028898 111655 None 0 Human Binding pKi = 9.1 9.1 11 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(F)cc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL328631 111655 None 0 Human Binding pKi = 9.1 9.1 11 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(F)cc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324737 207238 None 0 Human Binding pKi = 9.1 9.1 2 5
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL92860 207238 None 0 Human Binding pKi = 9.1 9.1 2 5
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44324737 207238 None 0 Human Binding pKi = 9.1 9.1 2 5
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL92860 207238 None 0 Human Binding pKi = 9.1 9.1 2 5
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1021/jm049619s
102 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
3659 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
8969 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
8969.0 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
CHEMBL15245 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
DB01392 4127 None 48 Human Binding pKi = 9.1 9.1 -2 49
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
25110718 193309 None 0 Human Binding pKi = 9.1 9.1 16 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL524153 193309 None 0 Human Binding pKi = 9.1 9.1 16 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
44330857 4394 None 0 Human Binding pKi = 9.1 9.1 5 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 493 8 0 8 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4OC)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL101361 4394 None 0 Human Binding pKi = 9.1 9.1 5 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 493 8 0 8 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4OC)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
136019934 144530 None 0 Human Binding pKi = 9.0 9.0 7 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
CHEMBL390718 144530 None 0 Human Binding pKi = 9.0 9.0 7 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
124 2981 None 47 Human Binding pKi = 9 9.0 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
2032 2981 None 47 Human Binding pKi = 9 9.0 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
4636 2981 None 47 Human Binding pKi = 9 9.0 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
4636.0 2981 None 47 Human Binding pKi = 9 9.0 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
CHEMBL762 2981 None 47 Human Binding pKi = 9 9.0 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
DB00935 2981 None 47 Human Binding pKi = 9 9.0 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
136 3292 None 32 Human Binding pKi = 9 9.0 3 15
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
223 3292 None 32 Human Binding pKi = 9 9.0 3 15
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
643606 3292 None 32 Human Binding pKi = 9 9.0 3 15
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
CHEMBL10347 3292 None 32 Human Binding pKi = 9 9.0 3 15
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
44402346 132739 None 0 Human Binding pKi = 9.0 9.0 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 530 7 4 5 3.9 O=C(NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)OCc1ccccc1 10.1016/j.bmcl.2005.03.116
CHEMBL369938 132739 None 0 Human Binding pKi = 9.0 9.0 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 530 7 4 5 3.9 O=C(NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)OCc1ccccc1 10.1016/j.bmcl.2005.03.116
135398737 958 None 93 Human Binding pKi = 8.9 8.9 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
135398737.0 958 None 93 Human Binding pKi = 8.9 8.9 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
38 958 None 93 Human Binding pKi = 8.9 8.9 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
722 958 None 93 Human Binding pKi = 8.9 8.9 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
CHEMBL42 958 None 93 Human Binding pKi = 8.9 8.9 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
DB00363 958 None 93 Human Binding pKi = 8.9 8.9 -3 89
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
52950140 17158 None 0 Human Binding pKi = 8.9 8.9 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 1 1 1 3.0 CC1(C)[C@@H]2c3ccccc3C[C@@]21c1c[nH]cn1 10.1021/jm1006269
CHEMBL1255770 17158 None 0 Human Binding pKi = 8.9 8.9 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 1 1 1 3.0 CC1(C)[C@@H]2c3ccccc3C[C@@]21c1c[nH]cn1 10.1021/jm1006269
107715 200945 None 22 Human Binding pKi = 8.9 8.9 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
CHEMBL1255837 200945 None 22 Human Binding pKi = 8.9 8.9 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
CHEMBL601773 200945 None 22 Human Binding pKi = 8.9 8.9 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
49781223 17252 None 0 Human Binding pKi = 8.9 8.9 -2 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 2 1 1 3.3 CC[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256610 17252 None 0 Human Binding pKi = 8.9 8.9 -2 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 2 1 1 3.3 CC[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
2389 3331 None 118 Human Binding pKi = 8.9 8.9 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
5073 3331 None 118 Human Binding pKi = 8.9 8.9 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
5073.0 3331 None 118 Human Binding pKi = 8.9 8.9 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
96 3331 None 118 Human Binding pKi = 8.9 8.9 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
CHEMBL85 3331 None 118 Human Binding pKi = 8.9 8.9 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
DB00734 3331 None 118 Human Binding pKi = 8.9 8.9 -10 67
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
10824121 120481 None 1 Rat Binding pKi = 8.9 8.9 - 1
In vitro binding affinity against alpha-2C adrenergic receptor of male Wistar ratIn vitro binding affinity against alpha-2C adrenergic receptor of male Wistar rat
ChEMBL 242 2 1 2 2.8 Brc1csc(Cc2c[nH]cn2)c1 10.1021/jm0003891
CHEMBL1203852 120481 None 1 Rat Binding pKi = 8.9 8.9 - 1
In vitro binding affinity against alpha-2C adrenergic receptor of male Wistar ratIn vitro binding affinity against alpha-2C adrenergic receptor of male Wistar rat
ChEMBL 242 2 1 2 2.8 Brc1csc(Cc2c[nH]cn2)c1 10.1021/jm0003891
CHEMBL354272 120481 None 1 Rat Binding pKi = 8.9 8.9 - 1
In vitro binding affinity against alpha-2C adrenergic receptor of male Wistar ratIn vitro binding affinity against alpha-2C adrenergic receptor of male Wistar rat
ChEMBL 242 2 1 2 2.8 Brc1csc(Cc2c[nH]cn2)c1 10.1021/jm0003891
44324800 206948 None 0 Human Binding pKi = 8.9 8.9 5 7
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL91157 206948 None 0 Human Binding pKi = 8.9 8.9 5 7
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
49781224 17143 None 0 Human Binding pKi = 8.8 8.8 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 238 3 1 1 3.7 CCC[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1255616 17143 None 0 Human Binding pKi = 8.8 8.8 -1 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 238 3 1 1 3.7 CCC[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
10531 1420 None 21 Human Binding pKi = 8.8 8.8 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
10531.0 1420 None 21 Human Binding pKi = 8.8 8.8 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
121 1420 None 21 Human Binding pKi = 8.8 8.8 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
888 1420 None 21 Human Binding pKi = 8.8 8.8 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
CHEMBL1732 1420 None 21 Human Binding pKi = 8.8 8.8 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
DB00320 1420 None 21 Human Binding pKi = 8.8 8.8 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
49781007 17241 None 0 Human Binding pKi = 8.8 8.8 2 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 254 4 1 2 3.3 CCCO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256566 17241 None 0 Human Binding pKi = 8.8 8.8 2 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 254 4 1 2 3.3 CCCO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
44324937 206913 None 0 Human Binding pKi = 8.8 8.8 -1 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 389 5 0 5 3.1 C(=C/c1ccccc1)\CN1CCN(CC2ON=C3c4ccccc4OCC32)CC1 10.1016/s0960-894x(03)00525-0
CHEMBL90943 206913 None 0 Human Binding pKi = 8.8 8.8 -1 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 389 5 0 5 3.1 C(=C/c1ccccc1)\CN1CCN(CC2ON=C3c4ccccc4OCC32)CC1 10.1016/s0960-894x(03)00525-0
1043 1582 None 14 Human Binding pKi = 8.7 8.7 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
149 1582 None 14 Human Binding pKi = 8.7 8.7 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
8223 1582 None 14 Human Binding pKi = 8.7 8.7 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
8223.0 1582 None 14 Human Binding pKi = 8.7 8.7 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
CHEMBL442 1582 None 14 Human Binding pKi = 8.7 8.7 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
DB00696 1582 None 14 Human Binding pKi = 8.7 8.7 -19 28
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
44579272 187095 None 0 Human Binding pKi = 8.7 8.7 5 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 499 7 0 9 4.3 c1ccc(Oc2ncccc2-c2noc(CN3CCCN(CC4COc5ccccc5O4)CC3)n2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL491420 187095 None 0 Human Binding pKi = 8.7 8.7 5 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 499 7 0 9 4.3 c1ccc(Oc2ncccc2-c2noc(CN3CCCN(CC4COc5ccccc5O4)CC3)n2)cc1 10.1016/j.bmcl.2008.08.055
102 4127 None 48 Human Binding pKi = 8.7 8.7 -2 49
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
3659 4127 None 48 Human Binding pKi = 8.7 8.7 -2 49
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
8969 4127 None 48 Human Binding pKi = 8.7 8.7 -2 49
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
8969.0 4127 None 48 Human Binding pKi = 8.7 8.7 -2 49
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
CHEMBL15245 4127 None 48 Human Binding pKi = 8.7 8.7 -2 49
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
DB01392 4127 None 48 Human Binding pKi = 8.7 8.7 -2 49
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
56944383 112119 None 0 Human Binding pKi = 8.7 8.7 -3 12
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 487 8 1 6 5.1 O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1 10.1021/jm401895u
CHEMBL3290012 112119 None 0 Human Binding pKi = 8.7 8.7 -3 12
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 487 8 1 6 5.1 O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1 10.1021/jm401895u
44324906 206787 None 0 Human Binding pKi = 8.7 8.7 -3 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 419 6 0 6 3.1 COc1ccc2c(c1)OCC1C2=NOC1CN1CCN(C/C=C/c2ccccc2)CC1 10.1016/s0960-894x(03)00525-0
CHEMBL90247 206787 None 0 Human Binding pKi = 8.7 8.7 -3 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 419 6 0 6 3.1 COc1ccc2c(c1)OCC1C2=NOC1CN1CCN(C/C=C/c2ccccc2)CC1 10.1016/s0960-894x(03)00525-0
44324725 206817 None 0 Human Binding pKi = 8.7 8.7 13 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 451 8 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCCc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL90419 206817 None 0 Human Binding pKi = 8.7 8.7 13 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 451 8 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCCc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
49781005 17214 None 0 Human Binding pKi = 8.7 8.7 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256503 17214 None 0 Human Binding pKi = 8.7 8.7 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
2389 3331 None 118 Human Binding pKi = 8 8.0 -10 67
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
5073 3331 None 118 Human Binding pKi = 8 8.0 -10 67
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
5073.0 3331 None 118 Human Binding pKi = 8 8.0 -10 67
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
96 3331 None 118 Human Binding pKi = 8 8.0 -10 67
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
CHEMBL85 3331 None 118 Human Binding pKi = 8 8.0 -10 67
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
DB00734 3331 None 118 Human Binding pKi = 8 8.0 -10 67
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
16655023 107441 None 2 Human Binding pKi = 8 8.0 5 7
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
CHEMBL318235 107441 None 2 Human Binding pKi = 8 8.0 5 7
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
44330621 4402 None 0 Human Binding pKi = 8 8.0 6 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 483 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccc(Cl)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL101411 4402 None 0 Human Binding pKi = 8 8.0 6 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 483 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccc(Cl)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324972 163372 None 0 Human Binding pKi = 8 8.0 2 4
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL419316 163372 None 0 Human Binding pKi = 8 8.0 2 4
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
49781006 17240 None 0 Human Binding pKi = 8.0 8.0 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 240 3 1 2 2.9 CCO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256565 17240 None 0 Human Binding pKi = 8.0 8.0 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 240 3 1 2 2.9 CCO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
441082 1163 None 48 Human Binding pKi = 8.0 8.0 -2 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
8981 1163 None 48 Human Binding pKi = 8.0 8.0 -2 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
CHEMBL191703 1163 None 48 Human Binding pKi = 8.0 8.0 -2 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
441082 1163 None 48 Human Binding pKi = 8.0 8.0 -2 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
8981 1163 None 48 Human Binding pKi = 8.0 8.0 -2 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
CHEMBL191703 1163 None 48 Human Binding pKi = 8.0 8.0 -2 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
10707358 179285 None 0 Human Binding pKi = 8.0 8.0 -7 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 272 4 1 3 3.2 c1ccc(CC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL47313 179285 None 0 Human Binding pKi = 8.0 8.0 -7 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 272 4 1 3 3.2 c1ccc(CC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
242 470 None 124 Human Binding pKi = 7 7.0 -23 51
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
34 470 None 124 Human Binding pKi = 7 7.0 -23 51
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
60795 470 None 124 Human Binding pKi = 7 7.0 -23 51
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
60795.0 470 None 124 Human Binding pKi = 7 7.0 -23 51
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
CHEMBL1112 470 None 124 Human Binding pKi = 7 7.0 -23 51
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
DB01238 470 None 124 Human Binding pKi = 7 7.0 -23 51
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
135398737 958 None 93 Human Binding pKi = 7 7.0 -3 89
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
135398737.0 958 None 93 Human Binding pKi = 7 7.0 -3 89
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
38 958 None 93 Human Binding pKi = 7 7.0 -3 89
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
722 958 None 93 Human Binding pKi = 7 7.0 -3 89
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
CHEMBL42 958 None 93 Human Binding pKi = 7 7.0 -3 89
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
DB00363 958 None 93 Human Binding pKi = 7 7.0 -3 89
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
135398745 2914 None 112 Human Binding pKi = 7 7.0 -30 65
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
135398745.0 2914 None 112 Human Binding pKi = 7 7.0 -30 65
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
47 2914 None 112 Human Binding pKi = 7 7.0 -30 65
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
CHEMBL715 2914 None 112 Human Binding pKi = 7 7.0 -30 65
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
DB00334 2914 None 112 Human Binding pKi = 7 7.0 -30 65
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
2337 3256 None 77 Human Binding pKi = 7 7.0 -10 62
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
50 3256 None 77 Human Binding pKi = 7 7.0 -10 62
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
5002 3256 None 77 Human Binding pKi = 7 7.0 -10 62
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
5002.0 3256 None 77 Human Binding pKi = 7 7.0 -10 62
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
CHEMBL716 3256 None 77 Human Binding pKi = 7 7.0 -10 62
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
DB01224 3256 None 77 Human Binding pKi = 7 7.0 -10 62
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
16090600 169181 None 0 Human Binding pKi = 7 7.0 10 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 6 2 4 5.1 Cc1nc2ccccc2c(Nc2ccc(NCCN3CCCC3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL440594 169181 None 0 Human Binding pKi = 7 7.0 10 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 6 2 4 5.1 Cc1nc2ccccc2c(Nc2ccc(NCCN3CCCC3)cc2)c1C 10.1016/j.ejmech.2010.12.026
9982218 101764 None 6 Human Binding pKi = 7 7.0 -12 6
Bnding affinity against cloned human Alpha-2C adrenergic receptor was evaluatedBnding affinity against cloned human Alpha-2C adrenergic receptor was evaluated
ChEMBL 471 9 2 5 4.1 O=[N+]([O-])c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1 10.1016/s0960-894x(02)00287-1
CHEMBL1435188 101764 None 6 Human Binding pKi = 7 7.0 -12 6
Bnding affinity against cloned human Alpha-2C adrenergic receptor was evaluatedBnding affinity against cloned human Alpha-2C adrenergic receptor was evaluated
ChEMBL 471 9 2 5 4.1 O=[N+]([O-])c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1 10.1016/s0960-894x(02)00287-1
CHEMBL299879 101764 None 6 Human Binding pKi = 7 7.0 -12 6
Bnding affinity against cloned human Alpha-2C adrenergic receptor was evaluatedBnding affinity against cloned human Alpha-2C adrenergic receptor was evaluated
ChEMBL 471 9 2 5 4.1 O=[N+]([O-])c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1 10.1016/s0960-894x(02)00287-1
16090600 169181 None 0 Human Binding pKi = 7 7.0 10 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 6 2 4 5.1 Cc1nc2ccccc2c(Nc2ccc(NCCN3CCCC3)cc2)c1C 10.1021/jm060262x
CHEMBL440594 169181 None 0 Human Binding pKi = 7 7.0 10 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 6 2 4 5.1 Cc1nc2ccccc2c(Nc2ccc(NCCN3CCCC3)cc2)c1C 10.1021/jm060262x
10793665 106952 None 0 Human Binding pKi = 6 6.0 -562 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 597 9 2 5 7.2 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)cc1 10.1021/jm980077m
CHEMBL314960 106952 None 0 Human Binding pKi = 6 6.0 -562 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 597 9 2 5 7.2 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)cc1 10.1021/jm980077m
42574 15287 None 90 Human Binding pKi = 6 6.0 -18 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 662 4 2 3 7.1 Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O nan
CHEMBL12131 15287 None 90 Human Binding pKi = 6 6.0 -18 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 662 4 2 3 7.1 Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O nan
153287553 171104 None 0 Human Binding pKi = 6 6.0 -158 6
Displacement of [3H]-Rauwolscine from human recombinant adrenergic Alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human recombinant adrenergic Alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 264 1 1 2 3.7 C[C@@]12CN(c3ccccc3)c3ccccc3[C@@H]1CCN2 10.1021/acsmedchemlett.9b00225
CHEMBL4457754 171104 None 0 Human Binding pKi = 6 6.0 -158 6
Displacement of [3H]-Rauwolscine from human recombinant adrenergic Alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human recombinant adrenergic Alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 264 1 1 2 3.7 C[C@@]12CN(c3ccccc3)c3ccccc3[C@@H]1CCN2 10.1021/acsmedchemlett.9b00225
2719 917 None 74 Human Binding pKi = 5 5.0 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
5535 917 None 74 Human Binding pKi = 5 5.0 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
607 917 None 74 Human Binding pKi = 5 5.0 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
CHEMBL76 917 None 74 Human Binding pKi = 5 5.0 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
DB00608 917 None 74 Human Binding pKi = 5 5.0 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
9817231 158236 None 22 Human Binding pKi = 5 5.0 -1 7
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 282 4 0 3 4.1 CCCN1CCC=C(c2cc(-c3ccc(C)cc3)no2)C1 10.1038/s41586-020-2286-9
CHEMBL4088272 158236 None 22 Human Binding pKi = 5 5.0 -1 7
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 282 4 0 3 4.1 CCCN1CCC=C(c2cc(-c3ccc(C)cc3)no2)C1 10.1038/s41586-020-2286-9
3598 187821 None 76 Human Binding pKi = 6.0 6.0 -1 7
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
CHEMBL496 187821 None 76 Human Binding pKi = 6.0 6.0 -1 7
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
11801828 206544 None 0 Human Binding pKi = 6.0 6.0 -63 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 606 9 3 6 5.0 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
CHEMBL88628 206544 None 0 Human Binding pKi = 6.0 6.0 -63 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 606 9 3 6 5.0 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
132584404 143349 None 0 Human Binding pKi = 6.0 6.0 -2 5
Displacement of [3H]Rauwolscine from human Alpha2C receptor expressed in MDCK cells measured after 90 mins by microbeta scintillation counting methodDisplacement of [3H]Rauwolscine from human Alpha2C receptor expressed in MDCK cells measured after 90 mins by microbeta scintillation counting method
ChEMBL 416 3 0 2 6.7 CCCN1CC[C@H]2c3cc4ccc(C(F)(F)F)cc4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32 10.1016/j.bmcl.2016.10.065
CHEMBL3897499 143349 None 0 Human Binding pKi = 6.0 6.0 -2 5
Displacement of [3H]Rauwolscine from human Alpha2C receptor expressed in MDCK cells measured after 90 mins by microbeta scintillation counting methodDisplacement of [3H]Rauwolscine from human Alpha2C receptor expressed in MDCK cells measured after 90 mins by microbeta scintillation counting method
ChEMBL 416 3 0 2 6.7 CCCN1CC[C@H]2c3cc4ccc(C(F)(F)F)cc4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32 10.1016/j.bmcl.2016.10.065
11333552 121715 None 5 Human Binding pKi = 5.0 5.0 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 223 4 1 4 1.1 COc1ccccc1OCC1CNCCO1 10.1016/j.bmc.2015.01.013
CHEMBL3588908 121715 None 5 Human Binding pKi = 5.0 5.0 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 223 4 1 4 1.1 COc1ccccc1OCC1CNCCO1 10.1016/j.bmc.2015.01.013
2351 3286 None 64 Human Binding pKi = 7.0 7.0 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
2820 3286 None 64 Human Binding pKi = 7.0 7.0 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
5035 3286 None 64 Human Binding pKi = 7.0 7.0 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
CHEMBL81 3286 None 64 Human Binding pKi = 7.0 7.0 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
DB00481 3286 None 64 Human Binding pKi = 7.0 7.0 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
122180567 121711 None 0 Human Binding pKi = 6.0 6.0 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 261 4 1 3 3.8 c1cncc(-c2ccccc2NCc2ccncc2)c1 10.1016/j.bmc.2015.01.013
CHEMBL3588904 121711 None 0 Human Binding pKi = 6.0 6.0 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 261 4 1 3 3.8 c1cncc(-c2ccccc2NCc2ccncc2)c1 10.1016/j.bmc.2015.01.013
11948707 166167 None 0 Human Binding pKi = 7.0 7.0 -269 13
Binding affinity to alpha 2C adrenergic receptor by radioligand binding assayBinding affinity to alpha 2C adrenergic receptor by radioligand binding assay
ChEMBL 373 7 0 8 0.6 COc1cccc(N2CCN(CCCCn3ncc(=O)n(C)c3=O)CC2)c1 10.1016/j.bmcl.2006.01.052
CHEMBL426317 166167 None 0 Human Binding pKi = 7.0 7.0 -269 13
Binding affinity to alpha 2C adrenergic receptor by radioligand binding assayBinding affinity to alpha 2C adrenergic receptor by radioligand binding assay
ChEMBL 373 7 0 8 0.6 COc1cccc(N2CCN(CCCCn3ncc(=O)n(C)c3=O)CC2)c1 10.1016/j.bmcl.2006.01.052
16090635 82515 None 0 Human Binding pKi = 7.0 7.0 5 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 378 4 1 4 4.7 CCc1c(C)nc2c(c1Nc1ccc(N3CCN(C)C(C)C3)cc1)CCCC2 10.1016/j.ejmech.2010.12.026
CHEMBL217768 82515 None 0 Human Binding pKi = 7.0 7.0 5 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 378 4 1 4 4.7 CCc1c(C)nc2c(c1Nc1ccc(N3CCN(C)C(C)C3)cc1)CCCC2 10.1016/j.ejmech.2010.12.026
44289035 100514 None 0 Human Binding pKi = 6.0 6.0 -575 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 524 7 1 4 4.4 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL291166 100514 None 0 Human Binding pKi = 6.0 6.0 -575 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 524 7 1 4 4.4 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
127036186 137414 None 0 Human Binding pKi = 6.0 6.0 -34 19
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 254 7 1 1 3.7 C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL3753318 137414 None 0 Human Binding pKi = 6.0 6.0 -34 19
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 254 7 1 1 3.7 C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12 10.1016/j.bmcl.2015.12.053
44210114 192716 None 19 Human Binding pKi = 8.0 8.0 -6 3
Binding affinity to alpha2C AR (unknown origin) assessed as inhibition constantBinding affinity to alpha2C AR (unknown origin) assessed as inhibition constant
ChEMBL 492 5 0 6 4.3 O=C1C2C3CCC(C3)C2C(=O)N1CC1CCCCC1CN1CCN(c2nsc3ccccc23)CC1 10.1016/j.bmcl.2021.128275
CHEMBL5219924 192716 None 19 Human Binding pKi = 8.0 8.0 -6 3
Binding affinity to alpha2C AR (unknown origin) assessed as inhibition constantBinding affinity to alpha2C AR (unknown origin) assessed as inhibition constant
ChEMBL 492 5 0 6 4.3 O=C1C2C3CCC(C3)C2C(=O)N1CC1CCCCC1CN1CCN(c2nsc3ccccc23)CC1 10.1016/j.bmcl.2021.128275
11293787 148213 None 0 Human Binding pKi = 8.0 8.0 27 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 447 6 0 5 5.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4F)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL393597 148213 None 0 Human Binding pKi = 8.0 8.0 27 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 447 6 0 5 5.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4F)cc13)CC2 10.1016/j.bmcl.2006.12.094
1393724 121903 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 222 3 1 2 2.7 N#Cc1cccc(-c2ccccc2CCN)c1 10.1016/j.bmc.2015.01.013
CHEMBL3590203 121903 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 222 3 1 2 2.7 N#Cc1cccc(-c2ccccc2CCN)c1 10.1016/j.bmc.2015.01.013
16090635 82515 None 0 Human Binding pKi = 7.0 7.0 5 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 378 4 1 4 4.7 CCc1c(C)nc2c(c1Nc1ccc(N3CCN(C)C(C)C3)cc1)CCCC2 10.1021/jm060262x
CHEMBL217768 82515 None 0 Human Binding pKi = 7.0 7.0 5 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 378 4 1 4 4.7 CCc1c(C)nc2c(c1Nc1ccc(N3CCN(C)C(C)C3)cc1)CCCC2 10.1021/jm060262x
46869265 16257 None 0 Human Binding pKi = 6.0 6.0 -5 7
Binding affinity to adrenergic Alpha-2C receptorBinding affinity to adrenergic Alpha-2C receptor
ChEMBL 295 1 3 3 3.1 Oc1ccc2c(c1O)C[C@@H](c1ccccc1)[C@@H]1CCNC[C@@H]21 10.1016/j.bmc.2010.07.052
CHEMBL1224527 16257 None 0 Human Binding pKi = 6.0 6.0 -5 7
Binding affinity to adrenergic Alpha-2C receptorBinding affinity to adrenergic Alpha-2C receptor
ChEMBL 295 1 3 3 3.1 Oc1ccc2c(c1O)C[C@@H](c1ccccc1)[C@@H]1CCNC[C@@H]21 10.1016/j.bmc.2010.07.052
CHEMBL5274312 193809 None 0 Human Binding pKi = 6.0 6.0 1 5
Binding affinity to adrenergic alpha 2c receptor (unknown origin)Binding affinity to adrenergic alpha 2c receptor (unknown origin)
ChEMBL 383 4 0 3 5.0 CC[Si](C#Cc1cccc2c1OC(C(F)(F)F)C([N+](=O)[O-])=C2)(CC)CC 10.1016/j.bmcl.2022.128981
10489502 4518 None 2 Human Binding pKi = 6.0 6.0 -11 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 227 2 2 2 3.5 Clc1cccc(Cl)c1Nc1ncc[nH]1 10.1021/jm9605142
CHEMBL1022 4518 None 2 Human Binding pKi = 6.0 6.0 -11 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 227 2 2 2 3.5 Clc1cccc(Cl)c1Nc1ncc[nH]1 10.1021/jm9605142
49836307 18785 None 0 Human Binding pKi = 7.0 7.0 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 C[C@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL1278085 18785 None 0 Human Binding pKi = 7.0 7.0 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 C[C@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
240 944 None 43 Human Binding pKi = 7.0 7.0 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
2769 944 None 43 Human Binding pKi = 7.0 7.0 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
44279790 944 None 43 Human Binding pKi = 7.0 7.0 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
660 944 None 43 Human Binding pKi = 7.0 7.0 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
CHEMBL1729 944 None 43 Human Binding pKi = 7.0 7.0 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
CHEMBL560739 944 None 43 Human Binding pKi = 7.0 7.0 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
DB00604 944 None 43 Human Binding pKi = 7.0 7.0 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
11386747 75491 None 9 Human Binding pKi = 6.0 6.0 -1 2
Selectivity interaction (Radioligand binding assay (MDS Pharma Service)) EUB0000296b ADRA2CSelectivity interaction (Radioligand binding assay (MDS Pharma Service)) EUB0000296b ADRA2C
ChEMBL 513 4 1 5 6.4 CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12 10.6019/CHEMBL5212743
CHEMBL204232 75491 None 9 Human Binding pKi = 6.0 6.0 -1 2
Selectivity interaction (Radioligand binding assay (MDS Pharma Service)) EUB0000296b ADRA2CSelectivity interaction (Radioligand binding assay (MDS Pharma Service)) EUB0000296b ADRA2C
ChEMBL 513 4 1 5 6.4 CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12 10.6019/CHEMBL5212743
11140347 204533 None 1 Human Binding pKi = 6.9 6.9 -18 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72768 204533 None 1 Human Binding pKi = 6.9 6.9 -18 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
71455894 83802 None 0 Human Binding pKi = 5.9 5.9 1 12
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 325 4 1 4 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmcl.2012.08.046
CHEMBL2205827 83802 None 0 Human Binding pKi = 5.9 5.9 1 12
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 325 4 1 4 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmcl.2012.08.046
71455894 83802 None 0 Human Binding pKi = 5.9 5.9 1 12
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 4 1 4 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmc.2013.07.045
CHEMBL2205827 83802 None 0 Human Binding pKi = 5.9 5.9 1 12
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 4 1 4 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmc.2013.07.045
104903 56344 None 17 Human Binding pKi = 5.9 5.9 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
CHEMBL1630578 56344 None 17 Human Binding pKi = 5.9 5.9 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
10841190 107042 None 0 Human Binding pKi = 5.9 5.9 -162 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 2 6 6.5 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(OC)cc1 10.1021/jm980077m
CHEMBL315538 107042 None 0 Human Binding pKi = 5.9 5.9 -162 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 2 6 6.5 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(OC)cc1 10.1021/jm980077m
44311789 204735 None 0 Human Binding pKi = 4.9 4.9 1 5
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 345 1 2 5 3.1 Brc1c(NC2=N[C@@H]3CCCC[C@@H]3N2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL74342 204735 None 0 Human Binding pKi = 4.9 4.9 1 5
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 345 1 2 5 3.1 Brc1c(NC2=N[C@@H]3CCCC[C@@H]3N2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
10220337 200451 None 53 Human Binding pKi = 5.9 5.9 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 236 2 0 2 2.7 Brc1cccc(Cn2ccnc2)c1 10.1016/j.bmc.2015.01.013
CHEMBL598391 200451 None 53 Human Binding pKi = 5.9 5.9 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 236 2 0 2 2.7 Brc1cccc(Cn2ccnc2)c1 10.1016/j.bmc.2015.01.013
2274 3173 None 58 Human Binding pKi = 7.9 7.9 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
4917 3173 None 58 Human Binding pKi = 7.9 7.9 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
4917.0 3173 None 58 Human Binding pKi = 7.9 7.9 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
7279 3173 None 58 Human Binding pKi = 7.9 7.9 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
CHEMBL728 3173 None 58 Human Binding pKi = 7.9 7.9 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
DB00433 3173 None 58 Human Binding pKi = 7.9 7.9 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
218362 204800 None 5 Human Binding pKi = 7.9 7.9 -5 4
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 216 1 1 3 2.0 c1ccc2c(c1)CCCC2NC1=NCCO1 10.1016/0960-894X(94)85032-1
CHEMBL75030 204800 None 5 Human Binding pKi = 7.9 7.9 -5 4
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 216 1 1 3 2.0 c1ccc2c(c1)CCCC2NC1=NCCO1 10.1016/0960-894X(94)85032-1
68712 100338 None 60 Human Binding pKi = 7.9 7.9 -1 5
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/j.bmc.2012.06.008
CHEMBL289480 100338 None 60 Human Binding pKi = 7.9 7.9 -1 5
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/j.bmc.2012.06.008
9883506 70564 None 0 Human Binding pKi = 7.9 7.9 1 6
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 282 3 3 5 2.3 Cc1ccc(N(NC2=NCCN2)c2cccc(O)c2)cc1 10.1016/j.bmcl.2005.07.083
CHEMBL194849 70564 None 0 Human Binding pKi = 7.9 7.9 1 6
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 282 3 3 5 2.3 Cc1ccc(N(NC2=NCCN2)c2cccc(O)c2)cc1 10.1016/j.bmcl.2005.07.083
9816048 187278 None 0 Human Binding pKi = 6.9 6.9 -12 3
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 231 1 4 5 1.2 Cc1c(NC2=NCCN2)ccc2c1NCCN2 10.1021/jm960359r
CHEMBL49284 187278 None 0 Human Binding pKi = 6.9 6.9 -12 3
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 231 1 4 5 1.2 Cc1c(NC2=NCCN2)ccc2c1NCCN2 10.1021/jm960359r
118717249 115125 None 0 Human Binding pKi = 5.9 5.9 -18 3
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 219 1 2 3 0.5 Fc1cccc2cnn(N=C3NCCN3)c12 10.1016/j.ejmech.2014.09.083
CHEMBL3343700 115125 None 0 Human Binding pKi = 5.9 5.9 -18 3
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 219 1 2 3 0.5 Fc1cccc2cnn(N=C3NCCN3)c12 10.1016/j.ejmech.2014.09.083
50985821 176218 None 31 Human Binding pKi = 5.9 5.9 2 3
Binding affinity to alpha2C receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C receptor (unknown origin) by radioligand displacement assay
ChEMBL 474 5 2 5 6.2 N=c1c2c(-c3ccccc3)c(-c3ccccc3)n(Cc3ccccc3)c2ncn1[C@H]1CC[C@H](O)CC1 10.1021/acs.jmedchem.2c00204
CHEMBL4594433 176218 None 31 Human Binding pKi = 5.9 5.9 2 3
Binding affinity to alpha2C receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C receptor (unknown origin) by radioligand displacement assay
ChEMBL 474 5 2 5 6.2 N=c1c2c(-c3ccccc3)c(-c3ccccc3)n(Cc3ccccc3)c2ncn1[C@H]1CC[C@H](O)CC1 10.1021/acs.jmedchem.2c00204
44292232 101321 None 0 Human Binding pKi = 6.9 6.9 -4 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 222 3 1 3 2.2 CCC[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL296660 101321 None 0 Human Binding pKi = 6.9 6.9 -4 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 222 3 1 3 2.2 CCC[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
9971924 184226 None 0 Human Binding pKi = 6.9 6.9 -3 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 298 5 1 3 3.4 c1ccc(CCC[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL48341 184226 None 0 Human Binding pKi = 6.9 6.9 -3 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 298 5 1 3 3.4 c1ccc(CCC[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
11221758 84617 None 0 Human Binding pKi = 5.9 5.9 -7 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1ccccc1[N+](=O)[O-])C1=NCCN1 10.1021/jm0408215
CHEMBL222138 84617 None 0 Human Binding pKi = 5.9 5.9 -7 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1ccccc1[N+](=O)[O-])C1=NCCN1 10.1021/jm0408215
49836304 18571 None 1 Human Binding pKi = 6.9 6.9 -2 3
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276219 18571 None 1 Human Binding pKi = 6.9 6.9 -2 3
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
49836304 18571 None 1 Human Binding pKi = 6.9 6.9 -2 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276219 18571 None 1 Human Binding pKi = 6.9 6.9 -2 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
49836305 18576 None 0 Human Binding pKi = 6.9 6.9 -2 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 C[C@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276248 18576 None 0 Human Binding pKi = 6.9 6.9 -2 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 C[C@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
56852956 112043 None 1 Human Binding pKi = 6.9 6.9 -32 9
Displacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assayDisplacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assay
ChEMBL 339 5 0 6 2.8 c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1016/j.bmc.2014.04.026
CHEMBL3289656 112043 None 1 Human Binding pKi = 6.9 6.9 -32 9
Displacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assayDisplacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assay
ChEMBL 339 5 0 6 2.8 c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1016/j.bmc.2014.04.026
24906203 187218 None 0 Human Binding pKi = 5.9 5.9 -3 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2ccc3c(c2)OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
CHEMBL492445 187218 None 0 Human Binding pKi = 5.9 5.9 -3 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2ccc3c(c2)OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
11380132 84419 None 0 Human Binding pKi = 5.9 5.9 -1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1ccccn1)C1=NCCN1 10.1021/jm0408215
CHEMBL221989 84419 None 0 Human Binding pKi = 5.9 5.9 -1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1ccccn1)C1=NCCN1 10.1021/jm0408215
56852956 112043 None 1 Human Binding pKi = 6.9 6.9 -32 9
Displacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assayDisplacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assay
ChEMBL 339 5 0 6 2.8 c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1016/j.bmc.2014.04.026
CHEMBL3289656 112043 None 1 Human Binding pKi = 6.9 6.9 -32 9
Displacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assayDisplacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assay
ChEMBL 339 5 0 6 2.8 c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1016/j.bmc.2014.04.026
44371744 50321 None 0 Human Binding pKi = 6.9 6.9 -7 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 270 7 1 3 2.9 C=CCc1cccc(CC=C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL157206 50321 None 0 Human Binding pKi = 6.9 6.9 -7 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 270 7 1 3 2.9 C=CCc1cccc(CC=C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
2585 803 None 103 Human Binding pKi = 7.9 7.9 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
2585.0 803 None 103 Human Binding pKi = 7.9 7.9 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
522 803 None 103 Human Binding pKi = 7.9 7.9 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
551 803 None 103 Human Binding pKi = 7.9 7.9 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
CHEMBL723 803 None 103 Human Binding pKi = 7.9 7.9 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
DB01136 803 None 103 Human Binding pKi = 7.9 7.9 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
44325044 207383 None 0 Human Binding pKi = 7.9 7.9 5 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 479 6 0 8 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4csc5ccccc45)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL93801 207383 None 0 Human Binding pKi = 7.9 7.9 5 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 479 6 0 8 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4csc5ccccc45)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
213041 17133 None 28 Human Binding pKi = 7.9 7.9 -2 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 230 2 1 1 3.0 CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1 10.1021/jm1006269
CHEMBL1255582 17133 None 28 Human Binding pKi = 7.9 7.9 -2 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 230 2 1 1 3.0 CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1 10.1021/jm1006269
CHEMBL4535474 213988 None 39 Human Binding pKi = 6.9 6.9 -1 6
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000320b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000320b ADRA2C
ChEMBL None None None CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1 10.6019/CHEMBL5212743
489 145 None 28 Human Binding pKi = 6.9 6.9 -380 12
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 401 7 1 8 1.0 COc1ccccc1N1CCN(CC1)CCCNc1c(C)c(=O)n(c(=O)n1C)C 10.1021/jm00018a001
5640 145 None 28 Human Binding pKi = 6.9 6.9 -380 12
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 401 7 1 8 1.0 COc1ccccc1N1CCN(CC1)CCCNc1c(C)c(=O)n(c(=O)n1C)C 10.1021/jm00018a001
CHEMBL420060 145 None 28 Human Binding pKi = 6.9 6.9 -380 12
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 401 7 1 8 1.0 COc1ccccc1N1CCN(CC1)CCCNc1c(C)c(=O)n(c(=O)n1C)C 10.1021/jm00018a001
11371902 141638 None 0 Human Binding pKi = 6.9 6.9 -2 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL385310 141638 None 0 Human Binding pKi = 6.9 6.9 -2 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
11371902 141638 None 0 Human Binding pKi = 6.9 6.9 -2 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm0408215
CHEMBL385310 141638 None 0 Human Binding pKi = 6.9 6.9 -2 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm0408215
11741010 83251 None 0 Human Binding pKi = 6.9 6.9 4 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1cc(C)c2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
CHEMBL218730 83251 None 0 Human Binding pKi = 6.9 6.9 4 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1cc(C)c2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
11741010 83251 None 0 Human Binding pKi = 6.9 6.9 4 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1cc(C)c2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
CHEMBL218730 83251 None 0 Human Binding pKi = 6.9 6.9 4 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1cc(C)c2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
135356876 174074 None 0 Human Binding pKi = 5.9 5.9 -7 3
Binding affinity to human alpha2C receptor expressed in MDCK cells by PDSP assayBinding affinity to human alpha2C receptor expressed in MDCK cells by PDSP assay
ChEMBL 464 5 2 6 5.5 O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)cc(-n2cc(-c3ccc(Cl)s3)nn2)c1 10.1021/acs.jmedchem.6b00044
CHEMBL4544251 174074 None 0 Human Binding pKi = 5.9 5.9 -7 3
Binding affinity to human alpha2C receptor expressed in MDCK cells by PDSP assayBinding affinity to human alpha2C receptor expressed in MDCK cells by PDSP assay
ChEMBL 464 5 2 6 5.5 O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)cc(-n2cc(-c3ccc(Cl)s3)nn2)c1 10.1021/acs.jmedchem.6b00044
9809007 172564 None 8 Human Binding pKi = 5.9 5.9 -724 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
CHEMBL448620 172564 None 8 Human Binding pKi = 5.9 5.9 -724 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
16090598 82455 None 0 Human Binding pKi = 6.9 6.9 5 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 3 1 4 5.4 Cc1nc2cccc(Cl)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217568 82455 None 0 Human Binding pKi = 6.9 6.9 5 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 3 1 4 5.4 Cc1nc2cccc(Cl)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
16090598 82455 None 0 Human Binding pKi = 6.9 6.9 5 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 3 1 4 5.4 Cc1nc2cccc(Cl)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL217568 82455 None 0 Human Binding pKi = 6.9 6.9 5 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 3 1 4 5.4 Cc1nc2cccc(Cl)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
71450548 83800 None 0 Human Binding pKi = 5.9 5.9 1 3
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1cccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)c1 10.1016/j.bmcl.2012.08.046
CHEMBL2205824 83800 None 0 Human Binding pKi = 5.9 5.9 1 3
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1cccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)c1 10.1016/j.bmcl.2012.08.046
42656257 121719 None 0 Human Binding pKi = 4.9 4.9 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 242 2 1 3 2.6 COc1ccc(C2NCCCn3cccc32)cc1 10.1016/j.bmc.2015.01.013
CHEMBL3588912 121719 None 0 Human Binding pKi = 4.9 4.9 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 242 2 1 3 2.6 COc1ccc(C2NCCCn3cccc32)cc1 10.1016/j.bmc.2015.01.013
26987 949 None 33 Human Binding pKi = 7.9 7.9 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
26987.0 949 None 33 Human Binding pKi = 7.9 7.9 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
6063 949 None 33 Human Binding pKi = 7.9 7.9 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
671 949 None 33 Human Binding pKi = 7.9 7.9 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
CHEMBL1626 949 None 33 Human Binding pKi = 7.9 7.9 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
DB00283 949 None 33 Human Binding pKi = 7.9 7.9 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
10198248 187449 None 40 Human Binding pKi = 5.9 5.9 -6 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 213 1 2 5 1.0 c1cnc2cc(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
CHEMBL49395 187449 None 40 Human Binding pKi = 5.9 5.9 -6 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 213 1 2 5 1.0 c1cnc2cc(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
13091268 78224 None 0 Human Binding pKi = 6.8 6.8 -158 14
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 401 6 1 3 5.0 O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
CHEMBL210578 78224 None 0 Human Binding pKi = 6.8 6.8 -158 14
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 401 6 1 3 5.0 O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
44582678 181574 None 0 Human Binding pKi = 6.8 6.8 3 10
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 401 9 1 4 4.3 COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(C)cc2)CC1 10.1016/j.bmc.2009.03.021
CHEMBL476839 181574 None 0 Human Binding pKi = 6.8 6.8 3 10
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 401 9 1 4 4.3 COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(C)cc2)CC1 10.1016/j.bmc.2009.03.021
11108001 10872 None 2 Human Binding pKi = 6.8 6.8 -12 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL117248 10872 None 2 Human Binding pKi = 6.8 6.8 -12 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL540542 10872 None 2 Human Binding pKi = 6.8 6.8 -12 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
11380133 169367 None 0 Human Binding pKi = 5.8 5.8 -5 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1ccncc1)C1=NCCN1 10.1021/jm0408215
CHEMBL442045 169367 None 0 Human Binding pKi = 5.8 5.8 -5 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1ccncc1)C1=NCCN1 10.1021/jm0408215
3151 1462 None 97 Human Binding pKi = 6.8 6.8 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
3151.0 1462 None 97 Human Binding pKi = 6.8 6.8 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
945 1462 None 97 Human Binding pKi = 6.8 6.8 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
965 1462 None 97 Human Binding pKi = 6.8 6.8 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
CHEMBL219916 1462 None 97 Human Binding pKi = 6.8 6.8 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
DB01184 1462 None 97 Human Binding pKi = 6.8 6.8 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
73291731 92491 None 0 Human Binding pKi = 6.8 6.8 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 232 5 1 3 2.4 CCCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
CHEMBL2431282 92491 None 0 Human Binding pKi = 6.8 6.8 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 232 5 1 3 2.4 CCCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
45487955 198310 None 0 Human Binding pKi = 6.8 6.8 -2 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 232 4 1 3 2.7 CCCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL576078 198310 None 0 Human Binding pKi = 6.8 6.8 -2 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 232 4 1 3 2.7 CCCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
9827677 168422 None 0 Human Binding pKi = 5.8 5.8 -7413 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 510 7 2 4 4.2 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
CHEMBL43491 168422 None 0 Human Binding pKi = 5.8 5.8 -7413 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 510 7 2 4 4.2 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
50878551 90745 None 61 Human Binding pKi = 5.8 5.8 -22 18
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL2391541 90745 None 61 Human Binding pKi = 5.8 5.8 -22 18
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2015.12.053
44455426 155149 None 0 Human Binding pKi = 6.8 6.8 -2 12
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 405 9 1 4 4.2 COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(F)cc2)CC1 10.1016/j.bmc.2009.03.021
CHEMBL402143 155149 None 0 Human Binding pKi = 6.8 6.8 -2 12
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 405 9 1 4 4.2 COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(F)cc2)CC1 10.1016/j.bmc.2009.03.021
144852560 170936 None 0 Human Binding pKi = 5.8 5.8 -85 4
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 343 2 2 5 3.8 Clc1ccc(C#Cc2nc(NC3CCCC3)c3nc[nH]c3n2)s1 10.1039/C8MD00317C
CHEMBL4455344 170936 None 0 Human Binding pKi = 5.8 5.8 -85 4
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 343 2 2 5 3.8 Clc1ccc(C#Cc2nc(NC3CCCC3)c3nc[nH]c3n2)s1 10.1039/C8MD00317C
71463063 83801 None 0 Human Binding pKi = 5.8 5.8 -2 8
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1 10.1016/j.bmcl.2012.08.046
CHEMBL2205825 83801 None 0 Human Binding pKi = 5.8 5.8 -2 8
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1 10.1016/j.bmcl.2012.08.046
21830793 91835 None 10 Human Binding pKi = 7.8 7.8 -100 45
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 373 7 0 8 0.6 COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1 10.1016/j.bmc.2013.05.050
CHEMBL2413154 91835 None 10 Human Binding pKi = 7.8 7.8 -100 45
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 373 7 0 8 0.6 COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1 10.1016/j.bmc.2013.05.050
10044968 96545 None 0 Human Binding pKi = 7.8 7.8 54 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
CHEMBL262901 96545 None 0 Human Binding pKi = 7.8 7.8 54 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
10044968 96545 None 0 Human Binding pKi = 7.8 7.8 54 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
CHEMBL262901 96545 None 0 Human Binding pKi = 7.8 7.8 54 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
44579231 181567 None 0 Human Binding pKi = 7.8 7.8 1 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 396 6 1 6 1.7 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1 10.1016/j.bmcl.2008.08.055
CHEMBL476774 181567 None 0 Human Binding pKi = 7.8 7.8 1 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 396 6 1 6 1.7 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1 10.1016/j.bmcl.2008.08.055
3158 56267 None 27 Human Binding pKi = 6.8 6.8 -1047 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 nan
3158.0 56267 None 27 Human Binding pKi = 6.8 6.8 -1047 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 nan
CHEMBL1628227 56267 None 27 Human Binding pKi = 6.8 6.8 -1047 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 nan
DB01142 56267 None 27 Human Binding pKi = 6.8 6.8 -1047 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CCC=C1c2ccccc2COc2ccccc21 nan
10609673 103776 None 0 Human Binding pKi = 5.8 5.8 -11 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 233 4 2 4 2.5 COc1ccc(Nc2ncc[nH]2)c(C)c1OC 10.1021/jm9605142
CHEMBL308863 103776 None 0 Human Binding pKi = 5.8 5.8 -11 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 233 4 2 4 2.5 COc1ccc(Nc2ncc[nH]2)c(C)c1OC 10.1021/jm9605142
118734875 118737 None 0 Human Binding pKi = 5.8 5.8 -489 3
Inhibition of alpha-2C adrenergic receptor (unknown origin)Inhibition of alpha-2C adrenergic receptor (unknown origin)
ChEMBL 327 6 1 4 2.4 C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1 10.1016/j.ejmech.2015.03.054
CHEMBL3417585 118737 None 0 Human Binding pKi = 5.8 5.8 -489 3
Inhibition of alpha-2C adrenergic receptor (unknown origin)Inhibition of alpha-2C adrenergic receptor (unknown origin)
ChEMBL 327 6 1 4 2.4 C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1 10.1016/j.ejmech.2015.03.054
73352414 92532 None 0 Human Binding pKi = 5.8 5.8 -2 5
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 257 3 1 1 3.3 C1CCC(CN[C@H]2C3C4CC5C6C4CC3C6C52)CC1 10.1016/j.bmc.2013.07.045
CHEMBL2432038 92532 None 0 Human Binding pKi = 5.8 5.8 -2 5
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 257 3 1 1 3.3 C1CCC(CN[C@H]2C3C4CC5C6C4CC3C6C52)CC1 10.1016/j.bmc.2013.07.045
737253 118503 None 139 Human Binding pKi = 5.8 5.8 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2ccc(N)cc2)CC1 10.1016/j.bmc.2015.01.013
CHEMBL341473 118503 None 139 Human Binding pKi = 5.8 5.8 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2ccc(N)cc2)CC1 10.1016/j.bmc.2015.01.013
32238 22655 None 114 Human Binding pKi = 4.8 4.8 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 256 3 1 3 2.9 OC(Cn1ccnc1)c1ccc(Cl)cc1Cl 10.1016/j.bmc.2015.01.013
CHEMBL1327 22655 None 114 Human Binding pKi = 4.8 4.8 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 256 3 1 3 2.9 OC(Cn1ccnc1)c1ccc(Cl)cc1Cl 10.1016/j.bmc.2015.01.013
44582705 186996 None 0 Human Binding pKi = 6.8 6.8 3 13
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 399 9 0 4 4.5 COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(C)cc2)CC1 10.1016/j.bmc.2009.03.021
CHEMBL490632 186996 None 0 Human Binding pKi = 6.8 6.8 3 13
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 399 9 0 4 4.5 COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(C)cc2)CC1 10.1016/j.bmc.2009.03.021
71463022 83698 None 7 Human Binding pKi = 5.8 5.8 -1 4
Displacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysisDisplacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysis
ChEMBL 436 8 0 5 5.3 COc1cc2oc(C(=O)N(CCCN3CCCCC3)c3ccccc3)c(C)c2cc1OC 10.1016/j.bmc.2012.09.044
CHEMBL2205362 83698 None 7 Human Binding pKi = 5.8 5.8 -1 4
Displacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysisDisplacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysis
ChEMBL 436 8 0 5 5.3 COc1cc2oc(C(=O)N(CCCN3CCCCC3)c3ccccc3)c(C)c2cc1OC 10.1016/j.bmc.2012.09.044
770500 121716 None 3 Human Binding pKi = 4.8 4.8 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 242 4 2 3 2.4 NCC(=O)Nc1ccccc1Oc1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL3588909 121716 None 3 Human Binding pKi = 4.8 4.8 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 242 4 2 3 2.4 NCC(=O)Nc1ccccc1Oc1ccccc1 10.1016/j.bmc.2015.01.013
4306793 121717 None 1 Human Binding pKi = 4.8 4.8 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 282 3 1 3 2.6 O=C(CCC1CCCC1)N1CCSC12CCNCC2 10.1016/j.bmc.2015.01.013
CHEMBL3588910 121717 None 1 Human Binding pKi = 4.8 4.8 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 282 3 1 3 2.6 O=C(CCC1CCCC1)N1CCSC12CCNCC2 10.1016/j.bmc.2015.01.013
10651654 111483 None 0 Human Binding pKi = 6.8 6.8 -85 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 631 9 2 5 7.8 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)c(Cl)c1 10.1021/jm980077m
CHEMBL327712 111483 None 0 Human Binding pKi = 6.8 6.8 -85 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 631 9 2 5 7.8 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)c(Cl)c1 10.1021/jm980077m
24906202 187217 None 0 Human Binding pKi = 5.8 5.8 -5 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2ccc3c(c2)OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
CHEMBL492444 187217 None 0 Human Binding pKi = 5.8 5.8 -5 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2ccc3c(c2)OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
3652 46244 None 70 Human Binding pKi = 4.8 4.8 -2 9
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 10.1038/s41586-020-2286-9
CHEMBL1535 46244 None 70 Human Binding pKi = 4.8 4.8 -2 9
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 10.1038/s41586-020-2286-9
16090626 82135 None 0 Human Binding pKi = 7.8 7.8 77 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 378 3 1 4 4.9 Cc1nc2ccc(F)cc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL216727 82135 None 0 Human Binding pKi = 7.8 7.8 77 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 378 3 1 4 4.9 Cc1nc2ccc(F)cc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
2142 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
4920903 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
502 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
5775 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
5775.0 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
CHEMBL597 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
DB00692 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
16090626 82135 None 0 Human Binding pKi = 7.8 7.8 77 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 378 3 1 4 4.9 Cc1nc2ccc(F)cc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL216727 82135 None 0 Human Binding pKi = 7.8 7.8 77 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 378 3 1 4 4.9 Cc1nc2ccc(F)cc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
9906978 42711 None 2 Human Binding pKi = 7.8 7.8 -1 12
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 361 6 1 3 4.0 O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
CHEMBL150161 42711 None 2 Human Binding pKi = 7.8 7.8 -1 12
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 361 6 1 3 4.0 O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
10527469 156265 None 3 Human Binding pKi = 7.8 7.8 -35 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 448 4 1 7 3.0 COc1cccc2c1CC[C@H]1CN(CCn3c(=O)[nH]c4c(sc5cccnc54)c3=O)C[C@@H]21 10.1021/jm970364a
CHEMBL40650 156265 None 3 Human Binding pKi = 7.8 7.8 -35 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 448 4 1 7 3.0 COc1cccc2c1CC[C@H]1CN(CCn3c(=O)[nH]c4c(sc5cccnc54)c3=O)C[C@@H]21 10.1021/jm970364a
11211035 85003 None 0 Human Binding pKi = 7.8 7.8 -1 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm061487a
CHEMBL223836 85003 None 0 Human Binding pKi = 7.8 7.8 -1 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm061487a
11211035 85003 None 0 Human Binding pKi = 7.8 7.8 -1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL223836 85003 None 0 Human Binding pKi = 7.8 7.8 -1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm0408215
2803 955 None 58 Human Binding pKi = 6.8 6.8 -4 19
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm990569e
2803.0 955 None 58 Human Binding pKi = 6.8 6.8 -4 19
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm990569e
516 955 None 58 Human Binding pKi = 6.8 6.8 -4 19
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm990569e
704 955 None 58 Human Binding pKi = 6.8 6.8 -4 19
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm990569e
CHEMBL134 955 None 58 Human Binding pKi = 6.8 6.8 -4 19
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm990569e
DB00575 955 None 58 Human Binding pKi = 6.8 6.8 -4 19
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm990569e
11393666 192986 None 0 Human Binding pKi = 6.8 6.8 -407 19
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 340 2 1 2 4.6 CC1(C)CN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CCN1 10.1016/j.bmcl.2022.128879
CHEMBL5201983 192986 None 0 Human Binding pKi = 6.8 6.8 -407 19
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 340 2 1 2 4.6 CC1(C)CN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CCN1 10.1016/j.bmcl.2022.128879
CHEMBL5222597 192986 None 0 Human Binding pKi = 6.8 6.8 -407 19
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 340 2 1 2 4.6 CC1(C)CN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CCN1 10.1016/j.bmcl.2022.128879
3952 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5353646 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5353646.0 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5443 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5702063 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
5702063.0 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
CHEMBL1331786 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
CHEMBL420 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
DB00629 1888 None 38 Human Binding pKi = 6.8 6.8 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N nan
92766 106542 None 35 Human Binding pKi = 6.8 6.8 -1 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12 10.1021/jm00019a001
CHEMBL31410 106542 None 35 Human Binding pKi = 6.8 6.8 -1 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12 10.1021/jm00019a001
44275807 98970 None 0 Human Binding pKi = 5.8 5.8 -1479 10
Binding affinity towards human Alpha-2C adrenergic receptorBinding affinity towards human Alpha-2C adrenergic receptor
ChEMBL 422 7 0 4 4.5 C[C@H]1CC[C@H](C)N1CCCOc1ccc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1 10.1016/s0960-894x(03)00118-5
CHEMBL27979 98970 None 0 Human Binding pKi = 5.8 5.8 -1479 10
Binding affinity towards human Alpha-2C adrenergic receptorBinding affinity towards human Alpha-2C adrenergic receptor
ChEMBL 422 7 0 4 4.5 C[C@H]1CC[C@H](C)N1CCCOc1ccc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1 10.1016/s0960-894x(03)00118-5
11199581 136559 None 0 Human Binding pKi = 5.8 5.8 -5 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1ccccc1O)C1=NCCN1 10.1021/jm0408215
CHEMBL373830 136559 None 0 Human Binding pKi = 5.8 5.8 -5 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1ccccc1O)C1=NCCN1 10.1021/jm0408215
132060746 163070 None 0 Human Binding pKi = 5.8 5.8 -9 5
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 405 4 0 4 4.4 O=C(OCc1ccccc1)N1Cc2ccc(N3CCN(C4CCCC4)CC3)cc2C1 10.1016/j.ejmech.2018.02.024
CHEMBL4176474 163070 None 0 Human Binding pKi = 5.8 5.8 -9 5
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 405 4 0 4 4.4 O=C(OCc1ccccc1)N1Cc2ccc(N3CCN(C4CCCC4)CC3)cc2C1 10.1016/j.ejmech.2018.02.024
9894818 98925 None 0 Human Binding pKi = 6.8 6.8 -93 7
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm00019a001
CHEMBL279436 98925 None 0 Human Binding pKi = 6.8 6.8 -93 7
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm00019a001
10859076 13682 None 0 Human Binding pKi = 6.8 6.8 -2 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1194763 13682 None 0 Human Binding pKi = 6.8 6.8 -2 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL553276 13682 None 0 Human Binding pKi = 6.8 6.8 -2 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
9894818 98925 None 0 Human Binding pKi = 6.8 6.8 -93 7
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL279436 98925 None 0 Human Binding pKi = 6.8 6.8 -93 7
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
21392988 204817 None 4 Human Binding pKi = 4.8 4.8 -1 3
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 156 0 0 4 -0.3 C1COC(N2CCOCC2)=N1 10.1016/0960-894X(94)85032-1
CHEMBL75201 204817 None 4 Human Binding pKi = 4.8 4.8 -1 3
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 156 0 0 4 -0.3 C1COC(N2CCOCC2)=N1 10.1016/0960-894X(94)85032-1
11109088 204180 None 0 Human Binding pKi = 6.8 6.8 -36 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 255 4 2 4 2.5 CSc1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70751 204180 None 0 Human Binding pKi = 6.8 6.8 -36 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 255 4 2 4 2.5 CSc1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
4567175 82476 None 5 Human Binding pKi = 5.8 5.8 -2 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 318 3 1 4 3.7 CN1CCN(c2ccc(Nc3ccnc4ccccc34)cc2)CC1 10.1016/j.ejmech.2010.12.026
CHEMBL217665 82476 None 5 Human Binding pKi = 5.8 5.8 -2 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 318 3 1 4 3.7 CN1CCN(c2ccc(Nc3ccnc4ccccc34)cc2)CC1 10.1016/j.ejmech.2010.12.026
12575 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
54459 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
54459.0 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
CHEMBL10316 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
DB12551 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
11346584 136984 None 0 Human Binding pKi = 7.8 7.8 1 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm061487a
CHEMBL374584 136984 None 0 Human Binding pKi = 7.8 7.8 1 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm061487a
12575 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
54459 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
54459.0 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
CHEMBL10316 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
DB12551 1988 None 30 Human Binding pKi = 7.8 7.8 -8 17
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
11346584 136984 None 0 Human Binding pKi = 7.8 7.8 1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL374584 136984 None 0 Human Binding pKi = 7.8 7.8 1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
11346584 136984 None 0 Human Binding pKi = 7.8 7.8 1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL374584 136984 None 0 Human Binding pKi = 7.8 7.8 1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm0408215
3584 3777 None 64 Human Binding pKi = 6.8 6.8 -50 13
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
5401 3777 None 64 Human Binding pKi = 6.8 6.8 -50 13
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
5401.0 3777 None 64 Human Binding pKi = 6.8 6.8 -50 13
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
7302 3777 None 64 Human Binding pKi = 6.8 6.8 -50 13
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
CHEMBL611 3777 None 64 Human Binding pKi = 6.8 6.8 -50 13
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
DB01162 3777 None 64 Human Binding pKi = 6.8 6.8 -50 13
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
4567175 82476 None 5 Human Binding pKi = 5.8 5.8 -2 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 318 3 1 4 3.7 CN1CCN(c2ccc(Nc3ccnc4ccccc34)cc2)CC1 10.1021/jm060262x
CHEMBL217665 82476 None 5 Human Binding pKi = 5.8 5.8 -2 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 318 3 1 4 3.7 CN1CCN(c2ccc(Nc3ccnc4ccccc34)cc2)CC1 10.1021/jm060262x
9960497 117075 None 0 Human Binding pKi = 5.8 5.8 -512 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
CHEMBL3392246 117075 None 0 Human Binding pKi = 5.8 5.8 -512 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
CHEMBL5273955 193788 None 0 Human Binding pKi = 4.8 4.8 -1 2
Displacement of [3H]RX821002 from human alpha2C receptor stably expressed in HEK293T cells by Cheng-Prusoff equation analysisDisplacement of [3H]RX821002 from human alpha2C receptor stably expressed in HEK293T cells by Cheng-Prusoff equation analysis
ChEMBL 305 3 2 2 4.1 C#Cc1cc(Nc2ccccc2C(=O)O)cc(C(F)(F)F)c1 10.1021/acs.jmedchem.2c01997
71452382 83794 None 0 Human Binding pKi = 5.8 5.8 -53 10
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1 10.1016/j.bmcl.2012.08.046
CHEMBL2205812 83794 None 0 Human Binding pKi = 5.8 5.8 -53 10
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1 10.1016/j.bmcl.2012.08.046
5472 205818 None 75 Human Binding pKi = 6.8 6.8 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
5472.0 205818 None 75 Human Binding pKi = 6.8 6.8 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
CHEMBL1717 205818 None 75 Human Binding pKi = 6.8 6.8 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
CHEMBL833 205818 None 75 Human Binding pKi = 6.8 6.8 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
DB00208 205818 None 75 Human Binding pKi = 6.8 6.8 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
9815633 99635 None 3 Human Binding pKi = 6.8 6.8 -44 6
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 204 1 1 2 2.9 c1nc(C2CCCc3sccc32)c[nH]1 10.1021/jm990569e
CHEMBL284213 99635 None 3 Human Binding pKi = 6.8 6.8 -44 6
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 204 1 1 2 2.9 c1nc(C2CCCc3sccc32)c[nH]1 10.1021/jm990569e
9815633 99635 None 3 Rat Binding pKi = 6.8 6.8 -44 6
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 204 1 1 2 2.9 c1nc(C2CCCc3sccc32)c[nH]1 10.1021/jm000128r
CHEMBL284213 99635 None 3 Rat Binding pKi = 6.8 6.8 -44 6
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 204 1 1 2 2.9 c1nc(C2CCCc3sccc32)c[nH]1 10.1021/jm000128r
21509921 104458 None 0 Human Binding pKi = 6.8 6.8 -16 24
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.7 CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104091 104458 None 0 Human Binding pKi = 6.8 6.8 -16 24
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.7 CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1 10.1016/j.bmcl.2013.12.024
73346042 91834 None 5 Human Binding pKi = 6.8 6.8 -1737 17
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 405 9 0 8 0.9 Cn1c(=O)cnn(CCCCN2CCN(c3ccccc3OCCF)CC2)c1=O 10.1016/j.bmc.2013.05.050
CHEMBL2413153 91834 None 5 Human Binding pKi = 6.8 6.8 -1737 17
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 405 9 0 8 0.9 Cn1c(=O)cnn(CCCCN2CCN(c3ccccc3OCCF)CC2)c1=O 10.1016/j.bmc.2013.05.050
21509921 104458 None 0 Human Binding pKi = 6.8 6.8 -16 24
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.7 CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104091 104458 None 0 Human Binding pKi = 6.8 6.8 -16 24
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.7 CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1 10.1016/j.bmcl.2013.12.024
599482 202984 None 9 Human Binding pKi = 5.8 5.8 -12 5
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 202 1 2 2 1.8 COc1ccc2c3c([nH]c2c1)CNCC3 10.1016/j.bmcl.2003.09.027
CHEMBL6310 202984 None 9 Human Binding pKi = 5.8 5.8 -12 5
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 202 1 2 2 1.8 COc1ccc2c3c([nH]c2c1)CNCC3 10.1016/j.bmcl.2003.09.027
49836302 18566 None 1 Human Binding pKi = 6.8 6.8 -1 3
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml400232p
CHEMBL1276139 18566 None 1 Human Binding pKi = 6.8 6.8 -1 3
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml400232p
49836302 18566 None 1 Human Binding pKi = 6.8 6.8 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/jm100977d
CHEMBL1276139 18566 None 1 Human Binding pKi = 6.8 6.8 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/jm100977d
49836302 18566 None 1 Human Binding pKi = 6.8 6.8 -1 3
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml300064v
CHEMBL1276139 18566 None 1 Human Binding pKi = 6.8 6.8 -1 3
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml300064v
71452387 83803 None 0 Human Binding pKi = 5.8 5.8 -1 7
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 2 1 4 1.7 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2 10.1016/j.bmcl.2012.08.046
CHEMBL2205829 83803 None 0 Human Binding pKi = 5.8 5.8 -1 7
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 2 1 4 1.7 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2 10.1016/j.bmcl.2012.08.046
71452387 83803 None 0 Human Binding pKi = 5.8 5.8 -1 7
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 309 2 1 4 1.7 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2 10.1016/j.bmc.2013.07.045
CHEMBL2205829 83803 None 0 Human Binding pKi = 5.8 5.8 -1 7
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 309 2 1 4 1.7 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2 10.1016/j.bmc.2013.07.045
11225732 93657 None 0 Human Binding pKi = 7.8 7.8 16 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 497 6 0 5 6.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4C(F)(F)F)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL246852 93657 None 0 Human Binding pKi = 7.8 7.8 16 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 497 6 0 5 6.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4C(F)(F)F)cc13)CC2 10.1016/j.bmcl.2006.12.094
1816 2540 None 102 Human Binding pKi = 7.8 7.8 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
4205 2540 None 102 Human Binding pKi = 7.8 7.8 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
4205.0 2540 None 102 Human Binding pKi = 7.8 7.8 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
7241 2540 None 102 Human Binding pKi = 7.8 7.8 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
CHEMBL654 2540 None 102 Human Binding pKi = 7.8 7.8 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
DB00370 2540 None 102 Human Binding pKi = 7.8 7.8 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
118734876 118738 None 0 Human Binding pKi = 5.8 5.8 -398 3
Inhibition of alpha-2C adrenergic receptor (unknown origin)Inhibition of alpha-2C adrenergic receptor (unknown origin)
ChEMBL 327 6 1 4 2.4 C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1 10.1016/j.ejmech.2015.03.054
CHEMBL3417586 118738 None 0 Human Binding pKi = 5.8 5.8 -398 3
Inhibition of alpha-2C adrenergic receptor (unknown origin)Inhibition of alpha-2C adrenergic receptor (unknown origin)
ChEMBL 327 6 1 4 2.4 C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1 10.1016/j.ejmech.2015.03.054
181743 178572 None 5 Human Binding pKi = 6.7 6.7 -91 22
Displacement of [3H]Clonidine from human adrenergic Alpha-2C receptorDisplacement of [3H]Clonidine from human adrenergic Alpha-2C receptor
ChEMBL 339 2 0 5 3.2 COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4 10.1016/j.bmcl.2009.11.053
CHEMBL467094 178572 None 5 Human Binding pKi = 6.7 6.7 -91 22
Displacement of [3H]Clonidine from human adrenergic Alpha-2C receptorDisplacement of [3H]Clonidine from human adrenergic Alpha-2C receptor
ChEMBL 339 2 0 5 3.2 COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4 10.1016/j.bmcl.2009.11.053
71452384 83797 None 0 Human Binding pKi = 5.7 5.7 -8 5
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 280 3 1 3 1.4 OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1 10.1016/j.bmcl.2012.08.046
CHEMBL2205816 83797 None 0 Human Binding pKi = 5.7 5.7 -8 5
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 280 3 1 3 1.4 OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1 10.1016/j.bmcl.2012.08.046
71452384 83797 None 0 Human Binding pKi = 5.7 5.7 -8 5
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 280 3 1 3 1.4 OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1 10.1016/j.bmc.2013.07.045
CHEMBL2205816 83797 None 0 Human Binding pKi = 5.7 5.7 -8 5
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 280 3 1 3 1.4 OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1 10.1016/j.bmc.2013.07.045
277 1301 None 62 Human Binding pKi = 6.7 6.7 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
2913 1301 None 62 Human Binding pKi = 6.7 6.7 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
2913.0 1301 None 62 Human Binding pKi = 6.7 6.7 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
765 1301 None 62 Human Binding pKi = 6.7 6.7 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
CHEMBL516 1301 None 62 Human Binding pKi = 6.7 6.7 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
DB00434 1301 None 62 Human Binding pKi = 6.7 6.7 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
71452383 83796 None 0 Human Binding pKi = 5.7 5.7 -1 3
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 339 5 1 4 2.0 COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmcl.2012.08.046
CHEMBL2205814 83796 None 0 Human Binding pKi = 5.7 5.7 -1 3
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 339 5 1 4 2.0 COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmcl.2012.08.046
12575 1988 None 30 Human Binding pKi = 7.7 7.7 -8 17
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
54459 1988 None 30 Human Binding pKi = 7.7 7.7 -8 17
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
54459.0 1988 None 30 Human Binding pKi = 7.7 7.7 -8 17
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
CHEMBL10316 1988 None 30 Human Binding pKi = 7.7 7.7 -8 17
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
DB12551 1988 None 30 Human Binding pKi = 7.7 7.7 -8 17
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
44438147 93489 None 0 Human Binding pKi = 7.7 7.7 19 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 406 5 1 9 2.5 COc1cc2c(cc1OC)CN(Cc1cnc(N)n3nc(-c4ccco4)nc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL246228 93489 None 0 Human Binding pKi = 7.7 7.7 19 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 406 5 1 9 2.5 COc1cc2c(cc1OC)CN(Cc1cnc(N)n3nc(-c4ccco4)nc13)CC2 10.1016/j.bmcl.2006.12.094
44438152 93608 None 0 Human Binding pKi = 7.7 7.7 42 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 459 7 0 6 5.7 COc1cccc(-c2cc3c(CN4CCc5cc(OC)c(OC)cc5C4)ccc(OC)c3o2)c1 10.1016/j.bmcl.2006.12.094
CHEMBL246639 93608 None 0 Human Binding pKi = 7.7 7.7 42 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 459 7 0 6 5.7 COc1cccc(-c2cc3c(CN4CCc5cc(OC)c(OC)cc5C4)ccc(OC)c3o2)c1 10.1016/j.bmcl.2006.12.094
10176999 103554 None 21 Human Binding pKi = 7.7 7.7 -11 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 231 2 2 4 2.2 Cc1c(Nc2ncc[nH]2)ccc2c1OCCO2 10.1021/jm9605142
CHEMBL308570 103554 None 21 Human Binding pKi = 7.7 7.7 -11 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 231 2 2 4 2.2 Cc1c(Nc2ncc[nH]2)ccc2c1OCCO2 10.1021/jm9605142
44402344 140959 None 0 Human Binding pKi = 7.7 7.7 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 340 1 3 3 2.6 O=C(O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL382310 140959 None 0 Human Binding pKi = 7.7 7.7 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 340 1 3 3 2.6 O=C(O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
10220053 206920 None 0 Human Binding pKi = 7.7 7.7 -3 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 218 2 1 2 1.9 Fc1ccc2c(c1)CC(CC1CN=CN1)C2 10.1016/s0960-894x(03)00525-0
CHEMBL90997 206920 None 0 Human Binding pKi = 7.7 7.7 -3 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 218 2 1 2 1.9 Fc1ccc2c(c1)CC(CC1CN=CN1)C2 10.1016/s0960-894x(03)00525-0
10220053 206920 None 0 Human Binding pKi = 7.7 7.7 -3 3
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 218 2 1 2 1.9 Fc1ccc2c(c1)CC(CC1CN=CN1)C2 10.1021/jm049619s
CHEMBL90997 206920 None 0 Human Binding pKi = 7.7 7.7 -3 3
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 218 2 1 2 1.9 Fc1ccc2c(c1)CC(CC1CN=CN1)C2 10.1021/jm049619s
10758200 63417 None 0 Human Binding pKi = 7.7 7.7 -5 5
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 322 4 0 3 3.2 c1ccc(CN2CCN(CC3CCc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL179648 63417 None 0 Human Binding pKi = 7.7 7.7 -5 5
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 322 4 0 3 3.2 c1ccc(CN2CCN(CC3CCc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
71151588 118258 None 0 Human Binding pKi = 6.7 6.7 -1905 10
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 518 9 1 7 3.6 NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1 10.1016/j.ejmech.2014.12.045
CHEMBL3409256 118258 None 0 Human Binding pKi = 6.7 6.7 -1905 10
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 518 9 1 7 3.6 NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1 10.1016/j.ejmech.2014.12.045
9895326 207027 None 0 Human Binding pKi = 6.7 6.7 -177 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 621 12 3 6 5.7 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(CC)N1 10.1021/jm980077m
CHEMBL91550 207027 None 0 Human Binding pKi = 6.7 6.7 -177 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 621 12 3 6 5.7 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(CC)N1 10.1021/jm980077m
44288769 101148 None 0 Human Binding pKi = 5.7 5.7 -1737 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 542 7 1 4 4.5 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL295395 101148 None 0 Human Binding pKi = 5.7 5.7 -1737 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 542 7 1 4 4.5 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
11301655 200 None 37 Human Binding pKi = 5.7 5.7 -1258 4
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 320 3 1 3 3.5 Cc1ccc(cc1C)N1CCN(CC1)Cc1nc2c([nH]1)cccc2 10.1021/acs.jmedchem.7b00151
8441 200 None 37 Human Binding pKi = 5.7 5.7 -1258 4
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 320 3 1 3 3.5 Cc1ccc(cc1C)N1CCN(CC1)Cc1nc2c([nH]1)cccc2 10.1021/acs.jmedchem.7b00151
CHEMBL127257 200 None 37 Human Binding pKi = 5.7 5.7 -1258 4
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 320 3 1 3 3.5 Cc1ccc(cc1C)N1CCN(CC1)Cc1nc2c([nH]1)cccc2 10.1021/acs.jmedchem.7b00151
44209472 70172 None 2 Human Binding pKi = 6.7 6.7 -107 11
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 315 6 0 4 2.8 Fc1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
CHEMBL1940420 70172 None 2 Human Binding pKi = 6.7 6.7 -107 11
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 315 6 0 4 2.8 Fc1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
3086326 204531 None 22 Human Binding pKi = 6.7 6.7 -5 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 247 1 2 5 1.7 Clc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL72753 204531 None 22 Human Binding pKi = 6.7 6.7 -5 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 247 1 2 5 1.7 Clc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
49781005 17214 None 0 Human Binding pKi = 6.7 6.7 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256503 17214 None 0 Human Binding pKi = 6.7 6.7 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
10934575 204486 None 0 Human Binding pKi = 6.7 6.7 -11 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 4 2 4 2.1 CSc1ccc(C)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72441 204486 None 0 Human Binding pKi = 6.7 6.7 -11 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 4 2 4 2.1 CSc1ccc(C)cc1NCC1=NCCN1 10.1021/jm000542r
44352207 18856 None 1 Human Binding pKi = 6.7 6.7 -4 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL128168 18856 None 1 Human Binding pKi = 6.7 6.7 -4 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm800250z
44352207 18856 None 1 Human Binding pKi = 6.7 6.7 -4 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL128168 18856 None 1 Human Binding pKi = 6.7 6.7 -4 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
44352207 18856 None 1 Human Binding pKi = 6.7 6.7 -4 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL128168 18856 None 1 Human Binding pKi = 6.7 6.7 -4 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
44352207 18856 None 1 Human Binding pKi = 6.7 6.7 -4 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL128168 18856 None 1 Human Binding pKi = 6.7 6.7 -4 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
44288874 101095 None 0 Human Binding pKi = 5.7 5.7 -1995 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 528 7 2 4 4.2 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
CHEMBL295001 101095 None 0 Human Binding pKi = 5.7 5.7 -1995 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 528 7 2 4 4.2 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
25142456 82406 None 2 Human Binding pKi = 8.7 8.7 3 9
Binding affinity to human cloned adrenergic alpha 2C receptor receptorBinding affinity to human cloned adrenergic alpha 2C receptor receptor
ChEMBL 269 0 3 4 2.1 Oc1cc2c(cc1O)C1c3ccccc3CNC1CO2 10.1021/jm0604979
CHEMBL217299 82406 None 2 Human Binding pKi = 8.7 8.7 3 9
Binding affinity to human cloned adrenergic alpha 2C receptor receptorBinding affinity to human cloned adrenergic alpha 2C receptor receptor
ChEMBL 269 0 3 4 2.1 Oc1cc2c(cc1O)C1c3ccccc3CNC1CO2 10.1021/jm0604979
44330679 208274 None 0 Human Binding pKi = 8.7 8.7 10 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 464 7 0 8 2.9 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccnc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL98889 208274 None 0 Human Binding pKi = 8.7 8.7 10 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 464 7 0 8 2.9 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccnc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
9928332 97180 None 5 Human Binding pKi = 8.7 8.7 -1 9
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 349 6 0 3 5.0 COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1 10.1016/s0960-894x(03)00525-0
CHEMBL268258 97180 None 5 Human Binding pKi = 8.7 8.7 -1 9
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 349 6 0 3 5.0 COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1 10.1016/s0960-894x(03)00525-0
9928332 97180 None 5 Human Binding pKi = 8.7 8.7 -1 9
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 349 6 0 3 5.0 COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1 10.1021/jm049619s
CHEMBL268258 97180 None 5 Human Binding pKi = 8.7 8.7 -1 9
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 349 6 0 3 5.0 COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1 10.1021/jm049619s
49781887 17144 None 0 Human Binding pKi = 8.7 8.7 -5 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
CHEMBL1255617 17144 None 0 Human Binding pKi = 8.7 8.7 -5 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
11079 2733 None 63 Human Binding pKi = 8.6 8.6 -2 5
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
3369 2733 None 63 Human Binding pKi = 8.6 8.6 -2 5
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
4436 2733 None 63 Human Binding pKi = 8.6 8.6 -2 5
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
4436.0 2733 None 63 Human Binding pKi = 8.6 8.6 -2 5
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
5509 2733 None 63 Human Binding pKi = 8.6 8.6 -2 5
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
CHEMBL761 2733 None 63 Human Binding pKi = 8.6 8.6 -2 5
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
DB06711 2733 None 63 Human Binding pKi = 8.6 8.6 -2 5
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
10045713 166105 None 0 Human Binding pKi = 8.6 8.6 309 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 386 3 1 4 5.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN4CCCCC4C3)cc2)c1C 10.1021/jm060262x
CHEMBL425983 166105 None 0 Human Binding pKi = 8.6 8.6 309 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 386 3 1 4 5.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN4CCCCC4C3)cc2)c1C 10.1021/jm060262x
44324887 165015 None 0 Human Binding pKi = 8.6 8.6 -2 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 419 6 0 6 3.1 COc1ccc2c(c1)C1=NOC(CN3CCN(C/C=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL422597 165015 None 0 Human Binding pKi = 8.6 8.6 -2 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 419 6 0 6 3.1 COc1ccc2c(c1)C1=NOC(CN3CCN(C/C=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
102 4127 None 48 Human Binding pKi = 8.6 8.6 -2 49
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
3659 4127 None 48 Human Binding pKi = 8.6 8.6 -2 49
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
8969 4127 None 48 Human Binding pKi = 8.6 8.6 -2 49
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
8969.0 4127 None 48 Human Binding pKi = 8.6 8.6 -2 49
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
CHEMBL15245 4127 None 48 Human Binding pKi = 8.6 8.6 -2 49
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
DB01392 4127 None 48 Human Binding pKi = 8.6 8.6 -2 49
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
10045713 166105 None 0 Human Binding pKi = 8.6 8.6 309 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 386 3 1 4 5.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN4CCCCC4C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL425983 166105 None 0 Human Binding pKi = 8.6 8.6 309 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 386 3 1 4 5.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN4CCCCC4C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
9805944 56227 None 37 Human Binding pKi = 8.6 8.6 -3 9
Displacement of [125I]HEAT from adrenergic Alpha-2C receptorDisplacement of [125I]HEAT from adrenergic Alpha-2C receptor
ChEMBL 462 7 2 3 4.7 CNC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1 10.1021/jm800510m
CHEMBL1627 56227 None 37 Human Binding pKi = 8.6 8.6 -3 9
Displacement of [125I]HEAT from adrenergic Alpha-2C receptorDisplacement of [125I]HEAT from adrenergic Alpha-2C receptor
ChEMBL 462 7 2 3 4.7 CNC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1 10.1021/jm800510m
73453 29616 None 24 Human Binding pKi = 8.6 8.6 -3 17
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 561 4 3 6 2.0 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 nan
CHEMBL1385840 29616 None 24 Human Binding pKi = 8.6 8.6 -3 17
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 561 4 3 6 2.0 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 nan
44579271 187094 None 0 Human Binding pKi = 8.6 8.6 22 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 475 9 0 7 4.2 c1ccc(Oc2ncccc2COCCN2CCCN(CC3COc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL491419 187094 None 0 Human Binding pKi = 8.6 8.6 22 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 475 9 0 7 4.2 c1ccc(Oc2ncccc2COCCN2CCCN(CC3COc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
49781887 17144 None 0 Human Binding pKi = 8.6 8.6 -5 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
CHEMBL1255617 17144 None 0 Human Binding pKi = 8.6 8.6 -5 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
44402345 71431 None 0 Human Binding pKi = 8.6 8.6 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 496 5 4 5 3.5 CC(C)(C)OC(=O)NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL196064 71431 None 0 Human Binding pKi = 8.6 8.6 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 496 5 4 5 3.5 CC(C)(C)OC(=O)NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
44330584 108119 None 0 Human Binding pKi = 8.6 8.6 1 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL319573 108119 None 0 Human Binding pKi = 8.6 8.6 1 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
52943739 17159 None 0 Human Binding pKi = 8.6 8.6 -6 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 2.6 C[C@]12C[C@@]1(c1c[nH]cn1)Cc1ccccc12 10.1021/jm1006269
CHEMBL1255771 17159 None 0 Human Binding pKi = 8.6 8.6 -6 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 2.6 C[C@]12C[C@@]1(c1c[nH]cn1)Cc1ccccc12 10.1021/jm1006269
135398737 958 None 93 Human Binding pKi = 8.5 8.5 -3 89
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
135398737.0 958 None 93 Human Binding pKi = 8.5 8.5 -3 89
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
38 958 None 93 Human Binding pKi = 8.5 8.5 -3 89
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
722 958 None 93 Human Binding pKi = 8.5 8.5 -3 89
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
CHEMBL42 958 None 93 Human Binding pKi = 8.5 8.5 -3 89
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
DB00363 958 None 93 Human Binding pKi = 8.5 8.5 -3 89
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
46225029 199333 None 0 Human Binding pKi = 7.7 7.7 - 1
Binding affinity to Alpha2C adrenoceptor receptorBinding affinity to Alpha2C adrenoceptor receptor
ChEMBL 297 4 1 2 2.4 Fc1cccc(CCNC23OC4C5C6CC(C7C6C4C72)C53)c1 10.1016/j.bmcl.2009.11.019
CHEMBL590615 199333 None 0 Human Binding pKi = 7.7 7.7 - 1
Binding affinity to Alpha2C adrenoceptor receptorBinding affinity to Alpha2C adrenoceptor receptor
ChEMBL 297 4 1 2 2.4 Fc1cccc(CCNC23OC4C5C6CC(C7C6C4C72)C53)c1 10.1016/j.bmcl.2009.11.019
16725934 147423 None 0 Human Binding pKi = 7.7 7.7 38 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 429 6 0 5 5.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL392992 147423 None 0 Human Binding pKi = 7.7 7.7 38 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 429 6 0 5 5.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4)cc13)CC2 10.1016/j.bmcl.2006.12.094
123981 16459 None 22 Human Binding pKi = 7.7 7.7 -4 8
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 195 0 0 1 2.4 CN1CCc2cccc(Cl)c2CC1 10.1021/jm00019a001
CHEMBL123349 16459 None 22 Human Binding pKi = 7.7 7.7 -4 8
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 195 0 0 1 2.4 CN1CCc2cccc(Cl)c2CC1 10.1021/jm00019a001
CHEMBL536803 16459 None 22 Human Binding pKi = 7.7 7.7 -4 8
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 195 0 0 1 2.4 CN1CCc2cccc(Cl)c2CC1 10.1021/jm00019a001
49781887 17144 None 0 Human Binding pKi = 7.7 7.7 -5 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
CHEMBL1255617 17144 None 0 Human Binding pKi = 7.7 7.7 -5 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
118656529 120690 None 0 Human Binding pKi = 6.7 6.7 2 4
Binding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assayBinding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assay
ChEMBL 325 8 1 5 2.6 Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1 10.1021/jm501719e
CHEMBL3407810 120690 None 0 Human Binding pKi = 6.7 6.7 2 4
Binding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assayBinding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assay
ChEMBL 325 8 1 5 2.6 Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1 10.1021/jm501719e
CHEMBL3547107 120690 None 0 Human Binding pKi = 6.7 6.7 2 4
Binding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assayBinding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assay
ChEMBL 325 8 1 5 2.6 Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1 10.1021/jm501719e
44401041 70487 None 0 Human Binding pKi = 6.7 6.7 -46 7
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 313 2 0 3 4.1 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL194659 70487 None 0 Human Binding pKi = 6.7 6.7 -46 7
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 313 2 0 3 4.1 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
12574 2605 None 88 Human Binding pKi = 5.7 5.7 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
4810 2605 None 88 Human Binding pKi = 5.7 5.7 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
4810.0 2605 None 88 Human Binding pKi = 5.7 5.7 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
CHEMBL19236 2605 None 88 Human Binding pKi = 5.7 5.7 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
DB09242 2605 None 88 Human Binding pKi = 5.7 5.7 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
10032383 110110 None 0 Human Binding pKi = 6.7 6.7 -194 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 666 15 4 8 4.2 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN)N1 10.1016/s0960-894x(99)00484-9
136680387 110110 None 0 Human Binding pKi = 6.7 6.7 -194 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 666 15 4 8 4.2 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN)N1 10.1016/s0960-894x(99)00484-9
CHEMBL323579 110110 None 0 Human Binding pKi = 6.7 6.7 -194 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 666 15 4 8 4.2 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN)N1 10.1016/s0960-894x(99)00484-9
24906200 193156 None 0 Human Binding pKi = 6.7 6.7 1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 328 5 1 3 4.5 c1ccc(-c2ccccc2OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
CHEMBL523048 193156 None 0 Human Binding pKi = 6.7 6.7 1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 328 5 1 3 4.5 c1ccc(-c2ccccc2OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
9816063 103074 None 0 Human Binding pKi = 6.7 6.7 -14 6
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 232 1 1 2 3.6 Cc1sc(C)c2c1CCCC2c1c[nH]cn1 10.1021/jm990569e
CHEMBL30739 103074 None 0 Human Binding pKi = 6.7 6.7 -14 6
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 232 1 1 2 3.6 Cc1sc(C)c2c1CCCC2c1c[nH]cn1 10.1021/jm990569e
2398 954 None 62 Human Binding pKi = 6.7 6.7 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
2801 954 None 62 Human Binding pKi = 6.7 6.7 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
2801.0 954 None 62 Human Binding pKi = 6.7 6.7 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
701 954 None 62 Human Binding pKi = 6.7 6.7 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
CHEMBL415 954 None 62 Human Binding pKi = 6.7 6.7 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
DB01242 954 None 62 Human Binding pKi = 6.7 6.7 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
2105 3054 None 37 Human Binding pKi = 6.7 6.7 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
47811 3054 None 37 Human Binding pKi = 6.7 6.7 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
48 3054 None 37 Human Binding pKi = 6.7 6.7 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
CHEMBL531 3054 None 37 Human Binding pKi = 6.7 6.7 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
DB01186 3054 None 37 Human Binding pKi = 6.7 6.7 -81 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
16090632 141716 None 0 Human Binding pKi = 6.7 6.7 46 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 348 4 3 5 3.3 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1 10.1021/jm060262x
CHEMBL385722 141716 None 0 Human Binding pKi = 6.7 6.7 46 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 348 4 3 5 3.3 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1 10.1021/jm060262x
9816063 103074 None 0 Rat Binding pKi = 6.7 6.7 -14 6
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 232 1 1 2 3.6 Cc1sc(C)c2c1CCCC2c1c[nH]cn1 10.1021/jm000128r
CHEMBL30739 103074 None 0 Rat Binding pKi = 6.7 6.7 -14 6
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 232 1 1 2 3.6 Cc1sc(C)c2c1CCCC2c1c[nH]cn1 10.1021/jm000128r
16090632 141716 None 0 Human Binding pKi = 6.7 6.7 46 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 348 4 3 5 3.3 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1 10.1016/j.ejmech.2010.12.026
CHEMBL385722 141716 None 0 Human Binding pKi = 6.7 6.7 46 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 348 4 3 5 3.3 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1 10.1016/j.ejmech.2010.12.026
15730 71118 None 80 Human Binding pKi = 5.7 5.7 1 10
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 206 7 1 1 4.3 CCCCCCCCc1ccc(O)cc1 nan
CHEMBL195437 71118 None 80 Human Binding pKi = 5.7 5.7 1 10
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 206 7 1 1 4.3 CCCCCCCCc1ccc(O)cc1 nan
53325861 56856 None 0 Human Binding pKi = 5.7 5.7 2 3
Inhibition of Alpha-2C adrenergic receptorInhibition of Alpha-2C adrenergic receptor
ChEMBL 297 4 0 1 3.4 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmcl.2010.11.075
CHEMBL1643902 56856 None 0 Human Binding pKi = 5.7 5.7 2 3
Inhibition of Alpha-2C adrenergic receptorInhibition of Alpha-2C adrenergic receptor
ChEMBL 297 4 0 1 3.4 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmcl.2010.11.075
53325861 56856 None 0 Human Binding pKi = 5.7 5.7 2 3
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 297 4 0 1 3.4 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
CHEMBL1643902 56856 None 0 Human Binding pKi = 5.7 5.7 2 3
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 297 4 0 1 3.4 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
126225 94976 None 5 Human Binding pKi = 7.7 7.7 -9 8
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 263 1 0 2 4.2 C=Cc1sc2ccc(Cl)c3c2c1CN(C)CC3 10.1021/jm00019a001
CHEMBL25467 94976 None 5 Human Binding pKi = 7.7 7.7 -9 8
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 263 1 0 2 4.2 C=Cc1sc2ccc(Cl)c3c2c1CN(C)CC3 10.1021/jm00019a001
3584 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
5401 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
5401.0 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
7302 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
CHEMBL611 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
DB01162 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
131829 204727 None 15 Human Binding pKi = 6.7 6.7 -33 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 295 1 4 5 1.7 Brc1c(NC2=NCCN2)ccc2c1NCCN2 10.1016/0960-894X(95)00391-6
CHEMBL74283 204727 None 15 Human Binding pKi = 6.7 6.7 -33 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 295 1 4 5 1.7 Brc1c(NC2=NCCN2)ccc2c1NCCN2 10.1016/0960-894X(95)00391-6
1548953 207679 None 27 Human Binding pKi = 6.7 6.7 1 17
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
CHEMBL954 207679 None 27 Human Binding pKi = 6.7 6.7 1 17
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
2683 102888 None 25 Human Binding pKi = 6.7 6.7 -30 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
CHEMBL305906 102888 None 25 Human Binding pKi = 6.7 6.7 -30 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
CHEMBL334255 102888 None 25 Human Binding pKi = 6.7 6.7 -30 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
11097789 102998 None 1 Human Binding pKi = 6.7 6.7 -43 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1cc(F)ccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL306792 102998 None 1 Human Binding pKi = 6.7 6.7 -43 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1cc(F)ccc1NCC1=NCCN1 10.1021/jm000542r
11140345 204171 None 0 Human Binding pKi = 6.7 6.7 -1 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70692 204171 None 0 Human Binding pKi = 6.7 6.7 -1 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
44401194 71295 None 0 Human Binding pKi = 6.7 6.7 -28 7
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 313 2 0 3 4.1 CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL195706 71295 None 0 Human Binding pKi = 6.7 6.7 -28 7
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 313 2 0 3 4.1 CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
1212 1662 None 50 Human Binding pKi = 7.7 7.7 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
204 1662 None 50 Human Binding pKi = 7.7 7.7 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
3372 1662 None 50 Human Binding pKi = 7.7 7.7 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
3372.0 1662 None 50 Human Binding pKi = 7.7 7.7 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
CHEMBL726 1662 None 50 Human Binding pKi = 7.7 7.7 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
DB00623 1662 None 50 Human Binding pKi = 7.7 7.7 -54 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
448537 160250 None 89 Human Binding pKi = 5.7 5.7 -21 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
CHEMBL411 160250 None 89 Human Binding pKi = 5.7 5.7 -21 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
26987 949 None 33 Human Binding pKi = 6.7 6.7 -107 21
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
26987.0 949 None 33 Human Binding pKi = 6.7 6.7 -107 21
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
6063 949 None 33 Human Binding pKi = 6.7 6.7 -107 21
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
671 949 None 33 Human Binding pKi = 6.7 6.7 -107 21
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
CHEMBL1626 949 None 33 Human Binding pKi = 6.7 6.7 -107 21
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
DB00283 949 None 33 Human Binding pKi = 6.7 6.7 -107 21
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
3584 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
5401 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
5401.0 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
7302 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
CHEMBL611 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
DB01162 3777 None 64 Human Binding pKi = 6.7 6.7 -50 13
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
42669828 121718 None 2 Human Binding pKi = 4.7 4.7 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 243 5 1 3 2.7 Cc1ccccc1Cn1ccnc1CNC(C)C 10.1016/j.bmc.2015.01.013
CHEMBL3588911 121718 None 2 Human Binding pKi = 4.7 4.7 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 243 5 1 3 2.7 Cc1ccccc1Cn1ccnc1CNC(C)C 10.1016/j.bmc.2015.01.013
15853467 208134 None 0 Human Binding pKi = 6.7 6.7 -67 6
Binding affinity against human Alpha-2C adrenergic receptorBinding affinity against human Alpha-2C adrenergic receptor
ChEMBL 692 16 3 8 5.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN=[N+]=[N-])N1 10.1016/s0960-894x(99)00484-9
CHEMBL98063 208134 None 0 Human Binding pKi = 6.7 6.7 -67 6
Binding affinity against human Alpha-2C adrenergic receptorBinding affinity against human Alpha-2C adrenergic receptor
ChEMBL 692 16 3 8 5.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN=[N+]=[N-])N1 10.1016/s0960-894x(99)00484-9
10326069 39296 None 1 Human Binding pKi = 5.7 5.7 -125 9
Binding affinity for recombinant human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand.Binding affinity for recombinant human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand.
ChEMBL 589 10 3 8 3.3 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(C(=O)OC)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980506g
CHEMBL147077 39296 None 1 Human Binding pKi = 5.7 5.7 -125 9
Binding affinity for recombinant human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand.Binding affinity for recombinant human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand.
ChEMBL 589 10 3 8 3.3 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(C(=O)OC)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980506g
73349359 92543 None 0 Human Binding pKi = 5.6 5.6 -3 8
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 341 6 1 4 2.9 COc1cc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC 10.1016/j.bmc.2013.07.045
CHEMBL2432051 92543 None 0 Human Binding pKi = 5.6 5.6 -3 8
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 341 6 1 4 2.9 COc1cc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC 10.1016/j.bmc.2013.07.045
44424855 85454 None 0 Human Binding pKi = 7.6 7.6 1 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
CHEMBL226636 85454 None 0 Human Binding pKi = 7.6 7.6 1 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
44330609 163452 None 0 Human Binding pKi = 7.6 7.6 -2 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL419894 163452 None 0 Human Binding pKi = 7.6 7.6 -2 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
10324985 76781 None 8 Human Binding pKi = 7.6 7.6 -17 17
Binding affinity to adrenergic alpha-2C receptorBinding affinity to adrenergic alpha-2C receptor
ChEMBL 423 7 0 8 1.7 COc1ccc2cccc(N3CCN(CCCCn4ncc(=O)n(C)c4=O)CC3)c2c1 10.1021/jm050725j
CHEMBL199824 76781 None 8 Human Binding pKi = 7.6 7.6 -17 17
Binding affinity to adrenergic alpha-2C receptorBinding affinity to adrenergic alpha-2C receptor
ChEMBL 423 7 0 8 1.7 COc1ccc2cccc(N3CCN(CCCCn4ncc(=O)n(C)c4=O)CC3)c2c1 10.1021/jm050725j
CHEMBL2068762 76781 None 8 Human Binding pKi = 7.6 7.6 -17 17
Binding affinity to adrenergic alpha-2C receptorBinding affinity to adrenergic alpha-2C receptor
ChEMBL 423 7 0 8 1.7 COc1ccc2cccc(N3CCN(CCCCn4ncc(=O)n(C)c4=O)CC3)c2c1 10.1021/jm050725j
9859437 168022 None 0 Human Binding pKi = 6.6 6.6 -38 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 230 2 3 4 2.3 Cc1c(Nc2ncc[nH]2)ccc2c1NCCO2 10.1021/jm9605142
CHEMBL432155 168022 None 0 Human Binding pKi = 6.6 6.6 -38 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 230 2 3 4 2.3 Cc1c(Nc2ncc[nH]2)ccc2c1NCCO2 10.1021/jm9605142
3303 2244 None 46 Human Binding pKi = 6.6 6.6 -338 15
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 326 3 1 3 3.5 Clc1ccc(cc1)N1CCN(CC1)Cc1c[nH]c2c1cccn2 10.1021/acs.jmedchem.7b00151
5311200 2244 None 46 Human Binding pKi = 6.6 6.6 -338 15
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 326 3 1 3 3.5 Clc1ccc(cc1)N1CCN(CC1)Cc1c[nH]c2c1cccn2 10.1021/acs.jmedchem.7b00151
CHEMBL267014 2244 None 46 Human Binding pKi = 6.6 6.6 -338 15
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 326 3 1 3 3.5 Clc1ccc(cc1)N1CCN(CC1)Cc1c[nH]c2c1cccn2 10.1021/acs.jmedchem.7b00151
13149 2545 None 36 Human Binding pKi = 5.6 5.6 -38 17
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 398 5 1 5 3.8 CC[C@@H]1CN2CCC3=C([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC 10.1021/acs.jmedchem.9b01465
3034396 2545 None 36 Human Binding pKi = 5.6 5.6 -38 17
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 398 5 1 5 3.8 CC[C@@H]1CN2CCC3=C([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC 10.1021/acs.jmedchem.9b01465
CHEMBL299031 2545 None 36 Human Binding pKi = 5.6 5.6 -38 17
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 398 5 1 5 3.8 CC[C@@H]1CN2CCC3=C([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC 10.1021/acs.jmedchem.9b01465
196129 67798 None 17 Human Binding pKi = 6.6 6.6 -295 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
CHEMBL1909065 67798 None 17 Human Binding pKi = 6.6 6.6 -295 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
70693375 77671 None 0 Human Binding pKi = 6.6 6.6 -5 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL2089155 77671 None 0 Human Binding pKi = 6.6 6.6 -5 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
11361608 84745 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL222928 84745 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
11361608 84745 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL222928 84745 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
11361608 84745 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222928 84745 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
11300487 85002 None 0 Human Binding pKi = 6.6 6.6 -5 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1ccccc1-c1ccccc1OC(C)C1=NCCN1 10.1021/jm0408215
CHEMBL223830 85002 None 0 Human Binding pKi = 6.6 6.6 -5 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1ccccc1-c1ccccc1OC(C)C1=NCCN1 10.1021/jm0408215
70693375 77671 None 0 Human Binding pKi = 6.6 6.6 -5 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL2089155 77671 None 0 Human Binding pKi = 6.6 6.6 -5 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
286547 67241 None 112 Human Binding pKi = 6.6 6.6 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2ccccc2N)CC1 10.1016/j.bmc.2015.01.013
CHEMBL1879790 67241 None 112 Human Binding pKi = 6.6 6.6 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2ccccc2N)CC1 10.1016/j.bmc.2015.01.013
4209 3163 None 75 Human Binding pKi = 7.6 7.6 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
4893 3163 None 75 Human Binding pKi = 7.6 7.6 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
4893.0 3163 None 75 Human Binding pKi = 7.6 7.6 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
503 3163 None 75 Human Binding pKi = 7.6 7.6 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
5385 3163 None 75 Human Binding pKi = 7.6 7.6 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
CHEMBL2 3163 None 75 Human Binding pKi = 7.6 7.6 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
DB00457 3163 None 75 Human Binding pKi = 7.6 7.6 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
44314198 104412 None 0 Human Binding pKi = 7.6 7.6 -8 4
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCCC1NC1=NCCO1 10.1016/0960-894X(94)85032-1
CHEMBL310335 104412 None 0 Human Binding pKi = 7.6 7.6 -8 4
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCCC1NC1=NCCO1 10.1016/0960-894X(94)85032-1
9815707 101469 None 0 Human Binding pKi = 7.6 7.6 -8 3
Inhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCC[C@@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL297752 101469 None 0 Human Binding pKi = 7.6 7.6 -8 3
Inhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCC[C@@H]1NC1=NCCO1 10.1021/jm9905256
10490084 204958 None 1 Human Binding pKi = 5.6 5.6 -11 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 237 2 2 2 2.9 Brc1ccccc1Nc1ncc[nH]1 10.1021/jm9605142
CHEMBL76457 204958 None 1 Human Binding pKi = 5.6 5.6 -11 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 237 2 2 2 2.9 Brc1ccccc1Nc1ncc[nH]1 10.1021/jm9605142
8447 188949 None 84 Human Binding pKi = 6.6 6.6 -3 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
CHEMBL508112 188949 None 84 Human Binding pKi = 6.6 6.6 -3 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
10603951 206516 None 0 Human Binding pKi = 6.6 6.6 -12 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 10 1 7 6.8 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)N(C)CCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL88448 206516 None 0 Human Binding pKi = 6.6 6.6 -12 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 10 1 7 6.8 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)N(C)CCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
10531532 207094 None 0 Human Binding pKi = 6.6 6.6 -28 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 594 9 2 7 6.0 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL91956 207094 None 0 Human Binding pKi = 6.6 6.6 -28 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 594 9 2 7 6.0 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
24906243 187248 None 0 Human Binding pKi = 6.6 6.6 -1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 310 3 1 5 2.5 COC1(C2=NCCN2)COc2cccc(-c3ccccc3)c2O1 10.1021/jm800250z
CHEMBL492648 187248 None 0 Human Binding pKi = 6.6 6.6 -1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 310 3 1 5 2.5 COC1(C2=NCCN2)COc2cccc(-c3ccccc3)c2O1 10.1021/jm800250z
11277479 84750 None 0 Human Binding pKi = 6.6 6.6 -4 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1cccc(-c2ccccc2OC(C)C2=NCCN2)c1 10.1021/jm0408215
CHEMBL222973 84750 None 0 Human Binding pKi = 6.6 6.6 -4 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1cccc(-c2ccccc2OC(C)C2=NCCN2)c1 10.1021/jm0408215
132060733 162124 None 0 Human Binding pKi = 5.6 5.6 -1 3
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 294 3 0 3 3.0 c1ccc(CN2Cc3ccc(N4CCOCC4)cc3C2)cc1 10.1016/j.ejmech.2018.02.024
CHEMBL4161503 162124 None 0 Human Binding pKi = 5.6 5.6 -1 3
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 294 3 0 3 3.0 c1ccc(CN2Cc3ccc(N4CCOCC4)cc3C2)cc1 10.1016/j.ejmech.2018.02.024
71452341 83697 None 7 Human Binding pKi = 6.6 6.6 3 4
Displacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysisDisplacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysis
ChEMBL 376 6 0 3 5.3 Cc1c(C(=O)N(CCCN2CCCCC2)c2ccccc2)oc2ccccc12 10.1016/j.bmc.2012.09.044
CHEMBL2205361 83697 None 7 Human Binding pKi = 6.6 6.6 3 4
Displacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysisDisplacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysis
ChEMBL 376 6 0 3 5.3 Cc1c(C(=O)N(CCCN2CCCCC2)c2ccccc2)oc2ccccc12 10.1016/j.bmc.2012.09.044
10109188 166075 None 0 Human Binding pKi = 7.6 7.6 43 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 4 1 4 4.6 CCc1c(C)nc2ccccc2c1Nc1ccc(N2CCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL425803 166075 None 0 Human Binding pKi = 7.6 7.6 43 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 4 1 4 4.6 CCc1c(C)nc2ccccc2c1Nc1ccc(N2CCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
100 3805 None 58 Human Binding pKi = 7.6 7.6 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
2637 3805 None 58 Human Binding pKi = 7.6 7.6 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
5452 3805 None 58 Human Binding pKi = 7.6 7.6 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
CHEMBL479 3805 None 58 Human Binding pKi = 7.6 7.6 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
DB00679 3805 None 58 Human Binding pKi = 7.6 7.6 -27 55
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
10109188 166075 None 0 Human Binding pKi = 7.6 7.6 43 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 4 1 4 4.6 CCc1c(C)nc2ccccc2c1Nc1ccc(N2CCN(C)CC2)cc1 10.1021/jm060262x
CHEMBL425803 166075 None 0 Human Binding pKi = 7.6 7.6 43 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 4 1 4 4.6 CCc1c(C)nc2ccccc2c1Nc1ccc(N2CCN(C)CC2)cc1 10.1021/jm060262x
44371755 48777 None 0 Human Binding pKi = 6.6 6.6 -21 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 3 1 3 2.1 Cc1cccc(C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL155866 48777 None 0 Human Binding pKi = 6.6 6.6 -21 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 3 1 3 2.1 Cc1cccc(C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
11173544 166261 None 0 Human Binding pKi = 6.6 6.6 -6 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1ccc(-c2ccccc2OC(C)C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL426900 166261 None 0 Human Binding pKi = 6.6 6.6 -6 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1ccc(-c2ccccc2OC(C)C2=NCCN2)cc1 10.1021/jm0408215
10221004 204231 None 0 Human Binding pKi = 5.6 5.6 -2 5
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 267 5 2 5 0.9 CCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70973 204231 None 0 Human Binding pKi = 5.6 5.6 -2 5
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 267 5 2 5 0.9 CCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
73355420 92551 None 0 Human Binding pKi = 5.6 5.6 2 2
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 355 6 0 4 3.3 COc1cc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC 10.1016/j.bmc.2013.07.045
CHEMBL2432061 92551 None 0 Human Binding pKi = 5.6 5.6 2 2
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 355 6 0 4 3.3 COc1cc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC 10.1016/j.bmc.2013.07.045
132060743 162236 None 0 Human Binding pKi = 6.6 6.6 1 13
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 351 3 0 4 3.1 CN1CCN(c2ccc3c(c2)CN(C(=O)OCc2ccccc2)C3)CC1 10.1016/j.ejmech.2018.02.024
CHEMBL4163428 162236 None 0 Human Binding pKi = 6.6 6.6 1 13
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 351 3 0 4 3.1 CN1CCN(c2ccc3c(c2)CN(C(=O)OCc2ccccc2)C3)CC1 10.1016/j.ejmech.2018.02.024
3168 9262 None 92 Human Binding pKi = 6.6 6.6 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
3168.0 9262 None 92 Human Binding pKi = 6.6 6.6 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
CHEMBL1108 9262 None 92 Human Binding pKi = 6.6 6.6 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
DB00450 9262 None 92 Human Binding pKi = 6.6 6.6 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
11090351 163391 None 0 Human Binding pKi = 6.6 6.6 2 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL419448 163391 None 0 Human Binding pKi = 6.6 6.6 2 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
16757089 92291 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL242693 92291 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
16757089 92291 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL242693 92291 None 1 Human Binding pKi = 6.6 6.6 -3 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
10220232 99721 None 6 Human Binding pKi = 7.6 7.6 -1 6
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 230 1 1 2 3.5 Cc1sc(C)c2c1CCC=C2c1c[nH]cn1 10.1021/jm990569e
CHEMBL284795 99721 None 6 Human Binding pKi = 7.6 7.6 -1 6
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 230 1 1 2 3.5 Cc1sc(C)c2c1CCC=C2c1c[nH]cn1 10.1021/jm990569e
135 2532 None 43 Human Binding pKi = 7.6 7.6 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
1796 2532 None 43 Human Binding pKi = 7.6 7.6 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
4184 2532 None 43 Human Binding pKi = 7.6 7.6 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
4184.0 2532 None 43 Human Binding pKi = 7.6 7.6 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
CHEMBL6437 2532 None 43 Human Binding pKi = 7.6 7.6 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
DB06148 2532 None 43 Human Binding pKi = 7.6 7.6 -6 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
10219 188796 None 37 Human Binding pKi = 7.6 7.6 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
CHEMBL493439 188796 None 37 Human Binding pKi = 7.6 7.6 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
CHEMBL50588 188796 None 37 Human Binding pKi = 7.6 7.6 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
44401243 168494 None 0 Human Binding pKi = 7.6 7.6 -10 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.6 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL435301 168494 None 0 Human Binding pKi = 7.6 7.6 -10 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.6 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1 10.1021/jm049632c
10220232 99721 None 6 Rat Binding pKi = 7.6 7.6 -1 6
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 230 1 1 2 3.5 Cc1sc(C)c2c1CCC=C2c1c[nH]cn1 10.1021/jm000128r
CHEMBL284795 99721 None 6 Rat Binding pKi = 7.6 7.6 -1 6
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 230 1 1 2 3.5 Cc1sc(C)c2c1CCC=C2c1c[nH]cn1 10.1021/jm000128r
24906199 187665 None 15 Human Binding pKi = 7.6 7.6 1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 258 4 1 3 3.1 CC(Oc1ccccc1C1CCCC1)C1=NCCN1 10.1021/jm800250z
CHEMBL495096 187665 None 15 Human Binding pKi = 7.6 7.6 1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 258 4 1 3 3.1 CC(Oc1ccccc1C1CCCC1)C1=NCCN1 10.1021/jm800250z
164615845 185190 None 0 Human Binding pKi = 5.6 5.6 -2 6
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 389 2 1 4 3.7 O=C(O)c1ccc(C#Cc2ccc3c(c2)C=C([N+](=O)[O-])C(C(F)(F)F)O3)cc1 10.1016/j.bmcl.2021.128008
CHEMBL4857492 185190 None 0 Human Binding pKi = 5.6 5.6 -2 6
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 389 2 1 4 3.7 O=C(O)c1ccc(C#Cc2ccc3c(c2)C=C([N+](=O)[O-])C(C(F)(F)F)O3)cc1 10.1016/j.bmcl.2021.128008
2162 41514 None 100 Human Binding pKi = 6.6 6.6 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
CHEMBL1491 41514 None 100 Human Binding pKi = 6.6 6.6 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
44269122 98109 None 2 Human Binding pKi = 6.6 6.6 -9 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 190 3 1 3 1.5 CC(Oc1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL273485 98109 None 2 Human Binding pKi = 6.6 6.6 -9 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 190 3 1 3 1.5 CC(Oc1ccccc1)C1=NCCN1 10.1021/jm800250z
45487144 197701 None 0 Human Binding pKi = 6.6 6.6 -9 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 190 2 1 3 1.7 CC(OC1=NCCN1)c1ccccc1 10.1021/jm901262f
CHEMBL571314 197701 None 0 Human Binding pKi = 6.6 6.6 -9 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 190 2 1 3 1.7 CC(OC1=NCCN1)c1ccccc1 10.1021/jm901262f
44269122 98109 None 2 Human Binding pKi = 6.6 6.6 -9 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 190 3 1 3 1.5 CC(Oc1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL273485 98109 None 2 Human Binding pKi = 6.6 6.6 -9 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 190 3 1 3 1.5 CC(Oc1ccccc1)C1=NCCN1 10.1021/jm100977d
10903226 13770 None 0 Human Binding pKi = 5.6 5.6 -3 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 281 6 2 5 1.3 CCCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1195368 13770 None 0 Human Binding pKi = 5.6 5.6 -3 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 281 6 2 5 1.3 CCCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL554416 13770 None 0 Human Binding pKi = 5.6 5.6 -3 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 281 6 2 5 1.3 CCCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
1353 1911 None 93 Human Binding pKi = 6.6 6.6 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
3559 1911 None 93 Human Binding pKi = 6.6 6.6 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
3559.0 1911 None 93 Human Binding pKi = 6.6 6.6 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
86 1911 None 93 Human Binding pKi = 6.6 6.6 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
CHEMBL54 1911 None 93 Human Binding pKi = 6.6 6.6 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
DB00502 1911 None 93 Human Binding pKi = 6.6 6.6 -87 83
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
11000184 13052 None 0 Human Binding pKi = 6.6 6.6 -6 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1190038 13052 None 0 Human Binding pKi = 6.6 6.6 -6 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL540035 13052 None 0 Human Binding pKi = 6.6 6.6 -6 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
45487089 197640 None 0 Human Binding pKi = 6.6 6.6 -10 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 204 2 1 3 2.0 Cc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL570863 197640 None 0 Human Binding pKi = 6.6 6.6 -10 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 204 2 1 3 2.0 Cc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
10923927 204178 None 0 Human Binding pKi = 5.6 5.6 -4 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 279 3 2 5 0.8 O=S1(=O)CCCc2cccc(NCC3=NCCN3)c21 10.1021/jm000542r
CHEMBL70740 204178 None 0 Human Binding pKi = 5.6 5.6 -4 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 279 3 2 5 0.8 O=S1(=O)CCCc2cccc(NCC3=NCCN3)c21 10.1021/jm000542r
3080926 155595 None 21 Human Binding pKi = 4.6 4.6 -10 3
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 186 1 1 3 1.8 c1ccc2oc(C3=NCCN3)cc2c1 10.1021/ml400232p
CHEMBL404505 155595 None 21 Human Binding pKi = 4.6 4.6 -10 3
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 186 1 1 3 1.8 c1ccc2oc(C3=NCCN3)cc2c1 10.1021/ml400232p
185076 187090 None 5 Human Binding pKi = 7.6 7.6 -7 7
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1021/jm960359r
CHEMBL49137 187090 None 5 Human Binding pKi = 7.6 7.6 -7 7
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1021/jm960359r
133 2496 None 52 Human Binding pKi = 7.6 7.6 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
1723 2496 None 52 Human Binding pKi = 7.6 7.6 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
28693 2496 None 52 Human Binding pKi = 7.6 7.6 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
CHEMBL19215 2496 None 52 Human Binding pKi = 7.6 7.6 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
DB13520 2496 None 52 Human Binding pKi = 7.6 7.6 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
185076 187090 None 5 Human Binding pKi = 7.6 7.6 -7 7
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1021/jm9605142
CHEMBL49137 187090 None 5 Human Binding pKi = 7.6 7.6 -7 7
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1021/jm9605142
3930 2151 None 43 Human Binding pKi = 7.6 7.6 53 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1016/j.ejmech.2010.12.026
540335 2151 None 43 Human Binding pKi = 7.6 7.6 53 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1016/j.ejmech.2010.12.026
CHEMBL106525 2151 None 43 Human Binding pKi = 7.6 7.6 53 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1016/j.ejmech.2010.12.026
139406787 177145 None 0 Human Binding pKi = 5.6 5.6 -2 4
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 492 5 2 5 5.8 O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)cc(-c2cn(-c3ccc(C(F)(F)F)cc3)nn2)c1 10.1021/acs.jmedchem.0c00745
CHEMBL4633982 177145 None 0 Human Binding pKi = 5.6 5.6 -2 4
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 492 5 2 5 5.8 O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)cc(-c2cn(-c3ccc(C(F)(F)F)cc3)nn2)c1 10.1021/acs.jmedchem.0c00745
11057 176149 None 23 Human Binding pKi = 6.6 6.6 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
3468 176149 None 23 Human Binding pKi = 6.6 6.6 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
CHEMBL459265 176149 None 23 Human Binding pKi = 6.6 6.6 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
CHEMBL64894 176149 None 23 Human Binding pKi = 6.6 6.6 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
57345628 71183 None 0 Human Binding pKi = 6.6 6.6 -26 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1956195 71183 None 0 Human Binding pKi = 6.6 6.6 -26 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
70695474 77672 None 0 Human Binding pKi = 6.6 6.6 -47 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL2089156 77672 None 0 Human Binding pKi = 6.6 6.6 -47 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
122442272 138348 None 0 Human Binding pKi = 6.6 6.6 -9 15
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
CHEMBL3769968 138348 None 0 Human Binding pKi = 6.6 6.6 -9 15
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
CHEMBL3771384 138348 None 0 Human Binding pKi = 6.6 6.6 -9 15
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
44371864 51141 None 0 Human Binding pKi = 6.6 6.6 -8 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 246 5 1 3 2.6 CCc1cccc(CC)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL157955 51141 None 0 Human Binding pKi = 6.6 6.6 -8 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 246 5 1 3 2.6 CCc1cccc(CC)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
57345628 71183 None 0 Human Binding pKi = 6.6 6.6 -26 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956195 71183 None 0 Human Binding pKi = 6.6 6.6 -26 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
57345628 71183 None 0 Human Binding pKi = 6.6 6.6 -26 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL1956195 71183 None 0 Human Binding pKi = 6.6 6.6 -26 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
70695474 77672 None 0 Human Binding pKi = 6.6 6.6 -47 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL2089156 77672 None 0 Human Binding pKi = 6.6 6.6 -47 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
122442272 138348 None 0 Human Binding pKi = 6.6 6.6 -9 15
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
CHEMBL3769968 138348 None 0 Human Binding pKi = 6.6 6.6 -9 15
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
CHEMBL3771384 138348 None 0 Human Binding pKi = 6.6 6.6 -9 15
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
73346336 92545 None 0 Human Binding pKi = 5.6 5.6 -5 6
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 5 0 2 3.0 CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
CHEMBL2432054 92545 None 0 Human Binding pKi = 5.6 5.6 -5 6
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 5 0 2 3.0 CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
3930 2151 None 43 Human Binding pKi = 7.6 7.6 53 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1021/jm060262x
540335 2151 None 43 Human Binding pKi = 7.6 7.6 53 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1021/jm060262x
CHEMBL106525 2151 None 43 Human Binding pKi = 7.6 7.6 53 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1021/jm060262x
518 3612 None 1 Human Binding pKi = 7.6 7.6 -1 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 299 0 0 2 3.8 CN1CCc2c3c(C1)c(Br)oc3ccc2Cl 10.1021/jm00019a001
9839317 3612 None 1 Human Binding pKi = 7.6 7.6 -1 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 299 0 0 2 3.8 CN1CCc2c3c(C1)c(Br)oc3ccc2Cl 10.1021/jm00019a001
CHEMBL123138 3612 None 1 Human Binding pKi = 7.6 7.6 -1 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 299 0 0 2 3.8 CN1CCc2c3c(C1)c(Br)oc3ccc2Cl 10.1021/jm00019a001
1268096 16165 None 26 Human Binding pKi = 7.6 7.6 3 4
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 352 1 1 4 3.2 COC(=O)C1=CO[C@@H](C)[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@H]12 10.1021/jm00019a001
CHEMBL122404 16165 None 26 Human Binding pKi = 7.6 7.6 3 4
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 352 1 1 4 3.2 COC(=O)C1=CO[C@@H](C)[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@H]12 10.1021/jm00019a001
185076 187090 None 5 Human Binding pKi = 7.6 7.6 -7 7
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL49137 187090 None 5 Human Binding pKi = 7.6 7.6 -7 7
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
3157 1470 None 71 Human Binding pKi = 6.6 6.6 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
3157.0 1470 None 71 Human Binding pKi = 6.6 6.6 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
7170 1470 None 71 Human Binding pKi = 6.6 6.6 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
954 1470 None 71 Human Binding pKi = 6.6 6.6 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
CHEMBL707 1470 None 71 Human Binding pKi = 6.6 6.6 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
DB00590 1470 None 71 Human Binding pKi = 6.6 6.6 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
10793963 99672 None 0 Human Binding pKi = 6.6 6.6 -30 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 11 2 7 6.8 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL284470 99672 None 0 Human Binding pKi = 6.6 6.6 -30 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 11 2 7 6.8 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
57345626 71180 None 2 Human Binding pKi = 6.6 6.6 -12 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1021/ml400232p
CHEMBL1956192 71180 None 2 Human Binding pKi = 6.6 6.6 -12 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1021/ml400232p
57345626 71180 None 2 Human Binding pKi = 6.6 6.6 -12 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956192 71180 None 2 Human Binding pKi = 6.6 6.6 -12 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1016/j.bmc.2012.01.035
44312037 204619 None 1 Human Binding pKi = 4.6 4.6 -2 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 308 1 1 5 2.9 Brc1c(NC2=NCCS2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL73392 204619 None 1 Human Binding pKi = 4.6 4.6 -2 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 308 1 1 5 2.9 Brc1c(NC2=NCCS2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
213 3853 None 55 Human Binding pKi = 6.6 6.6 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
2717 3853 None 55 Human Binding pKi = 6.6 6.6 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
5533 3853 None 55 Human Binding pKi = 6.6 6.6 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
5533.0 3853 None 55 Human Binding pKi = 6.6 6.6 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
CHEMBL621 3853 None 55 Human Binding pKi = 6.6 6.6 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
DB00656 3853 None 55 Human Binding pKi = 6.6 6.6 -6 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
2247 505 None 81 Human Binding pKi = 6.5 6.5 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
249 505 None 81 Human Binding pKi = 6.5 6.5 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
2603 505 None 81 Human Binding pKi = 6.5 6.5 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
CHEMBL296419 505 None 81 Human Binding pKi = 6.5 6.5 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
DB00637 505 None 81 Human Binding pKi = 6.5 6.5 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
2335 11848 None 22 Human Binding pKi = 6.5 6.5 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
8478 11848 None 22 Human Binding pKi = 6.5 6.5 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
CHEMBL1182210 11848 None 22 Human Binding pKi = 6.5 6.5 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
CHEMBL221753 11848 None 22 Human Binding pKi = 6.5 6.5 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
136680386 207703 None 0 Human Binding pKi = 6.5 6.5 -60 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 680 16 4 8 4.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCCN)N1 10.1016/s0960-894x(99)00484-9
44328801 207703 None 0 Human Binding pKi = 6.5 6.5 -60 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 680 16 4 8 4.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCCN)N1 10.1016/s0960-894x(99)00484-9
CHEMBL95578 207703 None 0 Human Binding pKi = 6.5 6.5 -60 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 680 16 4 8 4.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCCN)N1 10.1016/s0960-894x(99)00484-9
132060720 162489 None 0 Human Binding pKi = 5.5 5.5 -7 9
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 315 4 0 2 4.9 COc1cccc(-c2ccc3c(c2)CN(Cc2ccccc2)C3)c1 10.1016/j.ejmech.2018.02.024
CHEMBL4167315 162489 None 0 Human Binding pKi = 5.5 5.5 -7 9
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 315 4 0 2 4.9 COc1cccc(-c2ccc3c(c2)CN(Cc2ccccc2)C3)c1 10.1016/j.ejmech.2018.02.024
68712 100338 None 60 Human Binding pKi = 6.5 6.5 -1 5
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
CHEMBL289480 100338 None 60 Human Binding pKi = 6.5 6.5 -1 5
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
44371745 49289 None 0 Human Binding pKi = 6.5 6.5 -12 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 4 1 3 2.0 CCc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL156336 49289 None 0 Human Binding pKi = 6.5 6.5 -12 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 4 1 3 2.0 CCc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
25130235 187587 None 1 Human Binding pKi = 6.5 6.5 -8 11
Binding affinity to adrenergic Alpha-2C receptorBinding affinity to adrenergic Alpha-2C receptor
ChEMBL 294 2 1 6 1.3 CN1CCN(c2cc(-c3ccc(C#N)cc3)nc(N)n2)CC1 10.1021/jm8005959
CHEMBL494678 187587 None 1 Human Binding pKi = 6.5 6.5 -8 11
Binding affinity to adrenergic Alpha-2C receptorBinding affinity to adrenergic Alpha-2C receptor
ChEMBL 294 2 1 6 1.3 CN1CCN(c2cc(-c3ccc(C#N)cc3)nc(N)n2)CC1 10.1021/jm8005959
10682720 205162 None 0 Human Binding pKi = 6.5 6.5 -7 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 259 3 2 3 3.8 COc1cc(C)c(Nc2ncc[nH]2)cc1C(C)(C)C 10.1021/jm9605142
CHEMBL78190 205162 None 0 Human Binding pKi = 6.5 6.5 -7 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 259 3 2 3 3.8 COc1cc(C)c(Nc2ncc[nH]2)cc1C(C)(C)C 10.1021/jm9605142
44579186 181976 None 0 Human Binding pKi = 8.5 8.5 2 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 474 8 1 7 3.1 O=C(NCCN1CCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL478026 181976 None 0 Human Binding pKi = 8.5 8.5 2 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 474 8 1 7 3.1 O=C(NCCN1CCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
44402583 71414 None 0 Human Binding pKi = 8.5 8.5 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 425 5 4 4 2.5 O=C(O)CCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL195925 71414 None 0 Human Binding pKi = 8.5 8.5 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 425 5 4 4 2.5 O=C(O)CCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
44215744 207442 None 0 Human Binding pKi = 8.5 8.5 1 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccc5ccccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL94129 207442 None 0 Human Binding pKi = 8.5 8.5 1 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccc5ccccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
2389 3331 None 118 Human Binding pKi = 8.5 8.5 -10 67
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
5073 3331 None 118 Human Binding pKi = 8.5 8.5 -10 67
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
5073.0 3331 None 118 Human Binding pKi = 8.5 8.5 -10 67
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
96 3331 None 118 Human Binding pKi = 8.5 8.5 -10 67
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
CHEMBL85 3331 None 118 Human Binding pKi = 8.5 8.5 -10 67
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
DB00734 3331 None 118 Human Binding pKi = 8.5 8.5 -10 67
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
44438168 93818 None 0 Human Binding pKi = 8.5 8.5 53 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 533 7 0 7 4.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)N4CCC(N5CCCC5)CC4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL247665 93818 None 0 Human Binding pKi = 8.5 8.5 53 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 533 7 0 7 4.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)N4CCC(N5CCCC5)CC4)cc13)CC2 10.1016/j.bmcl.2006.12.094
11653915 124012 None 0 Human Binding pKi = 8.4 8.4 1 6
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 296 4 2 5 2.6 COc1cccc(N(NC2=NCCN2)c2ccc(C)cc2)c1 10.1016/j.bmcl.2005.07.083
CHEMBL362954 124012 None 0 Human Binding pKi = 8.4 8.4 1 6
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 296 4 2 5 2.6 COc1cccc(N(NC2=NCCN2)c2ccc(C)cc2)c1 10.1016/j.bmcl.2005.07.083
16090630 83237 None 0 Human Binding pKi = 8.4 8.4 309 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 4 2 5 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)(C)C3)cc2)c1CO 10.1021/jm060262x
CHEMBL218675 83237 None 0 Human Binding pKi = 8.4 8.4 309 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 4 2 5 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)(C)C3)cc2)c1CO 10.1021/jm060262x
135 2532 None 43 Human Binding pKi = 8.4 8.4 -6 58
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
1796 2532 None 43 Human Binding pKi = 8.4 8.4 -6 58
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
4184 2532 None 43 Human Binding pKi = 8.4 8.4 -6 58
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
4184.0 2532 None 43 Human Binding pKi = 8.4 8.4 -6 58
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
CHEMBL6437 2532 None 43 Human Binding pKi = 8.4 8.4 -6 58
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
DB06148 2532 None 43 Human Binding pKi = 8.4 8.4 -6 58
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
16090630 83237 None 0 Human Binding pKi = 8.4 8.4 309 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 4 2 5 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)(C)C3)cc2)c1CO 10.1016/j.ejmech.2010.12.026
CHEMBL218675 83237 None 0 Human Binding pKi = 8.4 8.4 309 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 4 2 5 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)(C)C3)cc2)c1CO 10.1016/j.ejmech.2010.12.026
2803 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960012o
2803.0 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960012o
516 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960012o
704 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960012o
CHEMBL134 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960012o
DB00575 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960012o
2216 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
2216.0 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
229 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
7117 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
CHEMBL647 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
DB00964 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
2803 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960359r
2803.0 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960359r
516 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960359r
704 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960359r
CHEMBL134 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960359r
DB00575 955 None 58 Human Binding pKi = 7.5 7.5 -4 19
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1021/jm960359r
1971 2866 None 38 Human Binding pKi = 7.5 7.5 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
2404 2866 None 38 Human Binding pKi = 7.5 7.5 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
4543 2866 None 38 Human Binding pKi = 7.5 7.5 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
4543.0 2866 None 38 Human Binding pKi = 7.5 7.5 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
CHEMBL445 2866 None 38 Human Binding pKi = 7.5 7.5 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
DB00540 2866 None 38 Human Binding pKi = 7.5 7.5 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
44325027 207074 None 0 Human Binding pKi = 7.5 7.5 1 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 474 6 0 8 3.2 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cnc5ccccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL91824 207074 None 0 Human Binding pKi = 7.5 7.5 1 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 474 6 0 8 3.2 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cnc5ccccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
521 1404 None 69 Human Binding pKi = 7.5 7.5 -30 7
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
5311068 1404 None 69 Human Binding pKi = 7.5 7.5 -30 7
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
5311068.0 1404 None 69 Human Binding pKi = 7.5 7.5 -30 7
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
835 1404 None 69 Human Binding pKi = 7.5 7.5 -30 7
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
CHEMBL778 1404 None 69 Human Binding pKi = 7.5 7.5 -30 7
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
DB00633 1404 None 69 Human Binding pKi = 7.5 7.5 -30 7
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
9960497 100476 None 0 Human Binding pKi = 6.5 6.5 -933 6
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
CHEMBL290860 100476 None 0 Human Binding pKi = 6.5 6.5 -933 6
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
9894818 98925 None 0 Human Binding pKi = 6.5 6.5 -93 7
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL279436 98925 None 0 Human Binding pKi = 6.5 6.5 -93 7
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
10333157 151238 None 0 Human Binding pKi = 6.5 6.5 -3 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL396013 151238 None 0 Human Binding pKi = 6.5 6.5 -3 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
10333157 151238 None 0 Human Binding pKi = 6.5 6.5 -3 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL396013 151238 None 0 Human Binding pKi = 6.5 6.5 -3 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
11246610 84312 None 0 Human Binding pKi = 6.5 6.5 -2 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1ccc([N+](=O)[O-])cc1)C1=NCCN1 10.1021/jm0408215
CHEMBL221523 84312 None 0 Human Binding pKi = 6.5 6.5 -2 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1ccc([N+](=O)[O-])cc1)C1=NCCN1 10.1021/jm0408215
44209480 70170 None 0 Human Binding pKi = 6.5 6.5 -281 11
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 313 6 0 3 3.4 Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
CHEMBL1940418 70170 None 0 Human Binding pKi = 6.5 6.5 -281 11
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 313 6 0 3 3.4 Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
73353884 92322 None 0 Human Binding pKi = 5.5 5.5 -2 8
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 295 3 1 3 2.7 c1cc2c(cc1CN[C@H]1C3C4CC5C6C4CC3C6C51)OCO2 10.1016/j.bmc.2013.07.045
CHEMBL2429890 92322 None 0 Human Binding pKi = 5.5 5.5 -2 8
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 295 3 1 3 2.7 c1cc2c(cc1CN[C@H]1C3C4CC5C6C4CC3C6C51)OCO2 10.1016/j.bmc.2013.07.045
11173568 84641 None 0 Human Binding pKi = 6.5 6.5 -8 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 281 4 2 4 2.7 CC(Oc1ccccc1-c1cccc(N)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222371 84641 None 0 Human Binding pKi = 6.5 6.5 -8 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 281 4 2 4 2.7 CC(Oc1ccccc1-c1cccc(N)c1)C1=NCCN1 10.1021/jm0408215
24906160 169456 None 0 Human Binding pKi = 5.5 5.5 -4 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 247 5 1 5 1.4 CO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL442815 169456 None 0 Human Binding pKi = 5.5 5.5 -4 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 247 5 1 5 1.4 CO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
75306277 109254 None 0 Human Binding pKi = 7.5 7.5 -15 23
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 308 0 0 3 4.2 CN1CCC2C(C1)c1cccc3c1N2c1ccccc1CS3 10.1039/C2MD00311B
CHEMBL3217984 109254 None 0 Human Binding pKi = 7.5 7.5 -15 23
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 308 0 0 3 4.2 CN1CCC2C(C1)c1cccc3c1N2c1ccccc1CS3 10.1039/C2MD00311B
49836308 18784 None 0 Human Binding pKi = 7.5 7.5 1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 C[C@@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL1278084 18784 None 0 Human Binding pKi = 7.5 7.5 1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 C[C@@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
44288945 168915 None 0 Human Binding pKi = 6.5 6.5 -794 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 485 7 2 3 4.4 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
CHEMBL43860 168915 None 0 Human Binding pKi = 6.5 6.5 -794 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 485 7 2 3 4.4 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
49836306 18575 None 0 Human Binding pKi = 6.5 6.5 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 C[C@@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276247 18575 None 0 Human Binding pKi = 6.5 6.5 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 C[C@@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
12488 1657 None 56 Human Binding pKi = 7.5 7.5 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
941361 1657 None 56 Human Binding pKi = 7.5 7.5 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
CHEMBL30008 1657 None 56 Human Binding pKi = 7.5 7.5 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
DB04841 1657 None 56 Human Binding pKi = 7.5 7.5 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
44402352 71626 None 0 Human Binding pKi = 7.5 7.5 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 396 4 4 4 1.9 NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL196344 71626 None 0 Human Binding pKi = 7.5 7.5 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 396 4 4 4 1.9 NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
10266032 188881 None 0 Human Binding pKi = 7.5 7.5 -2 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 286 5 1 3 3.5 c1ccc(CCC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL50720 188881 None 0 Human Binding pKi = 7.5 7.5 -2 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 286 5 1 3 3.5 c1ccc(CCC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
10841387 99618 None 0 Human Binding pKi = 6.5 6.5 -91 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 607 10 3 6 5.2 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
CHEMBL284103 99618 None 0 Human Binding pKi = 6.5 6.5 -91 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 607 10 3 6 5.2 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
9894818 98925 None 0 Human Binding pKi = 6.5 6.5 -93 7
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL279436 98925 None 0 Human Binding pKi = 6.5 6.5 -93 7
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
10841387 99618 None 0 Human Binding pKi = 6.5 6.5 -91 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 10 3 6 5.2 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL284103 99618 None 0 Human Binding pKi = 6.5 6.5 -91 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 10 3 6 5.2 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
44390749 63910 None 0 Human Binding pKi = 6.5 6.5 -173 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 607 11 3 6 5.3 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1016/s0960-894x(99)00484-9
CHEMBL180561 63910 None 0 Human Binding pKi = 6.5 6.5 -173 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 607 11 3 6 5.3 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1016/s0960-894x(99)00484-9
44579184 190953 None 4 Human Binding pKi = 7.5 7.5 2 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 340 4 0 5 2.7 COc1ccccc1N1CCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL518592 190953 None 4 Human Binding pKi = 7.5 7.5 2 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 340 4 0 5 2.7 COc1ccccc1N1CCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
294234 102893 None 3 Human Binding pKi = 7.5 7.5 -6 4
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 182 1 1 3 1.7 C1CCCC(NC2=NCCO2)CC1 10.1016/0960-894X(94)85032-1
CHEMBL305928 102893 None 3 Human Binding pKi = 7.5 7.5 -6 4
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 182 1 1 3 1.7 C1CCCC(NC2=NCCO2)CC1 10.1016/0960-894X(94)85032-1
487 3634 None 21 Human Binding pKi = 6.5 6.5 -912 11
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
60602 3634 None 21 Human Binding pKi = 6.5 6.5 -912 11
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
CHEMBL405355 3634 None 21 Human Binding pKi = 6.5 6.5 -912 11
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
DB09239 3634 None 21 Human Binding pKi = 6.5 6.5 -912 11
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
11186227 84722 None 0 Human Binding pKi = 6.5 6.5 -9 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1ccc(O)cc1)C1=NCCN1 10.1021/jm0408215
CHEMBL222798 84722 None 0 Human Binding pKi = 6.5 6.5 -9 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1ccc(O)cc1)C1=NCCN1 10.1021/jm0408215
44582676 189779 None 0 Human Binding pKi = 6.5 6.5 -2 17
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 403 9 0 4 4.3 COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(F)cc2)CC1 10.1016/j.bmc.2009.03.021
CHEMBL516088 189779 None 0 Human Binding pKi = 6.5 6.5 -2 17
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 403 9 0 4 4.3 COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(F)cc2)CC1 10.1016/j.bmc.2009.03.021
9884781 38674 None 1 Human Binding pKi = 6.5 6.5 -1 5
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 350 3 0 4 3.0 c1ccc2c(c1)CC(CN1CCN(c3ccc4c(c3)OCCO4)CC1)C2 10.1021/acs.jmedchem.7b00151
CHEMBL146556 38674 None 1 Human Binding pKi = 6.5 6.5 -1 5
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 350 3 0 4 3.0 c1ccc2c(c1)CC(CN1CCN(c3ccc4c(c3)OCCO4)CC1)C2 10.1021/acs.jmedchem.7b00151
24906196 187246 None 0 Human Binding pKi = 6.5 6.5 1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 261 6 1 5 1.8 CCO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL492639 187246 None 0 Human Binding pKi = 6.5 6.5 1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 261 6 1 5 1.8 CCO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL4778870 214047 None 8 Human Binding pKi = 5.5 5.5 -9 5
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL None None None CC1CCN(c2ccnc(NCc3cn(C)cn3)n2)CC1 10.6019/CHEMBL4800732
10319299 81587 None 0 Human Binding pKi = 7.5 7.5 48 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 408 4 1 4 5.7 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1-c1ccccc1 10.1016/j.ejmech.2010.12.026
CHEMBL216290 81587 None 0 Human Binding pKi = 7.5 7.5 48 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 408 4 1 4 5.7 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1-c1ccccc1 10.1016/j.ejmech.2010.12.026
10132386 97098 None 2 Human Binding pKi = 7.5 7.5 63 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 346 3 1 4 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL267464 97098 None 2 Human Binding pKi = 7.5 7.5 63 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 346 3 1 4 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C 10.1016/j.ejmech.2010.12.026
16090621 141575 None 0 Human Binding pKi = 7.5 7.5 2 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 422 5 1 4 5.6 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1Cc1ccccc1 10.1016/j.ejmech.2010.12.026
CHEMBL384925 141575 None 0 Human Binding pKi = 7.5 7.5 2 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 422 5 1 4 5.6 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1Cc1ccccc1 10.1016/j.ejmech.2010.12.026
9794524 204843 None 2 Human Binding pKi = 6.5 6.5 -10 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 225 2 2 4 2.4 Cc1c(Nc2ncc[nH]2)ccc2nccnc12 10.1021/jm9605142
CHEMBL75491 204843 None 2 Human Binding pKi = 6.5 6.5 -10 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 225 2 2 4 2.4 Cc1c(Nc2ncc[nH]2)ccc2nccnc12 10.1021/jm9605142
CHEMBL4778870 214047 None 8 Human Binding pKi = 5.5 5.5 -9 5
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL None None None CC1CCN(c2ccnc(NCc3cn(C)cn3)n2)CC1 10.6019/CHEMBL4800732
28417 40039 None 49 Human Binding pKi = 5.5 5.5 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
28417.0 40039 None 49 Human Binding pKi = 5.5 5.5 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
CHEMBL1479 40039 None 49 Human Binding pKi = 5.5 5.5 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
DB01406 40039 None 49 Human Binding pKi = 5.5 5.5 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
1267 3804 None 49 Human Binding pKi = 6.5 6.5 -144 26
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 10.1021/jm8003625
3035905 3804 None 49 Human Binding pKi = 6.5 6.5 -144 26
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 10.1021/jm8003625
CHEMBL260374 3804 None 49 Human Binding pKi = 6.5 6.5 -144 26
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 10.1021/jm8003625
CHEMBL4798829 214053 None 7 Human Binding pKi = 5.5 5.5 -6 2
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000752a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000752a ADRA2C
ChEMBL None None None c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1 10.6019/CHEMBL5212743
10319299 81587 None 0 Human Binding pKi = 7.5 7.5 48 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 408 4 1 4 5.7 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1-c1ccccc1 10.1021/jm060262x
CHEMBL216290 81587 None 0 Human Binding pKi = 7.5 7.5 48 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 408 4 1 4 5.7 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1-c1ccccc1 10.1021/jm060262x
10132386 97098 None 2 Human Binding pKi = 7.5 7.5 63 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 346 3 1 4 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C 10.1021/jm060262x
CHEMBL267464 97098 None 2 Human Binding pKi = 7.5 7.5 63 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 346 3 1 4 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C 10.1021/jm060262x
16090621 141575 None 0 Human Binding pKi = 7.5 7.5 2 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 422 5 1 4 5.6 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1Cc1ccccc1 10.1021/jm060262x
CHEMBL384925 141575 None 0 Human Binding pKi = 7.5 7.5 2 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 422 5 1 4 5.6 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1Cc1ccccc1 10.1021/jm060262x
10946567 16469 None 0 Human Binding pKi = 7.5 7.5 -28 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 265 1 0 2 4.1 CCc1sc2ccc(Cl)c3c2c1CN(C)CC3 10.1021/jm00019a001
CHEMBL123448 16469 None 0 Human Binding pKi = 7.5 7.5 -28 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 265 1 0 2 4.1 CCc1sc2ccc(Cl)c3c2c1CN(C)CC3 10.1021/jm00019a001
155561439 175666 None 0 Human Binding pKi = 5.5 5.5 -2 2
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 411 4 4 7 3.5 Oc1ccc(CCNc2nc(C#Cc3ccc(Cl)s3)nc3[nH]cnc23)cc1O 10.1039/C8MD00317C
CHEMBL4581568 175666 None 0 Human Binding pKi = 5.5 5.5 -2 2
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 411 4 4 7 3.5 Oc1ccc(CCNc2nc(C#Cc3ccc(Cl)s3)nc3[nH]cnc23)cc1O 10.1039/C8MD00317C
2286 3183 None 51 Human Binding pKi = 6.5 6.5 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
4927 3183 None 51 Human Binding pKi = 6.5 6.5 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
4927.0 3183 None 51 Human Binding pKi = 6.5 6.5 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
7282 3183 None 51 Human Binding pKi = 6.5 6.5 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
CHEMBL643 3183 None 51 Human Binding pKi = 6.5 6.5 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
DB01069 3183 None 51 Human Binding pKi = 6.5 6.5 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
44329026 208425 None 0 Human Binding pKi = 6.5 6.5 -69 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 679 16 3 7 6.1 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(CCCCOC)N1 10.1016/s0960-894x(99)00484-9
CHEMBL99864 208425 None 0 Human Binding pKi = 6.5 6.5 -69 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 679 16 3 7 6.1 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(CCCCOC)N1 10.1016/s0960-894x(99)00484-9
1028 291 None 71 Human Binding pKi = 6.5 6.5 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
139148732 291 None 71 Human Binding pKi = 6.5 6.5 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
479 291 None 71 Human Binding pKi = 6.5 6.5 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
5816 291 None 71 Human Binding pKi = 6.5 6.5 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
5816.0 291 None 71 Human Binding pKi = 6.5 6.5 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
CHEMBL679 291 None 71 Human Binding pKi = 6.5 6.5 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
DB00668 291 None 71 Human Binding pKi = 6.5 6.5 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
222757 99376 None 73 Human Binding pKi = 5.5 5.5 1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
CHEMBL282575 99376 None 73 Human Binding pKi = 5.5 5.5 1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
44325038 206916 None 0 Human Binding pKi = 7.4 7.4 3 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 474 6 0 8 3.2 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccc5ncccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL90966 206916 None 0 Human Binding pKi = 7.4 7.4 3 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 474 6 0 8 3.2 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccc5ncccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
3072540 82415 None 13 Human Binding pKi = 7.4 7.4 32 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 382 4 1 4 5.3 CCN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1 10.1016/j.ejmech.2010.12.026
CHEMBL217366 82415 None 13 Human Binding pKi = 7.4 7.4 32 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 382 4 1 4 5.3 CCN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1 10.1016/j.ejmech.2010.12.026
16757089 92291 None 1 Human Binding pKi = 6.4 6.4 -3 3
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL242693 92291 None 1 Human Binding pKi = 6.4 6.4 -3 3
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
2284 3182 None 33 Human Binding pKi = 7.4 7.4 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
4926 3182 None 33 Human Binding pKi = 7.4 7.4 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
7281 3182 None 33 Human Binding pKi = 7.4 7.4 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
CHEMBL564 3182 None 33 Human Binding pKi = 7.4 7.4 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
DB00420 3182 None 33 Human Binding pKi = 7.4 7.4 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
3072540 82415 None 13 Human Binding pKi = 7.4 7.4 32 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 382 4 1 4 5.3 CCN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1 10.1021/jm060262x
CHEMBL217366 82415 None 13 Human Binding pKi = 7.4 7.4 32 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 382 4 1 4 5.3 CCN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1 10.1021/jm060262x
242 470 None 124 Human Binding pKi = 7.4 7.4 -23 51
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
34 470 None 124 Human Binding pKi = 7.4 7.4 -23 51
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
60795 470 None 124 Human Binding pKi = 7.4 7.4 -23 51
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
60795.0 470 None 124 Human Binding pKi = 7.4 7.4 -23 51
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
CHEMBL1112 470 None 124 Human Binding pKi = 7.4 7.4 -23 51
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
DB01238 470 None 124 Human Binding pKi = 7.4 7.4 -23 51
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
9809007 172564 None 8 Human Binding pKi = 6.4 6.4 -724 6
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
CHEMBL448620 172564 None 8 Human Binding pKi = 6.4 6.4 -724 6
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
487 3634 None 21 Human Binding pKi = 6.4 6.4 -912 11
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00019a001
60602 3634 None 21 Human Binding pKi = 6.4 6.4 -912 11
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00019a001
CHEMBL405355 3634 None 21 Human Binding pKi = 6.4 6.4 -912 11
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00019a001
DB09239 3634 None 21 Human Binding pKi = 6.4 6.4 -912 11
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00019a001
4150 788 None 39 Human Binding pKi = 5.4 5.4 -95 11
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
5288 788 None 39 Human Binding pKi = 5.4 5.4 -95 11
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
644019 788 None 39 Human Binding pKi = 5.4 5.4 -95 11
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
644019.0 788 None 39 Human Binding pKi = 5.4 5.4 -95 11
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
CHEMBL190461 788 None 39 Human Binding pKi = 5.4 5.4 -95 11
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
DB09061 788 None 39 Human Binding pKi = 5.4 5.4 -95 11
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
9809007 172564 None 8 Human Binding pKi = 6.4 6.4 -724 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL448620 172564 None 8 Human Binding pKi = 6.4 6.4 -724 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
9851486 206699 None 0 Human Binding pKi = 6.4 6.4 -316 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 592 10 2 6 6.0 CC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL89685 206699 None 0 Human Binding pKi = 6.4 6.4 -316 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 592 10 2 6 6.0 CC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
73349362 92550 None 0 Human Binding pKi = 5.4 5.4 1 2
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 311 5 0 1 3.8 CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
CHEMBL2432060 92550 None 0 Human Binding pKi = 5.4 5.4 1 2
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 311 5 0 1 3.8 CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
16090633 80461 None 0 Human Binding pKi = 7.4 7.4 25 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 380 4 2 5 3.8 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1021/jm060262x
CHEMBL214661 80461 None 0 Human Binding pKi = 7.4 7.4 25 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 380 4 2 5 3.8 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1021/jm060262x
16090633 80461 None 0 Human Binding pKi = 7.4 7.4 25 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 380 4 2 5 3.8 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
CHEMBL214661 80461 None 0 Human Binding pKi = 7.4 7.4 25 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 380 4 2 5 3.8 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
57400959 71188 None 0 Human Binding pKi = 5.4 5.4 -1 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 268 4 1 5 0.9 CC(Oc1ccccc1S(C)(=O)=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956200 71188 None 0 Human Binding pKi = 5.4 5.4 -1 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 268 4 1 5 0.9 CC(Oc1ccccc1S(C)(=O)=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
124 2981 None 47 Human Binding pKi = 6.4 6.4 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
2032 2981 None 47 Human Binding pKi = 6.4 6.4 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
4636 2981 None 47 Human Binding pKi = 6.4 6.4 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
4636.0 2981 None 47 Human Binding pKi = 6.4 6.4 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
CHEMBL762 2981 None 47 Human Binding pKi = 6.4 6.4 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
DB00935 2981 None 47 Human Binding pKi = 6.4 6.4 -60 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
10436842 100256 None 0 Human Binding pKi = 5.4 5.4 -4786 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 524 7 1 4 4.6 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL288772 100256 None 0 Human Binding pKi = 5.4 5.4 -4786 7
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 524 7 1 4 4.6 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
16090597 141470 None 0 Human Binding pKi = 6.4 6.4 5 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1nc2c(C)ccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL384318 141470 None 0 Human Binding pKi = 6.4 6.4 5 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1nc2c(C)ccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
16090597 141470 None 0 Human Binding pKi = 6.4 6.4 5 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1nc2c(C)ccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL384318 141470 None 0 Human Binding pKi = 6.4 6.4 5 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1nc2c(C)ccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
10508332 105991 None 0 Human Binding pKi = 6.4 6.4 -269 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 638 11 2 8 6.4 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])c(OC)c1 10.1021/jm980077m
CHEMBL313160 105991 None 0 Human Binding pKi = 6.4 6.4 -269 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 638 11 2 8 6.4 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])c(OC)c1 10.1021/jm980077m
28918670 92487 None 2 Human Binding pKi = 6.4 6.4 -4 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 254 3 1 3 1.8 Brc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL2431279 92487 None 2 Human Binding pKi = 6.4 6.4 -4 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 254 3 1 3 1.8 Brc1ccccc1OCC1=NCCN1 10.1021/ml400232p
127036953 137515 None 0 Human Binding pKi = 6.4 6.4 -39 22
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 318 7 1 1 4.1 C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL3754166 137515 None 0 Human Binding pKi = 6.4 6.4 -39 22
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 318 7 1 1 4.1 C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2015.12.053
44269140 33553 None 0 Human Binding pKi = 6.4 6.4 -4 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 248 5 1 4 2.2 CC(C)Oc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL14208 33553 None 0 Human Binding pKi = 6.4 6.4 -4 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 248 5 1 4 2.2 CC(C)Oc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
73352415 92538 None 0 Human Binding pKi = 5.4 5.4 -2 4
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 293 4 0 2 2.5 CN(CCc1ccccc1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
CHEMBL2432044 92538 None 0 Human Binding pKi = 5.4 5.4 -2 4
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 293 4 0 2 2.5 CN(CCc1ccccc1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
10916464 204153 None 0 Human Binding pKi = 5.4 5.4 -8 5
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1cc(Cl)ccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70563 204153 None 0 Human Binding pKi = 5.4 5.4 -8 5
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1cc(Cl)ccc1NCC1=NCCN1 10.1021/jm000542r
12576 514 None 94 Human Binding pKi = 8.4 8.4 -2 6
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 10.1021/jm1006269
71310 514 None 94 Human Binding pKi = 8.4 8.4 -2 6
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 10.1021/jm1006269
CHEMBL353972 514 None 94 Human Binding pKi = 8.4 8.4 -2 6
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 10.1021/jm1006269
DB11481 514 None 94 Human Binding pKi = 8.4 8.4 -2 6
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 10.1021/jm1006269
44438166 93817 None 0 Human Binding pKi = 8.4 8.4 33 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 467 8 2 7 3.5 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCC(C)(C)N)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL247664 93817 None 0 Human Binding pKi = 8.4 8.4 33 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 467 8 2 7 3.5 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCC(C)(C)N)cc13)CC2 10.1016/j.bmcl.2006.12.094
46891598 7176 None 0 Human Binding pKi = 8.4 8.4 -2 2
Displacement of [3H]rauwolscine from adrenergic Alpha-2C receptorDisplacement of [3H]rauwolscine from adrenergic Alpha-2C receptor
ChEMBL 402 5 0 5 3.2 CN1CC2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1016/j.bmcl.2010.04.099
CHEMBL1085510 7176 None 0 Human Binding pKi = 8.4 8.4 -2 2
Displacement of [3H]rauwolscine from adrenergic Alpha-2C receptorDisplacement of [3H]rauwolscine from adrenergic Alpha-2C receptor
ChEMBL 402 5 0 5 3.2 CN1CC2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1016/j.bmcl.2010.04.099
44424855 85454 None 0 Human Binding pKi = 8.4 8.4 1 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
CHEMBL226636 85454 None 0 Human Binding pKi = 8.4 8.4 1 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
44324859 111612 None 0 Human Binding pKi = 8.3 8.3 4 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 461 6 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CC4=Cc5ccccc5C4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL328377 111612 None 0 Human Binding pKi = 8.3 8.3 4 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 461 6 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CC4=Cc5ccccc5C4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44324765 111568 None 0 Human Binding pKi = 8.3 8.3 2 5
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL328114 111568 None 0 Human Binding pKi = 8.3 8.3 2 5
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
16090631 82391 None 0 Human Binding pKi = 8.3 8.3 630 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 4 2 5 4.5 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C(C)O 10.1016/j.ejmech.2010.12.026
CHEMBL217253 82391 None 0 Human Binding pKi = 8.3 8.3 630 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 4 2 5 4.5 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C(C)O 10.1016/j.ejmech.2010.12.026
16090631 82391 None 0 Human Binding pKi = 8.3 8.3 630 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 4 2 5 4.5 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C(C)O 10.1021/jm060262x
CHEMBL217253 82391 None 0 Human Binding pKi = 8.3 8.3 630 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 4 2 5 4.5 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C(C)O 10.1021/jm060262x
3191 102858 None 97 Human Binding pKi = 7.4 7.4 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
3191.0 102858 None 97 Human Binding pKi = 7.4 7.4 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
CHEMBL305660 102858 None 97 Human Binding pKi = 7.4 7.4 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
DB11742 102858 None 97 Human Binding pKi = 7.4 7.4 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
10655607 204755 None 5 Human Binding pKi = 6.4 6.4 -5 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 199 2 3 3 2.0 c1c[nH]c(Nc2ccc3[nH]cnc3c2)n1 10.1021/jm9605142
CHEMBL74544 204755 None 5 Human Binding pKi = 6.4 6.4 -5 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 199 2 3 3 2.0 c1c[nH]c(Nc2ccc3[nH]cnc3c2)n1 10.1021/jm9605142
12304323 9048 None 5 Human Binding pKi = 5.4 5.4 - 1
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 464 4 8 12 -0.5 O=c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12 10.1021/np1000329
CHEMBL1098724 9048 None 5 Human Binding pKi = 5.4 5.4 - 1
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 464 4 8 12 -0.5 O=c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12 10.1021/np1000329
10507651 206507 None 0 Human Binding pKi = 6.4 6.4 -45 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 591 9 2 6 5.8 CC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
CHEMBL88388 206507 None 0 Human Binding pKi = 6.4 6.4 -45 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 591 9 2 6 5.8 CC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
10382537 204166 None 12 Human Binding pKi = 6.4 6.4 -60 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 339 1 2 5 1.6 Ic1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL70676 204166 None 12 Human Binding pKi = 6.4 6.4 -60 6
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 339 1 2 5 1.6 Ic1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL4748908 214035 None 1 Human Binding pKi = 6.4 6.4 -4 12
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL None None None CN1CCN(c2ccnc(NCCc3ccccc3)n2)CC1 10.6019/CHEMBL4800732
2353 101112 None 82 Human Binding pKi = 6.4 6.4 -1 4
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
CHEMBL12089 101112 None 82 Human Binding pKi = 6.4 6.4 -1 4
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
CHEMBL295124 101112 None 82 Human Binding pKi = 6.4 6.4 -1 4
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
CHEMBL4748908 214035 None 1 Human Binding pKi = 6.4 6.4 -4 12
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL None None None CN1CCN(c2ccnc(NCCc3ccccc3)n2)CC1 10.6019/CHEMBL4800732
10627021 107095 None 0 Human Binding pKi = 6.4 6.4 -301 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 577 9 2 5 6.8 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C)cc1 10.1021/jm980077m
CHEMBL315914 107095 None 0 Human Binding pKi = 6.4 6.4 -301 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 577 9 2 5 6.8 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C)cc1 10.1021/jm980077m
10317643 98540 None 0 Human Binding pKi = 7.4 7.4 32 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 380 4 2 5 3.8 CC1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
CHEMBL276417 98540 None 0 Human Binding pKi = 7.4 7.4 32 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 380 4 2 5 3.8 CC1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
10818003 106421 None 0 Human Binding pKi = 6.4 6.4 -7 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 649 12 3 6 6.2 CC(C)C1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C(C)C)N1 10.1021/jm980077m
CHEMBL313953 106421 None 0 Human Binding pKi = 6.4 6.4 -7 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 649 12 3 6 6.2 CC(C)C1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C(C)C)N1 10.1021/jm980077m
66561967 74704 None 0 Human Binding pKi = 5.4 5.4 -6 7
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 213 2 0 1 2.0 C1CC2CCC1N2CC12C3C4C5C3C1C5C42 10.1016/j.bmcl.2012.04.077
CHEMBL2030626 74704 None 0 Human Binding pKi = 5.4 5.4 -6 7
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 213 2 0 1 2.0 C1CC2CCC1N2CC12C3C4C5C3C1C5C42 10.1016/j.bmcl.2012.04.077
44421258 84746 None 0 Human Binding pKi = 5.4 5.4 -3 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL1204386 84746 None 0 Human Binding pKi = 5.4 5.4 -3 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL222933 84746 None 0 Human Binding pKi = 5.4 5.4 -3 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
127035062 136451 None 0 Human Binding pKi = 6.4 6.4 -14 19
Displacement of [3H]Rauwolscine from human recombinant alpha 2C receptor stably expressed in MDCK cells after 90 mins by scintillation counting methodDisplacement of [3H]Rauwolscine from human recombinant alpha 2C receptor stably expressed in MDCK cells after 90 mins by scintillation counting method
ChEMBL 447 12 0 5 5.2 COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC 10.1039/C4MD00418C
CHEMBL3735756 136451 None 0 Human Binding pKi = 6.4 6.4 -14 19
Displacement of [3H]Rauwolscine from human recombinant alpha 2C receptor stably expressed in MDCK cells after 90 mins by scintillation counting methodDisplacement of [3H]Rauwolscine from human recombinant alpha 2C receptor stably expressed in MDCK cells after 90 mins by scintillation counting method
ChEMBL 447 12 0 5 5.2 COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC 10.1039/C4MD00418C
10317643 98540 None 0 Human Binding pKi = 7.4 7.4 32 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 380 4 2 5 3.8 CC1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1021/jm060262x
CHEMBL276417 98540 None 0 Human Binding pKi = 7.4 7.4 32 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 380 4 2 5 3.8 CC1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1021/jm060262x
155770281 177747 None 0 Human Binding pKi = 5.4 5.4 -5 9
Binding affinity to alpha2c (unknown origin)Binding affinity to alpha2c (unknown origin)
ChEMBL 517 4 1 2 7.6 CC(=O)N1CCC(c2ccc(-c3cc(C(=O)O)cc4cc(-c5ccc(C(F)(F)F)cc5)ccc34)cc2)CC1 10.1021/acs.jmedchem.1c00164
CHEMBL4642592 177747 None 0 Human Binding pKi = 5.4 5.4 -5 9
Binding affinity to alpha2c (unknown origin)Binding affinity to alpha2c (unknown origin)
ChEMBL 517 4 1 2 7.6 CC(=O)N1CCC(c2ccc(-c3cc(C(=O)O)cc4cc(-c5ccc(C(F)(F)F)cc5)ccc34)cc2)CC1 10.1021/acs.jmedchem.1c00164
122186880 122980 None 0 Human Binding pKi = 6.4 6.4 -4 5
Binding affinity to alpha2C adrenoceptor (unknown origin)Binding affinity to alpha2C adrenoceptor (unknown origin)
ChEMBL 415 3 0 5 4.8 COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4 10.1016/j.bmcl.2015.07.012
CHEMBL3608450 122980 None 0 Human Binding pKi = 6.4 6.4 -4 5
Binding affinity to alpha2C adrenoceptor (unknown origin)Binding affinity to alpha2C adrenoceptor (unknown origin)
ChEMBL 415 3 0 5 4.8 COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4 10.1016/j.bmcl.2015.07.012
71463061 83795 None 0 Human Binding pKi = 5.4 5.4 -5 9
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 339 5 1 4 2.0 COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1OC 10.1016/j.bmcl.2012.08.046
CHEMBL2205813 83795 None 0 Human Binding pKi = 5.4 5.4 -5 9
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 339 5 1 4 2.0 COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1OC 10.1016/j.bmcl.2012.08.046
2435 722 None 100 Human Binding pKi = 7.4 7.4 -33 12
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
2435.0 722 None 100 Human Binding pKi = 7.4 7.4 -33 12
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
395 722 None 100 Human Binding pKi = 7.4 7.4 -33 12
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
520 722 None 100 Human Binding pKi = 7.4 7.4 -33 12
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
5386 722 None 100 Human Binding pKi = 7.4 7.4 -33 12
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
CHEMBL844 722 None 100 Human Binding pKi = 7.4 7.4 -33 12
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
DB00484 722 None 100 Human Binding pKi = 7.4 7.4 -33 12
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
44328654 107185 None 0 Human Binding pKi = 6.4 6.4 -114 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 663 14 3 6 6.7 CCCC1=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCC)=C(CC)N1 10.1016/s0960-894x(99)00484-9
CHEMBL316495 107185 None 0 Human Binding pKi = 6.4 6.4 -114 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 663 14 3 6 6.7 CCCC1=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCC)=C(CC)N1 10.1016/s0960-894x(99)00484-9
4011 82408 None 49 Human Binding pKi = 6.4 6.4 -28 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
CHEMBL21731 82408 None 49 Human Binding pKi = 6.4 6.4 -28 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
33630 178957 None 99 Human Binding pKi = 6.4 6.4 -9 28
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1016/j.bmcl.2018.10.036
CHEMBL47050 178957 None 99 Human Binding pKi = 6.4 6.4 -9 28
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1016/j.bmcl.2018.10.036
73213196 104460 None 4 Human Binding pKi = 6.4 6.4 -4 13
Binding affinity to adrenergic alpha 2C receptor (unknown origin)Binding affinity to adrenergic alpha 2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2014.05.016
CHEMBL3104093 104460 None 4 Human Binding pKi = 6.4 6.4 -4 13
Binding affinity to adrenergic alpha 2C receptor (unknown origin)Binding affinity to adrenergic alpha 2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2014.05.016
73213196 104460 None 4 Human Binding pKi = 6.4 6.4 -4 13
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104093 104460 None 4 Human Binding pKi = 6.4 6.4 -4 13
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2013.12.024
73213196 104460 None 4 Human Binding pKi = 6.4 6.4 -4 13
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104093 104460 None 4 Human Binding pKi = 6.4 6.4 -4 13
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2013.12.024
57401706 70171 None 0 Human Binding pKi = 7.4 7.4 -7 11
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 331 6 0 4 3.5 Fc1ccc(SCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
CHEMBL1940419 70171 None 0 Human Binding pKi = 7.4 7.4 -7 11
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 331 6 0 4 3.5 Fc1ccc(SCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
463 1405 None 22 Human Binding pKi = 6.4 6.4 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
6918097 1405 None 22 Human Binding pKi = 6.4 6.4 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
837 1405 None 22 Human Binding pKi = 6.4 6.4 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
CHEMBL2051956 1405 None 22 Human Binding pKi = 6.4 6.4 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
DB14068 1405 None 22 Human Binding pKi = 6.4 6.4 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
6918276 15611 None 7 Human Binding pKi = 6.3 6.3 -47 8
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 559 18 4 9 1.7 CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS nan
CHEMBL1221512 15611 None 7 Human Binding pKi = 6.3 6.3 -47 8
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 559 18 4 9 1.7 CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS nan
44269089 97005 None 0 Human Binding pKi = 6.3 6.3 -6 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 232 4 1 3 2.6 CC(Oc1ccccc1C(C)C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL266613 97005 None 0 Human Binding pKi = 6.3 6.3 -6 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 232 4 1 3 2.6 CC(Oc1ccccc1C(C)C)C1=NCCN1 10.1016/j.bmc.2012.01.035
9809007 172564 None 8 Human Binding pKi = 6.3 6.3 -724 6
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
CHEMBL448620 172564 None 8 Human Binding pKi = 6.3 6.3 -724 6
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
191 403 None 98 Human Binding pKi = 6.3 6.3 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
201 403 None 98 Human Binding pKi = 6.3 6.3 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
2170 403 None 98 Human Binding pKi = 6.3 6.3 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
2170.0 403 None 98 Human Binding pKi = 6.3 6.3 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
CHEMBL1113 403 None 98 Human Binding pKi = 6.3 6.3 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
DB00543 403 None 98 Human Binding pKi = 6.3 6.3 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
60838 183874 None 99 Human Binding pKi = 6.3 6.3 -1 2
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
CHEMBL481 183874 None 99 Human Binding pKi = 6.3 6.3 -1 2
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
44288847 165309 None 0 Human Binding pKi = 5.3 5.3 -3311 5
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 535 7 2 5 3.9 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
CHEMBL42335 165309 None 0 Human Binding pKi = 5.3 5.3 -3311 5
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 535 7 2 5 3.9 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
10769331 111533 None 0 Human Binding pKi = 7.3 7.3 -91 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 566 9 2 7 5.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc(Cl)c([N+](=O)[O-])c1 10.1021/jm980077m
CHEMBL327931 111533 None 0 Human Binding pKi = 7.3 7.3 -91 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 566 9 2 7 5.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc(Cl)c([N+](=O)[O-])c1 10.1021/jm980077m
135453290 133606 None 33 Human Binding pKi = 5.3 5.3 -1548 8
Displacement of [3H]clonidine from cloned human adrenergic Alpha-2C receptor expressed in Sf9 cellsDisplacement of [3H]clonidine from cloned human adrenergic Alpha-2C receptor expressed in Sf9 cells
ChEMBL 191 2 2 4 1.1 C[C@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
CHEMBL371300 133606 None 33 Human Binding pKi = 5.3 5.3 -1548 8
Displacement of [3H]clonidine from cloned human adrenergic Alpha-2C receptor expressed in Sf9 cellsDisplacement of [3H]clonidine from cloned human adrenergic Alpha-2C receptor expressed in Sf9 cells
ChEMBL 191 2 2 4 1.1 C[C@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
136680384 207655 None 0 Human Binding pKi = 6.3 6.3 -104 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 694 16 4 8 4.9 CCNC(=O)C1=C(CC)NC(COCCN)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
44328799 207655 None 0 Human Binding pKi = 6.3 6.3 -104 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 694 16 4 8 4.9 CCNC(=O)C1=C(CC)NC(COCCN)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
CHEMBL95290 207655 None 0 Human Binding pKi = 6.3 6.3 -104 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 694 16 4 8 4.9 CCNC(=O)C1=C(CC)NC(COCCN)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
71461344 83806 None 0 Human Binding pKi = 5.3 5.3 - 1
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 266 2 1 3 1.3 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccnc1 10.1016/j.bmc.2013.07.045
CHEMBL2205833 83806 None 0 Human Binding pKi = 5.3 5.3 - 1
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 266 2 1 3 1.3 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccnc1 10.1016/j.bmc.2013.07.045
73347827 92544 None 0 Human Binding pKi = 5.3 5.3 -2 4
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 311 4 0 2 2.6 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
CHEMBL2432052 92544 None 0 Human Binding pKi = 5.3 5.3 -2 4
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 311 4 0 2 2.6 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
1443 2028 None 34 Human Binding pKi = 6.3 6.3 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
33625 2028 None 34 Human Binding pKi = 6.3 6.3 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
501 2028 None 34 Human Binding pKi = 6.3 6.3 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
CHEMBL279516 2028 None 34 Human Binding pKi = 6.3 6.3 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
DB08950 2028 None 34 Human Binding pKi = 6.3 6.3 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
10474335 194692 None 23 Human Binding pKi = 6.3 6.3 -16 10
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 370 6 0 3 4.8 COc1cccc2c1CCCC2CCCN1CCN(C2CCCCC2)CC1 10.1038/s41586-020-2286-9
CHEMBL53325 194692 None 23 Human Binding pKi = 6.3 6.3 -16 10
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 370 6 0 3 4.8 COc1cccc2c1CCCC2CCCN1CCN(C2CCCCC2)CC1 10.1038/s41586-020-2286-9
10626982 111495 None 0 Human Binding pKi = 6.3 6.3 -8 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 575 9 2 6 5.9 CC1=C(C#N)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL327775 111495 None 0 Human Binding pKi = 6.3 6.3 -8 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 575 9 2 6 5.9 CC1=C(C#N)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
9947861 204162 None 0 Human Binding pKi = 5.3 5.3 -8 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70634 204162 None 0 Human Binding pKi = 5.3 5.3 -8 4
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
44269013 30342 None 1 Human Binding pKi = 6.3 6.3 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 218 5 1 3 2.0 CCCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL13917 30342 None 1 Human Binding pKi = 6.3 6.3 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 218 5 1 3 2.0 CCCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
57345625 71179 None 0 Human Binding pKi = 6.3 6.3 -16 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 224 3 1 3 2.1 CC(Oc1ccccc1Cl)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956191 71179 None 0 Human Binding pKi = 6.3 6.3 -16 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 224 3 1 3 2.1 CC(Oc1ccccc1Cl)C1=NCCN1 10.1016/j.bmc.2012.01.035
45487962 197485 None 0 Human Binding pKi = 6.3 6.3 -10 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 218 4 1 3 2.1 CCCc1ccccc1COC1=NCCN1 10.1021/jm901262f
CHEMBL569933 197485 None 0 Human Binding pKi = 6.3 6.3 -10 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 218 4 1 3 2.1 CCCc1ccccc1COC1=NCCN1 10.1021/jm901262f
44312198 204589 None 0 Human Binding pKi = 4.3 4.3 -1 4
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 292 1 1 5 2.2 Brc1c(NC2=NCCO2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL73164 204589 None 0 Human Binding pKi = 4.3 4.3 -1 4
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 292 1 1 5 2.2 Brc1c(NC2=NCCO2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
44579185 181814 None 1 Human Binding pKi = 8.3 8.3 7 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL477816 181814 None 1 Human Binding pKi = 8.3 8.3 7 3
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
10362866 82299 None 0 Human Binding pKi = 8.3 8.3 114 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217203 82299 None 0 Human Binding pKi = 8.3 8.3 114 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
10070896 83196 None 0 Human Binding pKi = 8.3 8.3 281 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 422 4 1 4 6.1 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1-c1ccccc1 10.1016/j.ejmech.2010.12.026
CHEMBL218457 83196 None 0 Human Binding pKi = 8.3 8.3 281 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 422 4 1 4 6.1 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1-c1ccccc1 10.1016/j.ejmech.2010.12.026
10362866 82299 None 0 Human Binding pKi = 8.3 8.3 114 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
CHEMBL217203 82299 None 0 Human Binding pKi = 8.3 8.3 114 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
10070896 83196 None 0 Human Binding pKi = 8.3 8.3 281 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 422 4 1 4 6.1 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1-c1ccccc1 10.1021/jm060262x
CHEMBL218457 83196 None 0 Human Binding pKi = 8.3 8.3 281 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 422 4 1 4 6.1 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1-c1ccccc1 10.1021/jm060262x
441975 16451 None 56 Human Binding pKi = 8.3 8.3 1 3
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 352 1 1 4 3.2 COC(=O)C1=CO[C@@H](C)[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12 10.1021/jm00019a001
CHEMBL123325 16451 None 56 Human Binding pKi = 8.3 8.3 1 3
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 352 1 1 4 3.2 COC(=O)C1=CO[C@@H](C)[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12 10.1021/jm00019a001
124 2981 None 47 Human Binding pKi = 8.3 8.3 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
2032 2981 None 47 Human Binding pKi = 8.3 8.3 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
4636 2981 None 47 Human Binding pKi = 8.3 8.3 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
4636.0 2981 None 47 Human Binding pKi = 8.3 8.3 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
CHEMBL762 2981 None 47 Human Binding pKi = 8.3 8.3 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
DB00935 2981 None 47 Human Binding pKi = 8.3 8.3 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
102 4127 None 48 Human Binding pKi = 8.3 8.3 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
3659 4127 None 48 Human Binding pKi = 8.3 8.3 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
8969 4127 None 48 Human Binding pKi = 8.3 8.3 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
8969.0 4127 None 48 Human Binding pKi = 8.3 8.3 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
CHEMBL15245 4127 None 48 Human Binding pKi = 8.3 8.3 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
DB01392 4127 None 48 Human Binding pKi = 8.3 8.3 -2 49
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
44402531 69612 None 0 Human Binding pKi = 8.3 8.3 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 468 5 4 6 0.9 COC(=O)CNC(=O)CNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL193458 69612 None 0 Human Binding pKi = 8.3 8.3 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 468 5 4 6 0.9 COC(=O)CNC(=O)CNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
44325075 111765 None 0 Human Binding pKi = 8.3 8.3 2 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 465 8 0 8 2.7 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCC(=O)c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL328735 111765 None 0 Human Binding pKi = 8.3 8.3 2 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 465 8 0 8 2.7 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCC(=O)c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
10473701 83238 None 0 Human Binding pKi = 8.3 8.3 165 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 3 1 4 4.8 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)(C)C2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL218679 83238 None 0 Human Binding pKi = 8.3 8.3 165 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 3 1 4 4.8 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)(C)C2)cc1 10.1016/j.ejmech.2010.12.026
10473701 83238 None 0 Human Binding pKi = 8.3 8.3 165 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 3 1 4 4.8 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)(C)C2)cc1 10.1021/jm060262x
CHEMBL218679 83238 None 0 Human Binding pKi = 8.3 8.3 165 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 3 1 4 4.8 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)(C)C2)cc1 10.1021/jm060262x
134551 358 None 27 Human Binding pKi = 8.3 8.3 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
271 358 None 27 Human Binding pKi = 8.3 8.3 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
885 358 None 27 Human Binding pKi = 8.3 8.3 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
CHEMBL1403281 358 None 27 Human Binding pKi = 8.3 8.3 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
49781005 17214 None 0 Human Binding pKi = 8.2 8.2 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256503 17214 None 0 Human Binding pKi = 8.2 8.2 -3 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
10251036 81885 None 0 Human Binding pKi = 8.2 8.2 70 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 410 4 2 5 4.7 CN1CCN(c2ccc(Nc3c(CO)cnc4cc(Cl)ccc34)cc2)CC1(C)C 10.1021/jm060262x
CHEMBL216464 81885 None 0 Human Binding pKi = 8.2 8.2 70 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 410 4 2 5 4.7 CN1CCN(c2ccc(Nc3c(CO)cnc4cc(Cl)ccc34)cc2)CC1(C)C 10.1021/jm060262x
10251036 81885 None 0 Human Binding pKi = 8.2 8.2 70 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 410 4 2 5 4.7 CN1CCN(c2ccc(Nc3c(CO)cnc4cc(Cl)ccc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
CHEMBL216464 81885 None 0 Human Binding pKi = 8.2 8.2 70 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 410 4 2 5 4.7 CN1CCN(c2ccc(Nc3c(CO)cnc4cc(Cl)ccc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
10475736 165863 None 0 Human Binding pKi = 7.3 7.3 26 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 4 2 5 4.1 CN1CCN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
CHEMBL424917 165863 None 0 Human Binding pKi = 7.3 7.3 26 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 4 2 5 4.1 CN1CCN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
10475736 165863 None 0 Human Binding pKi = 7.3 7.3 26 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 4 2 5 4.1 CN1CCN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CC1(C)C 10.1021/jm060262x
CHEMBL424917 165863 None 0 Human Binding pKi = 7.3 7.3 26 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 4 2 5 4.1 CN1CCN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CC1(C)C 10.1021/jm060262x
657255 199084 None 34 Human Binding pKi = 6.3 6.3 -8 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 nan
CHEMBL588119 199084 None 34 Human Binding pKi = 6.3 6.3 -8 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 nan
16090599 81545 None 0 Human Binding pKi = 5.3 5.3 1 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCCN(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL216072 81545 None 0 Human Binding pKi = 5.3 5.3 1 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCCN(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
50878551 90745 None 61 Human Binding pKi = 6.3 6.3 -22 18
Displacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysisDisplacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysis
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2013.03.066
CHEMBL2391541 90745 None 61 Human Binding pKi = 6.3 6.3 -22 18
Displacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysisDisplacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysis
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2013.03.066
45487958 198391 None 0 Human Binding pKi = 6.3 6.3 -14 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 190 2 1 3 1.5 Cc1ccccc1COC1=NCCN1 10.1021/jm901262f
CHEMBL576819 198391 None 0 Human Binding pKi = 6.3 6.3 -14 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 190 2 1 3 1.5 Cc1ccccc1COC1=NCCN1 10.1021/jm901262f
7059292 76300 None 7 Human Binding pKi = 5.3 5.3 -5 3
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 194 1 1 2 2.9 Clc1ccccc1NC1=NCCC1 10.1016/j.bmc.2012.06.008
CHEMBL2058633 76300 None 7 Human Binding pKi = 5.3 5.3 -5 3
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 194 1 1 2 2.9 Clc1ccccc1NC1=NCCC1 10.1016/j.bmc.2012.06.008
73346332 92535 None 0 Human Binding pKi = 5.3 5.3 -2 4
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 297 3 0 2 2.6 CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
CHEMBL2432041 92535 None 0 Human Binding pKi = 5.3 5.3 -2 4
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 297 3 0 2 2.6 CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
50878551 90745 None 61 Human Binding pKi = 6.3 6.3 -22 18
Displacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysisDisplacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysis
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2013.03.066
CHEMBL2391541 90745 None 61 Human Binding pKi = 6.3 6.3 -22 18
Displacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysisDisplacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysis
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2013.03.066
10198135 205125 None 3 Human Binding pKi = 6.3 6.3 -51 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 203 3 2 3 2.5 COc1ccc(Nc2ncc[nH]2)c(C)c1 10.1021/jm9605142
CHEMBL77913 205125 None 3 Human Binding pKi = 6.3 6.3 -51 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 203 3 2 3 2.5 COc1ccc(Nc2ncc[nH]2)c(C)c1 10.1021/jm9605142
44329027 4168 None 0 Human Binding pKi = 6.3 6.3 -26 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 637 13 3 7 4.9 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COC)N1 10.1016/s0960-894x(99)00484-9
CHEMBL100045 4168 None 0 Human Binding pKi = 6.3 6.3 -26 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 637 13 3 7 4.9 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COC)N1 10.1016/s0960-894x(99)00484-9
10177445 166042 None 0 Human Binding pKi = 7.3 7.3 32 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 4 1 4 5.2 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C(C)C 10.1016/j.ejmech.2010.12.026
CHEMBL425622 166042 None 0 Human Binding pKi = 7.3 7.3 32 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 4 1 4 5.2 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C(C)C 10.1016/j.ejmech.2010.12.026
10177445 166042 None 0 Human Binding pKi = 7.3 7.3 32 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 4 1 4 5.2 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C(C)C 10.1021/jm060262x
CHEMBL425622 166042 None 0 Human Binding pKi = 7.3 7.3 32 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 4 1 4 5.2 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C(C)C 10.1021/jm060262x
44292381 101394 None 0 Human Binding pKi = 7.3 7.3 -2 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 244 2 1 3 2.7 c1ccc([C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL297228 101394 None 0 Human Binding pKi = 7.3 7.3 -2 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 244 2 1 3 2.7 c1ccc([C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
46743607 121712 None 0 Human Binding pKi = 5.3 5.3 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 264 5 2 3 2.8 c1ccc(-c2nc(CNCc3cccnc3)c[nH]2)cc1 10.1016/j.bmc.2015.01.013
CHEMBL3588905 121712 None 0 Human Binding pKi = 5.3 5.3 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 264 5 2 3 2.8 c1ccc(-c2nc(CNCc3cccnc3)c[nH]2)cc1 10.1016/j.bmc.2015.01.013
71450550 83807 None 0 Human Binding pKi = 6.3 6.3 -1 16
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53 10.1016/j.bmcl.2012.08.046
CHEMBL2205836 83807 None 0 Human Binding pKi = 6.3 6.3 -1 16
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53 10.1016/j.bmcl.2012.08.046
8032110 121710 None 14 Human Binding pKi = 6.3 6.3 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 198 3 1 2 3.0 Cc1ccccc1NCc1ccncc1 10.1016/j.bmc.2015.01.013
CHEMBL3588903 121710 None 14 Human Binding pKi = 6.3 6.3 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 198 3 1 2 3.0 Cc1ccccc1NCc1ccncc1 10.1016/j.bmc.2015.01.013
16757182 153251 None 0 Human Binding pKi = 6.3 6.3 -7 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL397753 153251 None 0 Human Binding pKi = 6.3 6.3 -7 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
16757182 153251 None 0 Human Binding pKi = 6.3 6.3 -7 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL397753 153251 None 0 Human Binding pKi = 6.3 6.3 -7 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
2726 919 None 68 Human Binding pKi = 7.3 7.3 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
2726.0 919 None 68 Human Binding pKi = 7.3 7.3 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
621 919 None 68 Human Binding pKi = 7.3 7.3 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
83 919 None 68 Human Binding pKi = 7.3 7.3 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
CHEMBL71 919 None 68 Human Binding pKi = 7.3 7.3 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
DB00477 919 None 68 Human Binding pKi = 7.3 7.3 -31 72
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
2600 3779 None 74 Human Binding pKi = 6.3 6.3 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
2608 3779 None 74 Human Binding pKi = 6.3 6.3 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
5405 3779 None 74 Human Binding pKi = 6.3 6.3 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
CHEMBL17157 3779 None 74 Human Binding pKi = 6.3 6.3 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
DB00342 3779 None 74 Human Binding pKi = 6.3 6.3 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
2765 943 None 19 Human Binding pKi = 6.3 6.3 -15 9
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
515 943 None 19 Human Binding pKi = 6.3 6.3 -15 9
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
CHEMBL13852 943 None 19 Human Binding pKi = 6.3 6.3 -15 9
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
DB09202 943 None 19 Human Binding pKi = 6.3 6.3 -15 9
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
2765 943 None 19 Human Binding pKi = 6.3 6.3 -15 9
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
515 943 None 19 Human Binding pKi = 6.3 6.3 -15 9
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
CHEMBL13852 943 None 19 Human Binding pKi = 6.3 6.3 -15 9
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
DB09202 943 None 19 Human Binding pKi = 6.3 6.3 -15 9
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
49783209 17609 None 0 Human Binding pKi = 6.3 6.3 -281 26
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 396 7 1 6 3.8 CCCCN1CCC(COC(=O)c2cc(Cl)c(NC)c3c2OCCO3)CC1 10.1021/jm100668r
CHEMBL1258223 17609 None 0 Human Binding pKi = 6.3 6.3 -281 26
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 396 7 1 6 3.8 CCCCN1CCC(COC(=O)c2cc(Cl)c(NC)c3c2OCCO3)CC1 10.1021/jm100668r
71459604 83793 None 0 Human Binding pKi = 6.3 6.3 1 14
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1 10.1016/j.bmcl.2012.08.046
CHEMBL2205811 83793 None 0 Human Binding pKi = 6.3 6.3 1 14
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1 10.1016/j.bmcl.2012.08.046
2803 955 None 58 Human Binding pKi = 7.3 7.3 -4 19
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
2803.0 955 None 58 Human Binding pKi = 7.3 7.3 -4 19
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
516 955 None 58 Human Binding pKi = 7.3 7.3 -4 19
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
704 955 None 58 Human Binding pKi = 7.3 7.3 -4 19
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
CHEMBL134 955 None 58 Human Binding pKi = 7.3 7.3 -4 19
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
DB00575 955 None 58 Human Binding pKi = 7.3 7.3 -4 19
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/0960-894X(94)85032-1
237 204865 None 48 Human Binding pKi = 6.3 6.3 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
CHEMBL546257 204865 None 48 Human Binding pKi = 6.3 6.3 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
CHEMBL554190 204865 None 48 Human Binding pKi = 6.3 6.3 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
CHEMBL7568 204865 None 48 Human Binding pKi = 6.3 6.3 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
101333429 117076 None 0 Human Binding pKi = 6.3 6.3 -1412 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1 10.1021/jm00019a001
CHEMBL3392247 117076 None 0 Human Binding pKi = 6.3 6.3 -1412 6
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1 10.1021/jm00019a001
11564613 19413 None 108 Human Binding pKi = 6.3 6.3 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2cccc(N)c2)CC1 10.1016/j.bmc.2015.01.013
CHEMBL129399 19413 None 108 Human Binding pKi = 6.3 6.3 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2cccc(N)c2)CC1 10.1016/j.bmc.2015.01.013
CHEMBL1200633 208600 None 3 Human Binding pKi = 6.2 6.2 -1 8
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL None None None CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O nan
1201549 597 None 24 Human Binding pKi = 7.2 7.2 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
1201549.0 597 None 24 Human Binding pKi = 7.2 7.2 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
333 597 None 24 Human Binding pKi = 7.2 7.2 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
7601 597 None 24 Human Binding pKi = 7.2 7.2 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
CHEMBL1201203 597 None 24 Human Binding pKi = 7.2 7.2 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
CHEMBL438151 597 None 24 Human Binding pKi = 7.2 7.2 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
DB00245 597 None 24 Human Binding pKi = 7.2 7.2 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
10531766 206997 None 0 Human Binding pKi = 6.2 6.2 -512 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 9 2 7 6.3 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
CHEMBL91415 206997 None 0 Human Binding pKi = 6.2 6.2 -512 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 9 2 7 6.3 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
12699315 76298 None 0 Human Binding pKi = 5.2 5.2 -4 3
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 243 1 2 3 2.8 CC1CNC(Nc2c(Cl)cccc2Cl)=N1 10.1016/j.bmc.2012.06.008
CHEMBL2058631 76298 None 0 Human Binding pKi = 5.2 5.2 -4 3
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 243 1 2 3 2.8 CC1CNC(Nc2c(Cl)cccc2Cl)=N1 10.1016/j.bmc.2012.06.008
CHEMBL4513786 213967 None 7 Human Binding pKi = 5.2 5.2 -1047 8
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl ADRA2C
ChEMBL None None None CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC 10.6019/CHEMBL5212743
CHEMBL4796803 213967 None 7 Human Binding pKi = 5.2 5.2 -1047 8
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl ADRA2C
ChEMBL None None None CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC 10.6019/CHEMBL5212743
124 2981 None 47 Human Binding pKi = 7.2 7.2 -60 33
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
2032 2981 None 47 Human Binding pKi = 7.2 7.2 -60 33
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
4636 2981 None 47 Human Binding pKi = 7.2 7.2 -60 33
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
4636.0 2981 None 47 Human Binding pKi = 7.2 7.2 -60 33
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
CHEMBL762 2981 None 47 Human Binding pKi = 7.2 7.2 -60 33
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
DB00935 2981 None 47 Human Binding pKi = 7.2 7.2 -60 33
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
3561 19077 None 39 Human Binding pKi = 6.2 6.2 -2 11
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
CHEMBL1289 19077 None 39 Human Binding pKi = 6.2 6.2 -2 11
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
11448533 84691 None 0 Human Binding pKi = 5.2 5.2 1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 0 3 3.6 CC(Oc1ccccc1-c1ccccc1)C1=NCCO1 10.1021/jm0408215
CHEMBL222591 84691 None 0 Human Binding pKi = 5.2 5.2 1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 0 3 3.6 CC(Oc1ccccc1-c1ccccc1)C1=NCCO1 10.1021/jm0408215
11473729 84692 None 0 Human Binding pKi = 5.2 5.2 1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 265 4 0 2 4.4 CC(Oc1ccccc1-c1ccccc1)C1=NCCC1 10.1021/jm0408215
CHEMBL222593 84692 None 0 Human Binding pKi = 5.2 5.2 1 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 265 4 0 2 4.4 CC(Oc1ccccc1-c1ccccc1)C1=NCCC1 10.1021/jm0408215
44401164 69816 None 0 Human Binding pKi = 7.2 7.2 -309 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL193639 69816 None 0 Human Binding pKi = 7.2 7.2 -309 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
49783419 17749 None 0 Human Binding pKi = 6.2 6.2 -281 12
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 366 6 1 6 2.8 CCCCN1CCC(COC(=O)c2cc(F)c(N)c3c2OCCO3)CC1 10.1021/jm100668r
CHEMBL1258671 17749 None 0 Human Binding pKi = 6.2 6.2 -281 12
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 366 6 1 6 2.8 CCCCN1CCC(COC(=O)c2cc(F)c(N)c3c2OCCO3)CC1 10.1021/jm100668r
24771824 57343 None 57 Human Binding pKi = 6.2 6.2 1 2
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL5212743
CHEMBL1651534 57343 None 57 Human Binding pKi = 6.2 6.2 1 2
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL5212743
CHEMBL4780458 214048 None 0 Human Binding pKi = 6.2 6.2 -2 4
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000540a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000540a ADRA2C
ChEMBL None None None O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1 10.6019/CHEMBL5212743
44324765 111568 None 0 Human Binding pKi = 8.2 8.2 2 5
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL328114 111568 None 0 Human Binding pKi = 8.2 8.2 2 5
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
9846548 207325 None 0 Human Binding pKi = 8.2 8.2 1 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL93489 207325 None 0 Human Binding pKi = 8.2 8.2 1 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
10474679 97177 None 0 Human Binding pKi = 8.2 8.2 288 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 4.0 CN1CCN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
CHEMBL268217 97177 None 0 Human Binding pKi = 8.2 8.2 288 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 4.0 CN1CCN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
10474679 97177 None 0 Human Binding pKi = 8.2 8.2 288 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 4.0 CN1CCN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CC1(C)C 10.1021/jm060262x
CHEMBL268217 97177 None 0 Human Binding pKi = 8.2 8.2 288 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 4.0 CN1CCN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CC1(C)C 10.1021/jm060262x
6761 67799 None 19 Human Binding pKi = 8.2 8.2 -3 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
CHEMBL1909072 67799 None 19 Human Binding pKi = 8.2 8.2 -3 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
16090596 82291 None 0 Human Binding pKi = 8.2 8.2 158 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL217177 82291 None 0 Human Binding pKi = 8.2 8.2 158 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
16090596 82291 None 0 Human Binding pKi = 8.2 8.2 158 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217177 82291 None 0 Human Binding pKi = 8.2 8.2 158 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
44568347 191651 None 0 Human Binding pKi = 6.2 6.2 -28 15
Antagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assayAntagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 356 6 0 4 5.2 CCN(CC)CCCOC(=O)N1c2ccccc2Sc2ccccc21 10.1016/j.bmcl.2013.04.082
CHEMBL519609 191651 None 0 Human Binding pKi = 6.2 6.2 -28 15
Antagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assayAntagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 356 6 0 4 5.2 CCN(CC)CCCOC(=O)N1c2ccccc2Sc2ccccc21 10.1016/j.bmcl.2013.04.082
118717248 115124 None 0 Human Binding pKi = 6.2 6.2 -18 3
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 219 1 2 3 0.5 Fc1ccc2cnn(N=C3NCCN3)c2c1 10.1016/j.ejmech.2014.09.083
CHEMBL3343699 115124 None 0 Human Binding pKi = 6.2 6.2 -18 3
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 219 1 2 3 0.5 Fc1ccc2cnn(N=C3NCCN3)c2c1 10.1016/j.ejmech.2014.09.083
11098175 204170 None 0 Human Binding pKi = 6.2 6.2 -5 5
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 251 5 2 5 1.8 COc1ccc(SC)c(NCC2=NCCN2)c1 10.1021/jm000542r
CHEMBL70691 204170 None 0 Human Binding pKi = 6.2 6.2 -5 5
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 251 5 2 5 1.8 COc1ccc(SC)c(NCC2=NCCN2)c1 10.1021/jm000542r
11034737 204528 None 0 Human Binding pKi = 6.2 6.2 -3 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 289 4 2 4 2.8 CSc1ccc(C(F)(F)F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72724 204528 None 0 Human Binding pKi = 6.2 6.2 -3 6
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 289 4 2 4 2.8 CSc1ccc(C(F)(F)F)cc1NCC1=NCCN1 10.1021/jm000542r
57345627 71182 None 0 Human Binding pKi = 6.2 6.2 -8 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 230 4 1 3 2.5 C=C(C)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956194 71182 None 0 Human Binding pKi = 6.2 6.2 -8 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 230 4 1 3 2.5 C=C(C)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
5353853 17986 None 47 Human Binding pKi = 6.2 6.2 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
9556529 17986 None 47 Human Binding pKi = 6.2 6.2 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
CHEMBL1262 17986 None 47 Human Binding pKi = 6.2 6.2 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
441383 20333 None 57 Human Binding pKi = 7.2 7.2 2 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
CHEMBL1306 20333 None 57 Human Binding pKi = 7.2 7.2 2 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
2337 3256 None 77 Human Binding pKi = 7.2 7.2 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
50 3256 None 77 Human Binding pKi = 7.2 7.2 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
5002 3256 None 77 Human Binding pKi = 7.2 7.2 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
5002.0 3256 None 77 Human Binding pKi = 7.2 7.2 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
CHEMBL716 3256 None 77 Human Binding pKi = 7.2 7.2 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
DB01224 3256 None 77 Human Binding pKi = 7.2 7.2 -10 62
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
57401787 71253 None 0 Human Binding pKi = 5.2 5.2 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 308 3 1 4 2.3 c1ccc(C2(c3ccccc3)COCC(C3=NCCN3)O2)cc1 10.1016/j.bmc.2012.02.016
CHEMBL1956906 71253 None 0 Human Binding pKi = 5.2 5.2 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 308 3 1 4 2.3 c1ccc(C2(c3ccccc3)COCC(C3=NCCN3)O2)cc1 10.1016/j.bmc.2012.02.016
56645363 121490 None 12 Human Binding pKi = 6.2 6.2 2 4
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000313b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000313b ADRA2C
ChEMBL 311 3 1 4 3.8 CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 10.6019/CHEMBL5212743
CHEMBL3582478 121490 None 12 Human Binding pKi = 6.2 6.2 2 4
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000313b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000313b ADRA2C
ChEMBL 311 3 1 4 3.8 CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 10.6019/CHEMBL5212743
1960 2857 None 67 Human Binding pKi = 7.2 7.2 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
439260 2857 None 67 Human Binding pKi = 7.2 7.2 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
439260.0 2857 None 67 Human Binding pKi = 7.2 7.2 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
505 2857 None 67 Human Binding pKi = 7.2 7.2 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
CHEMBL1437 2857 None 67 Human Binding pKi = 7.2 7.2 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
DB00368 2857 None 67 Human Binding pKi = 7.2 7.2 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
49836303 18572 None 1 Human Binding pKi = 7.2 7.2 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276220 18572 None 1 Human Binding pKi = 7.2 7.2 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
49836303 18572 None 1 Human Binding pKi = 7.2 7.2 -10 4
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276220 18572 None 1 Human Binding pKi = 7.2 7.2 -10 4
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
1265 942 None 60 Human Binding pKi = 7.2 7.2 -112 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 270 7 1 3 3.0 O=C(c1ccc(cc1)OCCCc1[nH]cnc1)C1CC1 10.1021/jm8003625
6422124 942 None 60 Human Binding pKi = 7.2 7.2 -112 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 270 7 1 3 3.0 O=C(c1ccc(cc1)OCCCc1[nH]cnc1)C1CC1 10.1021/jm8003625
CHEMBL14638 942 None 60 Human Binding pKi = 7.2 7.2 -112 8
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 270 7 1 3 3.0 O=C(c1ccc(cc1)OCCCc1[nH]cnc1)C1CC1 10.1021/jm8003625
10508016 207156 None 0 Human Binding pKi = 6.2 6.2 -17 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 613 9 2 5 7.7 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2ccccc2c1 10.1021/jm980077m
CHEMBL92322 207156 None 0 Human Binding pKi = 6.2 6.2 -17 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 613 9 2 5 7.7 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2ccccc2c1 10.1021/jm980077m
72947314 92490 None 0 Human Binding pKi = 6.2 6.2 -8 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.0 c1ccc(OCC2=NCCN2)c(CC2CC2)c1 10.1021/ml400232p
CHEMBL2431281 92490 None 0 Human Binding pKi = 6.2 6.2 -8 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.0 c1ccc(OCC2=NCCN2)c(CC2CC2)c1 10.1021/ml400232p
127036932 137348 None 0 Human Binding pKi = 6.2 6.2 -20 22
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 274 7 1 1 4.0 C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL3752900 137348 None 0 Human Binding pKi = 6.2 6.2 -20 22
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 274 7 1 1 4.0 C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12 10.1016/j.bmcl.2015.12.053
57395732 71191 None 0 Human Binding pKi = 6.2 6.2 -1 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 342 5 1 3 4.8 CC(Oc1c(-c2ccccc2)cccc1-c1ccccc1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956203 71191 None 0 Human Binding pKi = 6.2 6.2 -1 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 342 5 1 3 4.8 CC(Oc1c(-c2ccccc2)cccc1-c1ccccc1)C1=NCCN1 10.1016/j.bmc.2012.01.035
2406 100404 None 89 Human Binding pKi = 6.2 6.2 -11 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
CHEMBL290106 100404 None 89 Human Binding pKi = 6.2 6.2 -11 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
122295 9868 None 7 Human Binding pKi = 7.2 7.2 -1 9
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 10.1021/jm00018a001
CHEMBL114166 9868 None 7 Human Binding pKi = 7.2 7.2 -1 9
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 10.1021/jm00018a001
122295 9868 None 7 Human Binding pKi = 7.2 7.2 -1 9
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 10.1021/jm00019a001
CHEMBL114166 9868 None 7 Human Binding pKi = 7.2 7.2 -1 9
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 10.1021/jm00019a001
44568614 187623 None 0 Human Binding pKi = 7.2 7.2 -1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 252 4 1 3 2.8 c1ccc(OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
CHEMBL494885 187623 None 0 Human Binding pKi = 7.2 7.2 -1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 252 4 1 3 2.8 c1ccc(OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
11265631 136409 None 0 Human Binding pKi = 7.2 7.2 2 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm061487a
CHEMBL373535 136409 None 0 Human Binding pKi = 7.2 7.2 2 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm061487a
11265631 136409 None 0 Human Binding pKi = 7.2 7.2 2 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
CHEMBL373535 136409 None 0 Human Binding pKi = 7.2 7.2 2 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
24882007 12473 None 1 Human Binding pKi = 6.2 6.2 -12 3
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 201 1 2 3 0.3 c1ccc2c(c1)cnn2N=C1NCCN1 10.1016/j.ejmech.2014.09.083
CHEMBL1186220 12473 None 1 Human Binding pKi = 6.2 6.2 -12 3
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 201 1 2 3 0.3 c1ccc2c(c1)cnn2N=C1NCCN1 10.1016/j.ejmech.2014.09.083
15675860 204429 None 0 Human Binding pKi = 6.2 6.2 -8 4
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 305 1 2 5 2.1 Cc1cnc2c(Br)c(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
CHEMBL72147 204429 None 0 Human Binding pKi = 6.2 6.2 -8 4
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 305 1 2 5 2.1 Cc1cnc2c(Br)c(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
44312036 204565 None 1 Human Binding pKi = 6.2 6.2 5 4
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 305 1 2 5 2.2 CC1CN=C(Nc2ccc3nccnc3c2Br)N1 10.1016/0960-894X(95)00391-6
CHEMBL72995 204565 None 1 Human Binding pKi = 6.2 6.2 5 4
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 305 1 2 5 2.2 CC1CN=C(Nc2ccc3nccnc3c2Br)N1 10.1016/0960-894X(95)00391-6
434526 77568 None 28 Human Binding pKi = 6.2 6.2 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 194 3 1 4 1.9 NCCSc1nc2ccccc2o1 10.1016/j.bmc.2015.01.013
CHEMBL2087646 77568 None 28 Human Binding pKi = 6.2 6.2 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 194 3 1 4 1.9 NCCSc1nc2ccccc2o1 10.1016/j.bmc.2015.01.013
44421258 84746 None 0 Human Binding pKi = 5.2 5.2 -3 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL1204386 84746 None 0 Human Binding pKi = 5.2 5.2 -3 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL222933 84746 None 0 Human Binding pKi = 5.2 5.2 -3 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
1960 2857 None 67 Mouse Binding pKi = 6.2 6.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
439260 2857 None 67 Mouse Binding pKi = 6.2 6.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
439260.0 2857 None 67 Mouse Binding pKi = 6.2 6.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
505 2857 None 67 Mouse Binding pKi = 6.2 6.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
CHEMBL1437 2857 None 67 Mouse Binding pKi = 6.2 6.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
DB00368 2857 None 67 Mouse Binding pKi = 6.2 6.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
68617 205527 None 62 Human Binding pKi = 6.2 6.2 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
CHEMBL1709 205527 None 62 Human Binding pKi = 6.2 6.2 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
CHEMBL809 205527 None 62 Human Binding pKi = 6.2 6.2 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
CHEMBL4777443 214046 None 0 Human Binding pKi = 6.2 6.2 -31 14
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000741a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000741a ADRA2C
ChEMBL None None None CC(C)(C)OC(=O)N1CCCC1CN[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1 10.6019/CHEMBL5212743
44288877 168599 None 0 Human Binding pKi = 5.2 5.2 -933 5
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 549 7 1 5 4.3 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL43594 168599 None 0 Human Binding pKi = 5.2 5.2 -933 5
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 549 7 1 5 4.3 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL4516843 213970 None 0 Human Binding pKi = 6.2 6.2 - 1
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000548a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000548a ADRA2C
ChEMBL None None None NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1 10.6019/CHEMBL5212743
49781004 17213 None 0 Human Binding pKi = 7.2 7.2 -5 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@@H]1c2ccccc2[C@H]2C[C@]21c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256502 17213 None 0 Human Binding pKi = 7.2 7.2 -5 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@@H]1c2ccccc2[C@H]2C[C@]21c1c[nH]cn1 10.1021/jm1006269
10848826 188880 None 0 Human Binding pKi = 7.2 7.2 -3 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 258 3 1 3 2.8 c1ccc(C[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL50719 188880 None 0 Human Binding pKi = 7.2 7.2 -3 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 258 3 1 3 2.8 c1ccc(C[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
57345629 71185 None 0 Human Binding pKi = 6.2 6.2 -45 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1956197 71185 None 0 Human Binding pKi = 6.2 6.2 -45 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1021/ml400232p
57345629 71185 None 0 Human Binding pKi = 6.2 6.2 -45 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956197 71185 None 0 Human Binding pKi = 6.2 6.2 -45 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
24906197 187666 None 0 Human Binding pKi = 6.2 6.2 -3 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 323 7 1 5 3.0 CC(Oc1ccccc1/C=N/OCc1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL495097 187666 None 0 Human Binding pKi = 6.2 6.2 -3 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 323 7 1 5 3.0 CC(Oc1ccccc1/C=N/OCc1ccccc1)C1=NCCN1 10.1021/jm800250z
44401042 124829 None 0 Human Binding pKi = 6.2 6.2 -181 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.6 CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL364270 124829 None 0 Human Binding pKi = 6.2 6.2 -181 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.6 CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL179334 63303 None 0 Human Binding pKi = 6.2 6.2 -3715 6
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 6.4 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@H]1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
36381 12942 None 5 Human Binding pKi = 6.2 6.2 -1 6
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 265 2 1 2 1.9 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1 10.1016/j.bmcl.2012.08.046
CHEMBL1189234 12942 None 5 Human Binding pKi = 6.2 6.2 -1 6
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 265 2 1 2 1.9 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1 10.1016/j.bmcl.2012.08.046
36381 12942 None 5 Human Binding pKi = 6.2 6.2 -1 6
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 265 2 1 2 1.9 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1 10.1016/j.bmc.2013.07.045
CHEMBL1189234 12942 None 5 Human Binding pKi = 6.2 6.2 -1 6
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 265 2 1 2 1.9 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1 10.1016/j.bmc.2013.07.045
73355415 92533 None 0 Human Binding pKi = 6.2 6.2 -3 13
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 277 3 1 1 2.1 C1C2C3CC4C2C2C1C3[C@H](NCC13C5C6C7C5C1C7C63)C42 10.1016/j.bmc.2013.07.045
CHEMBL2432039 92533 None 0 Human Binding pKi = 6.2 6.2 -3 13
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 277 3 1 1 2.1 C1C2C3CC4C2C2C1C3[C@H](NCC13C5C6C7C5C1C7C63)C42 10.1016/j.bmc.2013.07.045
9839050 112379 None 0 Human Binding pKi = 7.2 7.2 -144 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 293 2 0 2 3.8 CN(C)C[C@H]1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1 10.1021/jm049632c
CHEMBL329566 112379 None 0 Human Binding pKi = 7.2 7.2 -144 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 293 2 0 2 3.8 CN(C)C[C@H]1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1 10.1021/jm049632c
1593 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
30668 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
30668.0 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
9868 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
CHEMBL17860 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
DB04948 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
9923679 81762 None 0 Human Binding pKi = 6.2 6.2 -1 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 332 3 1 4 4.0 Cc1cc(Nc2ccc(N3CCN(C)CC3)cc2)c2ccccc2n1 10.1021/jm060262x
CHEMBL216399 81762 None 0 Human Binding pKi = 6.2 6.2 -1 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 332 3 1 4 4.0 Cc1cc(Nc2ccc(N3CCN(C)CC3)cc2)c2ccccc2n1 10.1021/jm060262x
9923679 81762 None 0 Human Binding pKi = 6.2 6.2 -1 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 332 3 1 4 4.0 Cc1cc(Nc2ccc(N3CCN(C)CC3)cc2)c2ccccc2n1 10.1016/j.ejmech.2010.12.026
CHEMBL216399 81762 None 0 Human Binding pKi = 6.2 6.2 -1 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 332 3 1 4 4.0 Cc1cc(Nc2ccc(N3CCN(C)CC3)cc2)c2ccccc2n1 10.1016/j.ejmech.2010.12.026
11058166 204705 None 0 Human Binding pKi = 6.2 6.2 -1 5
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1cccc(F)c1NCC1=NCCN1 10.1021/jm000542r
CHEMBL74114 204705 None 0 Human Binding pKi = 6.2 6.2 -1 5
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1cccc(F)c1NCC1=NCCN1 10.1021/jm000542r
24906241 192817 None 0 Human Binding pKi = 6.2 6.2 -2 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
CHEMBL522151 192817 None 0 Human Binding pKi = 6.2 6.2 -2 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
71457691 83799 None 0 Human Binding pKi = 6.2 6.2 -2 10
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1ccccc1CN1C2C3C4CC5C6C4C2C6C1(O)C53 10.1016/j.bmcl.2012.08.046
CHEMBL2205823 83799 None 0 Human Binding pKi = 6.2 6.2 -2 10
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1ccccc1CN1C2C3C4CC5C6C4C2C6C1(O)C53 10.1016/j.bmcl.2012.08.046
10045088 80588 None 0 Human Binding pKi = 8.1 8.1 407 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 3.9 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1CO 10.1016/j.ejmech.2010.12.026
CHEMBL214996 80588 None 0 Human Binding pKi = 8.1 8.1 407 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 3.9 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1CO 10.1016/j.ejmech.2010.12.026
10045088 80588 None 0 Human Binding pKi = 8.1 8.1 407 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 3.9 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1CO 10.1021/jm060262x
CHEMBL214996 80588 None 0 Human Binding pKi = 8.1 8.1 407 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 3.9 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1CO 10.1021/jm060262x
16090623 82454 None 0 Human Binding pKi = 8.1 8.1 77 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217567 82454 None 0 Human Binding pKi = 8.1 8.1 77 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
16090623 82454 None 0 Human Binding pKi = 8.1 8.1 77 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
CHEMBL217567 82454 None 0 Human Binding pKi = 8.1 8.1 77 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
129211 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
129211.0 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
2562 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
488 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
CHEMBL836 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
DB00706 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
49836301 18567 None 1 Human Binding pKi = 7.2 7.2 -1 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml400232p
CHEMBL1276140 18567 None 1 Human Binding pKi = 7.2 7.2 -1 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml400232p
44269006 32353 None 1 Human Binding pKi = 7.2 7.2 -1 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 5 1 3 1.8 C=CCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL14107 32353 None 1 Human Binding pKi = 7.2 7.2 -1 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 5 1 3 1.8 C=CCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
49836301 18567 None 1 Human Binding pKi = 7.2 7.2 -1 4
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/jm100977d
CHEMBL1276140 18567 None 1 Human Binding pKi = 7.2 7.2 -1 4
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/jm100977d
49836301 18567 None 1 Human Binding pKi = 7.2 7.2 -1 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml300064v
CHEMBL1276140 18567 None 1 Human Binding pKi = 7.2 7.2 -1 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml300064v
11140033 20683 None 0 Human Binding pKi = 6.2 6.2 -7 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 265 4 2 3 3.2 CC(Nc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL130884 20683 None 0 Human Binding pKi = 6.2 6.2 -7 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 265 4 2 3 3.2 CC(Nc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
11199593 137199 None 0 Human Binding pKi = 6.2 6.2 -2 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 1 3 3.8 CC(Sc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL374954 137199 None 0 Human Binding pKi = 6.2 6.2 -2 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 1 3 3.8 CC(Sc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
5318 15576 None 49 Human Binding pKi = 6.1 6.1 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
CHEMBL1200348 15576 None 49 Human Binding pKi = 6.1 6.1 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
CHEMBL1221 15576 None 49 Human Binding pKi = 6.1 6.1 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
44424855 85454 None 0 Human Binding pKi = 7.1 7.1 1 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
CHEMBL226636 85454 None 0 Human Binding pKi = 7.1 7.1 1 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
13178306 121709 None 2 Human Binding pKi = 7.1 7.1 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 187 3 2 2 2.3 Cc1ccccc1NCc1cnc[nH]1 10.1016/j.bmc.2015.01.013
CHEMBL3588902 121709 None 2 Human Binding pKi = 7.1 7.1 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 187 3 2 2 2.3 Cc1ccccc1NCc1cnc[nH]1 10.1016/j.bmc.2015.01.013
11360447 85001 None 0 Human Binding pKi = 7.1 7.1 -4 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1cccs1)C1=NCCN1 10.1021/jm0408215
CHEMBL223829 85001 None 0 Human Binding pKi = 7.1 7.1 -4 3
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1cccs1)C1=NCCN1 10.1021/jm0408215
10651080 105942 None 0 Human Binding pKi = 6.1 6.1 -83 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 592 9 3 6 4.7 CC1=C(C(N)=O)C(c2ccc3c(c2)OCO3)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL312871 105942 None 0 Human Binding pKi = 6.1 6.1 -83 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 592 9 3 6 4.7 CC1=C(C(N)=O)C(c2ccc3c(c2)OCO3)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
46743614 121713 None 0 Human Binding pKi = 5.1 5.1 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 317 4 1 3 2.7 CCNCC(=O)N1CCn2cccc2C1c1cccc(Cl)c1 10.1016/j.bmc.2015.01.013
CHEMBL3588906 121713 None 0 Human Binding pKi = 5.1 5.1 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 317 4 1 3 2.7 CCNCC(=O)N1CCn2cccc2C1c1cccc(Cl)c1 10.1016/j.bmc.2015.01.013
44401164 69816 None 0 Human Binding pKi = 7.1 7.1 -309 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL193639 69816 None 0 Human Binding pKi = 7.1 7.1 -309 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL508338 188966 None 0 Human Binding pKi = 6.1 6.1 -25 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL None None None None nan
490 191 None 8 Human Binding pKi = 7.1 7.1 -371 12
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 462 6 1 7 3.2 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1ccccc1 10.1016/s0960-894x(01)00159-7
9890547 191 None 8 Human Binding pKi = 7.1 7.1 -371 12
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 462 6 1 7 3.2 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1ccccc1 10.1016/s0960-894x(01)00159-7
CHEMBL268758 191 None 8 Human Binding pKi = 7.1 7.1 -371 12
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 462 6 1 7 3.2 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1ccccc1 10.1016/s0960-894x(01)00159-7
57395731 71190 None 0 Human Binding pKi = 5.1 5.1 -7 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 232 4 1 4 1.7 CC(=O)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956202 71190 None 0 Human Binding pKi = 5.1 5.1 -7 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 232 4 1 4 1.7 CC(=O)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
57403508 71252 None 0 Human Binding pKi = 5.1 5.1 -2 2
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 308 3 1 4 2.3 c1ccc(C2(c3ccccc3)COC(C3=NCCN3)CO2)cc1 10.1016/j.bmc.2012.02.016
CHEMBL1956905 71252 None 0 Human Binding pKi = 5.1 5.1 -2 2
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 308 3 1 4 2.3 c1ccc(C2(c3ccccc3)COC(C3=NCCN3)CO2)cc1 10.1016/j.bmc.2012.02.016
44401105 69576 None 0 Human Binding pKi = 6.1 6.1 -83 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 373 2 0 3 4.7 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Br)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL193435 69576 None 0 Human Binding pKi = 6.1 6.1 -83 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 373 2 0 3 4.7 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Br)cc3[C@H]2O1 10.1021/jm049632c
57399145 71184 None 0 Human Binding pKi = 6.1 6.1 -7 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 234 5 1 4 1.9 CCOc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956196 71184 None 0 Human Binding pKi = 6.1 6.1 -7 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 234 5 1 4 1.9 CCOc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
31101 729 None 40 Human Binding pKi = 7.1 7.1 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
31101.0 729 None 40 Human Binding pKi = 7.1 7.1 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
35 729 None 40 Human Binding pKi = 7.1 7.1 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
403 729 None 40 Human Binding pKi = 7.1 7.1 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
CHEMBL493 729 None 40 Human Binding pKi = 7.1 7.1 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
DB01200 729 None 40 Human Binding pKi = 7.1 7.1 -36 36
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
16090624 82401 None 0 Human Binding pKi = 7.1 7.1 13 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
CHEMBL217278 82401 None 0 Human Binding pKi = 7.1 7.1 13 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
16090624 82401 None 0 Human Binding pKi = 7.1 7.1 13 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
CHEMBL217278 82401 None 0 Human Binding pKi = 7.1 7.1 13 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
1836 2592 None 59 Human Binding pKi = 6.1 6.1 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
3340 2592 None 59 Human Binding pKi = 6.1 6.1 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
5281040 2592 None 59 Human Binding pKi = 6.1 6.1 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
5281040.0 2592 None 59 Human Binding pKi = 6.1 6.1 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
CHEMBL787 2592 None 59 Human Binding pKi = 6.1 6.1 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
DB00471 2592 None 59 Human Binding pKi = 6.1 6.1 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
16090634 82294 None 0 Human Binding pKi = 6.1 6.1 4 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 296 3 1 4 3.2 Cc1cncc(C)c1Nc1ccc(N2CCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL217180 82294 None 0 Human Binding pKi = 6.1 6.1 4 2
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 296 3 1 4 3.2 Cc1cncc(C)c1Nc1ccc(N2CCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
135398745 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
135398745.0 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
47 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
CHEMBL715 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
DB00334 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
25053351 173005 None 0 Human Binding pKi = 7.1 7.1 -371 4
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 455 4 1 3 5.0 CN[C@@H](C(=O)N(C)[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]24CN(C)[C@@H](C)[C@H]2CC[C@@H]34)C1)C(C)C 10.1021/jm8003625
CHEMBL451821 173005 None 0 Human Binding pKi = 7.1 7.1 -371 4
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 455 4 1 3 5.0 CN[C@@H](C(=O)N(C)[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]24CN(C)[C@@H](C)[C@H]2CC[C@@H]34)C1)C(C)C 10.1021/jm8003625
23622576 172772 None 0 Human Binding pKi = 7.1 7.1 -1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 3 3.5 CC(Oc1ccccc1C1CCCCC1)C1=NCCN1 10.1021/jm800250z
CHEMBL451229 172772 None 0 Human Binding pKi = 7.1 7.1 -1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 3 3.5 CC(Oc1ccccc1C1CCCCC1)C1=NCCN1 10.1021/jm800250z
73213195 104459 None 0 Human Binding pKi = 6.1 6.1 -26 12
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.6 CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104092 104459 None 0 Human Binding pKi = 6.1 6.1 -26 12
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.6 CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1 10.1016/j.bmcl.2013.12.024
16090599 81545 None 0 Human Binding pKi = 6.1 6.1 1 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCCN(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL216072 81545 None 0 Human Binding pKi = 6.1 6.1 1 2
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCCN(C)C3)cc2)c1C 10.1021/jm060262x
10579368 106004 None 0 Human Binding pKi = 6.1 6.1 -3 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 9 3 6 5.3 CC1=C(C(=O)O)C(c2ccc3c(c2)OCO3)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL313251 106004 None 0 Human Binding pKi = 6.1 6.1 -3 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 9 3 6 5.3 CC1=C(C(=O)O)C(c2ccc3c(c2)OCO3)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
73213195 104459 None 0 Human Binding pKi = 6.1 6.1 -26 12
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.6 CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104092 104459 None 0 Human Binding pKi = 6.1 6.1 -26 12
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.6 CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1 10.1016/j.bmcl.2013.12.024
3584 3777 None 64 Human Binding pKi = 7.1 7.1 -50 13
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
5401 3777 None 64 Human Binding pKi = 7.1 7.1 -50 13
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
5401.0 3777 None 64 Human Binding pKi = 7.1 7.1 -50 13
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
7302 3777 None 64 Human Binding pKi = 7.1 7.1 -50 13
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
CHEMBL611 3777 None 64 Human Binding pKi = 7.1 7.1 -50 13
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
DB01162 3777 None 64 Human Binding pKi = 7.1 7.1 -50 13
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
44401106 124327 None 0 Human Binding pKi = 7.1 7.1 -120 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL363581 124327 None 0 Human Binding pKi = 7.1 7.1 -120 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
44549156 18570 None 0 Human Binding pKi = 7.1 7.1 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276218 18570 None 0 Human Binding pKi = 7.1 7.1 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
45487956 198367 None 0 Human Binding pKi = 7.1 7.1 -3 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 230 3 1 3 2.6 CC(OC1=NCCN1)c1ccccc1C1CC1 10.1021/jm901262f
CHEMBL576623 198367 None 0 Human Binding pKi = 7.1 7.1 -3 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 230 3 1 3 2.6 CC(OC1=NCCN1)c1ccccc1C1CC1 10.1021/jm901262f
44549156 18570 None 0 Human Binding pKi = 7.1 7.1 -10 4
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276218 18570 None 0 Human Binding pKi = 7.1 7.1 -10 4
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
44292385 101121 None 0 Human Binding pKi = 7.1 7.1 -5 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 270 3 1 3 2.6 c1ccc(C[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL295186 101121 None 0 Human Binding pKi = 7.1 7.1 -5 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 270 3 1 3 2.6 c1ccc(C[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
11080 29085 None 79 Human Binding pKi = 5.1 5.1 -3 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 185 1 0 2 3.6 S=C=Nc1cccc2ccccc12 nan
CHEMBL1381098 29085 None 79 Human Binding pKi = 5.1 5.1 -3 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 185 1 0 2 3.6 S=C=Nc1cccc2ccccc12 nan
72947315 92489 None 0 Human Binding pKi = 6.1 6.1 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 232 5 1 4 1.6 c1ccc(OC2CC2)c(OCC2=NCCN2)c1 10.1021/ml400232p
CHEMBL2431280 92489 None 0 Human Binding pKi = 6.1 6.1 -10 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 232 5 1 4 1.6 c1ccc(OC2CC2)c(OCC2=NCCN2)c1 10.1021/ml400232p
127026052 137553 None 0 Human Binding pKi = 6.1 6.1 -47 19
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 258 7 1 1 3.5 C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL3754496 137553 None 0 Human Binding pKi = 6.1 6.1 -47 19
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 258 7 1 1 3.5 C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12 10.1016/j.bmcl.2015.12.053
44456400 12834 None 0 Human Binding pKi = 6.1 6.1 -3 10
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
CHEMBL1188501 12834 None 0 Human Binding pKi = 6.1 6.1 -3 10
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
CHEMBL2436555 12834 None 0 Human Binding pKi = 6.1 6.1 -3 10
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
CHEMBL536539 12834 None 0 Human Binding pKi = 6.1 6.1 -3 10
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
11750482 147421 None 0 Human Binding pKi = 8.1 8.1 19 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 419 6 0 6 5.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccco4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL392991 147421 None 0 Human Binding pKi = 8.1 8.1 19 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 419 6 0 6 5.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccco4)cc13)CC2 10.1016/j.bmcl.2006.12.094
44402579 132754 None 0 Human Binding pKi = 8.1 8.1 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 411 3 3 5 1.8 COC(=O)CNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL370005 132754 None 0 Human Binding pKi = 8.1 8.1 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 411 3 3 5 1.8 COC(=O)CNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
10318507 58953 None 0 Human Binding pKi = 8.1 8.1 104 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 3 1 4 5.4 Cc1nc2cc(Cl)ccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL1689423 58953 None 0 Human Binding pKi = 8.1 8.1 104 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 3 1 4 5.4 Cc1nc2cc(Cl)ccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
16090595 141401 None 0 Human Binding pKi = 8.1 8.1 109 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
CHEMBL383978 141401 None 0 Human Binding pKi = 8.1 8.1 109 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
10318507 58953 None 0 Human Binding pKi = 8.1 8.1 104 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 3 1 4 5.4 Cc1nc2cc(Cl)ccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL1689423 58953 None 0 Human Binding pKi = 8.1 8.1 104 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 3 1 4 5.4 Cc1nc2cc(Cl)ccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
16090595 141401 None 0 Human Binding pKi = 8.1 8.1 109 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
CHEMBL383978 141401 None 0 Human Binding pKi = 8.1 8.1 109 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
136019934 144530 None 0 Human Binding pKi = 8.1 8.1 7 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
CHEMBL390718 144530 None 0 Human Binding pKi = 8.1 8.1 7 3
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
2142 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
4920903 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
502 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
5775 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
5775.0 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
CHEMBL597 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
DB00692 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
16090622 82298 None 0 Human Binding pKi = 8.1 8.1 165 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 346 3 1 4 4.4 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)C2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL217202 82298 None 0 Human Binding pKi = 8.1 8.1 165 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 346 3 1 4 4.4 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)C2)cc1 10.1016/j.ejmech.2010.12.026
16090628 141787 None 0 Human Binding pKi = 8.1 8.1 309 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 4 1 4 5.3 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(N2CCCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL386169 141787 None 0 Human Binding pKi = 8.1 8.1 309 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 4 1 4 5.3 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(N2CCCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
16090622 82298 None 0 Human Binding pKi = 8.1 8.1 165 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 346 3 1 4 4.4 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)C2)cc1 10.1021/jm060262x
CHEMBL217202 82298 None 0 Human Binding pKi = 8.1 8.1 165 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 346 3 1 4 4.4 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)C2)cc1 10.1021/jm060262x
16090628 141787 None 0 Human Binding pKi = 8.1 8.1 309 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 4 1 4 5.3 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(N2CCCN(C)CC2)cc1 10.1021/jm060262x
CHEMBL386169 141787 None 0 Human Binding pKi = 8.1 8.1 309 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 4 1 4 5.3 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(N2CCCN(C)CC2)cc1 10.1021/jm060262x
44402477 133749 None 0 Human Binding pKi = 8.1 8.1 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 718 6 6 6 4.6 O=C(NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)[C@@H]1[C@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@H]21 10.1016/j.bmcl.2005.03.116
CHEMBL371516 133749 None 0 Human Binding pKi = 8.1 8.1 - 1
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 718 6 6 6 4.6 O=C(NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)[C@@H]1[C@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@H]21 10.1016/j.bmcl.2005.03.116
180 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
200 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
2160 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
2160.0 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
CHEMBL629 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
DB00321 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
9837551 101624 None 0 Human Binding pKi = 8.1 8.1 -7 3
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 232 1 3 5 1.2 Cc1c(NC2=NCCN2)ccc2c1NCCO2 10.1021/jm960359r
CHEMBL298936 101624 None 0 Human Binding pKi = 8.1 8.1 -7 3
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 232 1 3 5 1.2 Cc1c(NC2=NCCN2)ccc2c1NCCO2 10.1021/jm960359r
16090601 82392 None 0 Human Binding pKi = 8.1 8.1 199 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 3.9 Cc1c(CO)nc2ccccc2c1Nc1ccc(N2CCN(C)[C@H](C)C2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL217254 82392 None 0 Human Binding pKi = 8.1 8.1 199 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 3.9 Cc1c(CO)nc2ccccc2c1Nc1ccc(N2CCN(C)[C@H](C)C2)cc1 10.1016/j.ejmech.2010.12.026
10065083 32103 None 1 Human Binding pKi = 7.1 7.1 -12 10
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 328 6 0 5 2.4 O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1 10.1016/j.bmc.2011.12.019
CHEMBL140872 32103 None 1 Human Binding pKi = 7.1 7.1 -12 10
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 328 6 0 5 2.4 O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1 10.1016/j.bmc.2011.12.019
2142 3096 None 58 Human Binding pKi = 7.1 7.1 -7 36
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
4920903 3096 None 58 Human Binding pKi = 7.1 7.1 -7 36
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
502 3096 None 58 Human Binding pKi = 7.1 7.1 -7 36
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
5775 3096 None 58 Human Binding pKi = 7.1 7.1 -7 36
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
5775.0 3096 None 58 Human Binding pKi = 7.1 7.1 -7 36
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
CHEMBL597 3096 None 58 Human Binding pKi = 7.1 7.1 -7 36
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
DB00692 3096 None 58 Human Binding pKi = 7.1 7.1 -7 36
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
9828476 206924 None 0 Human Binding pKi = 7.1 7.1 -354 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 532 9 2 7 5.2 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL91022 206924 None 0 Human Binding pKi = 7.1 7.1 -354 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 532 9 2 7 5.2 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
5280953 97362 None 109 Human Binding pKi = 6.1 6.1 1 8
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 212 1 1 2 3.0 COc1ccc2c(c1)[nH]c1c(C)nccc12 10.1016/j.bmcl.2003.09.027
CHEMBL269538 97362 None 109 Human Binding pKi = 6.1 6.1 1 8
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 212 1 1 2 3.0 COc1ccc2c(c1)[nH]c1c(C)nccc12 10.1016/j.bmcl.2003.09.027
10508132 107017 None 0 Human Binding pKi = 6.1 6.1 -13 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 621 10 2 6 5.5 CC1=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)N(C)C)=C(C)N1 10.1021/jm980077m
CHEMBL315392 107017 None 0 Human Binding pKi = 6.1 6.1 -13 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 621 10 2 6 5.5 CC1=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)N(C)C)=C(C)N1 10.1021/jm980077m
491 192 None 9 Human Binding pKi = 7.1 7.1 -512 12
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 476 6 1 7 3.6 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1cccc(c1)C 10.1016/s0960-894x(01)00159-7
9891167 192 None 9 Human Binding pKi = 7.1 7.1 -512 12
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 476 6 1 7 3.6 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1cccc(c1)C 10.1016/s0960-894x(01)00159-7
CHEMBL13856 192 None 9 Human Binding pKi = 7.1 7.1 -512 12
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 476 6 1 7 3.6 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1cccc(c1)C 10.1016/s0960-894x(01)00159-7
16090627 81567 None 0 Human Binding pKi = 7.1 7.1 10 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 9 2 4 5.9 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(NCCN(CC)CC)cc1 10.1021/jm060262x
CHEMBL216197 81567 None 0 Human Binding pKi = 7.1 7.1 10 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 9 2 4 5.9 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(NCCN(CC)CC)cc1 10.1021/jm060262x
135398745 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
135398745.0 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
47 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
CHEMBL715 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
DB00334 2914 None 112 Human Binding pKi = 7.1 7.1 -30 65
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
16090627 81567 None 0 Human Binding pKi = 7.1 7.1 10 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 9 2 4 5.9 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(NCCN(CC)CC)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL216197 81567 None 0 Human Binding pKi = 7.1 7.1 10 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 9 2 4 5.9 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(NCCN(CC)CC)cc1 10.1016/j.ejmech.2010.12.026
2435 722 None 100 Human Binding pKi = 7.1 7.1 -33 12
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
2435.0 722 None 100 Human Binding pKi = 7.1 7.1 -33 12
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
395 722 None 100 Human Binding pKi = 7.1 7.1 -33 12
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
520 722 None 100 Human Binding pKi = 7.1 7.1 -33 12
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
5386 722 None 100 Human Binding pKi = 7.1 7.1 -33 12
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
CHEMBL844 722 None 100 Human Binding pKi = 7.1 7.1 -33 12
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
DB00484 722 None 100 Human Binding pKi = 7.1 7.1 -33 12
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
1242 3613 None 27 Human Binding pKi = 7.1 7.1 -4 18
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
935 3613 None 27 Human Binding pKi = 7.1 7.1 -4 18
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL286080 3613 None 27 Human Binding pKi = 7.1 7.1 -4 18
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
16090594 82125 None 0 Human Binding pKi = 7.1 7.1 10 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
CHEMBL216674 82125 None 0 Human Binding pKi = 7.1 7.1 10 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
24841480 183899 None 0 Human Binding pKi = 6.1 6.1 -416 20
Antagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assayAntagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 340 3 0 4 4.5 O=C(OCCN1CCCC1)N1c2ccccc2Sc2ccccc21 10.1016/j.bmcl.2013.04.082
CHEMBL481153 183899 None 0 Human Binding pKi = 6.1 6.1 -416 20
Antagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assayAntagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 340 3 0 4 4.5 O=C(OCCN1CCCC1)N1c2ccccc2Sc2ccccc21 10.1016/j.bmcl.2013.04.082
57402717 71187 None 2 Human Binding pKi = 6.1 6.1 -14 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 220 4 1 4 1.5 COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956199 71187 None 2 Human Binding pKi = 6.1 6.1 -14 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 220 4 1 4 1.5 COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
24906201 187353 None 0 Human Binding pKi = 6.1 6.1 -1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
CHEMBL493272 187353 None 0 Human Binding pKi = 6.1 6.1 -1 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
4657799 121714 None 3 Human Binding pKi = 5.1 5.1 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 254 5 1 2 2.7 NCCCN(C(=O)c1ccccc1)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL3588907 121714 None 3 Human Binding pKi = 5.1 5.1 - 1
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 254 5 1 2 2.7 NCCCN(C(=O)c1ccccc1)c1ccccc1 10.1016/j.bmc.2015.01.013
16090594 82125 None 0 Human Binding pKi = 7.1 7.1 10 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
CHEMBL216674 82125 None 0 Human Binding pKi = 7.1 7.1 10 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
44456400 12834 None 0 Human Binding pKi = 6.1 6.1 -3 10
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
CHEMBL1188501 12834 None 0 Human Binding pKi = 6.1 6.1 -3 10
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
CHEMBL2436555 12834 None 0 Human Binding pKi = 6.1 6.1 -3 10
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
CHEMBL536539 12834 None 0 Human Binding pKi = 6.1 6.1 -3 10
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
24906198 187664 None 3 Human Binding pKi = 7.1 7.1 -3 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
CHEMBL495095 187664 None 3 Human Binding pKi = 7.1 7.1 -3 4
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
44314200 102952 None 0 Human Binding pKi = 7.1 7.1 -3 4
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 230 1 1 3 2.4 c1ccc2c(c1)CCCC2NC1=NCCCO1 10.1016/0960-894X(94)85032-1
CHEMBL306377 102952 None 0 Human Binding pKi = 7.1 7.1 -3 4
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 230 1 1 3 2.4 c1ccc2c(c1)CCCC2NC1=NCCCO1 10.1016/0960-894X(94)85032-1
24906198 187664 None 3 Human Binding pKi = 7.1 7.1 -3 4
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL495095 187664 None 3 Human Binding pKi = 7.1 7.1 -3 4
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
45487145 197659 None 0 Human Binding pKi = 7.1 7.1 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 230 4 1 3 2.5 C=CCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL570973 197659 None 0 Human Binding pKi = 7.1 7.1 -1 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 230 4 1 3 2.5 C=CCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
24906198 187664 None 3 Human Binding pKi = 7.1 7.1 -3 4
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm100977d
CHEMBL495095 187664 None 3 Human Binding pKi = 7.1 7.1 -3 4
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm100977d
24906198 187664 None 3 Human Binding pKi = 7.1 7.1 -3 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml300064v
CHEMBL495095 187664 None 3 Human Binding pKi = 7.1 7.1 -3 4
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml300064v
44292386 101482 None 0 Human Binding pKi = 7.1 7.1 -5 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 296 4 1 3 3.5 C(=C/c1ccccc1)\C[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL297827 101482 None 0 Human Binding pKi = 7.1 7.1 -5 3
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 296 4 1 3 3.5 C(=C/c1ccccc1)\C[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
57339144 92238 None 78 Human Binding pKi = 6.1 6.1 -11 6
Selectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2CSelectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2C
ChEMBL 529 6 1 5 4.8 O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1 10.6019/CHEMBL5212743
CHEMBL2426364 92238 None 78 Human Binding pKi = 6.1 6.1 -11 6
Selectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2CSelectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2C
ChEMBL 529 6 1 5 4.8 O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1 10.6019/CHEMBL5212743
199798 74706 None 9 Human Binding pKi = 6.1 6.1 3 2
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 167 2 0 1 2.7 C1CCC(CN2CCCC2)CC1 10.1016/j.bmcl.2012.04.077
CHEMBL2030634 74706 None 9 Human Binding pKi = 6.1 6.1 3 2
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 167 2 0 1 2.7 C1CCC(CN2CCCC2)CC1 10.1016/j.bmcl.2012.04.077
73349361 92548 None 0 Human Binding pKi = 6.1 6.1 1 7
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 279 4 0 1 3.3 CN(CCc1ccccc1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
CHEMBL2432058 92548 None 0 Human Binding pKi = 6.1 6.1 1 7
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 279 4 0 1 3.3 CN(CCc1ccccc1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
16090625 82430 None 0 Human Binding pKi = 7.1 7.1 7 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1nc2cccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL217452 82430 None 0 Human Binding pKi = 7.1 7.1 7 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1nc2cccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
16090625 82430 None 0 Human Binding pKi = 7.1 7.1 7 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1nc2cccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217452 82430 None 0 Human Binding pKi = 7.1 7.1 7 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1nc2cccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
10674896 206644 None 0 Human Binding pKi = 6.1 6.1 -478 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 588 9 2 6 6.4 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C#N)cc1 10.1021/jm980077m
CHEMBL89243 206644 None 0 Human Binding pKi = 6.1 6.1 -478 6
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 588 9 2 6 6.4 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C#N)cc1 10.1021/jm980077m
57402718 71189 None 2 Human Binding pKi = 5.1 5.1 -8 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 4 1 4 1.3 CC(Oc1ccccc1C=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956201 71189 None 2 Human Binding pKi = 5.1 5.1 -8 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 4 1 4 1.3 CC(Oc1ccccc1C=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
3584 3777 None 64 Human Binding pKi = 6.1 6.1 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
5401 3777 None 64 Human Binding pKi = 6.1 6.1 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
5401.0 3777 None 64 Human Binding pKi = 6.1 6.1 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
7302 3777 None 64 Human Binding pKi = 6.1 6.1 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
CHEMBL611 3777 None 64 Human Binding pKi = 6.1 6.1 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
DB01162 3777 None 64 Human Binding pKi = 6.1 6.1 -50 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
9795515 204820 None 0 Human Binding pKi = 7.1 7.1 -17 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 273 3 2 3 4.1 COc1c(C(C)(C)C)cc(C)c(Nc2ncc[nH]2)c1C 10.1021/jm9605142
CHEMBL75257 204820 None 0 Human Binding pKi = 7.1 7.1 -17 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 273 3 2 3 4.1 COc1c(C(C)(C)C)cc(C)c(Nc2ncc[nH]2)c1C 10.1021/jm9605142
10632290 204746 None 5 Human Binding pKi = 5.1 5.1 -2 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 211 2 2 4 2.1 c1c[nH]c(Nc2ccc3nccnc3c2)n1 10.1021/jm9605142
CHEMBL74449 204746 None 5 Human Binding pKi = 5.1 5.1 -2 3
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 211 2 2 4 2.1 c1c[nH]c(Nc2ccc3nccnc3c2)n1 10.1021/jm9605142
44328920 108641 None 0 Human Binding pKi = 6.1 6.1 -77 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 705 14 3 7 5.9 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCC(F)(F)F)N1 10.1016/s0960-894x(99)00484-9
CHEMBL320736 108641 None 0 Human Binding pKi = 6.1 6.1 -77 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 705 14 3 7 5.9 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCC(F)(F)F)N1 10.1016/s0960-894x(99)00484-9
44324900 206898 None 0 Human Binding pKi = 7.1 7.1 2 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 423 6 0 7 2.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL90843 206898 None 0 Human Binding pKi = 7.1 7.1 2 3
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 423 6 0 7 2.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44325028 206971 None 0 Human Binding pKi = 7.1 7.1 2 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cccc5ccccc45)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL91297 206971 None 0 Human Binding pKi = 7.1 7.1 2 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cccc5ccccc45)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44325079 207185 None 0 Human Binding pKi = 7.1 7.1 2 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 437 7 0 7 2.7 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL92496 207185 None 0 Human Binding pKi = 7.1 7.1 2 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 437 7 0 7 2.7 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44324860 207498 None 0 Human Binding pKi = 7.1 7.1 1 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 479 6 0 8 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cc5ccccc5s4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL94435 207498 None 0 Human Binding pKi = 7.1 7.1 1 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 479 6 0 8 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cc5ccccc5s4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
49781008 17250 None 0 Human Binding pKi = 7.1 7.1 -7 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 254 3 1 2 3.3 CC(C)O[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256608 17250 None 0 Human Binding pKi = 7.1 7.1 -7 4
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 254 3 1 2 3.3 CC(C)O[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
24839550 137315 None 14 Human Binding pKi = 6.1 6.1 -14 15
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 240 7 1 1 3.4 C=CCN(CC=C)CCc1c[nH]c2ccccc12 10.1016/j.bmcl.2015.12.053
CHEMBL3752576 137315 None 14 Human Binding pKi = 6.1 6.1 -14 15
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 240 7 1 1 3.4 C=CCN(CC=C)CCc1c[nH]c2ccccc12 10.1016/j.bmcl.2015.12.053
16090601 82392 None 0 Human Binding pKi = 8.1 8.1 199 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 3.9 Cc1c(CO)nc2ccccc2c1Nc1ccc(N2CCN(C)[C@H](C)C2)cc1 10.1021/jm060262x
CHEMBL217254 82392 None 0 Human Binding pKi = 8.1 8.1 199 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 3.9 Cc1c(CO)nc2ccccc2c1Nc1ccc(N2CCN(C)[C@H](C)C2)cc1 10.1021/jm060262x
44579303 186772 None 0 Human Binding pKi = 8.0 8.0 - 1
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL488974 186772 None 0 Human Binding pKi = 8.0 8.0 - 1
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
16090602 82448 None 0 Human Binding pKi = 8.0 8.0 239 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 362 4 2 5 3.6 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1C 10.1021/jm060262x
CHEMBL217542 82448 None 0 Human Binding pKi = 8.0 8.0 239 3
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 362 4 2 5 3.6 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1C 10.1021/jm060262x
16090602 82448 None 0 Human Binding pKi = 8.0 8.0 239 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 362 4 2 5 3.6 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
CHEMBL217542 82448 None 0 Human Binding pKi = 8.0 8.0 239 3
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 362 4 2 5 3.6 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
2803 955 None 58 Human Binding pKi = 8.0 8.0 -4 19
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/j.bmc.2012.06.008
2803.0 955 None 58 Human Binding pKi = 8.0 8.0 -4 19
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/j.bmc.2012.06.008
516 955 None 58 Human Binding pKi = 8.0 8.0 -4 19
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/j.bmc.2012.06.008
704 955 None 58 Human Binding pKi = 8.0 8.0 -4 19
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/j.bmc.2012.06.008
CHEMBL134 955 None 58 Human Binding pKi = 8.0 8.0 -4 19
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/j.bmc.2012.06.008
DB00575 955 None 58 Human Binding pKi = 8.0 8.0 -4 19
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 10.1016/j.bmc.2012.06.008
44438161 147141 None 0 Human Binding pKi = 8.0 8.0 22 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 543 10 1 7 5.0 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4cccc(C(=O)NCCN(C)C)c4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL392771 147141 None 0 Human Binding pKi = 8.0 8.0 22 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 543 10 1 7 5.0 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4cccc(C(=O)NCCN(C)C)c4)cc13)CC2 10.1016/j.bmcl.2006.12.094
44438165 166784 None 0 Human Binding pKi = 8.0 8.0 48 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 467 9 1 7 3.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCCN(C)C)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL428407 166784 None 0 Human Binding pKi = 8.0 8.0 48 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 467 9 1 7 3.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCCN(C)C)cc13)CC2 10.1016/j.bmcl.2006.12.094
44330571 163999 None 0 Human Binding pKi = 8.0 8.0 2 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C\c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL420830 163999 None 0 Human Binding pKi = 8.0 8.0 2 2
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C\c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330571 163999 None 0 Human Binding pKi = 8.0 8.0 2 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C\c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL420830 163999 None 0 Human Binding pKi = 8.0 8.0 2 2
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C\c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44324737 207238 None 0 Human Binding pKi = 8.0 8.0 2 5
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL92860 207238 None 0 Human Binding pKi = 8.0 8.0 2 5
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44438148 93490 None 0 Human Binding pKi = 8.0 8.0 14 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 430 6 0 6 5.1 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccn4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL246229 93490 None 0 Human Binding pKi = 8.0 8.0 14 3
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 430 6 0 6 5.1 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccn4)cc13)CC2 10.1016/j.bmcl.2006.12.094
11465618 102398 None 23 Human Binding pKi = 8.0 8.0 -36 19
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 354 2 0 2 4.9 CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C 10.1016/j.bmcl.2022.128879
CHEMBL3039528 102398 None 23 Human Binding pKi = 8.0 8.0 -36 19
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 354 2 0 2 4.9 CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C 10.1016/j.bmcl.2022.128879
CHEMBL5191141 102398 None 23 Human Binding pKi = 8.0 8.0 -36 19
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 354 2 0 2 4.9 CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C 10.1016/j.bmcl.2022.128879
9809007 172564 None 8 Human Binding pKi = 6.0 6.0 -724 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
CHEMBL448620 172564 None 8 Human Binding pKi = 6.0 6.0 -724 6
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
24906159 187405 None 12 Human Binding pKi = 6.0 6.0 -3 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 233 4 2 5 1.3 CC(Oc1ccccc1/C=N/O)C1=NCCN1 10.1021/jm800250z
CHEMBL493675 187405 None 12 Human Binding pKi = 6.0 6.0 -3 3
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 233 4 2 5 1.3 CC(Oc1ccccc1/C=N/O)C1=NCCN1 10.1021/jm800250z
11186523 127511 None 0 Human Binding pKi = 7.0 7.0 -66 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1C[C@@H]2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL366164 127511 None 0 Human Binding pKi = 7.0 7.0 -66 9
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1C[C@@H]2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
1343 1889 None 62 Human Binding pKi = 6.0 6.0 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
3519 1889 None 62 Human Binding pKi = 6.0 6.0 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
3519.0 1889 None 62 Human Binding pKi = 6.0 6.0 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
522 1889 None 62 Human Binding pKi = 6.0 6.0 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
CHEMBL862 1889 None 62 Human Binding pKi = 6.0 6.0 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
DB01018 1889 None 62 Human Binding pKi = 6.0 6.0 -251 9
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
4209 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
4893 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
4893.0 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
503 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
5385 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
CHEMBL2 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
DB00457 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
9906978 42711 None 2 Human Binding pKi = 7.0 7.0 -1 12
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 361 6 1 3 4.0 O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
CHEMBL150161 42711 None 2 Human Binding pKi = 7.0 7.0 -1 12
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 361 6 1 3 4.0 O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
4209 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
4893 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
4893.0 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
503 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
5385 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
CHEMBL2 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
DB00457 3163 None 75 Human Binding pKi = 7.0 7.0 -181 33
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
1547484 940 None 74 Human Binding pKi = 7.0 7.0 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
1547484.0 940 None 74 Human Binding pKi = 7.0 7.0 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
654 940 None 74 Human Binding pKi = 7.0 7.0 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
9072 940 None 74 Human Binding pKi = 7.0 7.0 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
CHEMBL43064 940 None 74 Human Binding pKi = 7.0 7.0 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
DB00568 940 None 74 Human Binding pKi = 7.0 7.0 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
CHEMBL4520788 213975 None 10 Human Binding pKi = 7.0 7.0 -4 25
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000743a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000743a ADRA2C
ChEMBL None None None CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1 10.6019/CHEMBL5212743
5280805 85405 None 81 Human Binding pKi = 5.0 5.0 -29 3
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O 10.1021/np1000329
CHEMBL226335 85405 None 81 Human Binding pKi = 5.0 5.0 -29 3
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O 10.1021/np1000329
4407909 192866 None 1 Human Binding pKi = 6.0 6.0 -16 10
Binding affinity to alpha2c (unknown origin) assessed as inhibition constantBinding affinity to alpha2c (unknown origin) assessed as inhibition constant
ChEMBL 356 4 2 4 3.6 COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC 10.1021/acsmedchemlett.1c00694
CHEMBL5182943 192866 None 1 Human Binding pKi = 6.0 6.0 -16 10
Binding affinity to alpha2c (unknown origin) assessed as inhibition constantBinding affinity to alpha2c (unknown origin) assessed as inhibition constant
ChEMBL 356 4 2 4 3.6 COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC 10.1021/acsmedchemlett.1c00694
CHEMBL5221893 192866 None 1 Human Binding pKi = 6.0 6.0 -16 10
Binding affinity to alpha2c (unknown origin) assessed as inhibition constantBinding affinity to alpha2c (unknown origin) assessed as inhibition constant
ChEMBL 356 4 2 4 3.6 COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC 10.1021/acsmedchemlett.1c00694
57395663 71181 None 0 Human Binding pKi = 6.0 6.0 -5 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.5 CC(Oc1ccccc1C(F)(F)F)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956193 71181 None 0 Human Binding pKi = 6.0 6.0 -5 3
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.5 CC(Oc1ccccc1C(F)(F)F)C1=NCCN1 10.1016/j.bmc.2012.01.035
11043720 92172 None 0 Human Binding pKi = 6.0 6.0 -5 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL242265 92172 None 0 Human Binding pKi = 6.0 6.0 -5 3
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
11043720 92172 None 0 Human Binding pKi = 6.0 6.0 -5 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL242265 92172 None 0 Human Binding pKi = 6.0 6.0 -5 3
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
49783415 17678 None 0 Human Binding pKi = 6 6.0 -416 12
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 320 7 1 5 2.9 CCCCN1CCC(COC(=O)c2ccc(N)c(OC)c2)CC1 10.1021/jm100668r
CHEMBL1258452 17678 None 0 Human Binding pKi = 6 6.0 -416 12
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 320 7 1 5 2.9 CCCCN1CCC(COC(=O)c2ccc(N)c(OC)c2)CC1 10.1021/jm100668r
73355418 92546 None 0 Human Binding pKi = 6 6.0 1 3
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 5 0 3 3.3 COc1ccc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc1OC 10.1016/j.bmc.2013.07.045
CHEMBL2432056 92546 None 0 Human Binding pKi = 6 6.0 1 3
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 5 0 3 3.3 COc1ccc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc1OC 10.1016/j.bmc.2013.07.045
3952 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646.0 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5443 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5702063 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5702063.0 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL1331786 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL420 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
DB00629 1888 None 38 Human Binding pKd = 6.4 6.4 -19 12
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
108094 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
108094 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7908642
108094 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 8819505
526 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
526 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7908642
526 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 8819505
528 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
528 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7908642
528 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 8819505
CHEMBL10332 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
CHEMBL10332 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7908642
CHEMBL10332 3423 None 27 Human Binding pKd = 8.7 8.7 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 8819505
136 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
136 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
136 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 8819505
223 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
223 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
223 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 8819505
643606 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
643606 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
643606 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 8819505
CHEMBL10347 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
CHEMBL10347 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
CHEMBL10347 3292 None 32 Human Binding pKd = 9.5 9.5 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 8819505
None 216028 3H-RAUWOLSCINE 0 Human Binding pKi = 10.5 10.5 8 3
NoneNone
PDSP KiDatabase 339 0 0 3 3.3 CN1CCC2(CCN3CCC4=C(C3C2)OC5=CC=CC=C45)N(C1=O)C None
138107169 215952 3H-RAUWOLSCINE 0 Human Binding pKi = 10.4 10.4 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
22831402 215952 3H-RAUWOLSCINE 0 Human Binding pKi = 10.4 10.4 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
138107169 215952 3H-RAUWOLSCINE 0 North American opossum Binding pKi = 10.1 10.1 -3 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
22831402 215952 3H-RAUWOLSCINE 0 North American opossum Binding pKi = 10.1 10.1 -3 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
138107169 215952 3H-RAUWOLSCINE 0 Human Binding pKi = 9.9 9.9 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
22831402 215952 3H-RAUWOLSCINE 0 Human Binding pKi = 9.9 9.9 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
5268 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.9 9.9 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
53 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.9 9.9 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
CHEMBL300555 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.9 9.9 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
138107169 215952 3H-RAUWOLSCINE 0 Human Binding pKi = 9.9 9.9 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
22831402 215952 3H-RAUWOLSCINE 0 Human Binding pKi = 9.9 9.9 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
None 216029 3H-RAUWOLSCINE 0 Human Binding pKi = 9.9 9.9 2 3
NoneNone
PDSP KiDatabase 953 28 10 12 0.9 CCOC1=CC=C(C=C1)CC(C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)C)C(=O)NC(CC(=O)N)C(=O)NC(C=S)C(=O)NC(CCCCN)C(=O)N)NC(=O)CC3(CCCCC3)S None
102 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969.0 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
102 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969.0 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.7 9.7 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL1196898 216030 3H-RAUWOLSCINE 0 Human Binding pKi = 9.6 9.6 -1 3
NoneNone
PDSP KiDatabase 248 3 1 5 1.2 CCOC1(COC2=CC=CC=C2O1)C3=NCCN3 None
102 4127 3H-RX821002 48 Human Binding pKi = 9.6 9.6 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 4127 3H-RX821002 48 Human Binding pKi = 9.6 9.6 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 4127 3H-RX821002 48 Human Binding pKi = 9.6 9.6 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969.0 4127 3H-RX821002 48 Human Binding pKi = 9.6 9.6 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 4127 3H-RX821002 48 Human Binding pKi = 9.6 9.6 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 4127 3H-RX821002 48 Human Binding pKi = 9.6 9.6 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
5268 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.6 9.6 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
53 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.6 9.6 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
CHEMBL300555 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.6 9.6 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
None 215958 3H-RAUWOLSCINE 0 Human Binding pKi = 9.6 9.6 -4 19
NoneNone
PDSP KiDatabase 421 9 1 6 4.3 COC1=C(C(=CC=C1)OC)OCCNCC2C(OC3=CC=CC=C3O2)C4=CC=CC=C4 None
102 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.5 9.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.5 9.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.5 9.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969.0 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.5 9.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.5 9.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 4127 3H-RAUWOLSCINE 48 Human Binding pKi = 9.5 9.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
164512323 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 9.5 9.5 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
6419959 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 9.5 9.5 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
5268 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.4 9.4 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
53 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.4 9.4 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
CHEMBL300555 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.4 9.4 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
102 4127 3H-RAUWOLSCINE 48 North American opossum Binding pKi = 9.4 9.4 2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 4127 3H-RAUWOLSCINE 48 North American opossum Binding pKi = 9.4 9.4 2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 4127 3H-RAUWOLSCINE 48 North American opossum Binding pKi = 9.4 9.4 2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969.0 4127 3H-RAUWOLSCINE 48 North American opossum Binding pKi = 9.4 9.4 2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 4127 3H-RAUWOLSCINE 48 North American opossum Binding pKi = 9.4 9.4 2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 4127 3H-RAUWOLSCINE 48 North American opossum Binding pKi = 9.4 9.4 2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
None 215958 3H-RAUWOLSCINE 0 Human Binding pKi = 9.4 9.4 -4 19
NoneNone
PDSP KiDatabase 421 9 1 6 4.3 COC1=C(C(=CC=C1)OC)OCCNCC2C(OC3=CC=CC=C3O2)C4=CC=CC=C4 None
12576 514 3H-RAUWOLSCINE 94 Human Binding pKi = 9.3 9.3 -2 6
NoneNone
PDSP KiDatabase 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 None
71310 514 3H-RAUWOLSCINE 94 Human Binding pKi = 9.3 9.3 -2 6
NoneNone
PDSP KiDatabase 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 None
CHEMBL353972 514 3H-RAUWOLSCINE 94 Human Binding pKi = 9.3 9.3 -2 6
NoneNone
PDSP KiDatabase 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 None
DB11481 514 3H-RAUWOLSCINE 94 Human Binding pKi = 9.3 9.3 -2 6
NoneNone
PDSP KiDatabase 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 None
None 215961 3H-RAUWOLSCINE 0 Human Binding pKi = 9.3 9.3 1 5
NoneNone
PDSP KiDatabase 295 5 2 3 3.0 C1CC2=CC=CC=C2C(=O)C1CNCCC3=CC=C(C=C3)O None
138107169 215952 35S-GTPGammaS 0 Human Binding pKi = 9.3 9.3 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
22831402 215952 35S-GTPGammaS 0 Human Binding pKi = 9.3 9.3 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
12575 1988 3H-RAUWOLSCINE 30 Human Binding pKi = 9.3 9.3 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
54459 1988 3H-RAUWOLSCINE 30 Human Binding pKi = 9.3 9.3 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
54459.0 1988 3H-RAUWOLSCINE 30 Human Binding pKi = 9.3 9.3 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
CHEMBL10316 1988 3H-RAUWOLSCINE 30 Human Binding pKi = 9.3 9.3 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
DB12551 1988 3H-RAUWOLSCINE 30 Human Binding pKi = 9.3 9.3 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
None 216032 3H-RAUWOLSCINE 0 Human Binding pKi = 9.3 9.3 9 3
NoneNone
PDSP KiDatabase 401 6 1 5 0.6 CS(=O)(=O)NCCN(C1CCN2CCC3=CC=CC=C3C2C1)S(=O)(=O)C None
5268 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.2 9.2 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
53 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.2 9.2 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
CHEMBL300555 3656 3H-RAUWOLSCINE 40 Human Binding pKi = 9.2 9.2 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
5268 3656 3H-RAUWOLSCINE 40 North American opossum Binding pKi = 9.2 9.2 -2 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
53 3656 3H-RAUWOLSCINE 40 North American opossum Binding pKi = 9.2 9.2 -2 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
CHEMBL300555 3656 3H-RAUWOLSCINE 40 North American opossum Binding pKi = 9.2 9.2 -2 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
None 215958 3H-RAUWOLSCINE 0 Human Binding pKi = 9.1 9.1 -4 19
NoneNone
PDSP KiDatabase 421 9 1 6 4.3 COC1=C(C(=CC=C1)OC)OCCNCC2C(OC3=CC=CC=C3O2)C4=CC=CC=C4 None
2601 3780 3H-RX821002 33 Human Binding pKi = 9.1 9.1 -2 21
NoneNone
PDSP KiDatabase 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
443951 3780 3H-RX821002 33 Human Binding pKi = 9.1 9.1 -2 21
NoneNone
PDSP KiDatabase 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
56 3780 3H-RX821002 33 Human Binding pKi = 9.1 9.1 -2 21
NoneNone
PDSP KiDatabase 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
CHEMBL73151 3780 3H-RX821002 33 Human Binding pKi = 9.1 9.1 -2 21
NoneNone
PDSP KiDatabase 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
DB13399 3780 3H-RX821002 33 Human Binding pKi = 9.1 9.1 -2 21
NoneNone
PDSP KiDatabase 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
138107169 215952 3H-MK912 0 Human Binding pKi = 9.1 9.1 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
22831402 215952 3H-MK912 0 Human Binding pKi = 9.1 9.1 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
108094 3423 35S-GTPGammaS 27 Human Binding pKi = 9.1 9.1 -2 4
NoneNone
PDSP KiDatabase 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 None
526 3423 35S-GTPGammaS 27 Human Binding pKi = 9.1 9.1 -2 4
NoneNone
PDSP KiDatabase 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 None
528 3423 35S-GTPGammaS 27 Human Binding pKi = 9.1 9.1 -2 4
NoneNone
PDSP KiDatabase 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 None
CHEMBL10332 3423 35S-GTPGammaS 27 Human Binding pKi = 9.1 9.1 -2 4
NoneNone
PDSP KiDatabase 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 None
44438167 148970 UNDEFINED 0 Human Binding pKi = 9.1 9.1 52 3
NoneNone
PDSP KiDatabase 505 7 1 7 3.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NC4CN5CCC4CC5)cc13)CC2 None
CHEMBL394218 148970 UNDEFINED 0 Human Binding pKi = 9.1 9.1 52 3
NoneNone
PDSP KiDatabase 505 7 1 7 3.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NC4CN5CCC4CC5)cc13)CC2 None
None 215959 3H-RAUWOLSCINE 0 Human Binding pKi = 9.1 9.1 2 6
NoneNone
PDSP KiDatabase 358 4 0 3 2.8 CCCS(=O)(=O)N(C)C1CCN2CCC3=CC=CC=C3C2C1.Cl None
5268 3656 3H-MK912 40 Human Binding pKi = 9.0 9.0 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
53 3656 3H-MK912 40 Human Binding pKi = 9.0 9.0 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
CHEMBL300555 3656 3H-MK912 40 Human Binding pKi = 9.0 9.0 -1 18
NoneNone
PDSP KiDatabase 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 None
164512323 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 9.0 9.0 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
6419959 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 9.0 9.0 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
2389 3331 3H-CLONIDINE 118 Human Binding pKi = 8.9 8.9 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073 3331 3H-CLONIDINE 118 Human Binding pKi = 8.9 8.9 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073.0 3331 3H-CLONIDINE 118 Human Binding pKi = 8.9 8.9 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
96 3331 3H-CLONIDINE 118 Human Binding pKi = 8.9 8.9 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
CHEMBL85 3331 3H-CLONIDINE 118 Human Binding pKi = 8.9 8.9 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
DB00734 3331 3H-CLONIDINE 118 Human Binding pKi = 8.9 8.9 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
6040 216033 3H-RAUWOLSCINE 0 Human Binding pKi = 8.9 8.9 1 3
NoneNone
PDSP KiDatabase 233 2 0 3 2.3 C1CCN(CC1)CC2COC3=CC=CC=C3O2 None
41 1659 3H-RX821002 0 Human Binding pKi = 8.8 8.8 -1 17
NoneNone
PDSP KiDatabase 195 0 1 3 0.9 Fc1cccc2c1O[C@H]1CNC[C@@H]1O2 None
72036 1659 3H-RX821002 0 Human Binding pKi = 8.8 8.8 -1 17
NoneNone
PDSP KiDatabase 195 0 1 3 0.9 Fc1cccc2c1O[C@H]1CNC[C@@H]1O2 None
CHEMBL1765294 1659 3H-RX821002 0 Human Binding pKi = 8.8 8.8 -1 17
NoneNone
PDSP KiDatabase 195 0 1 3 0.9 Fc1cccc2c1O[C@H]1CNC[C@@H]1O2 None
None 215958 3H-RAUWOLSCINE 0 North American opossum Binding pKi = 8.8 8.8 -10 19
NoneNone
PDSP KiDatabase 421 9 1 6 4.3 COC1=C(C(=CC=C1)OC)OCCNCC2C(OC3=CC=CC=C3O2)C4=CC=CC=C4 None
164512323 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 8.8 8.8 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
6419959 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 8.8 8.8 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
219050 3373 3H-RX821002 25 Human Binding pKi = 8.8 8.8 -10 21
NoneNone
PDSP KiDatabase 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 None
52 3373 3H-RX821002 25 Human Binding pKi = 8.8 8.8 -10 21
NoneNone
PDSP KiDatabase 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 None
CHEMBL431367 3373 3H-RX821002 25 Human Binding pKi = 8.8 8.8 -10 21
NoneNone
PDSP KiDatabase 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 None
108094 3423 3H-MK912 27 Human Binding pKi = 8.8 8.8 -2 4
NoneNone
PDSP KiDatabase 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 None
526 3423 3H-MK912 27 Human Binding pKi = 8.8 8.8 -2 4
NoneNone
PDSP KiDatabase 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 None
528 3423 3H-MK912 27 Human Binding pKi = 8.8 8.8 -2 4
NoneNone
PDSP KiDatabase 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 None
CHEMBL10332 3423 3H-MK912 27 Human Binding pKi = 8.8 8.8 -2 4
NoneNone
PDSP KiDatabase 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 None
None 216707 UNDEFINED 0 Human Binding pKi = 8.7 8.7 -1 3
NoneNone
PDSP KiDatabase 390 1 2 4 3.1 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl None
102 4127 3H-RX821002 48 Rat Binding pKi = 8.0 8.0 -26 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 4127 3H-RX821002 48 Rat Binding pKi = 8.0 8.0 -26 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 4127 3H-RX821002 48 Rat Binding pKi = 8.0 8.0 -26 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969.0 4127 3H-RX821002 48 Rat Binding pKi = 8.0 8.0 -26 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 4127 3H-RX821002 48 Rat Binding pKi = 8.0 8.0 -26 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 4127 3H-RX821002 48 Rat Binding pKi = 8.0 8.0 -26 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
4209 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 8.0 8.0 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 8.0 8.0 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893.0 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 8.0 8.0 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
503 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 8.0 8.0 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
5385 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 8.0 8.0 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
CHEMBL2 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 8.0 8.0 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
DB00457 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 8.0 8.0 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
165193 215945 3H-RAUWOLSCINE 0 Human Binding pKi = 6 6.0 -4265 30
NoneNone
PDSP KiDatabase 259 6 2 3 2.6 CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O None
4946.0 215945 3H-RAUWOLSCINE 0 Human Binding pKi = 6 6.0 -4265 30
NoneNone
PDSP KiDatabase 259 6 2 3 2.6 CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O None
62882 215945 3H-RAUWOLSCINE 0 Human Binding pKi = 6 6.0 -4265 30
NoneNone
PDSP KiDatabase 259 6 2 3 2.6 CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O None
66366 215945 3H-RAUWOLSCINE 0 Human Binding pKi = 6 6.0 -4265 30
NoneNone
PDSP KiDatabase 259 6 2 3 2.6 CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O None
CHEMBL27 215945 3H-RAUWOLSCINE 0 Human Binding pKi = 6 6.0 -4265 30
NoneNone
PDSP KiDatabase 259 6 2 3 2.6 CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O None
DB00571 215945 3H-RAUWOLSCINE 0 Human Binding pKi = 6 6.0 -4265 30
NoneNone
PDSP KiDatabase 259 6 2 3 2.6 CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O None
119570 3159 3H-RX821002 96 Human Binding pKi = 5 5.0 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
119570.0 3159 3H-RX821002 96 Human Binding pKi = 5 5.0 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
2233 3159 3H-RX821002 96 Human Binding pKi = 5 5.0 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
953 3159 3H-RX821002 96 Human Binding pKi = 5 5.0 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
CHEMBL301265 3159 3H-RX821002 96 Human Binding pKi = 5 5.0 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
DB00413 3159 3H-RX821002 96 Human Binding pKi = 5 5.0 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
243 3202 3H-RAUWOLSCINE 91 Human Binding pKi = 5 5.0 -1096 34
NoneNone
PDSP KiDatabase 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N None
3052762 3202 3H-RAUWOLSCINE 91 Human Binding pKi = 5 5.0 -1096 34
NoneNone
PDSP KiDatabase 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N None
3052762.0 3202 3H-RAUWOLSCINE 91 Human Binding pKi = 5 5.0 -1096 34
NoneNone
PDSP KiDatabase 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N None
3502 3202 3H-RAUWOLSCINE 91 Human Binding pKi = 5 5.0 -1096 34
NoneNone
PDSP KiDatabase 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N None
CHEMBL117287 3202 3H-RAUWOLSCINE 91 Human Binding pKi = 5 5.0 -1096 34
NoneNone
PDSP KiDatabase 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N None
DB06480 3202 3H-RAUWOLSCINE 91 Human Binding pKi = 5 5.0 -1096 34
NoneNone
PDSP KiDatabase 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N None
2 3261 3H-RX821002 23 Human Binding pKi = 5 5.0 -2089 29
NoneNone
PDSP KiDatabase 219 2 1 2 2.0 CCCN1CCC[C@H]2[C@H]1Cc1cn[nH]c1C2 None
54562 3261 3H-RX821002 23 Human Binding pKi = 5 5.0 -2089 29
NoneNone
PDSP KiDatabase 219 2 1 2 2.0 CCCN1CCC[C@H]2[C@H]1Cc1cn[nH]c1C2 None
CHEMBL240773 3261 3H-RX821002 23 Human Binding pKi = 5 5.0 -2089 29
NoneNone
PDSP KiDatabase 219 2 1 2 2.0 CCCN1CCC[C@H]2[C@H]1Cc1cn[nH]c1C2 None
523 4106 35S-GTPGammaS 93 Human Binding pKi = 5 5.0 -2 5
NoneNone
PDSP KiDatabase 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C None
5707 4106 35S-GTPGammaS 93 Human Binding pKi = 5 5.0 -2 5
NoneNone
PDSP KiDatabase 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C None
CHEMBL297362 4106 35S-GTPGammaS 93 Human Binding pKi = 5 5.0 -2 5
NoneNone
PDSP KiDatabase 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C None
DB11477 4106 35S-GTPGammaS 93 Human Binding pKi = 5 5.0 -2 5
NoneNone
PDSP KiDatabase 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C None
2662 11384 3H-CLONIDINE 131 Human Binding pKi = 5 5.0 -41 30
NoneNone
PDSP KiDatabase 381 3 1 4 3.5 Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1 None
CHEMBL118 11384 3H-CLONIDINE 131 Human Binding pKi = 5 5.0 -41 30
NoneNone
PDSP KiDatabase 381 3 1 4 3.5 Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1 None
5090 15561 3H-CLONIDINE 106 Human Binding pKi = 5 5.0 -1348 30
NoneNone
PDSP KiDatabase 314 3 0 4 2.6 CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1 None
CHEMBL122 15561 3H-CLONIDINE 106 Human Binding pKi = 5 5.0 -1348 30
NoneNone
PDSP KiDatabase 314 3 0 4 2.6 CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1 None
156391 46800 3H-CLONIDINE 99 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 230 3 1 2 3.0 COc1ccc2cc([C@H](C)C(=O)O)ccc2c1 None
CHEMBL1200806 46800 3H-CLONIDINE 99 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 230 3 1 2 3.0 COc1ccc2cc([C@H](C)C(=O)O)ccc2c1 None
CHEMBL154 46800 3H-CLONIDINE 99 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 230 3 1 2 3.0 COc1ccc2cc([C@H](C)C(=O)O)ccc2c1 None
44603087 67792 UNDEFINED 0 Human Binding pKi = 5 5.0 -2951 6
NoneNone
PDSP KiDatabase 527 5 1 6 4.2 COc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccccc2I)cc1 None
CHEMBL1079079 67792 UNDEFINED 0 Human Binding pKi = 5 5.0 -2951 6
NoneNone
PDSP KiDatabase 527 5 1 6 4.2 COc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccccc2I)cc1 None
CHEMBL1908985 67792 UNDEFINED 0 Human Binding pKi = 5 5.0 -2951 6
NoneNone
PDSP KiDatabase 527 5 1 6 4.2 COc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccccc2I)cc1 None
10624 70300 125I-Clonidine 19 Human Binding pKi = 5 5.0 -776 33
NoneNone
PDSP KiDatabase 284 5 3 3 1.7 CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12 None
10624.0 70300 125I-Clonidine 19 Human Binding pKi = 5 5.0 -776 33
NoneNone
PDSP KiDatabase 284 5 3 3 1.7 CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12 None
138543650 70300 125I-Clonidine 19 Human Binding pKi = 5 5.0 -776 33
NoneNone
PDSP KiDatabase 284 5 3 3 1.7 CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12 None
CHEMBL194378 70300 125I-Clonidine 19 Human Binding pKi = 5 5.0 -776 33
NoneNone
PDSP KiDatabase 284 5 3 3 1.7 CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12 None
DB11664 70300 125I-Clonidine 19 Human Binding pKi = 5 5.0 -776 33
NoneNone
PDSP KiDatabase 284 5 3 3 1.7 CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12 None
2244 94233 3H-CLONIDINE 100 Human Binding pKi = 5 5.0 -1 27
NoneNone
PDSP KiDatabase 180 2 1 3 1.3 CC(=O)Oc1ccccc1C(=O)O None
CHEMBL25 94233 3H-CLONIDINE 100 Human Binding pKi = 5 5.0 -1 27
NoneNone
PDSP KiDatabase 180 2 1 3 1.3 CC(=O)Oc1ccccc1C(=O)O None
3663 99967 3H-CLONIDINE 83 Human Binding pKi = 5 5.0 -288 29
NoneNone
PDSP KiDatabase 504 0 6 8 5.1 Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65 None
CHEMBL286494 99967 3H-CLONIDINE 83 Human Binding pKi = 5 5.0 -288 29
NoneNone
PDSP KiDatabase 504 0 6 8 5.1 Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65 None
446220 133521 3H-CLONIDINE 14 Human Binding pKi = 5 5.0 -1778 45
NoneNone
PDSP KiDatabase 303 3 0 5 1.9 COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C None
CHEMBL370805 133521 3H-CLONIDINE 14 Human Binding pKi = 5 5.0 -1778 45
NoneNone
PDSP KiDatabase 303 3 0 5 1.9 COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C None
5280343 188275 3H-CLONIDINE 124 Human Binding pKi = 5 5.0 -147 32
NoneNone
PDSP KiDatabase 302 1 5 7 2.0 O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12 None
CHEMBL1520590 188275 3H-CLONIDINE 124 Human Binding pKi = 5 5.0 -147 32
NoneNone
PDSP KiDatabase 302 1 5 7 2.0 O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12 None
CHEMBL50 188275 3H-CLONIDINE 124 Human Binding pKi = 5 5.0 -147 32
NoneNone
PDSP KiDatabase 302 1 5 7 2.0 O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12 None
3672 192533 3H-CLONIDINE 136 Human Binding pKi = 5 5.0 -1 27
NoneNone
PDSP KiDatabase 206 4 1 1 3.1 CC(C)Cc1ccc(C(C)C(=O)O)cc1 None
CHEMBL521 192533 3H-CLONIDINE 136 Human Binding pKi = 5 5.0 -1 27
NoneNone
PDSP KiDatabase 206 4 1 1 3.1 CC(C)Cc1ccc(C(C)C(=O)O)cc1 None
54676228 193615 3H-CLONIDINE 112 Human Binding pKi = 5 5.0 -1 27
NoneNone
PDSP KiDatabase 331 2 2 5 1.6 CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O None
CHEMBL527 193615 3H-CLONIDINE 112 Human Binding pKi = 5 5.0 -1 27
NoneNone
PDSP KiDatabase 331 2 2 5 1.6 CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O None
4495 196535 3H-CLONIDINE 92 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 308 5 1 5 2.8 CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1 None
CHEMBL56367 196535 3H-CLONIDINE 92 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 308 5 1 5 2.8 CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1 None
54677470 200551 3H-CLONIDINE 115 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 351 2 2 6 2.0 Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1 None
CHEMBL1256873 200551 3H-CLONIDINE 115 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 351 2 2 6 2.0 Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1 None
CHEMBL599 200551 3H-CLONIDINE 115 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 351 2 2 6 2.0 Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1 None
5281600 203025 3H-CLONIDINE 92 Human Binding pKi = 5 5.0 -275 33
NoneNone
PDSP KiDatabase 538 3 6 10 5.1 O=c1cc(-c2ccc(O)c(-c3c(O)cc(O)c4c(=O)cc(-c5ccc(O)cc5)oc34)c2)oc2cc(O)cc(O)c12 None
CHEMBL63354 203025 3H-CLONIDINE 92 Human Binding pKi = 5 5.0 -275 33
NoneNone
PDSP KiDatabase 538 3 6 10 5.1 O=c1cc(-c2ccc(O)c(-c3c(O)cc(O)c4c(=O)cc(-c5ccc(O)cc5)oc34)c2)oc2cc(O)cc(O)c12 None
4054 205501 125I-Clonidine 72 Human Binding pKi = 5 5.0 -1 36
NoneNone
PDSP KiDatabase 179 0 1 1 2.7 CC12CC3CC(C)(C1)CC(N)(C3)C2 None
CHEMBL1699 205501 125I-Clonidine 72 Human Binding pKi = 5 5.0 -1 36
NoneNone
PDSP KiDatabase 179 0 1 1 2.7 CC12CC3CC(C)(C1)CC(N)(C3)C2 None
CHEMBL807 205501 125I-Clonidine 72 Human Binding pKi = 5 5.0 -1 36
NoneNone
PDSP KiDatabase 179 0 1 1 2.7 CC12CC3CC(C)(C1)CC(N)(C3)C2 None
119607 206203 3H-CLONIDINE 113 Human Binding pKi = 5 5.0 -97 27
NoneNone
PDSP KiDatabase 314 3 1 4 3.0 Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1 None
CHEMBL865 206203 3H-CLONIDINE 113 Human Binding pKi = 5 5.0 -97 27
NoneNone
PDSP KiDatabase 314 3 1 4 3.0 Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1 None
11954224 215953 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -4168 58
NoneNone
PDSP KiDatabase 581 4 3 6 2.0 CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C None
3251.0 215953 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -4168 58
NoneNone
PDSP KiDatabase 581 4 3 6 2.0 CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C None
CHEMBL1982133 215953 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -4168 58
NoneNone
PDSP KiDatabase 581 4 3 6 2.0 CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C None
DB00696 215953 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -4168 58
NoneNone
PDSP KiDatabase 581 4 3 6 2.0 CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C None
None 215993 3H-RAUWOLSCINE 0 Human Binding pKi = 5 5.0 -1 28
NoneNone
PDSP KiDatabase 329 2 0 4 3.6 CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.Cl None
25137849 216179 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 1 40
NoneNone
PDSP KiDatabase 165 3 2 2 1.3 CC(C(C1=CC=CC=C1)O)NC None
71290 216179 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 1 40
NoneNone
PDSP KiDatabase 165 3 2 2 1.3 CC(C(C1=CC=CC=C1)O)NC None
None 216311 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 33
NoneNone
PDSP KiDatabase 240 7 4 6 -0.8 C(C(C(=O)O)N)SSCC(C(=O)O)N None
None 216312 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 33
NoneNone
PDSP KiDatabase 149 4 2 3 0.2 CSCCC(C(=O)O)N None
None 216313 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 33
NoneNone
PDSP KiDatabase 135 3 3 3 -0.3 C(CS)C(C(=O)O)N None
None 216314 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 33
NoneNone
PDSP KiDatabase 121 2 3 3 -0.7 C(C(C(=O)O)N)S None
None 216315 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 28
NoneNone
PDSP KiDatabase 117 0 1 3 -0.0 C1CSC(=O)C1N None
None 216316 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 39
NoneNone
PDSP KiDatabase 153 3 3 3 -1.4 C(C(C(=O)O)N)S(=O)O None
None 216317 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 38
NoneNone
PDSP KiDatabase 169 3 3 4 -1.7 C(C(C(=O)O)N)S(=O)(=O)O None
None 216318 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 30
NoneNone
PDSP KiDatabase 183 4 3 4 -1.3 C(CS(=O)(=O)O)C(C(=O)O)N None
None 216327 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -16 28
NoneNone
PDSP KiDatabase 536 11 1 4 9.0 CC(C)C(=O)C12C(=O)C(=C(C(C1=O)(CC(C2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C None
4978 216328 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -16 28
NoneNone
PDSP KiDatabase 520 1 7 9 4.3 CC1=CC(=C2C3=C1C4=C5C(=C(C=C4CO)O)C(=O)C6=C(C=C(C7=C6C5=C3C8=C7C(=CC(=C8C2=O)O)O)O)O)O None
None 216329 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -2 28
NoneNone
PDSP KiDatabase 464 4 8 12 -0.6 C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O)O None
None 216331 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 28
NoneNone
PDSP KiDatabase 448 3 7 11 0.4 CC1C(C(C(C(O1)OC2=C(OC3=CC(=O)C=C(C3=C2O)O)C4=CC(=C(C=C4)O)O)O)O)O None
None 216342 3H-RX821002 0 Human Binding pKi = 5 5.0 -1862 19
NoneNone
PDSP KiDatabase 246 2 1 4 1.6 CCCN1CCCC2C1CC3=CN=C(N=C3C2)N None
135269 216389 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 222 5 1 3 2.5 CCCCC(=O)OC1=CC=CC=C1C(=O)O None
23681059 216390 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 28
NoneNone
PDSP KiDatabase 230 3 1 2 3.0 CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O None
5018304 216391 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 28
NoneNone
PDSP KiDatabase 317 4 1 3 0.0 C1=CC=C(C(=C1)CC(=O)[O-])NC2=C(C=CC=C2Cl)Cl.[Na+] None
84003 216392 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 27
NoneNone
PDSP KiDatabase 376 6 5 7 -0.0 C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O.C(C(CO)(CO)N)O None
123619 216393 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1412 26
NoneNone
PDSP KiDatabase 358 3 0 4 4.2 CC1=NC=C(C=C1)C2=NC=C(C=C2C3=CC=C(C=C3)S(=O)(=O)C)Cl None
119828 216394 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -1 29
NoneNone
PDSP KiDatabase 370 5 1 5 3.5 CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C None
None 216395 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -7 28
NoneNone
PDSP KiDatabase 517 8 2 5 5.2 CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)NCCC4=CC=C(C=C4)NC(=O)C None
None 216489 3H-CLONIDINE 0 Human Binding pKi = 5 5.0 -4570 27
NoneNone
PDSP KiDatabase 347 6 0 3 5.0 CC(=O)N(CC1=CC=CC=C1OC)C2=CC=CC=C2OC3=CC=CC=C3 None
115237 55585 3H-RAUWOLSCINE 119 Human Binding pKi = 8.0 8.0 -29 54
NoneNone
PDSP KiDatabase 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
115237.0 55585 3H-RAUWOLSCINE 119 Human Binding pKi = 8.0 8.0 -29 54
NoneNone
PDSP KiDatabase 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
CHEMBL1621 55585 3H-RAUWOLSCINE 119 Human Binding pKi = 8.0 8.0 -29 54
NoneNone
PDSP KiDatabase 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
DB01267 55585 3H-RAUWOLSCINE 119 Human Binding pKi = 8.0 8.0 -29 54
NoneNone
PDSP KiDatabase 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
11293787 148213 UNDEFINED 0 Human Binding pKi = 8.0 8.0 27 3
NoneNone
PDSP KiDatabase 447 6 0 5 5.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4F)cc13)CC2 None
CHEMBL393597 148213 UNDEFINED 0 Human Binding pKi = 8.0 8.0 27 3
NoneNone
PDSP KiDatabase 447 6 0 5 5.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4F)cc13)CC2 None
1343 1889 3H-MK912 62 Human Binding pKi = 6.0 6.0 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
3519 1889 3H-MK912 62 Human Binding pKi = 6.0 6.0 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
3519.0 1889 3H-MK912 62 Human Binding pKi = 6.0 6.0 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
522 1889 3H-MK912 62 Human Binding pKi = 6.0 6.0 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
CHEMBL862 1889 3H-MK912 62 Human Binding pKi = 6.0 6.0 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
DB01018 1889 3H-MK912 62 Human Binding pKi = 6.0 6.0 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
1615 167791 3H-CLONIDINE 24 Human Binding pKi = 6.0 6.0 -3 44
NoneNone
PDSP KiDatabase 193 3 1 3 1.6 CNC(C)Cc1ccc2c(c1)OCO2 None
CHEMBL43048 167791 3H-CLONIDINE 24 Human Binding pKi = 6.0 6.0 -3 44
NoneNone
PDSP KiDatabase 193 3 1 3 1.6 CNC(C)Cc1ccc2c(c1)OCO2 None
2726 919 3H-RAUWOLSCINE 68 North American opossum Binding pKi = 6.9 6.9 -67 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
2726.0 919 3H-RAUWOLSCINE 68 North American opossum Binding pKi = 6.9 6.9 -67 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
621 919 3H-RAUWOLSCINE 68 North American opossum Binding pKi = 6.9 6.9 -67 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
83 919 3H-RAUWOLSCINE 68 North American opossum Binding pKi = 6.9 6.9 -67 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL71 919 3H-RAUWOLSCINE 68 North American opossum Binding pKi = 6.9 6.9 -67 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
DB00477 919 3H-RAUWOLSCINE 68 North American opossum Binding pKi = 6.9 6.9 -67 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
1220 187 3H-RAUWOLSCINE 55 Human Binding pKi = 6.9 6.9 -93 44
NoneNone
PDSP KiDatabase 247 5 1 2 3.4 CCCN(C1CCc2c(C1)c(O)ccc2)CCC None
31 187 3H-RAUWOLSCINE 55 Human Binding pKi = 6.9 6.9 -93 44
NoneNone
PDSP KiDatabase 247 5 1 2 3.4 CCCN(C1CCc2c(C1)c(O)ccc2)CCC None
7 187 3H-RAUWOLSCINE 55 Human Binding pKi = 6.9 6.9 -93 44
NoneNone
PDSP KiDatabase 247 5 1 2 3.4 CCCN(C1CCc2c(C1)c(O)ccc2)CCC None
CHEMBL56 187 3H-RAUWOLSCINE 55 Human Binding pKi = 6.9 6.9 -93 44
NoneNone
PDSP KiDatabase 247 5 1 2 3.4 CCCN(C1CCc2c(C1)c(O)ccc2)CCC None
135409468 2035 3H-CLONIDINE 69 Human Binding pKi = 6.9 6.9 -41 39
NoneNone
PDSP KiDatabase 312 1 2 4 1.7 Clc1ccc2c(c1)NC(=c1c(=N2)cccc1)N1CCNCC1 None
333 2035 3H-CLONIDINE 69 Human Binding pKi = 6.9 6.9 -41 39
NoneNone
PDSP KiDatabase 312 1 2 4 1.7 Clc1ccc2c(c1)NC(=c1c(=N2)cccc1)N1CCNCC1 None
CHEMBL845 2035 3H-CLONIDINE 69 Human Binding pKi = 6.9 6.9 -41 39
NoneNone
PDSP KiDatabase 312 1 2 4 1.7 Clc1ccc2c(c1)NC(=c1c(=N2)cccc1)N1CCNCC1 None
186 1807 3H-CLONIDINE 52 Human Binding pKi = 5.9 5.9 -194 17
NoneNone
PDSP KiDatabase 295 5 1 2 3.7 OC(c1ccccc1)C1CCN(CC1)CCc1ccccc1 None
71781 1807 3H-CLONIDINE 52 Human Binding pKi = 5.9 5.9 -194 17
NoneNone
PDSP KiDatabase 295 5 1 2 3.7 OC(c1ccccc1)C1CCN(CC1)CCc1ccccc1 None
CHEMBL18972 1807 3H-CLONIDINE 52 Human Binding pKi = 5.9 5.9 -194 17
NoneNone
PDSP KiDatabase 295 5 1 2 3.7 OC(c1ccccc1)C1CCN(CC1)CCc1ccccc1 None
164512323 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 7.9 7.9 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
6419959 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 7.9 7.9 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
2142 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.9 7.9 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
4920903 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.9 7.9 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
502 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.9 7.9 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.9 7.9 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775.0 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.9 7.9 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
CHEMBL597 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.9 7.9 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
DB00692 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.9 7.9 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
2402 3370 3H-RX821002 62 Human Binding pKi = 5.9 5.9 -5 24
NoneNone
PDSP KiDatabase 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
5095 3370 3H-RX821002 62 Human Binding pKi = 5.9 5.9 -5 24
NoneNone
PDSP KiDatabase 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
5095.0 3370 3H-RX821002 62 Human Binding pKi = 5.9 5.9 -5 24
NoneNone
PDSP KiDatabase 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
7295 3370 3H-RX821002 62 Human Binding pKi = 5.9 5.9 -5 24
NoneNone
PDSP KiDatabase 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
CHEMBL589 3370 3H-RX821002 62 Human Binding pKi = 5.9 5.9 -5 24
NoneNone
PDSP KiDatabase 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
DB00268 3370 3H-RX821002 62 Human Binding pKi = 5.9 5.9 -5 24
NoneNone
PDSP KiDatabase 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
1212 1662 3H-RAUWOLSCINE 50 Human Binding pKi = 6.9 6.9 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
204 1662 3H-RAUWOLSCINE 50 Human Binding pKi = 6.9 6.9 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372 1662 3H-RAUWOLSCINE 50 Human Binding pKi = 6.9 6.9 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372.0 1662 3H-RAUWOLSCINE 50 Human Binding pKi = 6.9 6.9 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
CHEMBL726 1662 3H-RAUWOLSCINE 50 Human Binding pKi = 6.9 6.9 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
DB00623 1662 3H-RAUWOLSCINE 50 Human Binding pKi = 6.9 6.9 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
25137849 216179 3H-CLONIDINE 0 Human Binding pKi = 5.9 5.9 1 40
NoneNone
PDSP KiDatabase 165 3 2 2 1.3 CC(C(C1=CC=CC=C1)O)NC None
71290 216179 3H-CLONIDINE 0 Human Binding pKi = 5.9 5.9 1 40
NoneNone
PDSP KiDatabase 165 3 2 2 1.3 CC(C(C1=CC=CC=C1)O)NC None
7153 98020 3H-CLONIDINE 77 Human Binding pKi = 6.9 6.9 -6 34
NoneNone
PDSP KiDatabase 214 3 1 2 2.5 Cc1cc(Cl)ccc1OC(C)C(=O)O None
CHEMBL272942 98020 3H-CLONIDINE 77 Human Binding pKi = 6.9 6.9 -6 34
NoneNone
PDSP KiDatabase 214 3 1 2 2.5 Cc1cc(Cl)ccc1OC(C)C(=O)O None
3658 4107 35S-GTPGammaS 53 Human Binding pKi = 6.9 6.9 -17 8
NoneNone
PDSP KiDatabase 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
517 4107 35S-GTPGammaS 53 Human Binding pKi = 6.9 6.9 -17 8
NoneNone
PDSP KiDatabase 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
5709 4107 35S-GTPGammaS 53 Human Binding pKi = 6.9 6.9 -17 8
NoneNone
PDSP KiDatabase 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
5709.0 4107 35S-GTPGammaS 53 Human Binding pKi = 6.9 6.9 -17 8
NoneNone
PDSP KiDatabase 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
CHEMBL312448 4107 35S-GTPGammaS 53 Human Binding pKi = 6.9 6.9 -17 8
NoneNone
PDSP KiDatabase 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
DB06694 4107 35S-GTPGammaS 53 Human Binding pKi = 6.9 6.9 -17 8
NoneNone
PDSP KiDatabase 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
122211 462 3H-RAUWOLSCINE 0 Human Binding pKi = 7.9 7.9 -9 6
NoneNone
PDSP KiDatabase 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C None
524 462 3H-RAUWOLSCINE 0 Human Binding pKi = 7.9 7.9 -9 6
NoneNone
PDSP KiDatabase 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C None
3036780.0 107531 3H-RAUWOLSCINE 20 Human Binding pKi = 7.9 7.9 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
46780481 107531 3H-RAUWOLSCINE 20 Human Binding pKi = 7.9 7.9 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
9903970 107531 3H-RAUWOLSCINE 20 Human Binding pKi = 7.9 7.9 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
9903970.0 107531 3H-RAUWOLSCINE 20 Human Binding pKi = 7.9 7.9 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL3187365 107531 3H-RAUWOLSCINE 20 Human Binding pKi = 7.9 7.9 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL3544974 107531 3H-RAUWOLSCINE 20 Human Binding pKi = 7.9 7.9 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL504548 107531 3H-RAUWOLSCINE 20 Human Binding pKi = 7.9 7.9 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
DB06216 107531 3H-RAUWOLSCINE 20 Human Binding pKi = 7.9 7.9 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
None 216240 3H-RX821002 0 Rat Binding pKi = 7.9 7.9 47 2
NoneNone
PDSP KiDatabase 457 7 1 3 4.9 CCC(=O)NC1=C(C=C(C=C1C)C(=O)N2CCC(CC2)N(C)CCC3=CC=CC=C3)C.Cl None
2803 955 35S-GTPGammaS 58 Human Binding pKi = 6.9 6.9 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
2803.0 955 35S-GTPGammaS 58 Human Binding pKi = 6.9 6.9 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
516 955 35S-GTPGammaS 58 Human Binding pKi = 6.9 6.9 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
704 955 35S-GTPGammaS 58 Human Binding pKi = 6.9 6.9 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
CHEMBL134 955 35S-GTPGammaS 58 Human Binding pKi = 6.9 6.9 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
DB00575 955 35S-GTPGammaS 58 Human Binding pKi = 6.9 6.9 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
484 2858 35S-GTPGammaS 51 Human Binding pKi = 5.9 5.9 -2 35
NoneNone
PDSP KiDatabase 169 2 4 4 0.1 NCC(c1ccc(c(c1)O)O)O None
951 2858 35S-GTPGammaS 51 Human Binding pKi = 5.9 5.9 -2 35
NoneNone
PDSP KiDatabase 169 2 4 4 0.1 NCC(c1ccc(c(c1)O)O)O None
CHEMBL432 2858 35S-GTPGammaS 51 Human Binding pKi = 5.9 5.9 -2 35
NoneNone
PDSP KiDatabase 169 2 4 4 0.1 NCC(c1ccc(c(c1)O)O)O None
67409 216034 3H-RAUWOLSCINE 0 Human Binding pKi = 7.9 7.9 -2 3
NoneNone
PDSP KiDatabase 235 2 0 1 3.9 C=CCN1CC2=CC=CC=C2C3=CC=CC=C3C1 None
8966 216034 3H-RAUWOLSCINE 0 Human Binding pKi = 7.9 7.9 -2 3
NoneNone
PDSP KiDatabase 235 2 0 1 3.9 C=CCN1CC2=CC=CC=C2C3=CC=CC=C3C1 None
None 216035 3H-RAUWOLSCINE 0 Human Binding pKi = 7.9 7.9 -1 3
NoneNone
PDSP KiDatabase 200 3 1 1 2.8 CC1=C(C(=CC=C1)C)CCC2=CN=CN2 None
4209 3163 3H-CLONIDINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893 3163 3H-CLONIDINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893.0 3163 3H-CLONIDINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
503 3163 3H-CLONIDINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
5385 3163 3H-CLONIDINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
CHEMBL2 3163 3H-CLONIDINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
DB00457 3163 3H-CLONIDINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
185 4006 3H-CLONIDINE 60 Human Binding pKi = 5.8 5.8 -4466 37
NoneNone
PDSP KiDatabase 373 7 1 4 3.8 COc1cccc(c1OC)[C@@H](C1CCN(CC1)CCc1ccc(cc1)F)O None
5311271 4006 3H-CLONIDINE 60 Human Binding pKi = 5.8 5.8 -4466 37
NoneNone
PDSP KiDatabase 373 7 1 4 3.8 COc1cccc(c1OC)[C@@H](C1CCN(CC1)CCc1ccc(cc1)F)O None
CHEMBL74355 4006 3H-CLONIDINE 60 Human Binding pKi = 5.8 5.8 -4466 37
NoneNone
PDSP KiDatabase 373 7 1 4 3.8 COc1cccc(c1OC)[C@@H](C1CCN(CC1)CCc1ccc(cc1)F)O None
DB16351 4006 3H-CLONIDINE 60 Human Binding pKi = 5.8 5.8 -4466 37
NoneNone
PDSP KiDatabase 373 7 1 4 3.8 COc1cccc(c1OC)[C@@H](C1CCN(CC1)CCc1ccc(cc1)F)O None
4209 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893.0 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
503 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
5385 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
CHEMBL2 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
DB00457 3163 3H-RAUWOLSCINE 75 Human Binding pKi = 7.8 7.8 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
68602 205126 35S-GTPGammaS 80 Human Binding pKi = 7.8 7.8 -4 7
NoneNone
PDSP KiDatabase 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C None
CHEMBL77921 205126 35S-GTPGammaS 80 Human Binding pKi = 7.8 7.8 -4 7
NoneNone
PDSP KiDatabase 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C None
21830793 91835 3H-8-OH-DPAT 10 Bovine Binding pKi = 7.8 7.8 -102 45
NoneNone
PDSP KiDatabase 373 7 0 8 0.6 COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1 None
CHEMBL2413154 91835 3H-8-OH-DPAT 10 Bovine Binding pKi = 7.8 7.8 -102 45
NoneNone
PDSP KiDatabase 373 7 0 8 0.6 COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1 None
1223 953 3H-RAUWOLSCINE 41 Human Binding pKi = 7.8 7.8 -85 11
NoneNone
PDSP KiDatabase 308 6 2 3 3.2 Clc1ccc(cc1)CN=C(SCCCc1cnc[nH]1)N None
2790 953 3H-RAUWOLSCINE 41 Human Binding pKi = 7.8 7.8 -85 11
NoneNone
PDSP KiDatabase 308 6 2 3 3.2 Clc1ccc(cc1)CN=C(SCCCc1cnc[nH]1)N None
CHEMBL14690 953 3H-RAUWOLSCINE 41 Human Binding pKi = 7.8 7.8 -85 11
NoneNone
PDSP KiDatabase 308 6 2 3 3.2 Clc1ccc(cc1)CN=C(SCCCc1cnc[nH]1)N None
103 4153 3H-RAUWOLSCINE 61 Human Binding pKi = 6.8 6.8 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
2875 4153 3H-RAUWOLSCINE 61 Human Binding pKi = 6.8 6.8 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
5736 4153 3H-RAUWOLSCINE 61 Human Binding pKi = 6.8 6.8 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL285802 4153 3H-RAUWOLSCINE 61 Human Binding pKi = 6.8 6.8 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
DB09225 4153 3H-RAUWOLSCINE 61 Human Binding pKi = 6.8 6.8 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
133621 2012 35S-GTPGammaS 0 Human Binding pKi = 6.8 6.8 -3 5
NoneNone
PDSP KiDatabase 244 3 0 4 2.3 CCn1ccnc1CC1COc2c(O1)cccc2 None
3470 2012 35S-GTPGammaS 0 Human Binding pKi = 6.8 6.8 -3 5
NoneNone
PDSP KiDatabase 244 3 0 4 2.3 CCn1ccnc1CC1COc2c(O1)cccc2 None
CHEMBL347695 2012 35S-GTPGammaS 0 Human Binding pKi = 6.8 6.8 -3 5
NoneNone
PDSP KiDatabase 244 3 0 4 2.3 CCn1ccnc1CC1COc2c(O1)cccc2 None
179 400 125I-Clonidine 115 Human Binding pKi = 5.8 5.8 -40 49
NoneNone
PDSP KiDatabase 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
2159 400 125I-Clonidine 115 Human Binding pKi = 5.8 5.8 -40 49
NoneNone
PDSP KiDatabase 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
2159.0 400 125I-Clonidine 115 Human Binding pKi = 5.8 5.8 -40 49
NoneNone
PDSP KiDatabase 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
963 400 125I-Clonidine 115 Human Binding pKi = 5.8 5.8 -40 49
NoneNone
PDSP KiDatabase 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
CHEMBL243712 400 125I-Clonidine 115 Human Binding pKi = 5.8 5.8 -40 49
NoneNone
PDSP KiDatabase 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
DB06288 400 125I-Clonidine 115 Human Binding pKi = 5.8 5.8 -40 49
NoneNone
PDSP KiDatabase 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
162265 202274 3H-CLONIDINE 22 Human Binding pKi = 5.8 5.8 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
4786 202274 3H-CLONIDINE 22 Human Binding pKi = 5.8 5.8 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
CHEMBL61006 202274 3H-CLONIDINE 22 Human Binding pKi = 5.8 5.8 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
213 3853 125I-Clonidine 55 Human Binding pKi = 6.8 6.8 -6 44
NoneNone
PDSP KiDatabase 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
2717 3853 125I-Clonidine 55 Human Binding pKi = 6.8 6.8 -6 44
NoneNone
PDSP KiDatabase 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
5533 3853 125I-Clonidine 55 Human Binding pKi = 6.8 6.8 -6 44
NoneNone
PDSP KiDatabase 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
5533.0 3853 125I-Clonidine 55 Human Binding pKi = 6.8 6.8 -6 44
NoneNone
PDSP KiDatabase 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
CHEMBL621 3853 125I-Clonidine 55 Human Binding pKi = 6.8 6.8 -6 44
NoneNone
PDSP KiDatabase 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
DB00656 3853 125I-Clonidine 55 Human Binding pKi = 6.8 6.8 -6 44
NoneNone
PDSP KiDatabase 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
1524 2181 3H-RAUWOLSCINE 96 Human Binding pKi = 6.8 6.8 -120 52
NoneNone
PDSP KiDatabase 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 None
197 2181 3H-RAUWOLSCINE 96 Human Binding pKi = 6.8 6.8 -120 52
NoneNone
PDSP KiDatabase 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 None
3822 2181 3H-RAUWOLSCINE 96 Human Binding pKi = 6.8 6.8 -120 52
NoneNone
PDSP KiDatabase 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 None
3822.0 2181 3H-RAUWOLSCINE 96 Human Binding pKi = 6.8 6.8 -120 52
NoneNone
PDSP KiDatabase 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 None
88 2181 3H-RAUWOLSCINE 96 Human Binding pKi = 6.8 6.8 -120 52
NoneNone
PDSP KiDatabase 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 None
CHEMBL51 2181 3H-RAUWOLSCINE 96 Human Binding pKi = 6.8 6.8 -120 52
NoneNone
PDSP KiDatabase 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 None
DB12465 2181 3H-RAUWOLSCINE 96 Human Binding pKi = 6.8 6.8 -120 52
NoneNone
PDSP KiDatabase 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 None
3294 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
71360 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
71360.0 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
87 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
CHEMBL14376 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
DB04946 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
3294 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
71360 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
71360.0 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
87 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
CHEMBL14376 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
DB04946 2006 3H-RX821002 111 Human Binding pKi = 7.8 7.8 -16 45
NoneNone
PDSP KiDatabase 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
1028 291 35S-GTPGammaS 71 Human Binding pKi = 5.8 5.8 -67 30
NoneNone
PDSP KiDatabase 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
139148732 291 35S-GTPGammaS 71 Human Binding pKi = 5.8 5.8 -67 30
NoneNone
PDSP KiDatabase 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
479 291 35S-GTPGammaS 71 Human Binding pKi = 5.8 5.8 -67 30
NoneNone
PDSP KiDatabase 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
5816 291 35S-GTPGammaS 71 Human Binding pKi = 5.8 5.8 -67 30
NoneNone
PDSP KiDatabase 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
5816.0 291 35S-GTPGammaS 71 Human Binding pKi = 5.8 5.8 -67 30
NoneNone
PDSP KiDatabase 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
CHEMBL679 291 35S-GTPGammaS 71 Human Binding pKi = 5.8 5.8 -67 30
NoneNone
PDSP KiDatabase 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
DB00668 291 35S-GTPGammaS 71 Human Binding pKi = 5.8 5.8 -67 30
NoneNone
PDSP KiDatabase 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
3036780.0 107531 3H-CLONIDINE 20 Human Binding pKi = 7.8 7.8 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
46780481 107531 3H-CLONIDINE 20 Human Binding pKi = 7.8 7.8 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
9903970 107531 3H-CLONIDINE 20 Human Binding pKi = 7.8 7.8 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
9903970.0 107531 3H-CLONIDINE 20 Human Binding pKi = 7.8 7.8 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL3187365 107531 3H-CLONIDINE 20 Human Binding pKi = 7.8 7.8 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL3544974 107531 3H-CLONIDINE 20 Human Binding pKi = 7.8 7.8 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL504548 107531 3H-CLONIDINE 20 Human Binding pKi = 7.8 7.8 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
DB06216 107531 3H-CLONIDINE 20 Human Binding pKi = 7.8 7.8 -72 53
NoneNone
PDSP KiDatabase 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
1830 2590 3H-CLONIDINE 44 Human Binding pKi = 6.8 6.8 -6 28
NoneNone
PDSP KiDatabase 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
207 2590 3H-CLONIDINE 44 Human Binding pKi = 6.8 6.8 -6 28
NoneNone
PDSP KiDatabase 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
23897 2590 3H-CLONIDINE 44 Human Binding pKi = 6.8 6.8 -6 28
NoneNone
PDSP KiDatabase 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
23897.0 2590 3H-CLONIDINE 44 Human Binding pKi = 6.8 6.8 -6 28
NoneNone
PDSP KiDatabase 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
CHEMBL460 2590 3H-CLONIDINE 44 Human Binding pKi = 6.8 6.8 -6 28
NoneNone
PDSP KiDatabase 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
DB01618 2590 3H-CLONIDINE 44 Human Binding pKi = 6.8 6.8 -6 28
NoneNone
PDSP KiDatabase 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
1816 2540 3H-RAUWOLSCINE 102 Human Binding pKi = 7.7 7.7 -38 18
NoneNone
PDSP KiDatabase 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
4205 2540 3H-RAUWOLSCINE 102 Human Binding pKi = 7.7 7.7 -38 18
NoneNone
PDSP KiDatabase 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
4205.0 2540 3H-RAUWOLSCINE 102 Human Binding pKi = 7.7 7.7 -38 18
NoneNone
PDSP KiDatabase 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
7241 2540 3H-RAUWOLSCINE 102 Human Binding pKi = 7.7 7.7 -38 18
NoneNone
PDSP KiDatabase 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
CHEMBL654 2540 3H-RAUWOLSCINE 102 Human Binding pKi = 7.7 7.7 -38 18
NoneNone
PDSP KiDatabase 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
DB00370 2540 3H-RAUWOLSCINE 102 Human Binding pKi = 7.7 7.7 -38 18
NoneNone
PDSP KiDatabase 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
11225732 93657 UNDEFINED 0 Human Binding pKi = 7.7 7.7 16 3
NoneNone
PDSP KiDatabase 497 6 0 5 6.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4C(F)(F)F)cc13)CC2 None
CHEMBL246852 93657 UNDEFINED 0 Human Binding pKi = 7.7 7.7 16 3
NoneNone
PDSP KiDatabase 497 6 0 5 6.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4C(F)(F)F)cc13)CC2 None
3337 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
3337.0 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
65801 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
66264 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
91452 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
CHEMBL87493 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
DB00574 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
124 2981 3H-MK912 47 Human Binding pKi = 6.7 6.7 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
2032 2981 3H-MK912 47 Human Binding pKi = 6.7 6.7 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636 2981 3H-MK912 47 Human Binding pKi = 6.7 6.7 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636.0 2981 3H-MK912 47 Human Binding pKi = 6.7 6.7 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
CHEMBL762 2981 3H-MK912 47 Human Binding pKi = 6.7 6.7 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
DB00935 2981 3H-MK912 47 Human Binding pKi = 6.7 6.7 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
None 216239 3H-CLONIDINE 0 Human Binding pKi = 5.7 5.7 -27542 30
NoneNone
PDSP KiDatabase 316 7 3 3 3.0 CC(CF)NCC(COC1=CC=CC2=C1C3=CC=CC=C3N2)O None
12575 1988 UNDEFINED 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
54459 1988 UNDEFINED 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
54459.0 1988 UNDEFINED 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
CHEMBL10316 1988 UNDEFINED 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
DB12551 1988 UNDEFINED 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
44438147 93489 UNDEFINED 0 Human Binding pKi = 7.7 7.7 19 3
NoneNone
PDSP KiDatabase 406 5 1 9 2.5 COc1cc2c(cc1OC)CN(Cc1cnc(N)n3nc(-c4ccco4)nc13)CC2 None
CHEMBL246228 93489 UNDEFINED 0 Human Binding pKi = 7.7 7.7 19 3
NoneNone
PDSP KiDatabase 406 5 1 9 2.5 COc1cc2c(cc1OC)CN(Cc1cnc(N)n3nc(-c4ccco4)nc13)CC2 None
44438152 93608 UNDEFINED 0 Human Binding pKi = 7.7 7.7 42 3
NoneNone
PDSP KiDatabase 459 7 0 6 5.7 COc1cccc(-c2cc3c(CN4CCc5cc(OC)c(OC)cc5C4)ccc(OC)c3o2)c1 None
CHEMBL246639 93608 UNDEFINED 0 Human Binding pKi = 7.7 7.7 42 3
NoneNone
PDSP KiDatabase 459 7 0 6 5.7 COc1cccc(-c2cc3c(CN4CCc5cc(OC)c(OC)cc5C4)ccc(OC)c3o2)c1 None
12575 1988 35S-GTPGammaS 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
54459 1988 35S-GTPGammaS 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
54459.0 1988 35S-GTPGammaS 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
CHEMBL10316 1988 35S-GTPGammaS 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
DB12551 1988 35S-GTPGammaS 30 Human Binding pKi = 7.7 7.7 -8 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
135 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 6.7 6.7 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
1796 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 6.7 6.7 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 6.7 6.7 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184.0 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 6.7 6.7 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
CHEMBL6437 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 6.7 6.7 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
DB06148 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 6.7 6.7 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
2435 722 35S-GTPGammaS 100 Human Binding pKi = 5.7 5.7 -33 12
NoneNone
PDSP KiDatabase 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
2435.0 722 35S-GTPGammaS 100 Human Binding pKi = 5.7 5.7 -33 12
NoneNone
PDSP KiDatabase 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
395 722 35S-GTPGammaS 100 Human Binding pKi = 5.7 5.7 -33 12
NoneNone
PDSP KiDatabase 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
520 722 35S-GTPGammaS 100 Human Binding pKi = 5.7 5.7 -33 12
NoneNone
PDSP KiDatabase 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
5386 722 35S-GTPGammaS 100 Human Binding pKi = 5.7 5.7 -33 12
NoneNone
PDSP KiDatabase 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
CHEMBL844 722 35S-GTPGammaS 100 Human Binding pKi = 5.7 5.7 -33 12
NoneNone
PDSP KiDatabase 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
DB00484 722 35S-GTPGammaS 100 Human Binding pKi = 5.7 5.7 -33 12
NoneNone
PDSP KiDatabase 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
3337 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
3337.0 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
65801 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
66264 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
91452 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
CHEMBL87493 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
DB00574 206367 3H-CLONIDINE 27 Human Binding pKi = 6.7 6.7 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
12575 1988 3H-RAUWOLSCINE 30 North American opossum Binding pKi = 8.6 8.6 -1 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
54459 1988 3H-RAUWOLSCINE 30 North American opossum Binding pKi = 8.6 8.6 -1 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
54459.0 1988 3H-RAUWOLSCINE 30 North American opossum Binding pKi = 8.6 8.6 -1 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
CHEMBL10316 1988 3H-RAUWOLSCINE 30 North American opossum Binding pKi = 8.6 8.6 -1 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
DB12551 1988 3H-RAUWOLSCINE 30 North American opossum Binding pKi = 8.6 8.6 -1 17
NoneNone
PDSP KiDatabase 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 None
68602 205126 3H-RX821002 80 Human Binding pKi = 8.6 8.6 -4 7
NoneNone
PDSP KiDatabase 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C None
CHEMBL77921 205126 3H-RX821002 80 Human Binding pKi = 8.6 8.6 -4 7
NoneNone
PDSP KiDatabase 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C None
123981 16459 3H-RAUWOLSCINE 22 Human Binding pKi = 8.6 8.6 -4 8
NoneNone
PDSP KiDatabase 195 0 0 1 2.4 CN1CCc2cccc(Cl)c2CC1 None
CHEMBL123349 16459 3H-RAUWOLSCINE 22 Human Binding pKi = 8.6 8.6 -4 8
NoneNone
PDSP KiDatabase 195 0 0 1 2.4 CN1CCc2cccc(Cl)c2CC1 None
CHEMBL536803 16459 3H-RAUWOLSCINE 22 Human Binding pKi = 8.6 8.6 -4 8
NoneNone
PDSP KiDatabase 195 0 0 1 2.4 CN1CCc2cccc(Cl)c2CC1 None
12576 514 3H-RAUWOLSCINE 94 North American opossum Binding pKi = 8.6 8.6 -4 6
NoneNone
PDSP KiDatabase 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 None
71310 514 3H-RAUWOLSCINE 94 North American opossum Binding pKi = 8.6 8.6 -4 6
NoneNone
PDSP KiDatabase 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 None
CHEMBL353972 514 3H-RAUWOLSCINE 94 North American opossum Binding pKi = 8.6 8.6 -4 6
NoneNone
PDSP KiDatabase 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 None
DB11481 514 3H-RAUWOLSCINE 94 North American opossum Binding pKi = 8.6 8.6 -4 6
NoneNone
PDSP KiDatabase 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 None
135398737 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.5 8.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
135398737.0 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.5 8.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
38 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.5 8.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
722 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.5 8.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
CHEMBL42 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.5 8.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
DB00363 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.5 8.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
16725934 147423 UNDEFINED 0 Human Binding pKi = 7.7 7.7 38 3
NoneNone
PDSP KiDatabase 429 6 0 5 5.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4)cc13)CC2 None
CHEMBL392992 147423 UNDEFINED 0 Human Binding pKi = 7.7 7.7 38 3
NoneNone
PDSP KiDatabase 429 6 0 5 5.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4)cc13)CC2 None
138107169 215952 3H-RAUWOLSCINE 0 North American opossum Binding pKi = 7.7 7.7 -3 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
22831402 215952 3H-RAUWOLSCINE 0 North American opossum Binding pKi = 7.7 7.7 -3 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
2216 446 35S-GTPGammaS 50 Human Binding pKi = 7.7 7.7 -3 6
NoneNone
PDSP KiDatabase 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
2216.0 446 35S-GTPGammaS 50 Human Binding pKi = 7.7 7.7 -3 6
NoneNone
PDSP KiDatabase 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
229 446 35S-GTPGammaS 50 Human Binding pKi = 7.7 7.7 -3 6
NoneNone
PDSP KiDatabase 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
7117 446 35S-GTPGammaS 50 Human Binding pKi = 7.7 7.7 -3 6
NoneNone
PDSP KiDatabase 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
CHEMBL647 446 35S-GTPGammaS 50 Human Binding pKi = 7.7 7.7 -3 6
NoneNone
PDSP KiDatabase 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
DB00964 446 35S-GTPGammaS 50 Human Binding pKi = 7.7 7.7 -3 6
NoneNone
PDSP KiDatabase 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
135398745 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 6.7 6.7 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
135398745.0 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 6.7 6.7 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
47 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 6.7 6.7 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
CHEMBL715 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 6.7 6.7 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
DB00334 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 6.7 6.7 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
None 216135 3H-CLONIDINE 0 Human Binding pKi = 5.7 5.7 -2238 24
NoneNone
PDSP KiDatabase 772 16 4 10 5.5 CN(C)CCONC(=CC=C1C=CC(=O)C=C1)C2=CC=CC=C2F.CN(C)CCONC(=CC=C1C=CC(=O)C=C1)C2=CC=CC=C2F.C(=CC(=O)O)C(=O)O None
6917970 3691 3H-CLONIDINE 61 Human Binding pKi = 6.7 6.7 -48 34
NoneNone
PDSP KiDatabase 327 2 2 5 2.8 COc1cc2CCN3[C@H](c2cc1O)Cc1c(C3)c(OC)c(cc1)O None
8370 3691 3H-CLONIDINE 61 Human Binding pKi = 6.7 6.7 -48 34
NoneNone
PDSP KiDatabase 327 2 2 5 2.8 COc1cc2CCN3[C@H](c2cc1O)Cc1c(C3)c(OC)c(cc1)O None
CHEMBL487387 3691 3H-CLONIDINE 61 Human Binding pKi = 6.7 6.7 -48 34
NoneNone
PDSP KiDatabase 327 2 2 5 2.8 COc1cc2CCN3[C@H](c2cc1O)Cc1c(C3)c(OC)c(cc1)O None
None 216341 3H-RX821002 0 Human Binding pKi = 7.7 7.7 -29 19
NoneNone
PDSP KiDatabase 451 8 2 4 3.2 CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C None
2695 3841 3H-RAUWOLSCINE 81 Human Binding pKi = 6.7 6.7 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
5504 3841 3H-RAUWOLSCINE 81 Human Binding pKi = 6.7 6.7 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
7310 3841 3H-RAUWOLSCINE 81 Human Binding pKi = 6.7 6.7 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
CHEMBL770 3841 3H-RAUWOLSCINE 81 Human Binding pKi = 6.7 6.7 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
DB00797 3841 3H-RAUWOLSCINE 81 Human Binding pKi = 6.7 6.7 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
2726 919 3H-RAUWOLSCINE 68 Human Binding pKi = 6.6 6.6 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
2726.0 919 3H-RAUWOLSCINE 68 Human Binding pKi = 6.6 6.6 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
621 919 3H-RAUWOLSCINE 68 Human Binding pKi = 6.6 6.6 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
83 919 3H-RAUWOLSCINE 68 Human Binding pKi = 6.6 6.6 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL71 919 3H-RAUWOLSCINE 68 Human Binding pKi = 6.6 6.6 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
DB00477 919 3H-RAUWOLSCINE 68 Human Binding pKi = 6.6 6.6 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
124 2981 35S-GTPGammaS 47 Human Binding pKi = 6.6 6.6 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
2032 2981 35S-GTPGammaS 47 Human Binding pKi = 6.6 6.6 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636 2981 35S-GTPGammaS 47 Human Binding pKi = 6.6 6.6 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636.0 2981 35S-GTPGammaS 47 Human Binding pKi = 6.6 6.6 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
CHEMBL762 2981 35S-GTPGammaS 47 Human Binding pKi = 6.6 6.6 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
DB00935 2981 35S-GTPGammaS 47 Human Binding pKi = 6.6 6.6 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
3337 206367 3H-CLONIDINE 27 Human Binding pKi = 6.6 6.6 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
3337.0 206367 3H-CLONIDINE 27 Human Binding pKi = 6.6 6.6 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
65801 206367 3H-CLONIDINE 27 Human Binding pKi = 6.6 6.6 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
66264 206367 3H-CLONIDINE 27 Human Binding pKi = 6.6 6.6 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
91452 206367 3H-CLONIDINE 27 Human Binding pKi = 6.6 6.6 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
CHEMBL87493 206367 3H-CLONIDINE 27 Human Binding pKi = 6.6 6.6 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
DB00574 206367 3H-CLONIDINE 27 Human Binding pKi = 6.6 6.6 -13 40
NoneNone
PDSP KiDatabase 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
1353 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.6 6.6 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.6 6.6 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559.0 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.6 6.6 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
86 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.6 6.6 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
CHEMBL54 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.6 6.6 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
DB00502 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.6 6.6 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
2142 3096 35S-GTPGammaS 58 Human Binding pKi = 6.6 6.6 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
4920903 3096 35S-GTPGammaS 58 Human Binding pKi = 6.6 6.6 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
502 3096 35S-GTPGammaS 58 Human Binding pKi = 6.6 6.6 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775 3096 35S-GTPGammaS 58 Human Binding pKi = 6.6 6.6 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775.0 3096 35S-GTPGammaS 58 Human Binding pKi = 6.6 6.6 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
CHEMBL597 3096 35S-GTPGammaS 58 Human Binding pKi = 6.6 6.6 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
DB00692 3096 35S-GTPGammaS 58 Human Binding pKi = 6.6 6.6 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
104911 216019 3H-CLONIDINE 0 Human Binding pKi = 5.6 5.6 -10715 37
NoneNone
PDSP KiDatabase 530 7 0 5 5.1 COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4.Cl.Cl.Cl None
135 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 6.6 6.6 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
1796 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 6.6 6.6 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 6.6 6.6 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184.0 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 6.6 6.6 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
CHEMBL6437 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 6.6 6.6 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
DB06148 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 6.6 6.6 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
10297 27112 3H-CLONIDINE 30 Human Binding pKi = 6.6 6.6 1 42
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 C[C@H](N)[C@H](O)c1ccccc1 None
CHEMBL136560 27112 3H-CLONIDINE 30 Human Binding pKi = 6.6 6.6 1 42
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 C[C@H](N)[C@H](O)c1ccccc1 None
5524 216464 35S-GTPGammaS 0 Human Binding pKi = 6.6 6.6 -2 4
NoneNone
PDSP KiDatabase 215 1 2 3 1.9 C1CCC2=C(C1)C=CC=C2NC3=NCCN3 None
138107169 215952 3H-RAUWOLSCINE 0 Human Binding pKi = 7.6 7.6 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
22831402 215952 3H-RAUWOLSCINE 0 Human Binding pKi = 7.6 7.6 -1 22
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O None
31101 729 3H-RX821002 40 Human Binding pKi = 7.6 7.6 -36 36
NoneNone
PDSP KiDatabase 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
31101.0 729 3H-RX821002 40 Human Binding pKi = 7.6 7.6 -36 36
NoneNone
PDSP KiDatabase 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
35 729 3H-RX821002 40 Human Binding pKi = 7.6 7.6 -36 36
NoneNone
PDSP KiDatabase 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
403 729 3H-RX821002 40 Human Binding pKi = 7.6 7.6 -36 36
NoneNone
PDSP KiDatabase 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
CHEMBL493 729 3H-RX821002 40 Human Binding pKi = 7.6 7.6 -36 36
NoneNone
PDSP KiDatabase 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
DB01200 729 3H-RX821002 40 Human Binding pKi = 7.6 7.6 -36 36
NoneNone
PDSP KiDatabase 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
2337 3256 125I-Clonidine 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
2337 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
50 3256 125I-Clonidine 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
50 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002 3256 125I-Clonidine 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002.0 3256 125I-Clonidine 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002.0 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
CHEMBL716 3256 125I-Clonidine 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
CHEMBL716 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
DB01224 3256 125I-Clonidine 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
DB01224 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
1212 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
204 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372.0 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
CHEMBL726 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
DB00623 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
135398745 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
135398745.0 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
47 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
CHEMBL715 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
DB00334 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
162265 202274 3H-CLONIDINE 22 Human Binding pKi = 5.6 5.6 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
4786 202274 3H-CLONIDINE 22 Human Binding pKi = 5.6 5.6 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
CHEMBL61006 202274 3H-CLONIDINE 22 Human Binding pKi = 5.6 5.6 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
1212 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
204 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372.0 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
CHEMBL726 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
DB00623 1662 3H-CLONIDINE 50 Human Binding pKi = 7.5 7.5 -54 65
NoneNone
PDSP KiDatabase 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
135398745 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
135398745.0 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
47 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
CHEMBL715 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
DB00334 2914 3H-CLONIDINE 112 Human Binding pKi = 7.5 7.5 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
2142 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.5 7.5 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
4920903 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.5 7.5 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
502 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.5 7.5 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.5 7.5 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775.0 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.5 7.5 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
CHEMBL597 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.5 7.5 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
DB00692 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 7.5 7.5 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
2337 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
50 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002.0 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
CHEMBL716 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
DB01224 3256 3H-CLONIDINE 77 Human Binding pKi = 7.5 7.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
2181 3128 3H-RAUWOLSCINE 46 Human Binding pKi = 6.5 6.5 -36 35
NoneNone
PDSP KiDatabase 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
4830 3128 3H-RAUWOLSCINE 46 Human Binding pKi = 6.5 6.5 -36 35
NoneNone
PDSP KiDatabase 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
4830.0 3128 3H-RAUWOLSCINE 46 Human Binding pKi = 6.5 6.5 -36 35
NoneNone
PDSP KiDatabase 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
92 3128 3H-RAUWOLSCINE 46 Human Binding pKi = 6.5 6.5 -36 35
NoneNone
PDSP KiDatabase 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
CHEMBL440294 3128 3H-RAUWOLSCINE 46 Human Binding pKi = 6.5 6.5 -36 35
NoneNone
PDSP KiDatabase 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
DB09286 3128 3H-RAUWOLSCINE 46 Human Binding pKi = 6.5 6.5 -36 35
NoneNone
PDSP KiDatabase 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
102 4127 3H-MK912 48 Human Binding pKi = 8.5 8.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 4127 3H-MK912 48 Human Binding pKi = 8.5 8.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 4127 3H-MK912 48 Human Binding pKi = 8.5 8.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969.0 4127 3H-MK912 48 Human Binding pKi = 8.5 8.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 4127 3H-MK912 48 Human Binding pKi = 8.5 8.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 4127 3H-MK912 48 Human Binding pKi = 8.5 8.5 -2 49
NoneNone
PDSP KiDatabase 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
None 215958 3H-MK912 0 Human Binding pKi = 8.5 8.5 -4 19
NoneNone
PDSP KiDatabase 421 9 1 6 4.3 COC1=C(C(=CC=C1)OC)OCCNCC2C(OC3=CC=CC=C3O2)C4=CC=CC=C4 None
2389 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.5 8.5 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.5 8.5 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073.0 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.5 8.5 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
96 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.5 8.5 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
CHEMBL85 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.5 8.5 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
DB00734 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.5 8.5 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
931 216463 35S-GTPGammaS 0 Human Binding pKi = 8.5 8.5 1 4
NoneNone
PDSP KiDatabase 128 0 0 0 2.8 C1=CC=C2C=CC=CC2=C1 None
44438168 93818 UNDEFINED 0 Human Binding pKi = 8.5 8.5 53 3
NoneNone
PDSP KiDatabase 533 7 0 7 4.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)N4CCC(N5CCCC5)CC4)cc13)CC2 None
CHEMBL247665 93818 UNDEFINED 0 Human Binding pKi = 8.5 8.5 53 3
NoneNone
PDSP KiDatabase 533 7 0 7 4.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)N4CCC(N5CCCC5)CC4)cc13)CC2 None
115237 55585 3H-CLONIDINE 119 Human Binding pKi = 8.4 8.4 -29 54
NoneNone
PDSP KiDatabase 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
115237.0 55585 3H-CLONIDINE 119 Human Binding pKi = 8.4 8.4 -29 54
NoneNone
PDSP KiDatabase 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
CHEMBL1621 55585 3H-CLONIDINE 119 Human Binding pKi = 8.4 8.4 -29 54
NoneNone
PDSP KiDatabase 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
DB01267 55585 3H-CLONIDINE 119 Human Binding pKi = 8.4 8.4 -29 54
NoneNone
PDSP KiDatabase 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
135 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.4 8.4 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
1796 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.4 8.4 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.4 8.4 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184.0 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.4 8.4 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
CHEMBL6437 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.4 8.4 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
DB06148 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.4 8.4 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
122211 462 3H-RAUWOLSCINE 0 Human Binding pKi = 8.4 8.4 -9 6
NoneNone
PDSP KiDatabase 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C None
524 462 3H-RAUWOLSCINE 0 Human Binding pKi = 8.4 8.4 -9 6
NoneNone
PDSP KiDatabase 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C None
4209 3163 35S-GTPGammaS 75 Human Binding pKi = 7.5 7.5 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893 3163 35S-GTPGammaS 75 Human Binding pKi = 7.5 7.5 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893.0 3163 35S-GTPGammaS 75 Human Binding pKi = 7.5 7.5 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
503 3163 35S-GTPGammaS 75 Human Binding pKi = 7.5 7.5 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
5385 3163 35S-GTPGammaS 75 Human Binding pKi = 7.5 7.5 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
CHEMBL2 3163 35S-GTPGammaS 75 Human Binding pKi = 7.5 7.5 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
DB00457 3163 35S-GTPGammaS 75 Human Binding pKi = 7.5 7.5 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
124 2981 3H-RAUWOLSCINE 47 Human Binding pKi = 7.5 7.5 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
2032 2981 3H-RAUWOLSCINE 47 Human Binding pKi = 7.5 7.5 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636 2981 3H-RAUWOLSCINE 47 Human Binding pKi = 7.5 7.5 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636.0 2981 3H-RAUWOLSCINE 47 Human Binding pKi = 7.5 7.5 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
CHEMBL762 2981 3H-RAUWOLSCINE 47 Human Binding pKi = 7.5 7.5 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
DB00935 2981 3H-RAUWOLSCINE 47 Human Binding pKi = 7.5 7.5 -60 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
122211 462 3H-MK912 0 Human Binding pKi = 7.5 7.5 -9 6
NoneNone
PDSP KiDatabase 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C None
524 462 3H-MK912 0 Human Binding pKi = 7.5 7.5 -9 6
NoneNone
PDSP KiDatabase 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C None
None 216036 3H-RAUWOLSCINE 0 Human Binding pKi = 6.5 6.5 -5 3
NoneNone
PDSP KiDatabase 334 4 1 4 4.6 CN(C)CCCN1C2=C(C=C(C=C2)O)SC3=C1C=C(C=C3)Cl None
2142 3096 3H-RAUWOLSCINE 58 North American opossum Binding pKi = 7.5 7.5 -12 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
4920903 3096 3H-RAUWOLSCINE 58 North American opossum Binding pKi = 7.5 7.5 -12 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
502 3096 3H-RAUWOLSCINE 58 North American opossum Binding pKi = 7.5 7.5 -12 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775 3096 3H-RAUWOLSCINE 58 North American opossum Binding pKi = 7.5 7.5 -12 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775.0 3096 3H-RAUWOLSCINE 58 North American opossum Binding pKi = 7.5 7.5 -12 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
CHEMBL597 3096 3H-RAUWOLSCINE 58 North American opossum Binding pKi = 7.5 7.5 -12 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
DB00692 3096 3H-RAUWOLSCINE 58 North American opossum Binding pKi = 7.5 7.5 -12 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
135398737 958 3H-CLONIDINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
135398737 958 3H-RAUWOLSCINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
135398737.0 958 3H-CLONIDINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
135398737.0 958 3H-RAUWOLSCINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
38 958 3H-CLONIDINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
38 958 3H-RAUWOLSCINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
722 958 3H-CLONIDINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
722 958 3H-RAUWOLSCINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
CHEMBL42 958 3H-CLONIDINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
CHEMBL42 958 3H-RAUWOLSCINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
DB00363 958 3H-CLONIDINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
DB00363 958 3H-RAUWOLSCINE 93 Human Binding pKi = 7.5 7.5 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
3075702 217332 3H-RAUWOLSCINE 0 Human Binding pKi = 6.5 6.5 1 37
NoneNone
PDSP KiDatabase 198 3 1 3 1.5 C1CNC1COC2=CN=C(C=C2)Cl None
1267 3804 3H-RAUWOLSCINE 49 Human Binding pKi = 6.5 6.5 -144 26
NoneNone
PDSP KiDatabase 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 None
3035905 3804 3H-RAUWOLSCINE 49 Human Binding pKi = 6.5 6.5 -144 26
NoneNone
PDSP KiDatabase 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 None
CHEMBL260374 3804 3H-RAUWOLSCINE 49 Human Binding pKi = 6.5 6.5 -144 26
NoneNone
PDSP KiDatabase 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 None
2337 3256 3H-RAUWOLSCINE 77 Human Binding pKi = 6.5 6.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
50 3256 3H-RAUWOLSCINE 77 Human Binding pKi = 6.5 6.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002 3256 3H-RAUWOLSCINE 77 Human Binding pKi = 6.5 6.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002.0 3256 3H-RAUWOLSCINE 77 Human Binding pKi = 6.5 6.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
CHEMBL716 3256 3H-RAUWOLSCINE 77 Human Binding pKi = 6.5 6.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
DB01224 3256 3H-RAUWOLSCINE 77 Human Binding pKi = 6.5 6.5 -10 62
NoneNone
PDSP KiDatabase 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
4209 3163 3H-RAUWOLSCINE 75 North American opossum Binding pKi = 7.4 7.4 -229 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893 3163 3H-RAUWOLSCINE 75 North American opossum Binding pKi = 7.4 7.4 -229 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893.0 3163 3H-RAUWOLSCINE 75 North American opossum Binding pKi = 7.4 7.4 -229 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
503 3163 3H-RAUWOLSCINE 75 North American opossum Binding pKi = 7.4 7.4 -229 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
5385 3163 3H-RAUWOLSCINE 75 North American opossum Binding pKi = 7.4 7.4 -229 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
CHEMBL2 3163 3H-RAUWOLSCINE 75 North American opossum Binding pKi = 7.4 7.4 -229 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
DB00457 3163 3H-RAUWOLSCINE 75 North American opossum Binding pKi = 7.4 7.4 -229 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
25058166 215960 3H-RX821002 0 Human Binding pKi = 7.4 7.4 -18 27
NoneNone
PDSP KiDatabase 267 0 2 3 2.9 CN1CCC2=CC=CC3=C2C1CC4=C3C(=C(C=C4)O)O None
6852389 215960 3H-RX821002 0 Human Binding pKi = 7.4 7.4 -18 27
NoneNone
PDSP KiDatabase 267 0 2 3 2.9 CN1CCC2=CC=CC3=C2C1CC4=C3C(=C(C=C4)O)O None
242 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
34 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795.0 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
CHEMBL1112 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
DB01238 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
2726 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
2726.0 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
621 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
83 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL71 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
DB00477 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
242 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
34 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795.0 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
CHEMBL1112 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
DB01238 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
2695 3841 35S-GTPGammaS 81 Human Binding pKi = 5.4 5.4 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
5504 3841 35S-GTPGammaS 81 Human Binding pKi = 5.4 5.4 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
7310 3841 35S-GTPGammaS 81 Human Binding pKi = 5.4 5.4 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
CHEMBL770 3841 35S-GTPGammaS 81 Human Binding pKi = 5.4 5.4 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
DB00797 3841 35S-GTPGammaS 81 Human Binding pKi = 5.4 5.4 -30 6
NoneNone
PDSP KiDatabase 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
16362 3125 3H-CLONIDINE 71 Human Binding pKi = 6.4 6.4 -263 30
NoneNone
PDSP KiDatabase 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
16362.0 3125 3H-CLONIDINE 71 Human Binding pKi = 6.4 6.4 -263 30
NoneNone
PDSP KiDatabase 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
2172 3125 3H-CLONIDINE 71 Human Binding pKi = 6.4 6.4 -263 30
NoneNone
PDSP KiDatabase 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
90 3125 3H-CLONIDINE 71 Human Binding pKi = 6.4 6.4 -263 30
NoneNone
PDSP KiDatabase 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
CHEMBL1423 3125 3H-CLONIDINE 71 Human Binding pKi = 6.4 6.4 -263 30
NoneNone
PDSP KiDatabase 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
DB01100 3125 3H-CLONIDINE 71 Human Binding pKi = 6.4 6.4 -263 30
NoneNone
PDSP KiDatabase 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
242 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
34 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795.0 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
CHEMBL1112 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
DB01238 470 3H-CLONIDINE 124 Human Binding pKi = 7.4 7.4 -23 51
NoneNone
PDSP KiDatabase 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
1343 1889 35S-GTPGammaS 62 Human Binding pKi = 5.4 5.4 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
3519 1889 35S-GTPGammaS 62 Human Binding pKi = 5.4 5.4 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
3519.0 1889 35S-GTPGammaS 62 Human Binding pKi = 5.4 5.4 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
522 1889 35S-GTPGammaS 62 Human Binding pKi = 5.4 5.4 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
CHEMBL862 1889 35S-GTPGammaS 62 Human Binding pKi = 5.4 5.4 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
DB01018 1889 35S-GTPGammaS 62 Human Binding pKi = 5.4 5.4 -251 9
NoneNone
PDSP KiDatabase 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
214 3860 3H-CLONIDINE 58 Human Binding pKi = 6.4 6.4 -60 30
NoneNone
PDSP KiDatabase 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
2740 3860 3H-CLONIDINE 58 Human Binding pKi = 6.4 6.4 -60 30
NoneNone
PDSP KiDatabase 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
5566 3860 3H-CLONIDINE 58 Human Binding pKi = 6.4 6.4 -60 30
NoneNone
PDSP KiDatabase 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
5566.0 3860 3H-CLONIDINE 58 Human Binding pKi = 6.4 6.4 -60 30
NoneNone
PDSP KiDatabase 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
66064 3860 3H-CLONIDINE 58 Human Binding pKi = 6.4 6.4 -60 30
NoneNone
PDSP KiDatabase 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
CHEMBL422 3860 3H-CLONIDINE 58 Human Binding pKi = 6.4 6.4 -60 30
NoneNone
PDSP KiDatabase 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
DB00831 3860 3H-CLONIDINE 58 Human Binding pKi = 6.4 6.4 -60 30
NoneNone
PDSP KiDatabase 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
None 217653 UNDEFINED 0 Human Binding pKi = 8.4 8.4 - 1
NoneNone
PDSP KiDatabase 464 4 8 12 -0.5 C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O)O None
135398737 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.4 8.4 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
135398737.0 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.4 8.4 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
38 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.4 8.4 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
722 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.4 8.4 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
CHEMBL42 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.4 8.4 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
DB00363 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.4 8.4 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
44438166 93817 UNDEFINED 0 Human Binding pKi = 8.4 8.4 33 3
NoneNone
PDSP KiDatabase 467 8 2 7 3.5 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCC(C)(C)N)cc13)CC2 None
CHEMBL247664 93817 UNDEFINED 0 Human Binding pKi = 8.4 8.4 33 3
NoneNone
PDSP KiDatabase 467 8 2 7 3.5 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCC(C)(C)N)cc13)CC2 None
135 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 8.4 8.4 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
1796 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 8.4 8.4 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 8.4 8.4 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184.0 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 8.4 8.4 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
CHEMBL6437 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 8.4 8.4 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
DB06148 2532 3H-RAUWOLSCINE 43 North American opossum Binding pKi = 8.4 8.4 -14 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
3652 46244 None 70 Human Binding pKi = 8.3 8.3 -2 9
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 None
CHEMBL1535 46244 None 70 Human Binding pKi = 8.3 8.3 -2 9
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 None
None 216329 3H-CLONIDINE 0 Human Binding pKi = 5.4 5.4 -2 28
NoneNone
PDSP KiDatabase 464 4 8 12 -0.6 C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O)O None
11079 2733 35S-GTPGammaS 63 Human Binding pKi = 6.4 6.4 -2 5
NoneNone
PDSP KiDatabase 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
3369 2733 35S-GTPGammaS 63 Human Binding pKi = 6.4 6.4 -2 5
NoneNone
PDSP KiDatabase 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
4436 2733 35S-GTPGammaS 63 Human Binding pKi = 6.4 6.4 -2 5
NoneNone
PDSP KiDatabase 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
4436.0 2733 35S-GTPGammaS 63 Human Binding pKi = 6.4 6.4 -2 5
NoneNone
PDSP KiDatabase 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
5509 2733 35S-GTPGammaS 63 Human Binding pKi = 6.4 6.4 -2 5
NoneNone
PDSP KiDatabase 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
CHEMBL761 2733 35S-GTPGammaS 63 Human Binding pKi = 6.4 6.4 -2 5
NoneNone
PDSP KiDatabase 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
DB06711 2733 35S-GTPGammaS 63 Human Binding pKi = 6.4 6.4 -2 5
NoneNone
PDSP KiDatabase 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
2726 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
2726.0 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
621 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
83 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL71 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
DB00477 919 3H-RAUWOLSCINE 68 Human Binding pKi = 7.4 7.4 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
6852400 215937 3H-RAUWOLSCINE 0 Human Binding pKi = 7.4 7.4 -104 22
NoneNone
PDSP KiDatabase 361 0 1 2 4.8 CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O None
73759726 215937 3H-RAUWOLSCINE 0 Human Binding pKi = 7.4 7.4 -104 22
NoneNone
PDSP KiDatabase 361 0 1 2 4.8 CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O None
104870 98880 3H-RX821002 47 Human Binding pKi = 7.4 7.4 -3 21
NoneNone
PDSP KiDatabase 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
5374 98880 3H-RX821002 47 Human Binding pKi = 7.4 7.4 -3 21
NoneNone
PDSP KiDatabase 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
CHEMBL279085 98880 3H-RX821002 47 Human Binding pKi = 7.4 7.4 -3 21
NoneNone
PDSP KiDatabase 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
122295 9868 3H-RAUWOLSCINE 7 Human Binding pKi = 7.4 7.4 -1 9
NoneNone
PDSP KiDatabase 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 None
CHEMBL114166 9868 3H-RAUWOLSCINE 7 Human Binding pKi = 7.4 7.4 -1 9
NoneNone
PDSP KiDatabase 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 None
None 216239 3H-CLONIDINE 0 Human Binding pKi = 5.4 5.4 -27542 30
NoneNone
PDSP KiDatabase 316 7 3 3 3.0 CC(CF)NCC(COC1=CC=CC2=C1C3=CC=CC=C3N2)O None
3952 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5353646 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5353646.0 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5443 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5702063 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5702063.0 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
CHEMBL1331786 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
CHEMBL420 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
DB00629 1888 35S-GTPGammaS 38 Human Binding pKi = 6.4 6.4 -19 12
NoneNone
PDSP KiDatabase 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
45266826 217691 3H-RAUWOLSCINE 0 Human Binding pKi = 5.4 5.4 -6 8
NoneNone
PDSP KiDatabase 177 3 1 2 1.8 CC1=CC=C(C=C1)C(=O)C(C)NC None
2435 3590 3H-CLONIDINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
2435 3590 3H-RAUWOLSCINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
60149 3590 3H-CLONIDINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
60149 3590 3H-RAUWOLSCINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
98 3590 3H-CLONIDINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
98 3590 3H-RAUWOLSCINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
CHEMBL12713 3590 3H-CLONIDINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
CHEMBL12713 3590 3H-RAUWOLSCINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
DB06144 3590 3H-CLONIDINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
DB06144 3590 3H-RAUWOLSCINE 83 Human Binding pKi = 6.4 6.4 -104 48
NoneNone
PDSP KiDatabase 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
2726 919 3H-CLONIDINE 68 Human Binding pKi = 7.3 7.3 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
2726.0 919 3H-CLONIDINE 68 Human Binding pKi = 7.3 7.3 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
621 919 3H-CLONIDINE 68 Human Binding pKi = 7.3 7.3 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
83 919 3H-CLONIDINE 68 Human Binding pKi = 7.3 7.3 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL71 919 3H-CLONIDINE 68 Human Binding pKi = 7.3 7.3 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
DB00477 919 3H-CLONIDINE 68 Human Binding pKi = 7.3 7.3 -31 72
NoneNone
PDSP KiDatabase 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
68712 100338 35S-GTPGammaS 60 Human Binding pKi = 5.3 5.3 -1 5
NoneNone
PDSP KiDatabase 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 None
CHEMBL289480 100338 35S-GTPGammaS 60 Human Binding pKi = 5.3 5.3 -1 5
NoneNone
PDSP KiDatabase 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 None
122211 462 3H-RAUWOLSCINE 0 North American opossum Binding pKi = 7.3 7.3 -30 6
NoneNone
PDSP KiDatabase 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C None
524 462 3H-RAUWOLSCINE 0 North American opossum Binding pKi = 7.3 7.3 -30 6
NoneNone
PDSP KiDatabase 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C None
2719 917 None 74 Human Binding pKi = 8.3 8.3 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
5535 917 None 74 Human Binding pKi = 8.3 8.3 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
607 917 None 74 Human Binding pKi = 8.3 8.3 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
CHEMBL76 917 None 74 Human Binding pKi = 8.3 8.3 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
DB00608 917 None 74 Human Binding pKi = 8.3 8.3 -6 11
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
164512323 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 8.3 8.3 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
6419959 216031 3H-RAUWOLSCINE 0 Human Binding pKi = 8.3 8.3 5 5
NoneNone
PDSP KiDatabase 352 1 1 4 3.2 CC1C2CN3CCC4=C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45 None
2142 3096 3H-RX821002 58 Human Binding pKi = 8.3 8.3 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
4920903 3096 3H-RX821002 58 Human Binding pKi = 8.3 8.3 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
502 3096 3H-RX821002 58 Human Binding pKi = 8.3 8.3 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775 3096 3H-RX821002 58 Human Binding pKi = 8.3 8.3 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775.0 3096 3H-RX821002 58 Human Binding pKi = 8.3 8.3 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
CHEMBL597 3096 3H-RX821002 58 Human Binding pKi = 8.3 8.3 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
DB00692 3096 3H-RX821002 58 Human Binding pKi = 8.3 8.3 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5280805 85405 None 81 Human Binding pKi = 8.3 8.3 -29 3
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
Drug Central 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O None
CHEMBL226335 85405 None 81 Human Binding pKi = 8.3 8.3 -29 3
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
Drug Central 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O None
135 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.3 8.3 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
1796 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.3 8.3 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.3 8.3 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184.0 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.3 8.3 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
CHEMBL6437 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.3 8.3 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
DB06148 2532 3H-RAUWOLSCINE 43 Human Binding pKi = 8.3 8.3 -6 58
NoneNone
PDSP KiDatabase 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
2695 3841 None 81 Human Binding pKi = 8.3 8.3 -30 6
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
5504 3841 None 81 Human Binding pKi = 8.3 8.3 -30 6
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
7310 3841 None 81 Human Binding pKi = 8.3 8.3 -30 6
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
CHEMBL770 3841 None 81 Human Binding pKi = 8.3 8.3 -30 6
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
DB00797 3841 None 81 Human Binding pKi = 8.3 8.3 -30 6
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
222757 99376 None 73 Human Binding pKi = 8.3 8.3 1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O None
CHEMBL282575 99376 None 73 Human Binding pKi = 8.3 8.3 1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O None
28417 40039 None 49 Human Binding pKi = 8.3 8.3 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C None
28417.0 40039 None 49 Human Binding pKi = 8.3 8.3 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C None
CHEMBL1479 40039 None 49 Human Binding pKi = 8.3 8.3 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C None
DB01406 40039 None 49 Human Binding pKi = 8.3 8.3 -1 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C None
448537 160250 None 89 Human Binding pKi = 8.3 8.3 -21 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 None
CHEMBL411 160250 None 89 Human Binding pKi = 8.3 8.3 -21 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 None
12574 2605 None 88 Human Binding pKi = 8.2 8.2 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
4810 2605 None 88 Human Binding pKi = 8.2 8.2 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
4810.0 2605 None 88 Human Binding pKi = 8.2 8.2 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
CHEMBL19236 2605 None 88 Human Binding pKi = 8.2 8.2 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
DB09242 2605 None 88 Human Binding pKi = 8.2 8.2 -87 6
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
6018 11065 None 96 Human Binding pKi = 8.2 8.2 -1 3
NoneNone
Drug Central 317 4 0 4 3.2 COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2 None
CHEMBL117785 11065 None 96 Human Binding pKi = 8.2 8.2 -1 3
NoneNone
Drug Central 317 4 0 4 3.2 COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2 None
2402 3370 None 62 Human Binding pKi = 8.2 8.2 -5 24
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
5095 3370 None 62 Human Binding pKi = 8.2 8.2 -5 24
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
5095.0 3370 None 62 Human Binding pKi = 8.2 8.2 -5 24
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
7295 3370 None 62 Human Binding pKi = 8.2 8.2 -5 24
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
CHEMBL589 3370 None 62 Human Binding pKi = 8.2 8.2 -5 24
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
DB00268 3370 None 62 Human Binding pKi = 8.2 8.2 -5 24
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
104903 56344 None 17 Human Binding pKi = 8.2 8.2 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 None
CHEMBL1630578 56344 None 17 Human Binding pKi = 8.2 8.2 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 None
3598 187821 None 76 Human Binding pKi = 8.2 8.2 -1 7
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl None
CHEMBL496 187821 None 76 Human Binding pKi = 8.2 8.2 -1 7
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl None
2803 955 35S-GTPGammaS 58 Human Binding pKi = 6.3 6.3 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
2803.0 955 35S-GTPGammaS 58 Human Binding pKi = 6.3 6.3 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
516 955 35S-GTPGammaS 58 Human Binding pKi = 6.3 6.3 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
704 955 35S-GTPGammaS 58 Human Binding pKi = 6.3 6.3 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
CHEMBL134 955 35S-GTPGammaS 58 Human Binding pKi = 6.3 6.3 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
DB00575 955 35S-GTPGammaS 58 Human Binding pKi = 6.3 6.3 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
11954259 215979 3H-CLONIDINE 0 Human Binding pKi = 7.3 7.3 -173 43
NoneNone
PDSP KiDatabase 443 5 0 5 3.5 CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C None
11954259 215979 3H-CLONIDINE 0 Human Binding pKi = 7.3 7.3 -173 43
NoneNone
PDSP KiDatabase 443 5 0 5 3.5 CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C None
119570 3159 3H-CLONIDINE 96 Human Binding pKi = 7.3 7.3 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
119570.0 3159 3H-CLONIDINE 96 Human Binding pKi = 7.3 7.3 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
2233 3159 3H-CLONIDINE 96 Human Binding pKi = 7.3 7.3 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
953 3159 3H-CLONIDINE 96 Human Binding pKi = 7.3 7.3 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
CHEMBL301265 3159 3H-CLONIDINE 96 Human Binding pKi = 7.3 7.3 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
DB00413 3159 3H-CLONIDINE 96 Human Binding pKi = 7.3 7.3 -89 40
NoneNone
PDSP KiDatabase 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
100 3805 3H-RAUWOLSCINE 58 Human Binding pKi = 6.3 6.3 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
2637 3805 3H-RAUWOLSCINE 58 Human Binding pKi = 6.3 6.3 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
5452 3805 3H-RAUWOLSCINE 58 Human Binding pKi = 6.3 6.3 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
CHEMBL479 3805 3H-RAUWOLSCINE 58 Human Binding pKi = 6.3 6.3 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
DB00679 3805 3H-RAUWOLSCINE 58 Human Binding pKi = 6.3 6.3 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
1353 1911 3H-CLONIDINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
1353 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559 1911 3H-CLONIDINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559.0 1911 3H-CLONIDINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559.0 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
86 1911 3H-CLONIDINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
86 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
CHEMBL54 1911 3H-CLONIDINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
CHEMBL54 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
DB00502 1911 3H-CLONIDINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
DB00502 1911 3H-RAUWOLSCINE 93 Human Binding pKi = 6.3 6.3 -87 83
NoneNone
PDSP KiDatabase 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
4209 3163 3H-MK912 75 Human Binding pKi = 7.2 7.2 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893 3163 3H-MK912 75 Human Binding pKi = 7.2 7.2 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893.0 3163 3H-MK912 75 Human Binding pKi = 7.2 7.2 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
503 3163 3H-MK912 75 Human Binding pKi = 7.2 7.2 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
5385 3163 3H-MK912 75 Human Binding pKi = 7.2 7.2 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
CHEMBL2 3163 3H-MK912 75 Human Binding pKi = 7.2 7.2 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
DB00457 3163 3H-MK912 75 Human Binding pKi = 7.2 7.2 -181 33
NoneNone
PDSP KiDatabase 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
484 2858 35S-GTPGammaS 51 Human Binding pKi = 6.2 6.2 -2 35
NoneNone
PDSP KiDatabase 169 2 4 4 0.1 NCC(c1ccc(c(c1)O)O)O None
951 2858 35S-GTPGammaS 51 Human Binding pKi = 6.2 6.2 -2 35
NoneNone
PDSP KiDatabase 169 2 4 4 0.1 NCC(c1ccc(c(c1)O)O)O None
CHEMBL432 2858 35S-GTPGammaS 51 Human Binding pKi = 6.2 6.2 -2 35
NoneNone
PDSP KiDatabase 169 2 4 4 0.1 NCC(c1ccc(c(c1)O)O)O None
2865 4143 3H-CLONIDINE 73 Human Binding pKi = 7.2 7.2 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
59 4143 3H-CLONIDINE 73 Human Binding pKi = 7.2 7.2 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854 4143 3H-CLONIDINE 73 Human Binding pKi = 7.2 7.2 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854.0 4143 3H-CLONIDINE 73 Human Binding pKi = 7.2 7.2 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
CHEMBL708 4143 3H-CLONIDINE 73 Human Binding pKi = 7.2 7.2 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
DB00246 4143 3H-CLONIDINE 73 Human Binding pKi = 7.2 7.2 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
162265 202274 3H-CLONIDINE 22 Human Binding pKi = 6.2 6.2 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
4786 202274 3H-CLONIDINE 22 Human Binding pKi = 6.2 6.2 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
CHEMBL61006 202274 3H-CLONIDINE 22 Human Binding pKi = 6.2 6.2 -8 43
NoneNone
PDSP KiDatabase 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
4158 205341 None 21 Human Binding pKi = 8.2 8.2 1 21
NoneNone
Drug Central 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
CHEMBL1722 205341 None 21 Human Binding pKi = 8.2 8.2 1 21
NoneNone
Drug Central 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
CHEMBL796 205341 None 21 Human Binding pKi = 8.2 8.2 1 21
NoneNone
Drug Central 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
10836 14467 None 14 Human Binding pKi = 8.2 8.2 -1 9
NoneNone
Drug Central 149 3 1 1 1.8 CN[C@@H](C)Cc1ccccc1 None
CHEMBL1201201 14467 None 14 Human Binding pKi = 8.2 8.2 -1 9
NoneNone
Drug Central 149 3 1 1 1.8 CN[C@@H](C)Cc1ccccc1 None
1836 2592 None 59 Human Binding pKi = 8.2 8.2 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
3340 2592 None 59 Human Binding pKi = 8.2 8.2 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
5281040 2592 None 59 Human Binding pKi = 8.2 8.2 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
5281040.0 2592 None 59 Human Binding pKi = 8.2 8.2 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
CHEMBL787 2592 None 59 Human Binding pKi = 8.2 8.2 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
DB00471 2592 None 59 Human Binding pKi = 8.2 8.2 -31 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
5318 15576 None 49 Human Binding pKi = 8.2 8.2 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 None
CHEMBL1200348 15576 None 49 Human Binding pKi = 8.2 8.2 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 None
CHEMBL1221 15576 None 49 Human Binding pKi = 8.2 8.2 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 None
1960 2857 None 67 Mouse Binding pKi = 8.2 8.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
439260 2857 None 67 Mouse Binding pKi = 8.2 8.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
439260.0 2857 None 67 Mouse Binding pKi = 8.2 8.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
505 2857 None 67 Mouse Binding pKi = 8.2 8.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
CHEMBL1437 2857 None 67 Mouse Binding pKi = 8.2 8.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
DB00368 2857 None 67 Mouse Binding pKi = 8.2 8.2 -12 26
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
68617 205527 None 62 Human Binding pKi = 8.2 8.2 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 None
CHEMBL1709 205527 None 62 Human Binding pKi = 8.2 8.2 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 None
CHEMBL809 205527 None 62 Human Binding pKi = 8.2 8.2 -9 26
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 None
2406 100404 None 89 Human Binding pKi = 8.2 8.2 -11 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O None
CHEMBL290106 100404 None 89 Human Binding pKi = 8.2 8.2 -11 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O None
5353853 17986 None 47 Human Binding pKi = 8.2 8.2 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 None
9556529 17986 None 47 Human Binding pKi = 8.2 8.2 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 None
CHEMBL1262 17986 None 47 Human Binding pKi = 8.2 8.2 -11 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 None
3561 19077 None 39 Human Binding pKi = 8.2 8.2 -2 11
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl None
CHEMBL1289 19077 None 39 Human Binding pKi = 8.2 8.2 -2 11
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl None
237 204865 None 48 Human Binding pKi = 8.2 8.2 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 None
CHEMBL546257 204865 None 48 Human Binding pKi = 8.2 8.2 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 None
CHEMBL554190 204865 None 48 Human Binding pKi = 8.2 8.2 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 None
CHEMBL7568 204865 None 48 Human Binding pKi = 8.2 8.2 -1 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 None
2600 3779 None 74 Human Binding pKi = 8.2 8.2 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
2608 3779 None 74 Human Binding pKi = 8.2 8.2 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
5405 3779 None 74 Human Binding pKi = 8.2 8.2 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
CHEMBL17157 3779 None 74 Human Binding pKi = 8.2 8.2 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
DB00342 3779 None 74 Human Binding pKi = 8.2 8.2 -4 13
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
2342 599 None 39 Human Binding pKi = 8.2 8.2 -1 6
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
331 599 None 39 Human Binding pKi = 8.2 8.2 -1 6
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
7124 599 None 39 Human Binding pKi = 8.2 8.2 -1 6
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
CHEMBL1201250 599 None 39 Human Binding pKi = 8.2 8.2 -1 6
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
DB00767 599 None 39 Human Binding pKi = 8.2 8.2 -1 6
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
1353 1911 None 93 Human Binding pKi = 8.2 8.2 -87 83
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559 1911 None 93 Human Binding pKi = 8.2 8.2 -87 83
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559.0 1911 None 93 Human Binding pKi = 8.2 8.2 -87 83
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
86 1911 None 93 Human Binding pKi = 8.2 8.2 -87 83
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
CHEMBL54 1911 None 93 Human Binding pKi = 8.2 8.2 -87 83
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
DB00502 1911 None 93 Human Binding pKi = 8.2 8.2 -87 83
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
657255 199084 None 34 Human Binding pKi = 8.2 8.2 -8 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 12 2 3 5.6 CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 None
CHEMBL588119 199084 None 34 Human Binding pKi = 8.2 8.2 -8 15
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 12 2 3 5.6 CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 None
1443 2028 None 34 Human Binding pKi = 8.2 8.2 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
33625 2028 None 34 Human Binding pKi = 8.2 8.2 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
501 2028 None 34 Human Binding pKi = 8.2 8.2 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
CHEMBL279516 2028 None 34 Human Binding pKi = 8.2 8.2 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
DB08950 2028 None 34 Human Binding pKi = 8.2 8.2 -11 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
191 403 None 98 Human Binding pKi = 8.2 8.2 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
201 403 None 98 Human Binding pKi = 8.2 8.2 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
2170 403 None 98 Human Binding pKi = 8.2 8.2 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
2170.0 403 None 98 Human Binding pKi = 8.2 8.2 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
CHEMBL1113 403 None 98 Human Binding pKi = 8.2 8.2 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
DB00543 403 None 98 Human Binding pKi = 8.2 8.2 -39 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
60838 183874 None 99 Human Binding pKi = 8.2 8.2 -1 2
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC None
CHEMBL481 183874 None 99 Human Binding pKi = 8.2 8.2 -1 2
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC None
463 1405 None 22 Human Binding pKi = 8.2 8.2 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
6918097 1405 None 22 Human Binding pKi = 8.2 8.2 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
837 1405 None 22 Human Binding pKi = 8.2 8.2 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
CHEMBL2051956 1405 None 22 Human Binding pKi = 8.2 8.2 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
DB14068 1405 None 22 Human Binding pKi = 8.2 8.2 -48 12
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
33630 178957 None 99 Human Binding pKi = 8.2 8.2 -9 28
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
Drug Central 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 None
CHEMBL47050 178957 None 99 Human Binding pKi = 8.2 8.2 -9 28
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
Drug Central 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 None
2435 3590 None 83 Human Binding pKi = 8.2 8.2 -104 48
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
60149 3590 None 83 Human Binding pKi = 8.2 8.2 -104 48
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
98 3590 None 83 Human Binding pKi = 8.2 8.2 -104 48
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
CHEMBL12713 3590 None 83 Human Binding pKi = 8.2 8.2 -104 48
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
DB06144 3590 None 83 Human Binding pKi = 8.2 8.2 -104 48
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
4011 82408 None 49 Human Binding pKi = 8.2 8.2 -28 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 None
CHEMBL21731 82408 None 49 Human Binding pKi = 8.2 8.2 -28 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 None
11079 2733 None 63 Human Binding pKi = 8.2 8.2 -2 5
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
3369 2733 None 63 Human Binding pKi = 8.2 8.2 -2 5
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
4436 2733 None 63 Human Binding pKi = 8.2 8.2 -2 5
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
4436.0 2733 None 63 Human Binding pKi = 8.2 8.2 -2 5
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
5509 2733 None 63 Human Binding pKi = 8.2 8.2 -2 5
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
CHEMBL761 2733 None 63 Human Binding pKi = 8.2 8.2 -2 5
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
DB06711 2733 None 63 Human Binding pKi = 8.2 8.2 -2 5
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
214 3860 None 58 Human Binding pKi = 8.2 8.2 -60 30
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
2740 3860 None 58 Human Binding pKi = 8.2 8.2 -60 30
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
5566 3860 None 58 Human Binding pKi = 8.2 8.2 -60 30
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
5566.0 3860 None 58 Human Binding pKi = 8.2 8.2 -60 30
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
66064 3860 None 58 Human Binding pKi = 8.2 8.2 -60 30
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
CHEMBL422 3860 None 58 Human Binding pKi = 8.2 8.2 -60 30
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
DB00831 3860 None 58 Human Binding pKi = 8.2 8.2 -60 30
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
16362 3125 None 71 Human Binding pKi = 8.2 8.2 -263 30
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
16362.0 3125 None 71 Human Binding pKi = 8.2 8.2 -263 30
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
2172 3125 None 71 Human Binding pKi = 8.2 8.2 -263 30
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
90 3125 None 71 Human Binding pKi = 8.2 8.2 -263 30
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
CHEMBL1423 3125 None 71 Human Binding pKi = 8.2 8.2 -263 30
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
DB01100 3125 None 71 Human Binding pKi = 8.2 8.2 -263 30
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
1028 291 None 71 Human Binding pKi = 8.2 8.2 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
139148732 291 None 71 Human Binding pKi = 8.2 8.2 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
479 291 None 71 Human Binding pKi = 8.2 8.2 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
5816 291 None 71 Human Binding pKi = 8.2 8.2 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
5816.0 291 None 71 Human Binding pKi = 8.2 8.2 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
CHEMBL679 291 None 71 Human Binding pKi = 8.2 8.2 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
DB00668 291 None 71 Human Binding pKi = 8.2 8.2 -67 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
2286 3183 None 51 Human Binding pKi = 8.2 8.2 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
4927 3183 None 51 Human Binding pKi = 8.2 8.2 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
4927.0 3183 None 51 Human Binding pKi = 8.2 8.2 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
7282 3183 None 51 Human Binding pKi = 8.2 8.2 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
CHEMBL643 3183 None 51 Human Binding pKi = 8.2 8.2 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
DB01069 3183 None 51 Human Binding pKi = 8.2 8.2 -15 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
2247 505 None 81 Human Binding pKi = 8.2 8.2 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
249 505 None 81 Human Binding pKi = 8.2 8.2 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
2603 505 None 81 Human Binding pKi = 8.2 8.2 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
CHEMBL296419 505 None 81 Human Binding pKi = 8.2 8.2 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
DB00637 505 None 81 Human Binding pKi = 8.2 8.2 -25 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
2335 11848 None 22 Human Binding pKi = 8.2 8.2 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 None
8478 11848 None 22 Human Binding pKi = 8.2 8.2 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 None
CHEMBL1182210 11848 None 22 Human Binding pKi = 8.2 8.2 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 None
CHEMBL221753 11848 None 22 Human Binding pKi = 8.2 8.2 -2 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 None
2181 3128 None 46 Human Binding pKi = 8.2 8.2 -36 35
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
4830 3128 None 46 Human Binding pKi = 8.2 8.2 -36 35
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
4830.0 3128 None 46 Human Binding pKi = 8.2 8.2 -36 35
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
92 3128 None 46 Human Binding pKi = 8.2 8.2 -36 35
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
CHEMBL440294 3128 None 46 Human Binding pKi = 8.2 8.2 -36 35
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
DB09286 3128 None 46 Human Binding pKi = 8.2 8.2 -36 35
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
3157 1470 None 71 Human Binding pKi = 8.2 8.2 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
3157.0 1470 None 71 Human Binding pKi = 8.2 8.2 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
7170 1470 None 71 Human Binding pKi = 8.2 8.2 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
954 1470 None 71 Human Binding pKi = 8.2 8.2 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
CHEMBL707 1470 None 71 Human Binding pKi = 8.2 8.2 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
DB00590 1470 None 71 Human Binding pKi = 8.2 8.2 -39 10
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
11057 176149 None 23 Human Binding pKi = 8.2 8.2 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 None
3468 176149 None 23 Human Binding pKi = 8.2 8.2 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 None
CHEMBL459265 176149 None 23 Human Binding pKi = 8.2 8.2 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 None
CHEMBL64894 176149 None 23 Human Binding pKi = 8.2 8.2 -1 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 None
5524 216464 None 0 Human Binding pKi = 8.2 8.2 -2 4
NoneNone
Drug Central 215 1 2 3 1.9 C1CCC2=C(C1)C=CC=C2NC3=NCCN3 None
2162 41514 None 100 Human Binding pKi = 8.2 8.2 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl None
CHEMBL1491 41514 None 100 Human Binding pKi = 8.2 8.2 -1 6
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl None
3168 9262 None 92 Human Binding pKi = 8.2 8.2 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 None
3168.0 9262 None 92 Human Binding pKi = 8.2 8.2 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 None
CHEMBL1108 9262 None 92 Human Binding pKi = 8.2 8.2 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 None
DB00450 9262 None 92 Human Binding pKi = 8.2 8.2 -63 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 None
1548955 88581 None 20 Human Binding pKi = 8.2 8.2 -1 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 405 9 0 2 6.6 CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1 None
2800 88581 None 20 Human Binding pKi = 8.2 8.2 -1 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 405 9 0 2 6.6 CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1 None
CHEMBL2355051 88581 None 20 Human Binding pKi = 8.2 8.2 -1 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 405 9 0 2 6.6 CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1 None
2398 954 None 62 Human Binding pKi = 8.2 8.2 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
2801 954 None 62 Human Binding pKi = 8.2 8.2 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
2801.0 954 None 62 Human Binding pKi = 8.2 8.2 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
701 954 None 62 Human Binding pKi = 8.2 8.2 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
CHEMBL415 954 None 62 Human Binding pKi = 8.2 8.2 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
DB01242 954 None 62 Human Binding pKi = 8.2 8.2 -4 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
104870 98880 None 47 Human Binding pKi = 8.2 8.2 -3 21
NoneNone
Drug Central 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
5374 98880 None 47 Human Binding pKi = 8.2 8.2 -3 21
NoneNone
Drug Central 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
CHEMBL279085 98880 None 47 Human Binding pKi = 8.2 8.2 -3 21
NoneNone
Drug Central 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
66265 94013 None 15 Human Binding pKi = 8.2 8.2 -1 19
NoneNone
Drug Central 231 4 1 1 3.2 CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1 None
CHEMBL248702 94013 None 15 Human Binding pKi = 8.2 8.2 -1 19
NoneNone
Drug Central 231 4 1 1 3.2 CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1 None
277 1301 None 62 Human Binding pKi = 8.2 8.2 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
2913 1301 None 62 Human Binding pKi = 8.2 8.2 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
2913.0 1301 None 62 Human Binding pKi = 8.2 8.2 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
765 1301 None 62 Human Binding pKi = 8.2 8.2 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
CHEMBL516 1301 None 62 Human Binding pKi = 8.2 8.2 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
DB00434 1301 None 62 Human Binding pKi = 8.2 8.2 -42 50
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
1830 2590 None 44 Human Binding pKi = 8.2 8.2 -6 28
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
207 2590 None 44 Human Binding pKi = 8.2 8.2 -6 28
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
23897 2590 None 44 Human Binding pKi = 8.2 8.2 -6 28
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
23897.0 2590 None 44 Human Binding pKi = 8.2 8.2 -6 28
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
CHEMBL460 2590 None 44 Human Binding pKi = 8.2 8.2 -6 28
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
DB01618 2590 None 44 Human Binding pKi = 8.2 8.2 -6 28
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
5472 205818 None 75 Human Binding pKi = 8.2 8.2 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
5472.0 205818 None 75 Human Binding pKi = 8.2 8.2 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
CHEMBL1717 205818 None 75 Human Binding pKi = 8.2 8.2 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
CHEMBL833 205818 None 75 Human Binding pKi = 8.2 8.2 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
DB00208 205818 None 75 Human Binding pKi = 8.2 8.2 -1 3
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
3952 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5353646 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5353646.0 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5443 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5702063 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
5702063.0 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
CHEMBL1331786 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
CHEMBL420 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
DB00629 1888 None 38 Human Binding pKi = 8.2 8.2 -19 12
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N None
213 3853 None 55 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
2717 3853 None 55 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
5533 3853 None 55 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
5533.0 3853 None 55 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
CHEMBL621 3853 None 55 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
DB00656 3853 None 55 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
3151 1462 None 97 Human Binding pKi = 8.2 8.2 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
3151.0 1462 None 97 Human Binding pKi = 8.2 8.2 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
945 1462 None 97 Human Binding pKi = 8.2 8.2 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
965 1462 None 97 Human Binding pKi = 8.2 8.2 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
CHEMBL219916 1462 None 97 Human Binding pKi = 8.2 8.2 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
DB01184 1462 None 97 Human Binding pKi = 8.2 8.2 -40 27
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
3584 3777 None 64 Human Binding pKi = 8.2 8.2 -50 13
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
5401 3777 None 64 Human Binding pKi = 8.2 8.2 -50 13
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
5401.0 3777 None 64 Human Binding pKi = 8.2 8.2 -50 13
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
7302 3777 None 64 Human Binding pKi = 8.2 8.2 -50 13
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
CHEMBL611 3777 None 64 Human Binding pKi = 8.2 8.2 -50 13
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
DB01162 3777 None 64 Human Binding pKi = 8.2 8.2 -50 13
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
3658 4107 None 53 Human Binding pKi = 8.2 8.2 -17 8
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
517 4107 None 53 Human Binding pKi = 8.2 8.2 -17 8
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
5709 4107 None 53 Human Binding pKi = 8.2 8.2 -17 8
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
5709.0 4107 None 53 Human Binding pKi = 8.2 8.2 -17 8
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
CHEMBL312448 4107 None 53 Human Binding pKi = 8.2 8.2 -17 8
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
DB06694 4107 None 53 Human Binding pKi = 8.2 8.2 -17 8
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
240 944 None 43 Human Binding pKi = 8.2 8.2 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
2769 944 None 43 Human Binding pKi = 8.2 8.2 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
44279790 944 None 43 Human Binding pKi = 8.2 8.2 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
660 944 None 43 Human Binding pKi = 8.2 8.2 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
CHEMBL1729 944 None 43 Human Binding pKi = 8.2 8.2 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
CHEMBL560739 944 None 43 Human Binding pKi = 8.2 8.2 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
DB00604 944 None 43 Human Binding pKi = 8.2 8.2 -5 24
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
2351 3286 None 64 Human Binding pKi = 8.2 8.2 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
2820 3286 None 64 Human Binding pKi = 8.2 8.2 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
5035 3286 None 64 Human Binding pKi = 8.2 8.2 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
CHEMBL81 3286 None 64 Human Binding pKi = 8.2 8.2 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
DB00481 3286 None 64 Human Binding pKi = 8.2 8.2 -4 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
1576 216326 3H-CLONIDINE 0 Human Binding pKi = 6.2 6.2 1 40
NoneNone
PDSP KiDatabase 163 3 1 2 1.5 CC(C(=O)C1=CC=CC=C1)NC None
1222 1664 3H-RAUWOLSCINE 49 Human Binding pKi = 7.2 7.2 -34 33
NoneNone
PDSP KiDatabase 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
3396 1664 3H-RAUWOLSCINE 49 Human Binding pKi = 7.2 7.2 -34 33
NoneNone
PDSP KiDatabase 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
3396.0 1664 3H-RAUWOLSCINE 49 Human Binding pKi = 7.2 7.2 -34 33
NoneNone
PDSP KiDatabase 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
85 1664 3H-RAUWOLSCINE 49 Human Binding pKi = 7.2 7.2 -34 33
NoneNone
PDSP KiDatabase 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
CHEMBL46516 1664 3H-RAUWOLSCINE 49 Human Binding pKi = 7.2 7.2 -34 33
NoneNone
PDSP KiDatabase 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
DB04842 1664 3H-RAUWOLSCINE 49 Human Binding pKi = 7.2 7.2 -34 33
NoneNone
PDSP KiDatabase 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
103 4153 3H-CLONIDINE 61 Human Binding pKi = 7.2 7.2 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
2875 4153 3H-CLONIDINE 61 Human Binding pKi = 7.2 7.2 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
5736 4153 3H-CLONIDINE 61 Human Binding pKi = 7.2 7.2 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL285802 4153 3H-CLONIDINE 61 Human Binding pKi = 7.2 7.2 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
DB09225 4153 3H-CLONIDINE 61 Human Binding pKi = 7.2 7.2 -33 53
NoneNone
PDSP KiDatabase 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
2803 955 3H-RX821002 58 Human Binding pKi = 7.2 7.2 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
2803.0 955 3H-RX821002 58 Human Binding pKi = 7.2 7.2 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
516 955 3H-RX821002 58 Human Binding pKi = 7.2 7.2 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
704 955 3H-RX821002 58 Human Binding pKi = 7.2 7.2 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
CHEMBL134 955 3H-RX821002 58 Human Binding pKi = 7.2 7.2 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
DB00575 955 3H-RX821002 58 Human Binding pKi = 7.2 7.2 -4 19
NoneNone
PDSP KiDatabase 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
15897 2862 3H-CLONIDINE 0 Human Binding pKi = 6.2 6.2 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
215 2862 3H-CLONIDINE 0 Human Binding pKi = 6.2 6.2 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
CHEMBL1979333 2862 3H-CLONIDINE 0 Human Binding pKi = 6.2 6.2 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
2105 3054 3H-RX821002 37 Human Binding pKi = 7.2 7.2 -81 33
NoneNone
PDSP KiDatabase 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
47811 3054 3H-RX821002 37 Human Binding pKi = 7.2 7.2 -81 33
NoneNone
PDSP KiDatabase 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
48 3054 3H-RX821002 37 Human Binding pKi = 7.2 7.2 -81 33
NoneNone
PDSP KiDatabase 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
CHEMBL531 3054 3H-RX821002 37 Human Binding pKi = 7.2 7.2 -81 33
NoneNone
PDSP KiDatabase 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
DB01186 3054 3H-RX821002 37 Human Binding pKi = 7.2 7.2 -81 33
NoneNone
PDSP KiDatabase 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
2202 3132 3H-RX821002 96 Human Binding pKi = 7.2 7.2 1 21
NoneNone
PDSP KiDatabase 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
4850 3132 3H-RX821002 96 Human Binding pKi = 7.2 7.2 1 21
NoneNone
PDSP KiDatabase 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
4850.0 3132 3H-RX821002 96 Human Binding pKi = 7.2 7.2 1 21
NoneNone
PDSP KiDatabase 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
49 3132 3H-RX821002 96 Human Binding pKi = 7.2 7.2 1 21
NoneNone
PDSP KiDatabase 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
CHEMBL1371770 3132 3H-RX821002 96 Human Binding pKi = 7.2 7.2 1 21
NoneNone
PDSP KiDatabase 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
DB12478 3132 3H-RX821002 96 Human Binding pKi = 7.2 7.2 1 21
NoneNone
PDSP KiDatabase 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
11141 345 None 50 Human Binding pKi = 8.2 8.2 1 2
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
120 345 None 50 Human Binding pKi = 8.2 8.2 1 2
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
135413504 345 None 50 Human Binding pKi = 8.2 8.2 1 2
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
135413504.0 345 None 50 Human Binding pKi = 8.2 8.2 1 2
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
43008 345 None 50 Human Binding pKi = 8.2 8.2 1 2
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
CHEMBL290194 345 None 50 Human Binding pKi = 8.2 8.2 1 2
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
DB01425 345 None 50 Human Binding pKi = 8.2 8.2 1 2
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
1547484 940 None 74 Human Binding pKi = 8.2 8.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
1547484.0 940 None 74 Human Binding pKi = 8.2 8.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
654 940 None 74 Human Binding pKi = 8.2 8.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
9072 940 None 74 Human Binding pKi = 8.2 8.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
CHEMBL43064 940 None 74 Human Binding pKi = 8.2 8.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
DB00568 940 None 74 Human Binding pKi = 8.2 8.2 -4 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
103 4153 None 61 Human Binding pKi = 8.2 8.2 -33 53
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
2875 4153 None 61 Human Binding pKi = 8.2 8.2 -33 53
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
5736 4153 None 61 Human Binding pKi = 8.2 8.2 -33 53
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL285802 4153 None 61 Human Binding pKi = 8.2 8.2 -33 53
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
DB09225 4153 None 61 Human Binding pKi = 8.2 8.2 -33 53
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
209 3057 None 97 Human Binding pKi = 8.2 8.2 -34 23
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
2113 3057 None 97 Human Binding pKi = 8.2 8.2 -34 23
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4748 3057 None 97 Human Binding pKi = 8.2 8.2 -34 23
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4748.0 3057 None 97 Human Binding pKi = 8.2 8.2 -34 23
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
CHEMBL567 3057 None 97 Human Binding pKi = 8.2 8.2 -34 23
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
DB00850 3057 None 97 Human Binding pKi = 8.2 8.2 -34 23
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
2726 919 None 68 Human Binding pKi = 8.2 8.2 -31 72
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
2726.0 919 None 68 Human Binding pKi = 8.2 8.2 -31 72
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
621 919 None 68 Human Binding pKi = 8.2 8.2 -31 72
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
83 919 None 68 Human Binding pKi = 8.2 8.2 -31 72
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL71 919 None 68 Human Binding pKi = 8.2 8.2 -31 72
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
DB00477 919 None 68 Human Binding pKi = 8.2 8.2 -31 72
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
1613 2348 None 53 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
205 2348 None 53 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
3964 2348 None 53 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
3964.0 2348 None 53 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
CHEMBL831 2348 None 53 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
DB00408 2348 None 53 Human Binding pKi = 8.2 8.2 -6 44
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
2865 4143 None 73 Human Binding pKi = 8.2 8.2 -64 53
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
59 4143 None 73 Human Binding pKi = 8.2 8.2 -64 53
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854 4143 None 73 Human Binding pKi = 8.2 8.2 -64 53
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854.0 4143 None 73 Human Binding pKi = 8.2 8.2 -64 53
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
CHEMBL708 4143 None 73 Human Binding pKi = 8.2 8.2 -64 53
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
DB00246 4143 None 73 Human Binding pKi = 8.2 8.2 -64 53
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
100 3805 None 58 Human Binding pKi = 8.2 8.2 -27 55
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
2637 3805 None 58 Human Binding pKi = 8.2 8.2 -27 55
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
5452 3805 None 58 Human Binding pKi = 8.2 8.2 -27 55
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
CHEMBL479 3805 None 58 Human Binding pKi = 8.2 8.2 -27 55
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
DB00679 3805 None 58 Human Binding pKi = 8.2 8.2 -27 55
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
1593 2340 None 66 Human Binding pKi = 8.2 8.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
30668 2340 None 66 Human Binding pKi = 8.2 8.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
30668.0 2340 None 66 Human Binding pKi = 8.2 8.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
9868 2340 None 66 Human Binding pKi = 8.2 8.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
CHEMBL17860 2340 None 66 Human Binding pKi = 8.2 8.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
DB04948 2340 None 66 Human Binding pKi = 8.2 8.2 -6 4
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
1960 2857 None 67 Human Binding pKi = 8.1 8.1 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
439260 2857 None 67 Human Binding pKi = 8.1 8.1 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
439260.0 2857 None 67 Human Binding pKi = 8.1 8.1 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
505 2857 None 67 Human Binding pKi = 8.1 8.1 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
CHEMBL1437 2857 None 67 Human Binding pKi = 8.1 8.1 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
DB00368 2857 None 67 Human Binding pKi = 8.1 8.1 -20 26
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
2105 3054 None 37 Human Binding pKi = 8.1 8.1 -81 33
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
47811 3054 None 37 Human Binding pKi = 8.1 8.1 -81 33
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
48 3054 None 37 Human Binding pKi = 8.1 8.1 -81 33
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
CHEMBL531 3054 None 37 Human Binding pKi = 8.1 8.1 -81 33
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
DB01186 3054 None 37 Human Binding pKi = 8.1 8.1 -81 33
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
2202 3132 None 96 Human Binding pKi = 8.1 8.1 1 21
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
4850 3132 None 96 Human Binding pKi = 8.1 8.1 1 21
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
4850.0 3132 None 96 Human Binding pKi = 8.1 8.1 1 21
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
49 3132 None 96 Human Binding pKi = 8.1 8.1 1 21
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
CHEMBL1371770 3132 None 96 Human Binding pKi = 8.1 8.1 1 21
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
DB12478 3132 None 96 Human Binding pKi = 8.1 8.1 1 21
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
441383 20333 None 57 Human Binding pKi = 8.1 8.1 2 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 None
CHEMBL1306 20333 None 57 Human Binding pKi = 8.1 8.1 2 16
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 None
1222 1664 None 49 Human Binding pKi = 8.1 8.1 -34 33
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
3396 1664 None 49 Human Binding pKi = 8.1 8.1 -34 33
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
3396.0 1664 None 49 Human Binding pKi = 8.1 8.1 -34 33
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
85 1664 None 49 Human Binding pKi = 8.1 8.1 -34 33
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
CHEMBL46516 1664 None 49 Human Binding pKi = 8.1 8.1 -34 33
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
DB04842 1664 None 49 Human Binding pKi = 8.1 8.1 -34 33
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
1201549 597 None 24 Human Binding pKi = 8.1 8.1 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
1201549.0 597 None 24 Human Binding pKi = 8.1 8.1 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
333 597 None 24 Human Binding pKi = 8.1 8.1 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
7601 597 None 24 Human Binding pKi = 8.1 8.1 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
CHEMBL1201203 597 None 24 Human Binding pKi = 8.1 8.1 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
CHEMBL438151 597 None 24 Human Binding pKi = 8.1 8.1 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
DB00245 597 None 24 Human Binding pKi = 8.1 8.1 -18 20
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
212 3806 None 47 Human Binding pKi = 8.1 8.1 -6 25
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
2639 3806 None 47 Human Binding pKi = 8.1 8.1 -6 25
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
941651 3806 None 47 Human Binding pKi = 8.1 8.1 -6 25
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
941651.0 3806 None 47 Human Binding pKi = 8.1 8.1 -6 25
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
CHEMBL1201 3806 None 47 Human Binding pKi = 8.1 8.1 -6 25
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
DB01623 3806 None 47 Human Binding pKi = 8.1 8.1 -6 25
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
3191 102858 None 97 Human Binding pKi = 8.1 8.1 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 None
3191.0 102858 None 97 Human Binding pKi = 8.1 8.1 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 None
CHEMBL305660 102858 None 97 Human Binding pKi = 8.1 8.1 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 None
DB11742 102858 None 97 Human Binding pKi = 8.1 8.1 -3 25
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 None
228 445 None 28 Human Binding pKi = 8.1 8.1 -3 24
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
33 445 None 28 Human Binding pKi = 8.1 8.1 -3 24
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
6005 445 None 28 Human Binding pKi = 8.1 8.1 -3 24
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
6005.0 445 None 28 Human Binding pKi = 8.1 8.1 -3 24
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
CHEMBL53 445 None 28 Human Binding pKi = 8.1 8.1 -3 24
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
DB00714 445 None 28 Human Binding pKi = 8.1 8.1 -3 24
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
242 470 None 124 Human Binding pKi = 8.1 8.1 -23 51
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
34 470 None 124 Human Binding pKi = 8.1 8.1 -23 51
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795 470 None 124 Human Binding pKi = 8.1 8.1 -23 51
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795.0 470 None 124 Human Binding pKi = 8.1 8.1 -23 51
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
CHEMBL1112 470 None 124 Human Binding pKi = 8.1 8.1 -23 51
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
DB01238 470 None 124 Human Binding pKi = 8.1 8.1 -23 51
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
2284 3182 None 33 Human Binding pKi = 8.1 8.1 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
4926 3182 None 33 Human Binding pKi = 8.1 8.1 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
7281 3182 None 33 Human Binding pKi = 8.1 8.1 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
CHEMBL564 3182 None 33 Human Binding pKi = 8.1 8.1 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
DB00420 3182 None 33 Human Binding pKi = 8.1 8.1 -7 29
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
12488 1657 None 56 Human Binding pKi = 8.1 8.1 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
941361 1657 None 56 Human Binding pKi = 8.1 8.1 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
CHEMBL30008 1657 None 56 Human Binding pKi = 8.1 8.1 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
DB04841 1657 None 56 Human Binding pKi = 8.1 8.1 -2 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
2216 446 None 50 Human Binding pKi = 8.1 8.1 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
2216.0 446 None 50 Human Binding pKi = 8.1 8.1 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
229 446 None 50 Human Binding pKi = 8.1 8.1 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
7117 446 None 50 Human Binding pKi = 8.1 8.1 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
CHEMBL647 446 None 50 Human Binding pKi = 8.1 8.1 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
DB00964 446 None 50 Human Binding pKi = 8.1 8.1 -3 6
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
1971 2866 None 38 Human Binding pKi = 8.1 8.1 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
2404 2866 None 38 Human Binding pKi = 8.1 8.1 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
4543 2866 None 38 Human Binding pKi = 8.1 8.1 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
4543.0 2866 None 38 Human Binding pKi = 8.1 8.1 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
CHEMBL445 2866 None 38 Human Binding pKi = 8.1 8.1 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
DB00540 2866 None 38 Human Binding pKi = 8.1 8.1 -3 30
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
1212 1662 None 50 Human Binding pKi = 8.1 8.1 -54 65
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
204 1662 None 50 Human Binding pKi = 8.1 8.1 -54 65
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372 1662 None 50 Human Binding pKi = 8.1 8.1 -54 65
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372.0 1662 None 50 Human Binding pKi = 8.1 8.1 -54 65
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
CHEMBL726 1662 None 50 Human Binding pKi = 8.1 8.1 -54 65
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
DB00623 1662 None 50 Human Binding pKi = 8.1 8.1 -54 65
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
135398745 2914 None 112 Human Binding pKi = 8.1 8.1 -30 65
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
135398745.0 2914 None 112 Human Binding pKi = 8.1 8.1 -30 65
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
47 2914 None 112 Human Binding pKi = 8.1 8.1 -30 65
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
CHEMBL715 2914 None 112 Human Binding pKi = 8.1 8.1 -30 65
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
DB00334 2914 None 112 Human Binding pKi = 8.1 8.1 -30 65
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
3389 217711 None 0 Human Binding pKi = 8.1 8.1 -1 26
NoneNone
Drug Central 549 12 0 6 6.8 CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1 None
133 2496 None 52 Human Binding pKi = 8.1 8.1 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
1723 2496 None 52 Human Binding pKi = 8.1 8.1 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
28693 2496 None 52 Human Binding pKi = 8.1 8.1 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
CHEMBL19215 2496 None 52 Human Binding pKi = 8.1 8.1 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
DB13520 2496 None 52 Human Binding pKi = 8.1 8.1 -26 42
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
10219 188796 None 37 Human Binding pKi = 8.1 8.1 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 None
CHEMBL493439 188796 None 37 Human Binding pKi = 8.1 8.1 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 None
CHEMBL50588 188796 None 37 Human Binding pKi = 8.1 8.1 -2 5
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 None
31101 729 None 40 Human Binding pKi = 8.1 8.1 -36 36
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
31101.0 729 None 40 Human Binding pKi = 8.1 8.1 -36 36
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
35 729 None 40 Human Binding pKi = 8.1 8.1 -36 36
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
403 729 None 40 Human Binding pKi = 8.1 8.1 -36 36
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
CHEMBL493 729 None 40 Human Binding pKi = 8.1 8.1 -36 36
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
DB01200 729 None 40 Human Binding pKi = 8.1 8.1 -36 36
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
4209 3163 None 75 Human Binding pKi = 8.1 8.1 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893 3163 None 75 Human Binding pKi = 8.1 8.1 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893.0 3163 None 75 Human Binding pKi = 8.1 8.1 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
503 3163 None 75 Human Binding pKi = 8.1 8.1 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
5385 3163 None 75 Human Binding pKi = 8.1 8.1 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
CHEMBL2 3163 None 75 Human Binding pKi = 8.1 8.1 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
DB00457 3163 None 75 Human Binding pKi = 8.1 8.1 -181 33
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
37 778 None 60 Human Binding pKi = 8.1 8.1 -5 17
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
460 778 None 60 Human Binding pKi = 8.1 8.1 -5 17
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
54746 778 None 60 Human Binding pKi = 8.1 8.1 -5 17
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
54746.0 778 None 60 Human Binding pKi = 8.1 8.1 -5 17
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
CHEMBL1201087 778 None 60 Human Binding pKi = 8.1 8.1 -5 17
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
DB00248 778 None 60 Human Binding pKi = 8.1 8.1 -5 17
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
1816 2540 None 102 Human Binding pKi = 8.1 8.1 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
4205 2540 None 102 Human Binding pKi = 8.1 8.1 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
4205.0 2540 None 102 Human Binding pKi = 8.1 8.1 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
7241 2540 None 102 Human Binding pKi = 8.1 8.1 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
CHEMBL654 2540 None 102 Human Binding pKi = 8.1 8.1 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
DB00370 2540 None 102 Human Binding pKi = 8.1 8.1 -38 18
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
3294 2006 None 111 Human Binding pKi = 8.1 8.1 -16 45
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
71360 2006 None 111 Human Binding pKi = 8.1 8.1 -16 45
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
71360.0 2006 None 111 Human Binding pKi = 8.1 8.1 -16 45
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
87 2006 None 111 Human Binding pKi = 8.1 8.1 -16 45
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
CHEMBL14376 2006 None 111 Human Binding pKi = 8.1 8.1 -16 45
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
DB04946 2006 None 111 Human Binding pKi = 8.1 8.1 -16 45
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
26987 949 None 33 Human Binding pKi = 8.1 8.1 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
26987.0 949 None 33 Human Binding pKi = 8.1 8.1 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
6063 949 None 33 Human Binding pKi = 8.1 8.1 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
671 949 None 33 Human Binding pKi = 8.1 8.1 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
CHEMBL1626 949 None 33 Human Binding pKi = 8.1 8.1 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
DB00283 949 None 33 Human Binding pKi = 8.1 8.1 -107 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
2585 803 None 103 Human Binding pKi = 8.1 8.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
2585.0 803 None 103 Human Binding pKi = 8.1 8.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
522 803 None 103 Human Binding pKi = 8.1 8.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
551 803 None 103 Human Binding pKi = 8.1 8.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
CHEMBL723 803 None 103 Human Binding pKi = 8.1 8.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
DB01136 803 None 103 Human Binding pKi = 8.1 8.1 -16 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
68712 100338 None 60 Human Binding pKi = 8.1 8.1 -1 5
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
Drug Central 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 None
CHEMBL289480 100338 None 60 Human Binding pKi = 8.1 8.1 -1 5
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
Drug Central 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 None
2274 3173 None 58 Human Binding pKi = 8.1 8.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4917 3173 None 58 Human Binding pKi = 8.1 8.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4917.0 3173 None 58 Human Binding pKi = 8.1 8.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
7279 3173 None 58 Human Binding pKi = 8.1 8.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
CHEMBL728 3173 None 58 Human Binding pKi = 8.1 8.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
DB00433 3173 None 58 Human Binding pKi = 8.1 8.1 -4 31
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
213046 2385 None 59 Human Binding pKi = 8.1 8.1 -10 9
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
213046.0 2385 None 59 Human Binding pKi = 8.1 8.1 -10 9
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
4168 2385 None 59 Human Binding pKi = 8.1 8.1 -10 9
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
7461 2385 None 59 Human Binding pKi = 8.1 8.1 -10 9
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
CHEMBL1237021 2385 None 59 Human Binding pKi = 8.1 8.1 -10 9
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
DB08815 2385 None 59 Human Binding pKi = 8.1 8.1 -10 9
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
25137849 216179 3H-CLONIDINE 0 Human Binding pKi = 6.2 6.2 1 40
NoneNone
PDSP KiDatabase 165 3 2 2 1.3 CC(C(C1=CC=CC=C1)O)NC None
71290 216179 3H-CLONIDINE 0 Human Binding pKi = 6.2 6.2 1 40
NoneNone
PDSP KiDatabase 165 3 2 2 1.3 CC(C(C1=CC=CC=C1)O)NC None
124 2981 3H-RAUWOLSCINE 47 North American opossum Binding pKi = 7.1 7.1 -104 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
2032 2981 3H-RAUWOLSCINE 47 North American opossum Binding pKi = 7.1 7.1 -104 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636 2981 3H-RAUWOLSCINE 47 North American opossum Binding pKi = 7.1 7.1 -104 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636.0 2981 3H-RAUWOLSCINE 47 North American opossum Binding pKi = 7.1 7.1 -104 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
CHEMBL762 2981 3H-RAUWOLSCINE 47 North American opossum Binding pKi = 7.1 7.1 -104 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
DB00935 2981 3H-RAUWOLSCINE 47 North American opossum Binding pKi = 7.1 7.1 -104 33
NoneNone
PDSP KiDatabase 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
100 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
2637 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
5452 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
CHEMBL479 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
DB00679 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
100 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
2637 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
5452 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
CHEMBL479 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
DB00679 3805 3H-CLONIDINE 58 Human Binding pKi = 7.1 7.1 -27 55
NoneNone
PDSP KiDatabase 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
2683 3834 3H-RAUWOLSCINE 60 Human Binding pKi = 7.1 7.1 1 4
NoneNone
PDSP KiDatabase 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
5487 3834 3H-RAUWOLSCINE 60 Human Binding pKi = 7.1 7.1 1 4
NoneNone
PDSP KiDatabase 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
5487.0 3834 3H-RAUWOLSCINE 60 Human Binding pKi = 7.1 7.1 1 4
NoneNone
PDSP KiDatabase 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
7308 3834 3H-RAUWOLSCINE 60 Human Binding pKi = 7.1 7.1 1 4
NoneNone
PDSP KiDatabase 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
CHEMBL1079 3834 3H-RAUWOLSCINE 60 Human Binding pKi = 7.1 7.1 1 4
NoneNone
PDSP KiDatabase 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
DB00697 3834 3H-RAUWOLSCINE 60 Human Binding pKi = 7.1 7.1 1 4
NoneNone
PDSP KiDatabase 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
None 216325 3H-CLONIDINE 0 Human Binding pKi = 6.1 6.1 1 40
NoneNone
PDSP KiDatabase 149 2 1 2 1.2 CC(C(=O)C1=CC=CC=C1)N None
2865 4143 3H-CLONIDINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
2865 4143 3H-RAUWOLSCINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
59 4143 3H-CLONIDINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
59 4143 3H-RAUWOLSCINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854 4143 3H-CLONIDINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854 4143 3H-RAUWOLSCINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854.0 4143 3H-CLONIDINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854.0 4143 3H-RAUWOLSCINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
CHEMBL708 4143 3H-CLONIDINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
CHEMBL708 4143 3H-RAUWOLSCINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
DB00246 4143 3H-CLONIDINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
DB00246 4143 3H-RAUWOLSCINE 73 Human Binding pKi = 7.1 7.1 -64 53
NoneNone
PDSP KiDatabase 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
1613 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
205 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
3964 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
3964.0 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
CHEMBL831 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
DB00408 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
11750482 147421 UNDEFINED 0 Human Binding pKi = 8.1 8.1 19 3
NoneNone
PDSP KiDatabase 419 6 0 6 5.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccco4)cc13)CC2 None
CHEMBL392991 147421 UNDEFINED 0 Human Binding pKi = 8.1 8.1 19 3
NoneNone
PDSP KiDatabase 419 6 0 6 5.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccco4)cc13)CC2 None
180 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
200 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
2160 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
2160.0 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
CHEMBL629 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
DB00321 401 None 56 Human Binding pKi = 8.1 8.1 -16 40
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
2142 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
4920903 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
502 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775.0 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
CHEMBL597 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
DB00692 3096 None 58 Human Binding pKi = 8.1 8.1 -7 36
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
129211 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
129211.0 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
2562 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
488 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
CHEMBL836 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
DB00706 3749 None 78 Human Binding pKi = 8.1 8.1 -51 15
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
6761 67799 None 19 Human Binding pKi = 8.1 8.1 -3 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 None
CHEMBL1909072 67799 None 19 Human Binding pKi = 8.1 8.1 -3 18
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 None
115237 55585 None 119 Human Binding pKi = 8.1 8.1 -29 54
NoneNone
Drug Central 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
115237.0 55585 None 119 Human Binding pKi = 8.1 8.1 -29 54
NoneNone
Drug Central 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
CHEMBL1621 55585 None 119 Human Binding pKi = 8.1 8.1 -29 54
NoneNone
Drug Central 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
DB01267 55585 None 119 Human Binding pKi = 8.1 8.1 -29 54
NoneNone
Drug Central 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
134551 358 None 27 Human Binding pKi = 8.1 8.1 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C None
271 358 None 27 Human Binding pKi = 8.1 8.1 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C None
885 358 None 27 Human Binding pKi = 8.1 8.1 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C None
CHEMBL1403281 358 None 27 Human Binding pKi = 8.1 8.1 -5 21
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C None
135 2532 None 43 Human Binding pKi = 8.1 8.1 -6 58
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
1796 2532 None 43 Human Binding pKi = 8.1 8.1 -6 58
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184 2532 None 43 Human Binding pKi = 8.1 8.1 -6 58
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184.0 2532 None 43 Human Binding pKi = 8.1 8.1 -6 58
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
CHEMBL6437 2532 None 43 Human Binding pKi = 8.1 8.1 -6 58
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
DB06148 2532 None 43 Human Binding pKi = 8.1 8.1 -6 58
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
2389 3331 None 118 Human Binding pKi = 8.1 8.1 -10 67
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073 3331 None 118 Human Binding pKi = 8.1 8.1 -10 67
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073.0 3331 None 118 Human Binding pKi = 8.1 8.1 -10 67
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
96 3331 None 118 Human Binding pKi = 8.1 8.1 -10 67
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
CHEMBL85 3331 None 118 Human Binding pKi = 8.1 8.1 -10 67
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
DB00734 3331 None 118 Human Binding pKi = 8.1 8.1 -10 67
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
135398737 958 None 93 Human Binding pKi = 8.1 8.1 -3 89
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
135398737.0 958 None 93 Human Binding pKi = 8.1 8.1 -3 89
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
38 958 None 93 Human Binding pKi = 8.1 8.1 -3 89
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
722 958 None 93 Human Binding pKi = 8.1 8.1 -3 89
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
CHEMBL42 958 None 93 Human Binding pKi = 8.1 8.1 -3 89
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
DB00363 958 None 93 Human Binding pKi = 8.1 8.1 -3 89
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
11954224 215953 None 0 Human Binding pKi = 8.1 8.1 -4168 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C None
3251.0 215953 None 0 Human Binding pKi = 8.1 8.1 -4168 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C None
CHEMBL1982133 215953 None 0 Human Binding pKi = 8.1 8.1 -4168 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C None
DB00696 215953 None 0 Human Binding pKi = 8.1 8.1 -4168 58
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C None
10531 1420 None 21 Human Binding pKi = 8.1 8.1 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
10531.0 1420 None 21 Human Binding pKi = 8.1 8.1 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
121 1420 None 21 Human Binding pKi = 8.1 8.1 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
888 1420 None 21 Human Binding pKi = 8.1 8.1 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
CHEMBL1732 1420 None 21 Human Binding pKi = 8.1 8.1 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
DB00320 1420 None 21 Human Binding pKi = 8.1 8.1 -9 23
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
107715 200945 None 22 Human Binding pKi = 8.1 8.1 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O None
CHEMBL1255837 200945 None 22 Human Binding pKi = 8.1 8.1 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O None
CHEMBL601773 200945 None 22 Human Binding pKi = 8.1 8.1 -7 19
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O None
1613 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
205 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
3964 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
3964.0 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
CHEMBL831 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
DB00408 2348 3H-CLONIDINE 53 Human Binding pKi = 7.1 7.1 -6 44
NoneNone
PDSP KiDatabase 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
10836 14467 3H-CLONIDINE 14 Human Binding pKi = 6.1 6.1 -1 9
NoneNone
PDSP KiDatabase 149 3 1 1 1.8 CN[C@@H](C)Cc1ccccc1 None
CHEMBL1201201 14467 3H-CLONIDINE 14 Human Binding pKi = 6.1 6.1 -1 9
NoneNone
PDSP KiDatabase 149 3 1 1 1.8 CN[C@@H](C)Cc1ccccc1 None
135398745 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 7.1 7.1 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
135398745.0 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 7.1 7.1 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
47 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 7.1 7.1 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
CHEMBL715 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 7.1 7.1 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
DB00334 2914 3H-RAUWOLSCINE 112 Human Binding pKi = 7.1 7.1 -30 65
NoneNone
PDSP KiDatabase 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
209 3057 3H-CLONIDINE 97 Human Binding pKi = 7.1 7.1 -34 23
NoneNone
PDSP KiDatabase 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
2113 3057 3H-CLONIDINE 97 Human Binding pKi = 7.1 7.1 -34 23
NoneNone
PDSP KiDatabase 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4748 3057 3H-CLONIDINE 97 Human Binding pKi = 7.1 7.1 -34 23
NoneNone
PDSP KiDatabase 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4748.0 3057 3H-CLONIDINE 97 Human Binding pKi = 7.1 7.1 -34 23
NoneNone
PDSP KiDatabase 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
CHEMBL567 3057 3H-CLONIDINE 97 Human Binding pKi = 7.1 7.1 -34 23
NoneNone
PDSP KiDatabase 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
DB00850 3057 3H-CLONIDINE 97 Human Binding pKi = 7.1 7.1 -34 23
NoneNone
PDSP KiDatabase 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4158 205341 125I-Clonidine 21 Human Binding pKi = 6.1 6.1 1 21
NoneNone
PDSP KiDatabase 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
CHEMBL1722 205341 125I-Clonidine 21 Human Binding pKi = 6.1 6.1 1 21
NoneNone
PDSP KiDatabase 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
CHEMBL796 205341 125I-Clonidine 21 Human Binding pKi = 6.1 6.1 1 21
NoneNone
PDSP KiDatabase 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
134 2514 3H-CLONIDINE 24 Human Binding pKi = 7.1 7.1 -21 67
NoneNone
PDSP KiDatabase 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
1775 2514 3H-CLONIDINE 24 Human Binding pKi = 7.1 7.1 -21 67
NoneNone
PDSP KiDatabase 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
9681 2514 3H-CLONIDINE 24 Human Binding pKi = 7.1 7.1 -21 67
NoneNone
PDSP KiDatabase 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
9681.0 2514 3H-CLONIDINE 24 Human Binding pKi = 7.1 7.1 -21 67
NoneNone
PDSP KiDatabase 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
CHEMBL1065 2514 3H-CLONIDINE 24 Human Binding pKi = 7.1 7.1 -21 67
NoneNone
PDSP KiDatabase 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
DB00247 2514 3H-CLONIDINE 24 Human Binding pKi = 7.1 7.1 -21 67
NoneNone
PDSP KiDatabase 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
124 2981 None 47 Human Binding pKi = 8.1 8.1 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
2032 2981 None 47 Human Binding pKi = 8.1 8.1 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636 2981 None 47 Human Binding pKi = 8.1 8.1 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636.0 2981 None 47 Human Binding pKi = 8.1 8.1 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
CHEMBL762 2981 None 47 Human Binding pKi = 8.1 8.1 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
DB00935 2981 None 47 Human Binding pKi = 8.1 8.1 -60 33
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
None 216330 UNDEFINED 0 Human Binding pKi = 8.1 8.1 -8 28
NoneNone
PDSP KiDatabase 610 6 10 16 -1.7 CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O None
2601 3780 None 33 Human Binding pKi = 8.0 8.0 -2 21
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
443951 3780 None 33 Human Binding pKi = 8.0 8.0 -2 21
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
56 3780 None 33 Human Binding pKi = 8.0 8.0 -2 21
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
CHEMBL73151 3780 None 33 Human Binding pKi = 8.0 8.0 -2 21
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
DB13399 3780 None 33 Human Binding pKi = 8.0 8.0 -2 21
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
135398737 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.0 8.0 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
135398737.0 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.0 8.0 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
38 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.0 8.0 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
722 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.0 8.0 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
CHEMBL42 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.0 8.0 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
DB00363 958 3H-RAUWOLSCINE 93 Human Binding pKi = 8.0 8.0 -3 89
NoneNone
PDSP KiDatabase 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
2389 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.0 8.0 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.0 8.0 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073.0 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.0 8.0 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
96 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.0 8.0 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
CHEMBL85 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.0 8.0 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
DB00734 3331 3H-RAUWOLSCINE 118 Human Binding pKi = 8.0 8.0 -10 67
NoneNone
PDSP KiDatabase 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
1588 2325 None 27 Human Binding pKi = 8.0 8.0 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
28864 2325 None 27 Human Binding pKi = 8.0 8.0 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
28864.0 2325 None 27 Human Binding pKi = 8.0 8.0 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
43 2325 None 27 Human Binding pKi = 8.0 8.0 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
CHEMBL157138 2325 None 27 Human Binding pKi = 8.0 8.0 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
DB00589 2325 None 27 Human Binding pKi = 8.0 8.0 -3 44
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
11978813 721 None 79 Human Binding pKi = 8.0 8.0 -11 24
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
11978813.0 721 None 79 Human Binding pKi = 8.0 8.0 -11 24
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
5014 721 None 79 Human Binding pKi = 8.0 8.0 -11 24
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
7672 721 None 79 Human Binding pKi = 8.0 8.0 -11 24
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
CHEMBL2105760 721 None 79 Human Binding pKi = 8.0 8.0 -11 24
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
DB09128 721 None 79 Human Binding pKi = 8.0 8.0 -11 24
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
102 4127 None 48 Human Binding pKi = 8.0 8.0 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 4127 None 48 Human Binding pKi = 8.0 8.0 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 4127 None 48 Human Binding pKi = 8.0 8.0 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969.0 4127 None 48 Human Binding pKi = 8.0 8.0 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 4127 None 48 Human Binding pKi = 8.0 8.0 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 4127 None 48 Human Binding pKi = 8.0 8.0 -2 49
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
521 1404 None 69 Human Binding pKi = 8.0 8.0 -30 7
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
5311068 1404 None 69 Human Binding pKi = 8.0 8.0 -30 7
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
5311068.0 1404 None 69 Human Binding pKi = 8.0 8.0 -30 7
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
835 1404 None 69 Human Binding pKi = 8.0 8.0 -30 7
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
CHEMBL778 1404 None 69 Human Binding pKi = 8.0 8.0 -30 7
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
DB00633 1404 None 69 Human Binding pKi = 8.0 8.0 -30 7
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
44438161 147141 UNDEFINED 0 Human Binding pKi = 8.0 8.0 22 3
NoneNone
PDSP KiDatabase 543 10 1 7 5.0 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4cccc(C(=O)NCCN(C)C)c4)cc13)CC2 None
CHEMBL392771 147141 UNDEFINED 0 Human Binding pKi = 8.0 8.0 22 3
NoneNone
PDSP KiDatabase 543 10 1 7 5.0 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4cccc(C(=O)NCCN(C)C)c4)cc13)CC2 None
44438165 166784 UNDEFINED 0 Human Binding pKi = 8.0 8.0 48 3
NoneNone
PDSP KiDatabase 467 9 1 7 3.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCCN(C)C)cc13)CC2 None
CHEMBL428407 166784 UNDEFINED 0 Human Binding pKi = 8.0 8.0 48 3
NoneNone
PDSP KiDatabase 467 9 1 7 3.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCCN(C)C)cc13)CC2 None
44438148 93490 UNDEFINED 0 Human Binding pKi = 8.0 8.0 14 3
NoneNone
PDSP KiDatabase 430 6 0 6 5.1 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccn4)cc13)CC2 None
CHEMBL246229 93490 UNDEFINED 0 Human Binding pKi = 8.0 8.0 14 3
NoneNone
PDSP KiDatabase 430 6 0 6 5.1 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccn4)cc13)CC2 None
2142 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 8.0 8.0 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
4920903 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 8.0 8.0 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
502 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 8.0 8.0 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 8.0 8.0 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775.0 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 8.0 8.0 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
CHEMBL597 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 8.0 8.0 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
DB00692 3096 3H-RAUWOLSCINE 58 Human Binding pKi = 8.0 8.0 -7 36
NoneNone
PDSP KiDatabase 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
15897 2862 3H-CLONIDINE 0 Human Binding pKi = 6.0 6.0 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
215 2862 3H-CLONIDINE 0 Human Binding pKi = 6.0 6.0 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
CHEMBL1979333 2862 3H-CLONIDINE 0 Human Binding pKi = 6.0 6.0 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
68602 205126 35S-GTPGammaS 80 Human Binding pKi = 7.0 7.0 -4 7
NoneNone
PDSP KiDatabase 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C None
CHEMBL77921 205126 35S-GTPGammaS 80 Human Binding pKi = 7.0 7.0 -4 7
NoneNone
PDSP KiDatabase 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C None
15897 2862 3H-CLONIDINE 0 Human Binding pKi = 6.0 6.0 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
215 2862 3H-CLONIDINE 0 Human Binding pKi = 6.0 6.0 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
CHEMBL1979333 2862 3H-CLONIDINE 0 Human Binding pKi = 6.0 6.0 -29 36
NoneNone
PDSP KiDatabase 203 2 1 1 2.6 CC(Cc1cccc(c1)C(F)(F)F)N None
104870 98880 35S-GTPGammaS 47 Human Binding pKi = 6.0 6.0 -3 21
NoneNone
PDSP KiDatabase 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
5374 98880 35S-GTPGammaS 47 Human Binding pKi = 6.0 6.0 -3 21
NoneNone
PDSP KiDatabase 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
CHEMBL279085 98880 35S-GTPGammaS 47 Human Binding pKi = 6.0 6.0 -3 21
NoneNone
PDSP KiDatabase 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
None 216330 3H-CLONIDINE 0 Human Binding pKi = 5.0 5.0 -8 28
NoneNone
PDSP KiDatabase 610 6 10 16 -1.7 CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O None
1593 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
30668 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
30668.0 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
9868 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
CHEMBL17860 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
DB04948 2340 None 66 Human Binding pKi = 7.2 7.2 -6 4
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
1816 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
1816 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
4205 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
4205 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
4205.0 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
4205.0 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
7241 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
7241 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
CHEMBL654 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
CHEMBL654 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
DB00370 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
DB00370 2540 None 102 Human Binding pKi = 7.4 7.4 -38 18
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
2695 3841 None 81 Human Binding pKi = 5.4 5.4 -30 6
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
5504 3841 None 81 Human Binding pKi = 5.4 5.4 -30 6
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
7310 3841 None 81 Human Binding pKi = 5.4 5.4 -30 6
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
CHEMBL770 3841 None 81 Human Binding pKi = 5.4 5.4 -30 6
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
DB00797 3841 None 81 Human Binding pKi = 5.4 5.4 -30 6
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
13129 2966 None 0 Human Binding pKi = 10.6 10.6 - 1
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.8 C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC 33296042
71301276 2966 None 0 Human Binding pKi = 10.6 10.6 - 1
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.8 C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC 33296042
CHEMBL4297312 2966 None 0 Human Binding pKi = 10.6 10.6 - 1
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.8 C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC 33296042
DB12057 2966 None 0 Human Binding pKi = 10.6 10.6 - 1
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.8 C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC 33296042
12574 2605 None 88 Human Binding pKi = 4.8 4.8 -87 6
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810 2605 None 88 Human Binding pKi = 4.8 4.8 -87 6
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810.0 2605 None 88 Human Binding pKi = 4.8 4.8 -87 6
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
CHEMBL19236 2605 None 88 Human Binding pKi = 4.8 4.8 -87 6
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
DB09242 2605 None 88 Human Binding pKi = 4.8 4.8 -87 6
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
523 4106 None 93 Human Binding pKi = 5.4 5.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
523 4106 None 93 Human Binding pKi = 5.4 5.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 9605427
5707 4106 None 93 Human Binding pKi = 5.4 5.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
5707 4106 None 93 Human Binding pKi = 5.4 5.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 9605427
CHEMBL297362 4106 None 93 Human Binding pKi = 5.4 5.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
CHEMBL297362 4106 None 93 Human Binding pKi = 5.4 5.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 9605427
DB11477 4106 None 93 Human Binding pKi = 5.4 5.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
DB11477 4106 None 93 Human Binding pKi = 5.4 5.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 9605427
1028 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
1028 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
139148732 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
139148732 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
479 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
479 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
5816 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
5816.0 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816.0 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
CHEMBL679 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL679 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
DB00668 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00668 291 None 71 Human Binding pKi = 5.4 5.4 -67 30
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
1960 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
1960 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
1960 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
1960 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
439260 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
439260 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
439260.0 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260.0 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260.0 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
439260.0 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
505 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
505 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
505 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
505 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
CHEMBL1437 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
CHEMBL1437 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL1437 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
CHEMBL1437 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
DB00368 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
DB00368 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00368 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
DB00368 2857 None 67 Human Binding pKi = 5.7 5.7 -20 26
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
1343 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
1343 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
3519 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
3519.0 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519.0 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
522 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
522 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
CHEMBL862 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
CHEMBL862 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
DB01018 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
DB01018 1889 None 62 Human Binding pKi = 5.8 5.8 -251 9
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
4508 3139 None 98 Human Binding pKi = 6 6.0 -199 12
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
4866774 3139 None 98 Human Binding pKi = 6 6.0 -199 12
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
509 3139 None 98 Human Binding pKi = 6 6.0 -199 12
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
838 3139 None 98 Human Binding pKi = 6 6.0 -199 12
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
838.0 3139 None 98 Human Binding pKi = 6 6.0 -199 12
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
CHEMBL1740 3139 None 98 Human Binding pKi = 6 6.0 -199 12
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
DB11124 3139 None 98 Human Binding pKi = 6 6.0 -199 12
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
11079 2733 None 63 Human Binding pKi = 6.4 6.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
3369 2733 None 63 Human Binding pKi = 6.4 6.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436 2733 None 63 Human Binding pKi = 6.4 6.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436.0 2733 None 63 Human Binding pKi = 6.4 6.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
5509 2733 None 63 Human Binding pKi = 6.4 6.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
CHEMBL761 2733 None 63 Human Binding pKi = 6.4 6.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
DB06711 2733 None 63 Human Binding pKi = 6.4 6.4 -2 5
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
121850 726 None 0 Human Binding pKi = 6.5 6.5 -41 3
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 35224877
121850 726 None 0 Human Binding pKi = 6.5 6.5 -41 3
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 7996470
525 726 None 0 Human Binding pKi = 6.5 6.5 -41 3
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 35224877
525 726 None 0 Human Binding pKi = 6.5 6.5 -41 3
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 7996470
CHEMBL216097 726 None 0 Human Binding pKi = 6.5 6.5 -41 3
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 35224877
CHEMBL216097 726 None 0 Human Binding pKi = 6.5 6.5 -41 3
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 7996470
124 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
124 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
124 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
124 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
2032 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
2032 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
2032 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
2032 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
4636 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
4636 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
4636 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
4636.0 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636.0 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
4636.0 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
4636.0 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
CHEMBL762 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
CHEMBL762 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
CHEMBL762 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
CHEMBL762 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
DB00935 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
DB00935 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
DB00935 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
DB00935 2981 None 47 Human Binding pKi = 6.6 6.6 -60 33
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
2435 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
2435 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
2435 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
2435 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
2435 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
2435.0 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
2435.0 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
2435.0 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
2435.0 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
2435.0 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
395 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
395 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
395 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
395 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
395 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
520 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
520 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
520 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
520 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
520 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
5386 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
5386 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
5386 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
5386 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
5386 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
CHEMBL844 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
CHEMBL844 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
CHEMBL844 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
CHEMBL844 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
CHEMBL844 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
DB00484 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
DB00484 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
DB00484 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
DB00484 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
DB00484 722 None 100 Human Binding pKi = 6.7 6.7 -33 12
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
2726 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
2726 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
2726 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
2726.0 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
2726.0 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
2726.0 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
621 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
621 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
621 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
83 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
83 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
83 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
CHEMBL71 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
CHEMBL71 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
CHEMBL71 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
DB00477 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
DB00477 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
DB00477 919 None 68 Human Binding pKi = 6.7 6.7 -31 72
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
2803 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
2803 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
2803 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
2803 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
2803.0 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
2803.0 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
2803.0 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
2803.0 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
516 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
516 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
516 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
516 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
704 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
704 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
704 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
704 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
CHEMBL134 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
CHEMBL134 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
CHEMBL134 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
CHEMBL134 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
DB00575 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
DB00575 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
DB00575 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
DB00575 955 None 58 Human Binding pKi = 6.9 6.9 -4 19
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
3658 4107 None 53 Human Binding pKi = 7 7.0 -17 8
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
517 4107 None 53 Human Binding pKi = 7 7.0 -17 8
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
5709 4107 None 53 Human Binding pKi = 7 7.0 -17 8
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
5709.0 4107 None 53 Human Binding pKi = 7 7.0 -17 8
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
CHEMBL312448 4107 None 53 Human Binding pKi = 7 7.0 -17 8
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
DB06694 4107 None 53 Human Binding pKi = 7 7.0 -17 8
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
12575 1988 None 30 Human Binding pKi = 7.2 7.2 -8 17
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
54459 1988 None 30 Human Binding pKi = 7.2 7.2 -8 17
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
54459.0 1988 None 30 Human Binding pKi = 7.2 7.2 -8 17
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
CHEMBL10316 1988 None 30 Human Binding pKi = 7.2 7.2 -8 17
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
DB12551 1988 None 30 Human Binding pKi = 7.2 7.2 -8 17
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
2105 3054 None 37 Human Binding pKi = 7.2 7.2 -81 33
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
47811 3054 None 37 Human Binding pKi = 7.2 7.2 -81 33
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
48 3054 None 37 Human Binding pKi = 7.2 7.2 -81 33
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
CHEMBL531 3054 None 37 Human Binding pKi = 7.2 7.2 -81 33
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
DB01186 3054 None 37 Human Binding pKi = 7.2 7.2 -81 33
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
4209 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
4209 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
4209 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
4209 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
4893 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
4893 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
4893 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
4893 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
4893.0 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
4893.0 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
4893.0 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
4893.0 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
503 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
503 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
503 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
503 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
5385 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
5385 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
5385 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
5385 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
CHEMBL2 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
CHEMBL2 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
CHEMBL2 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
CHEMBL2 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
DB00457 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
DB00457 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
DB00457 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
DB00457 3163 None 75 Human Binding pKi = 7.3 7.3 -181 33
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
2216 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
2216 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
2216.0 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
2216.0 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
229 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
229 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
7117 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
7117 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
CHEMBL647 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
CHEMBL647 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
DB00964 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
DB00964 446 None 50 Human Binding pKi = 7.5 7.5 -3 6
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
122211 462 None 0 Human Binding pKi = 7.6 7.6 -9 6
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 1353247
122211 462 None 0 Human Binding pKi = 7.6 7.6 -9 6
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 35224877
122211 462 None 0 Human Binding pKi = 7.6 7.6 -9 6
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 7908642
122211 462 None 0 Human Binding pKi = 7.6 7.6 -9 6
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 7996470
524 462 None 0 Human Binding pKi = 7.6 7.6 -9 6
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 1353247
524 462 None 0 Human Binding pKi = 7.6 7.6 -9 6
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 35224877
524 462 None 0 Human Binding pKi = 7.6 7.6 -9 6
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 7908642
524 462 None 0 Human Binding pKi = 7.6 7.6 -9 6
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 7996470
31101 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
31101 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
31101.0 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
31101.0 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
35 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
35 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
403 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
403 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
CHEMBL493 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
CHEMBL493 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
DB01200 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
DB01200 729 None 40 Human Binding pKi = 7.6 7.6 -36 36
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
213046 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
213046 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
213046.0 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
213046.0 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
4168 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
4168 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
7461 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
7461 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
CHEMBL1237021 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
CHEMBL1237021 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
DB08815 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
DB08815 2385 None 59 Human Binding pKi = 7.7 7.7 -10 9
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
2741 350 None 0 Human Binding pKi = 7.7 7.7 - 1
UnclassifiedUnclassified
Guide to Pharmacology 314 5 1 2 4.8 C/C(=C\C=C\C(=C\C(=O)O)\C)/C=C/C1=C(C)C(=O)CCC1(C)C 15771415
6437063 350 None 0 Human Binding pKi = 7.7 7.7 - 1
UnclassifiedUnclassified
Guide to Pharmacology 314 5 1 2 4.8 C/C(=C\C=C\C(=C\C(=O)O)\C)/C=C/C1=C(C)C(=O)CCC1(C)C 15771415
CHEMBL104049 350 None 0 Human Binding pKi = 7.7 7.7 - 1
UnclassifiedUnclassified
Guide to Pharmacology 314 5 1 2 4.8 C/C(=C\C=C\C(=C\C(=O)O)\C)/C=C/C1=C(C)C(=O)CCC1(C)C 15771415
2142 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 1353247
2142 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 35224877
2142 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 7908642
4920903 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 1353247
4920903 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 35224877
4920903 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 7908642
502 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 1353247
502 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 35224877
502 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 7908642
5775 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 1353247
5775 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 35224877
5775 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 7908642
5775.0 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 1353247
5775.0 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 35224877
5775.0 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 7908642
CHEMBL597 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 1353247
CHEMBL597 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 35224877
CHEMBL597 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 7908642
DB00692 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 1353247
DB00692 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 35224877
DB00692 3096 None 58 Human Binding pKi = 7.8 7.8 -7 36
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 7908642
11959 1536 None 0 Human Binding pKi = 7.9 7.9 -4 4
UnclassifiedUnclassified
Guide to Pharmacology 405 5 1 7 3.0 Cn1c(=O)c(c(cn1)NCCN1CCC(CC1)c1noc2c1ccc(c2)F)Cl 22824189
9909267 1536 None 0 Human Binding pKi = 7.9 7.9 -4 4
UnclassifiedUnclassified
Guide to Pharmacology 405 5 1 7 3.0 Cn1c(=O)c(c(cn1)NCCN1CCC(CC1)c1noc2c1ccc(c2)F)Cl 22824189
521 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
521 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
521 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
521 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
5311068 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
5311068 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
5311068 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
5311068.0 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068.0 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
5311068.0 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
5311068.0 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
835 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
835 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
835 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
835 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
CHEMBL778 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
CHEMBL778 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
CHEMBL778 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
CHEMBL778 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
DB00633 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
DB00633 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
DB00633 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
DB00633 1404 None 69 Human Binding pKi = 8.2 8.2 -30 7
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
108094 3423 None 27 Human Binding pKi = 8.4 8.4 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
108094 3423 None 27 Human Binding pKi = 8.4 8.4 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7996470
526 3423 None 27 Human Binding pKi = 8.4 8.4 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
526 3423 None 27 Human Binding pKi = 8.4 8.4 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7996470
528 3423 None 27 Human Binding pKi = 8.4 8.4 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
528 3423 None 27 Human Binding pKi = 8.4 8.4 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7996470
CHEMBL10332 3423 None 27 Human Binding pKi = 8.4 8.4 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
CHEMBL10332 3423 None 27 Human Binding pKi = 8.4 8.4 -2 4
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7996470
12576 514 None 94 Human Binding pKi = 8.5 8.5 -2 6
UnclassifiedUnclassified
Guide to Pharmacology 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 35224877
71310 514 None 94 Human Binding pKi = 8.5 8.5 -2 6
UnclassifiedUnclassified
Guide to Pharmacology 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 35224877
CHEMBL353972 514 None 94 Human Binding pKi = 8.5 8.5 -2 6
UnclassifiedUnclassified
Guide to Pharmacology 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 35224877
DB11481 514 None 94 Human Binding pKi = 8.5 8.5 -2 6
UnclassifiedUnclassified
Guide to Pharmacology 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 35224877
499 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 1353247
499 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 35224877
499 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7908642
499 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7996470
5685 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 1353247
5685 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 35224877
5685 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7908642
5685 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7996470
CHEMBL25554 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 1353247
CHEMBL25554 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 35224877
CHEMBL25554 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7908642
CHEMBL25554 4077 None 18 Human Binding pKi = 8.8 8.8 -3 14
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7996470
5268 3656 None 40 Human Binding pKi = 8.9 8.9 -1 18
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 35224877
5268 3656 None 40 Human Binding pKi = 8.9 8.9 -1 18
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 7996470
53 3656 None 40 Human Binding pKi = 8.9 8.9 -1 18
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 35224877
53 3656 None 40 Human Binding pKi = 8.9 8.9 -1 18
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 7996470
CHEMBL300555 3656 None 40 Human Binding pKi = 8.9 8.9 -1 18
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 35224877
CHEMBL300555 3656 None 40 Human Binding pKi = 8.9 8.9 -1 18
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 7996470
13130 2965 None 0 Human Binding pKi = 8.9 8.9 - 1
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.9 [H][C@@]12N(CCC[C@@]1(C)OCC)CCC3=C2OC4=C3C=CC=C4 23718812
171037438 2965 None 0 Human Binding pKi = 8.9 8.9 - 1
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.9 [H][C@@]12N(CCC[C@@]1(C)OCC)CCC3=C2OC4=C3C=CC=C4 23718812
102 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
102 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
102 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
102 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
3659 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
3659 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
3659 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
3659 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
8969 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
8969 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
8969 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
8969 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
8969.0 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
8969.0 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
8969.0 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
8969.0 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
CHEMBL15245 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
CHEMBL15245 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
CHEMBL15245 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
CHEMBL15245 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
DB01392 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
DB01392 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
DB01392 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
DB01392 4127 None 48 Human Binding pKi = 9 9.0 -2 49
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
136 3292 None 32 Human Binding pKi = 9.1 9.1 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
223 3292 None 32 Human Binding pKi = 9.1 9.1 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
643606 3292 None 32 Human Binding pKi = 9.1 9.1 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
CHEMBL10347 3292 None 32 Human Binding pKi = 9.1 9.1 3 15
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
13128 3400 None 0 Human Binding pKi = 9.4 9.4 3 3
UnclassifiedUnclassified
Guide to Pharmacology 364 3 0 4 2.4 CCS(=O)(=O)N1CCC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C=C(C=C4)OC 35224877
9908992 3400 None 0 Human Binding pKi = 9.4 9.4 3 3
UnclassifiedUnclassified
Guide to Pharmacology 364 3 0 4 2.4 CCS(=O)(=O)N1CCC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C=C(C=C4)OC 35224877
CHEMBL4303564 3400 None 0 Human Binding pKi = 9.4 9.4 3 3
UnclassifiedUnclassified
Guide to Pharmacology 364 3 0 4 2.4 CCS(=O)(=O)N1CCC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C=C(C=C4)OC 35224877
1588 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
1588 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
1588 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
28864 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
28864 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
28864 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
28864.0 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
28864.0 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
28864.0 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
43 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
43 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
43 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
CHEMBL157138 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
CHEMBL157138 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
CHEMBL157138 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
DB00589 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
DB00589 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
DB00589 2325 None 27 Human Binding pKi = 9.6 9.6 -3 44
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
12577 2563 None 0 Human Binding pKi = 9.9 9.9 15 3
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 35224877
189711 2563 None 0 Human Binding pKi = 9.9 9.9 15 3
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 35224877
CHEMBL1257057 2563 None 0 Human Binding pKi = 9.9 9.9 15 3
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 35224877
179 400 None 115 Human Binding pKi None 8.2 8.2 -40 49
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
2159 400 None 115 Human Binding pKi None 8.2 8.2 -40 49
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
2159.0 400 None 115 Human Binding pKi None 8.2 8.2 -40 49
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
963 400 None 115 Human Binding pKi None 8.2 8.2 -40 49
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
CHEMBL243712 400 None 115 Human Binding pKi None 8.2 8.2 -40 49
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
DB06288 400 None 115 Human Binding pKi None 8.2 8.2 -40 49
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
162265 202274 None 22 Human Binding pKi None 8.2 8.2 -8 43
NoneNone
Drug Central 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
4786 202274 None 22 Human Binding pKi None 8.2 8.2 -8 43
NoneNone
Drug Central 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
CHEMBL61006 202274 None 22 Human Binding pKi None 8.2 8.2 -8 43
NoneNone
Drug Central 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
3337 206367 None 27 Human Binding pKi None 8.2 8.2 -13 40
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
3337.0 206367 None 27 Human Binding pKi None 8.2 8.2 -13 40
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
65801 206367 None 27 Human Binding pKi None 8.2 8.2 -13 40
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
66264 206367 None 27 Human Binding pKi None 8.2 8.2 -13 40
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
91452 206367 None 27 Human Binding pKi None 8.2 8.2 -13 40
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
CHEMBL87493 206367 None 27 Human Binding pKi None 8.2 8.2 -13 40
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
DB00574 206367 None 27 Human Binding pKi None 8.2 8.2 -13 40
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
134 2514 None 24 Human Binding pKi None 8.2 8.2 -21 67
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
1775 2514 None 24 Human Binding pKi None 8.2 8.2 -21 67
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
9681 2514 None 24 Human Binding pKi None 8.2 8.2 -21 67
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
9681.0 2514 None 24 Human Binding pKi None 8.2 8.2 -21 67
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
CHEMBL1065 2514 None 24 Human Binding pKi None 8.2 8.2 -21 67
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
DB00247 2514 None 24 Human Binding pKi None 8.2 8.2 -21 67
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
119570 3159 None 96 Human Binding pKi None 8.1 8.1 -89 40
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
119570.0 3159 None 96 Human Binding pKi None 8.1 8.1 -89 40
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
2233 3159 None 96 Human Binding pKi None 8.1 8.1 -89 40
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
953 3159 None 96 Human Binding pKi None 8.1 8.1 -89 40
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
CHEMBL301265 3159 None 96 Human Binding pKi None 8.1 8.1 -89 40
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
DB00413 3159 None 96 Human Binding pKi None 8.1 8.1 -89 40
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
3036780.0 107531 None 20 Human Binding pKi None 8.1 8.1 -72 53
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
46780481 107531 None 20 Human Binding pKi None 8.1 8.1 -72 53
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
9903970 107531 None 20 Human Binding pKi None 8.1 8.1 -72 53
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
9903970.0 107531 None 20 Human Binding pKi None 8.1 8.1 -72 53
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL3187365 107531 None 20 Human Binding pKi None 8.1 8.1 -72 53
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL3544974 107531 None 20 Human Binding pKi None 8.1 8.1 -72 53
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL504548 107531 None 20 Human Binding pKi None 8.1 8.1 -72 53
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
DB06216 107531 None 20 Human Binding pKi None 8.1 8.1 -72 53
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
2202 3132 None 96 Human Binding pKi None 7.2 7.2 1 21
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
4850 3132 None 96 Human Binding pKi None 7.2 7.2 1 21
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
4850.0 3132 None 96 Human Binding pKi None 7.2 7.2 1 21
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
49 3132 None 96 Human Binding pKi None 7.2 7.2 1 21
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
CHEMBL1371770 3132 None 96 Human Binding pKi None 7.2 7.2 1 21
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
DB12478 3132 None 96 Human Binding pKi None 7.2 7.2 1 21
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
228 445 None 28 Human Binding pKi None 7.4 7.4 -3 24
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
33 445 None 28 Human Binding pKi None 7.4 7.4 -3 24
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
6005 445 None 28 Human Binding pKi None 7.4 7.4 -3 24
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
6005.0 445 None 28 Human Binding pKi None 7.4 7.4 -3 24
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
CHEMBL53 445 None 28 Human Binding pKi None 7.4 7.4 -3 24
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
DB00714 445 None 28 Human Binding pKi None 7.4 7.4 -3 24
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
37 778 None 60 Human Binding pKi None 7.7 7.7 -5 17
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
460 778 None 60 Human Binding pKi None 7.7 7.7 -5 17
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
54746 778 None 60 Human Binding pKi None 7.7 7.7 -5 17
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
54746.0 778 None 60 Human Binding pKi None 7.7 7.7 -5 17
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
CHEMBL1201087 778 None 60 Human Binding pKi None 7.7 7.7 -5 17
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
DB00248 778 None 60 Human Binding pKi None 7.7 7.7 -5 17
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
219050 3373 None 25 Human Binding pKi None 8.8 8.8 -10 21
UnclassifiedUnclassified
Guide to Pharmacology 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 12388666
52 3373 None 25 Human Binding pKi None 8.8 8.8 -10 21
UnclassifiedUnclassified
Guide to Pharmacology 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 12388666
CHEMBL431367 3373 None 25 Human Binding pKi None 8.8 8.8 -10 21
UnclassifiedUnclassified
Guide to Pharmacology 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 12388666
2601 3780 None 33 Human Binding pKi None 9.1 9.1 -2 21
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
443951 3780 None 33 Human Binding pKi None 9.1 9.1 -2 21
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
56 3780 None 33 Human Binding pKi None 9.1 9.1 -2 21
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
CHEMBL73151 3780 None 33 Human Binding pKi None 9.1 9.1 -2 21
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
DB13399 3780 None 33 Human Binding pKi None 9.1 9.1 -2 21
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666